id	sid	tid	token	lemma	pos
chd-130	1	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-130	1	2	e1	e1	NOUN
chd-130	1	3	cancer	cancer	NOUN
chd-130	1	4	health	health	NOUN
chd-130	1	5	disparities	disparity	NOUN
chd-130	1	6	research	research	VERB
chd-130	1	7	a	a	DET
chd-130	1	8	genetic	genetic	ADJ
chd-130	1	9	roadmap	roadmap	NOUN
chd-130	1	10	of	of	ADP
chd-130	1	11	gallbladder	gallbladder	NOUN
chd-130	1	12	cancer	cancer	NOUN
chd-130	1	13	disparities	disparity	NOUN
chd-130	1	14	:	:	PUNCT
chd-130	1	15	a	a	DET
chd-130	1	16	potential	potential	NOUN
chd-130	1	17	for	for	ADP
chd-130	1	18	development	development	NOUN
chd-130	1	19	of	of	ADP
chd-130	1	20	targeted	target	VERB
chd-130	1	21	therapies	therapy	NOUN
chd-130	1	22	madhuri	madhuri	PROPN
chd-130	1	23	r.	r.	PROPN
chd-130	1	24	kashyap1	kashyap1	PROPN
chd-130	1	25	,	,	PUNCT
chd-130	1	26	claudia	claudia	PROPN
chd-130	1	27	p.	p.	PROPN
chd-130	1	28	garcia1	garcia1	PROPN
chd-130	1	29	,	,	PUNCT
chd-130	1	30	ana	ana	PROPN
chd-130	1	31	laura	laura	PROPN
chd-130	1	32	leal1	leal1	PROPN
chd-130	1	33	,	,	PUNCT
chd-130	1	34	balraj	balraj	VERB
chd-130	1	35	mittal2	mittal2	PROPN
chd-130	1	36	,	,	PUNCT
chd-130	1	37	mahendra	mahendra	PROPN
chd-130	1	38	k.	k.	PROPN
chd-130	1	39	singh1	singh1	PROPN
chd-130	1	40	$	$	SYM
chd-130	1	41	1division	1division	NUM
chd-130	1	42	of	of	ADP
chd-130	1	43	molecular	molecular	ADJ
chd-130	1	44	oncology	oncology	NOUN
chd-130	1	45	,	,	PUNCT
chd-130	1	46	department	department	NOUN
chd-130	1	47	of	of	ADP
chd-130	1	48	surgery	surgery	NOUN
chd-130	1	49	,	,	PUNCT
chd-130	1	50	university	university	NOUN
chd-130	1	51	of	of	ADP
chd-130	1	52	miami	miami	PROPN
chd-130	1	53	miller	miller	PROPN
chd-130	1	54	school	school	PROPN
chd-130	1	55	of	of	ADP
chd-130	1	56	medicine	medicine	NOUN
chd-130	1	57	,	,	PUNCT
chd-130	1	58	sylvester	sylvest	ADJ
chd-130	1	59	comprehensive	comprehensive	ADJ
chd-130	1	60	cancer	cancer	NOUN
chd-130	1	61	center	center	NOUN
chd-130	1	62	,	,	PUNCT
chd-130	1	63	miami	miami	PROPN
chd-130	1	64	,	,	PUNCT
chd-130	1	65	florida	florida	PROPN
chd-130	1	66	,	,	PUNCT
chd-130	1	67	usa	usa	PROPN
chd-130	1	68	.	.	PROPN
chd-130	1	69	email	email	NOUN
chd-130	1	70	:	:	PUNCT
chd-130	1	71	mahendra.singh@miami.edu	mahendra.singh@miami.edu	X
chd-130	1	72	2emeritus	2emeritus	NUM
chd-130	1	73	professor	professor	NOUN
chd-130	1	74	,	,	PUNCT
chd-130	1	75	ambedkar	ambedkar	PROPN
chd-130	1	76	university	university	PROPN
chd-130	1	77	,	,	PUNCT
chd-130	1	78	lucknow	lucknow	PROPN
chd-130	1	79	,	,	PUNCT
chd-130	1	80	up	up	ADP
chd-130	1	81	,	,	PUNCT
chd-130	1	82	india	india	PROPN
chd-130	1	83	.	.	PUNCT
chd-130	2	1	$	$	SYM
chd-130	2	2	corresponding	correspond	VERB
chd-130	2	3	author	author	NOUN
chd-130	2	4	:	:	PUNCT
chd-130	2	5	mahendra.singh@med.miami.edu	mahendra.singh@med.miami.edu	X
chd-130	2	6	abstract	abstract	ADJ
chd-130	2	7	gallbladder	gallbladder	NOUN
chd-130	2	8	cancer	cancer	NOUN
chd-130	2	9	(	(	PUNCT
chd-130	2	10	gbc	gbc	PROPN
chd-130	2	11	)	)	PUNCT
chd-130	2	12	is	be	AUX
chd-130	2	13	an	an	DET
chd-130	2	14	aggressive	aggressive	ADJ
chd-130	2	15	disease	disease	NOUN
chd-130	2	16	with	with	ADP
chd-130	2	17	a	a	DET
chd-130	2	18	dismal	dismal	ADJ
chd-130	2	19	prognosis	prognosis	NOUN
chd-130	2	20	and	and	CCONJ
chd-130	2	21	resistance	resistance	NOUN
chd-130	2	22	to	to	ADP
chd-130	2	23	chemotherapy	chemotherapy	NOUN
chd-130	2	24	.	.	PUNCT
chd-130	3	1	due	due	ADP
chd-130	3	2	to	to	ADP
chd-130	3	3	difficulties	difficulty	NOUN
chd-130	3	4	in	in	ADP
chd-130	3	5	early	early	ADJ
chd-130	3	6	diagnosis	diagnosis	NOUN
chd-130	3	7	of	of	ADP
chd-130	3	8	gbc	gbc	PROPN
chd-130	3	9	,	,	PUNCT
chd-130	3	10	about	about	ADV
chd-130	3	11	90	90	NUM
chd-130	3	12	%	%	NOUN
chd-130	3	13	of	of	ADP
chd-130	3	14	patients	patient	NOUN
chd-130	3	15	are	be	AUX
chd-130	3	16	detected	detect	VERB
chd-130	3	17	at	at	ADP
chd-130	3	18	advanced	advanced	ADJ
chd-130	3	19	stages	stage	NOUN
chd-130	3	20	with	with	ADP
chd-130	3	21	palliative	palliative	ADJ
chd-130	3	22	care	care	NOUN
chd-130	3	23	being	be	AUX
chd-130	3	24	the	the	DET
chd-130	3	25	only	only	ADJ
chd-130	3	26	viable	viable	ADJ
chd-130	3	27	option	option	NOUN
chd-130	3	28	.	.	PUNCT
chd-130	4	1	while	while	SCONJ
chd-130	4	2	surgery	surgery	NOUN
chd-130	4	3	remains	remain	VERB
chd-130	4	4	the	the	DET
chd-130	4	5	mainstay	mainstay	NOUN
chd-130	4	6	treatment	treatment	NOUN
chd-130	4	7	for	for	ADP
chd-130	4	8	early	early	ADJ
chd-130	4	9	gbc	gbc	PROPN
chd-130	4	10	,	,	PUNCT
chd-130	4	11	most	most	ADJ
chd-130	4	12	patients	patient	NOUN
chd-130	4	13	who	who	PRON
chd-130	4	14	undergo	undergo	VERB
chd-130	4	15	surgical	surgical	ADJ
chd-130	4	16	resection	resection	NOUN
chd-130	4	17	suffer	suffer	VERB
chd-130	4	18	from	from	ADP
chd-130	4	19	the	the	DET
chd-130	4	20	high	high	ADJ
chd-130	4	21	rates	rate	NOUN
chd-130	4	22	of	of	ADP
chd-130	4	23	recurrence	recurrence	NOUN
chd-130	4	24	.	.	PUNCT
chd-130	5	1	unfortunately	unfortunately	ADV
chd-130	5	2	for	for	ADP
chd-130	5	3	many	many	ADJ
chd-130	5	4	patients	patient	NOUN
chd-130	5	5	,	,	PUNCT
chd-130	5	6	surgical	surgical	ADJ
chd-130	5	7	resection	resection	NOUN
chd-130	5	8	is	be	AUX
chd-130	5	9	not	not	PART
chd-130	5	10	considered	consider	VERB
chd-130	5	11	a	a	DET
chd-130	5	12	possibility	possibility	NOUN
chd-130	5	13	due	due	ADP
chd-130	5	14	to	to	ADP
chd-130	5	15	the	the	DET
chd-130	5	16	stage	stage	NOUN
chd-130	5	17	at	at	ADP
chd-130	5	18	which	which	PRON
chd-130	5	19	they	they	PRON
chd-130	5	20	are	be	AUX
chd-130	5	21	diagnosed	diagnose	VERB
chd-130	5	22	.	.	PUNCT
chd-130	6	1	adjuvant	adjuvant	ADJ
chd-130	6	2	therapies	therapy	NOUN
chd-130	6	3	in	in	ADP
chd-130	6	4	the	the	DET
chd-130	6	5	form	form	NOUN
chd-130	6	6	of	of	ADP
chd-130	6	7	radiation	radiation	NOUN
chd-130	6	8	and/or	and/or	CCONJ
chd-130	6	9	embolization	embolization	NOUN
chd-130	6	10	of	of	ADP
chd-130	6	11	the	the	DET
chd-130	6	12	tumor	tumor	NOUN
chd-130	6	13	have	have	AUX
chd-130	6	14	been	be	AUX
chd-130	6	15	probed	probe	VERB
chd-130	6	16	for	for	ADP
chd-130	6	17	the	the	DET
chd-130	6	18	disease	disease	NOUN
chd-130	6	19	with	with	ADP
chd-130	6	20	moderate	moderate	ADJ
chd-130	6	21	success	success	NOUN
chd-130	6	22	.	.	PUNCT
chd-130	7	1	while	while	SCONJ
chd-130	7	2	there	there	PRON
chd-130	7	3	have	have	AUX
chd-130	7	4	been	be	AUX
chd-130	7	5	multiple	multiple	ADJ
chd-130	7	6	studies	study	NOUN
chd-130	7	7	(	(	PUNCT
chd-130	7	8	both	both	CCONJ
chd-130	7	9	retrospective	retrospective	ADJ
chd-130	7	10	and	and	CCONJ
chd-130	7	11	pooled	pool	VERB
chd-130	7	12	analysis	analysis	NOUN
chd-130	7	13	)	)	PUNCT
chd-130	7	14	that	that	PRON
chd-130	7	15	suggest	suggest	VERB
chd-130	7	16	an	an	DET
chd-130	7	17	added	add	VERB
chd-130	7	18	advantage	advantage	NOUN
chd-130	7	19	of	of	ADP
chd-130	7	20	combining	combine	VERB
chd-130	7	21	adjuvant	adjuvant	ADJ
chd-130	7	22	therapy	therapy	NOUN
chd-130	7	23	with	with	ADP
chd-130	7	24	surgical	surgical	ADJ
chd-130	7	25	resection	resection	NOUN
chd-130	7	26	,	,	PUNCT
chd-130	7	27	data	datum	NOUN
chd-130	7	28	from	from	ADP
chd-130	7	29	prospective	prospective	ADJ
chd-130	7	30	studies	study	NOUN
chd-130	7	31	is	be	AUX
chd-130	7	32	limited	limited	ADJ
chd-130	7	33	.	.	PUNCT
chd-130	8	1	interestingly	interestingly	ADV
chd-130	8	2	,	,	PUNCT
chd-130	8	3	gbc	gbc	PROPN
chd-130	8	4	affects	affect	VERB
chd-130	8	5	women	woman	NOUN
chd-130	8	6	,	,	PUNCT
chd-130	8	7	american	american	PROPN
chd-130	8	8	indians	indians	PROPN
chd-130	8	9	,	,	PUNCT
chd-130	8	10	alaska	alaska	PROPN
chd-130	8	11	natives	native	NOUN
chd-130	8	12	,	,	PUNCT
chd-130	8	13	black	black	ADJ
chd-130	8	14	people	people	NOUN
chd-130	8	15	,	,	PUNCT
chd-130	8	16	and	and	CCONJ
chd-130	8	17	certain	certain	ADJ
chd-130	8	18	ethnic	ethnic	ADJ
chd-130	8	19	groups	group	NOUN
chd-130	8	20	in	in	ADP
chd-130	8	21	peculiar	peculiar	ADJ
chd-130	8	22	geographic	geographic	ADJ
chd-130	8	23	locations	location	NOUN
chd-130	8	24	such	such	ADJ
chd-130	8	25	as	as	ADP
chd-130	8	26	chile	chile	PROPN
chd-130	8	27	,	,	PUNCT
chd-130	8	28	india	india	PROPN
chd-130	8	29	,	,	PUNCT
chd-130	8	30	china	china	PROPN
chd-130	8	31	more	more	ADJ
chd-130	8	32	than	than	ADP
chd-130	8	33	other	other	ADJ
chd-130	8	34	groups	group	NOUN
chd-130	8	35	elsewhere	elsewhere	ADV
chd-130	8	36	.	.	PUNCT
chd-130	9	1	these	these	DET
chd-130	9	2	disparities	disparity	NOUN
chd-130	9	3	in	in	ADP
chd-130	9	4	gender	gender	NOUN
chd-130	9	5	and	and	CCONJ
chd-130	9	6	ethnicities	ethnicity	NOUN
chd-130	9	7	demonstrate	demonstrate	VERB
chd-130	9	8	the	the	DET
chd-130	9	9	need	need	NOUN
chd-130	9	10	for	for	ADP
chd-130	9	11	better	well	ADJ
chd-130	9	12	understanding	understanding	NOUN
chd-130	9	13	of	of	ADP
chd-130	9	14	underlying	underlie	VERB
chd-130	9	15	genetic	genetic	ADJ
chd-130	9	16	events	event	NOUN
chd-130	9	17	of	of	ADP
chd-130	9	18	gbc	gbc	NOUN
chd-130	9	19	so	so	SCONJ
chd-130	9	20	that	that	SCONJ
chd-130	9	21	molecularly	molecularly	ADV
chd-130	9	22	targeted	target	VERB
chd-130	9	23	therapies	therapy	NOUN
chd-130	9	24	could	could	AUX
chd-130	9	25	be	be	AUX
chd-130	9	26	developed	develop	VERB
chd-130	9	27	to	to	PART
chd-130	9	28	provide	provide	VERB
chd-130	9	29	hope	hope	NOUN
chd-130	9	30	for	for	ADP
chd-130	9	31	improving	improve	VERB
chd-130	9	32	treatment	treatment	NOUN
chd-130	9	33	response	response	NOUN
chd-130	9	34	and	and	CCONJ
chd-130	9	35	better	well	ADJ
chd-130	9	36	outcome	outcome	NOUN
chd-130	9	37	.	.	PUNCT
chd-130	10	1	however	however	ADV
chd-130	10	2	,	,	PUNCT
chd-130	10	3	for	for	ADP
chd-130	10	4	gbc	gbc	NOUN
chd-130	10	5	not	not	PART
chd-130	10	6	much	much	ADJ
chd-130	10	7	progress	progress	NOUN
chd-130	10	8	has	have	AUX
chd-130	10	9	been	be	AUX
chd-130	10	10	made	make	VERB
chd-130	10	11	mainly	mainly	ADV
chd-130	10	12	due	due	ADP
chd-130	10	13	to	to	ADP
chd-130	10	14	the	the	DET
chd-130	10	15	lack	lack	NOUN
chd-130	10	16	of	of	ADP
chd-130	10	17	understanding	understanding	NOUN
chd-130	10	18	of	of	ADP
chd-130	10	19	molecular	molecular	ADJ
chd-130	10	20	pathogenesis	pathogenesis	NOUN
chd-130	10	21	of	of	ADP
chd-130	10	22	this	this	DET
chd-130	10	23	disease	disease	NOUN
chd-130	10	24	.	.	PUNCT
chd-130	11	1	this	this	DET
chd-130	11	2	article	article	NOUN
chd-130	11	3	presents	present	VERB
chd-130	11	4	a	a	DET
chd-130	11	5	review	review	NOUN
chd-130	11	6	of	of	ADP
chd-130	11	7	literature	literature	NOUN
chd-130	11	8	focused	focus	VERB
chd-130	11	9	on	on	ADP
chd-130	11	10	molecular	molecular	ADJ
chd-130	11	11	and	and	CCONJ
chd-130	11	12	genetic	genetic	ADJ
chd-130	11	13	alterations	alteration	NOUN
chd-130	11	14	in	in	ADP
chd-130	11	15	gbc	gbc	PROPN
chd-130	11	16	,	,	PUNCT
chd-130	11	17	and	and	CCONJ
chd-130	11	18	as	as	ADP
chd-130	11	19	to	to	ADP
chd-130	11	20	how	how	SCONJ
chd-130	11	21	effective	effective	ADJ
chd-130	11	22	targeted	target	VERB
chd-130	11	23	therapeutic	therapeutic	ADJ
chd-130	11	24	strategies	strategy	NOUN
chd-130	11	25	can	can	AUX
chd-130	11	26	be	be	AUX
chd-130	11	27	developed	develop	VERB
chd-130	11	28	with	with	ADP
chd-130	11	29	demonstrated	demonstrate	VERB
chd-130	11	30	survival	survival	NOUN
chd-130	11	31	benefit	benefit	NOUN
chd-130	11	32	.	.	PUNCT
chd-130	12	1	keywords	keyword	NOUN
chd-130	12	2	:	:	PUNCT
chd-130	12	3	gallbladder	gallbladder	NOUN
chd-130	12	4	cancer	cancer	NOUN
chd-130	12	5	,	,	PUNCT
chd-130	12	6	gbc	gbc	PROPN
chd-130	12	7	,	,	PUNCT
chd-130	12	8	gallstone	gallstone	NOUN
chd-130	12	9	,	,	PUNCT
chd-130	12	10	genetic	genetic	ADJ
chd-130	12	11	polymorphism	polymorphism	NOUN
chd-130	12	12	,	,	PUNCT
chd-130	12	13	mutation	mutation	NOUN
chd-130	12	14	,	,	PUNCT
chd-130	12	15	targeted	target	VERB
chd-130	12	16	therapy	therapy	NOUN
chd-130	12	17	,	,	PUNCT
chd-130	12	18	molecular	molecular	ADJ
chd-130	12	19	pathogenesis	pathogenesis	NOUN
chd-130	12	20	,	,	PUNCT
chd-130	12	21	health	health	NOUN
chd-130	12	22	disparity	disparity	NOUN
chd-130	12	23	citation	citation	NOUN
chd-130	12	24	:	:	PUNCT
chd-130	12	25	kashyap	kashyap	PROPN
chd-130	12	26	mr	mr	PROPN
chd-130	12	27	et	et	PROPN
chd-130	12	28	al	al	PROPN
chd-130	12	29	(	(	PUNCT
chd-130	12	30	2020	2020	NUM
chd-130	12	31	)	)	PUNCT
chd-130	12	32	a	a	DET
chd-130	12	33	genetic	genetic	ADJ
chd-130	12	34	roadmap	roadmap	NOUN
chd-130	12	35	of	of	ADP
chd-130	12	36	gallbladder	gallbladder	NOUN
chd-130	12	37	cancer	cancer	NOUN
chd-130	12	38	disparities	disparity	NOUN
chd-130	12	39	:	:	PUNCT
chd-130	12	40	a	a	DET
chd-130	12	41	potential	potential	NOUN
chd-130	12	42	for	for	ADP
chd-130	12	43	development	development	NOUN
chd-130	12	44	of	of	ADP
chd-130	12	45	targeted	target	VERB
chd-130	12	46	therapies	therapy	NOUN
chd-130	12	47	.	.	PUNCT
chd-130	13	1	cancer	cancer	NOUN
chd-130	13	2	health	health	NOUN
chd-130	13	3	disparities	disparity	NOUN
chd-130	13	4	4	4	NUM
chd-130	13	5	:	:	PUNCT
chd-130	13	6	e1	e1	NOUN
chd-130	13	7	-	-	PUNCT
chd-130	13	8	e24	e24	NOUN
chd-130	13	9	.	.	PUNCT
chd-130	14	1	doi:10.9777	doi:10.9777	PROPN
chd-130	14	2	/	/	SYM
chd-130	14	3	chd.2019.1014	chd.2019.1014	PROPN
chd-130	14	4	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-130	14	5	e2	e2	PROPN
chd-130	14	6	cancer	cancer	NOUN
chd-130	14	7	health	health	NOUN
chd-130	14	8	disparities	disparity	NOUN
chd-130	14	9	research	research	NOUN
chd-130	14	10	introduction	introduction	NOUN
chd-130	14	11	early	early	ADJ
chd-130	14	12	detection	detection	NOUN
chd-130	14	13	of	of	ADP
chd-130	14	14	gbc	gbc	PROPN
chd-130	14	15	has	have	AUX
chd-130	14	16	been	be	AUX
chd-130	14	17	challenging	challenge	VERB
chd-130	14	18	despite	despite	SCONJ
chd-130	14	19	advancements	advancement	NOUN
chd-130	14	20	in	in	ADP
chd-130	14	21	medical	medical	ADJ
chd-130	14	22	imaging	imaging	NOUN
chd-130	14	23	technologies	technology	NOUN
chd-130	14	24	such	such	ADJ
chd-130	14	25	as	as	ADP
chd-130	14	26	contrast	contrast	NOUN
chd-130	14	27	tomography	tomography	NOUN
chd-130	14	28	(	(	PUNCT
chd-130	14	29	ct	ct	NOUN
chd-130	14	30	)	)	PUNCT
chd-130	14	31	and	and	CCONJ
chd-130	14	32	ultrasound	ultrasound	NOUN
chd-130	14	33	scanning	scanning	NOUN
chd-130	14	34	.	.	PUNCT
chd-130	15	1	the	the	DET
chd-130	15	2	majority	majority	NOUN
chd-130	15	3	of	of	ADP
chd-130	15	4	the	the	DET
chd-130	15	5	cases	case	NOUN
chd-130	15	6	are	be	AUX
chd-130	15	7	detected	detect	VERB
chd-130	15	8	incidentally	incidentally	ADV
chd-130	15	9	during	during	ADP
chd-130	15	10	surgery	surgery	NOUN
chd-130	15	11	for	for	ADP
chd-130	15	12	cholelithiasis	cholelithiasis	NOUN
chd-130	15	13	and	and	CCONJ
chd-130	15	14	hence	hence	ADV
chd-130	15	15	detected	detect	VERB
chd-130	15	16	at	at	ADP
chd-130	15	17	very	very	ADV
chd-130	15	18	advanced	advanced	ADJ
chd-130	15	19	stage	stage	NOUN
chd-130	15	20	of	of	ADP
chd-130	15	21	the	the	DET
chd-130	15	22	disease	disease	NOUN
chd-130	15	23	.	.	PUNCT
chd-130	16	1	gbcs	gbc	NOUN
chd-130	16	2	are	be	AUX
chd-130	16	3	the	the	DET
chd-130	16	4	commonest	common	ADJ
chd-130	16	5	biliary	biliary	ADJ
chd-130	16	6	tract	tract	NOUN
chd-130	16	7	cancers	cancer	NOUN
chd-130	16	8	worldwide	worldwide	ADV
chd-130	16	9	.	.	PUNCT
chd-130	17	1	the	the	DET
chd-130	17	2	main	main	ADJ
chd-130	17	3	associated	associated	ADJ
chd-130	17	4	risk	risk	NOUN
chd-130	17	5	factors	factor	NOUN
chd-130	17	6	for	for	ADP
chd-130	17	7	the	the	DET
chd-130	17	8	development	development	NOUN
chd-130	17	9	of	of	ADP
chd-130	17	10	gbc	gbc	PROPN
chd-130	17	11	include	include	VERB
chd-130	17	12	,	,	PUNCT
chd-130	17	13	obesity	obesity	NOUN
chd-130	17	14	,	,	PUNCT
chd-130	17	15	chronic	chronic	ADJ
chd-130	17	16	asymptomatic	asymptomatic	ADJ
chd-130	17	17	cholelithiasis	cholelithiasis	NOUN
chd-130	17	18	,	,	PUNCT
chd-130	17	19	female	female	ADJ
chd-130	17	20	gender	gender	NOUN
chd-130	17	21	,	,	PUNCT
chd-130	17	22	smoking	smoking	NOUN
chd-130	17	23	,	,	PUNCT
chd-130	17	24	chronic	chronic	ADJ
chd-130	17	25	infections	infection	NOUN
chd-130	17	26	of	of	ADP
chd-130	17	27	the	the	DET
chd-130	17	28	gallbladder	gallbladder	NOUN
chd-130	17	29	(	(	PUNCT
chd-130	17	30	especially	especially	ADV
chd-130	17	31	salmonella	salmonella	NOUN
chd-130	17	32	)	)	PUNCT
chd-130	17	33	,	,	PUNCT
chd-130	17	34	diabetes	diabetes	NOUN
chd-130	17	35	and	and	CCONJ
chd-130	17	36	certain	certain	ADJ
chd-130	17	37	medications	medication	NOUN
chd-130	17	38	such	such	ADJ
chd-130	17	39	as	as	ADP
chd-130	17	40	methyldopa	methyldopa	NOUN
chd-130	17	41	,	,	PUNCT
chd-130	17	42	ocps	ocp	NOUN
chd-130	17	43	,	,	PUNCT
chd-130	17	44	and	and	CCONJ
chd-130	17	45	isoniazid	isoniazid	NOUN
chd-130	17	46	.	.	PUNCT
chd-130	18	1	they	they	PRON
chd-130	18	2	are	be	AUX
chd-130	18	3	also	also	ADV
chd-130	18	4	known	know	VERB
chd-130	18	5	to	to	PART
chd-130	18	6	be	be	AUX
chd-130	18	7	associated	associate	VERB
chd-130	18	8	with	with	ADP
chd-130	18	9	gallbladder	gallbladder	NOUN
chd-130	18	10	polyps	polyp	NOUN
chd-130	18	11	,	,	PUNCT
chd-130	18	12	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	18	13	duct	duct	NOUN
chd-130	18	14	abnormalities	abnormality	NOUN
chd-130	18	15	,	,	PUNCT
chd-130	18	16	congenital	congenital	ADJ
chd-130	18	17	biliary	biliary	ADJ
chd-130	18	18	cysts	cyst	NOUN
chd-130	18	19	,	,	PUNCT
chd-130	18	20	and	and	CCONJ
chd-130	18	21	carcinogen	carcinogen	PROPN
chd-130	18	22	exposure	exposure	NOUN
chd-130	18	23	(	(	PUNCT
chd-130	18	24	lazcanoponce	lazcanoponce	PROPN
chd-130	18	25	et	et	PROPN
chd-130	18	26	al	al	PROPN
chd-130	18	27	.	.	PROPN
chd-130	18	28	,	,	PUNCT
chd-130	18	29	2001	2001	NUM
chd-130	18	30	)	)	PUNCT
chd-130	18	31	.	.	PUNCT
chd-130	19	1	gbc	gbc	PROPN
chd-130	19	2	is	be	AUX
chd-130	19	3	indeed	indeed	ADV
chd-130	19	4	a	a	DET
chd-130	19	5	cancer	cancer	NOUN
chd-130	19	6	type	type	NOUN
chd-130	19	7	with	with	ADP
chd-130	19	8	layers	layer	NOUN
chd-130	19	9	of	of	ADP
chd-130	19	10	disparities	disparity	NOUN
chd-130	19	11	associated	associate	VERB
chd-130	19	12	with	with	ADP
chd-130	19	13	it	it	PRON
chd-130	19	14	.	.	PUNCT
chd-130	20	1	the	the	DET
chd-130	20	2	disease	disease	NOUN
chd-130	20	3	prevalence	prevalence	NOUN
chd-130	20	4	and	and	CCONJ
chd-130	20	5	incidence	incidence	NOUN
chd-130	20	6	is	be	AUX
chd-130	20	7	extremely	extremely	ADV
chd-130	20	8	high	high	ADJ
chd-130	20	9	in	in	ADP
chd-130	20	10	latin	latin	PROPN
chd-130	20	11	america	america	PROPN
chd-130	20	12	and	and	CCONJ
chd-130	20	13	asia	asia	PROPN
chd-130	20	14	,	,	PUNCT
chd-130	20	15	and	and	CCONJ
chd-130	20	16	comparatively	comparatively	ADV
chd-130	20	17	high	high	ADJ
chd-130	20	18	in	in	ADP
chd-130	20	19	some	some	DET
chd-130	20	20	european	european	ADJ
chd-130	20	21	countries	country	NOUN
chd-130	20	22	such	such	ADJ
chd-130	20	23	as	as	ADP
chd-130	20	24	hungary	hungary	PROPN
chd-130	20	25	and	and	CCONJ
chd-130	20	26	poland	poland	PROPN
chd-130	20	27	.	.	PUNCT
chd-130	21	1	gbc	gbc	NOUN
chd-130	21	2	incidence	incidence	NOUN
chd-130	21	3	in	in	ADP
chd-130	21	4	the	the	DET
chd-130	21	5	united	united	PROPN
chd-130	21	6	states	states	PROPN
chd-130	21	7	,	,	PUNCT
chd-130	21	8	however	however	ADV
chd-130	21	9	,	,	PUNCT
chd-130	21	10	is	be	AUX
chd-130	21	11	low	low	ADJ
chd-130	21	12	.	.	PUNCT
chd-130	22	1	chile	chile	NOUN
chd-130	22	2	accounts	account	NOUN
chd-130	22	3	for	for	ADP
chd-130	22	4	the	the	DET
chd-130	22	5	highest	high	ADJ
chd-130	22	6	incidence	incidence	NOUN
chd-130	22	7	and	and	CCONJ
chd-130	22	8	mortality	mortality	NOUN
chd-130	22	9	rates	rate	NOUN
chd-130	22	10	of	of	ADP
chd-130	22	11	gbc	gbc	PROPN
chd-130	22	12	in	in	ADP
chd-130	22	13	the	the	DET
chd-130	22	14	world	world	NOUN
chd-130	22	15	,	,	PUNCT
chd-130	22	16	with	with	ADP
chd-130	22	17	a	a	DET
chd-130	22	18	higher	high	ADJ
chd-130	22	19	death	death	NOUN
chd-130	22	20	rate	rate	NOUN
chd-130	22	21	in	in	ADP
chd-130	22	22	women	woman	NOUN
chd-130	22	23	(	(	PUNCT
chd-130	22	24	15.6	15.6	NUM
chd-130	22	25	per	per	ADP
chd-130	22	26	100,000	100,000	NUM
chd-130	22	27	)	)	PUNCT
chd-130	22	28	compared	compare	VERB
chd-130	22	29	to	to	ADP
chd-130	22	30	men	man	NOUN
chd-130	22	31	(	(	PUNCT
chd-130	22	32	7.0	7.0	NUM
chd-130	22	33	per	per	ADP
chd-130	22	34	100,000	100,000	NUM
chd-130	22	35	)	)	PUNCT
chd-130	22	36	(	(	PUNCT
chd-130	22	37	andia	andia	NOUN
chd-130	22	38	et	et	PROPN
chd-130	22	39	al	al	PROPN
chd-130	22	40	.	.	PROPN
chd-130	22	41	,	,	PUNCT
chd-130	22	42	2008	2008	NUM
chd-130	22	43	)	)	PUNCT
chd-130	22	44	.	.	PUNCT
chd-130	23	1	it	it	PRON
chd-130	23	2	is	be	AUX
chd-130	23	3	also	also	ADV
chd-130	23	4	the	the	DET
chd-130	23	5	leading	lead	VERB
chd-130	23	6	cause	cause	NOUN
chd-130	23	7	of	of	ADP
chd-130	23	8	death	death	NOUN
chd-130	23	9	in	in	ADP
chd-130	23	10	these	these	DET
chd-130	23	11	women	woman	NOUN
chd-130	23	12	,	,	PUNCT
chd-130	23	13	overtaking	overtake	VERB
chd-130	23	14	breast	breast	NOUN
chd-130	23	15	,	,	PUNCT
chd-130	23	16	lung	lung	NOUN
chd-130	23	17	and	and	CCONJ
chd-130	23	18	cervical	cervical	ADJ
chd-130	23	19	cancers	cancer	NOUN
chd-130	23	20	.	.	PUNCT
chd-130	24	1	the	the	DET
chd-130	24	2	southern	southern	ADJ
chd-130	24	3	region	region	NOUN
chd-130	24	4	of	of	ADP
chd-130	24	5	chile	chile	PROPN
chd-130	24	6	exhibits	exhibit	VERB
chd-130	24	7	a	a	DET
chd-130	24	8	higher	high	ADJ
chd-130	24	9	incidence	incidence	NOUN
chd-130	24	10	and	and	CCONJ
chd-130	24	11	mortality	mortality	NOUN
chd-130	24	12	of	of	ADP
chd-130	24	13	the	the	DET
chd-130	24	14	disease	disease	NOUN
chd-130	24	15	where	where	SCONJ
chd-130	24	16	there	there	PRON
chd-130	24	17	is	be	VERB
chd-130	24	18	a	a	DET
chd-130	24	19	large	large	ADJ
chd-130	24	20	population	population	NOUN
chd-130	24	21	of	of	ADP
chd-130	24	22	the	the	DET
chd-130	24	23	mapuche	mapuche	PROPN
chd-130	24	24	(	(	PUNCT
chd-130	24	25	amerindian	amerindian	ADJ
chd-130	24	26	)	)	PUNCT
chd-130	24	27	tribe	tribe	NOUN
chd-130	24	28	,	,	PUNCT
chd-130	24	29	known	know	VERB
chd-130	24	30	to	to	PART
chd-130	24	31	have	have	VERB
chd-130	24	32	the	the	DET
chd-130	24	33	highest	high	ADJ
chd-130	24	34	incidence	incidence	NOUN
chd-130	24	35	of	of	ADP
chd-130	24	36	gbc	gbc	PROPN
chd-130	24	37	.	.	PUNCT
chd-130	25	1	interestingly	interestingly	ADV
chd-130	25	2	,	,	PUNCT
chd-130	25	3	this	this	DET
chd-130	25	4	geographic	geographic	ADJ
chd-130	25	5	area	area	NOUN
chd-130	25	6	of	of	ADP
chd-130	25	7	chile	chile	PROPN
chd-130	25	8	has	have	VERB
chd-130	25	9	poor	poor	ADJ
chd-130	25	10	access	access	NOUN
chd-130	25	11	to	to	ADP
chd-130	25	12	medical	medical	ADJ
chd-130	25	13	and	and	CCONJ
chd-130	25	14	surgical	surgical	ADJ
chd-130	25	15	facilities	facility	NOUN
chd-130	25	16	attributable	attributable	ADJ
chd-130	25	17	to	to	ADP
chd-130	25	18	extreme	extreme	ADJ
chd-130	25	19	poverty	poverty	NOUN
chd-130	25	20	in	in	ADP
chd-130	25	21	this	this	DET
chd-130	25	22	part	part	NOUN
chd-130	25	23	of	of	ADP
chd-130	25	24	the	the	DET
chd-130	25	25	country	country	NOUN
chd-130	25	26	(	(	PUNCT
chd-130	25	27	andia	andia	NOUN
chd-130	25	28	et	et	PROPN
chd-130	25	29	al	al	PROPN
chd-130	25	30	.	.	PROPN
chd-130	25	31	,	,	PUNCT
chd-130	25	32	2008	2008	NUM
chd-130	25	33	)	)	PUNCT
chd-130	25	34	.	.	PUNCT
chd-130	26	1	worldwide	worldwide	ADV
chd-130	26	2	,	,	PUNCT
chd-130	26	3	incidence	incidence	NOUN
chd-130	26	4	of	of	ADP
chd-130	26	5	the	the	DET
chd-130	26	6	disease	disease	NOUN
chd-130	26	7	has	have	AUX
chd-130	26	8	been	be	AUX
chd-130	26	9	shown	show	VERB
chd-130	26	10	to	to	PART
chd-130	26	11	increase	increase	VERB
chd-130	26	12	with	with	ADP
chd-130	26	13	age	age	NOUN
chd-130	26	14	and	and	CCONJ
chd-130	26	15	is	be	AUX
chd-130	26	16	found	find	VERB
chd-130	26	17	to	to	PART
chd-130	26	18	be	be	AUX
chd-130	26	19	two	two	NUM
chd-130	26	20	to	to	PART
chd-130	26	21	six	six	NUM
chd-130	26	22	times	time	NOUN
chd-130	26	23	higher	high	ADJ
chd-130	26	24	in	in	ADP
chd-130	26	25	women	woman	NOUN
chd-130	26	26	than	than	ADP
chd-130	26	27	in	in	ADP
chd-130	26	28	men	man	NOUN
chd-130	26	29	(	(	PUNCT
chd-130	26	30	singh	singh	PROPN
chd-130	26	31	et	et	PROPN
chd-130	26	32	al	al	PROPN
chd-130	26	33	.	.	PROPN
chd-130	26	34	,	,	PUNCT
chd-130	26	35	2004a	2004a	NUM
chd-130	26	36	)	)	PUNCT
chd-130	26	37	.	.	PUNCT
chd-130	27	1	interestingly	interestingly	ADV
chd-130	27	2	,	,	PUNCT
chd-130	27	3	patients	patient	NOUN
chd-130	27	4	with	with	ADP
chd-130	27	5	gbc	gbc	PROPN
chd-130	27	6	in	in	ADP
chd-130	27	7	india	india	PROPN
chd-130	27	8	are	be	AUX
chd-130	27	9	usually	usually	ADV
chd-130	27	10	younger	young	ADJ
chd-130	27	11	ones	one	NOUN
chd-130	27	12	as	as	ADP
chd-130	27	13	compared	compare	VERB
chd-130	27	14	to	to	ADP
chd-130	27	15	their	their	PRON
chd-130	27	16	counterparts	counterpart	NOUN
chd-130	27	17	in	in	ADP
chd-130	27	18	the	the	DET
chd-130	27	19	west	west	NOUN
chd-130	27	20	who	who	PRON
chd-130	27	21	are	be	AUX
chd-130	27	22	typically	typically	ADV
chd-130	27	23	in	in	ADP
chd-130	27	24	the	the	DET
chd-130	27	25	5th	5th	ADJ
chd-130	27	26	and	and	CCONJ
chd-130	27	27	6th	6th	ADJ
chd-130	27	28	decade	decade	NOUN
chd-130	27	29	of	of	ADP
chd-130	27	30	their	their	PRON
chd-130	27	31	age	age	NOUN
chd-130	27	32	at	at	ADP
chd-130	27	33	the	the	DET
chd-130	27	34	time	time	NOUN
chd-130	27	35	of	of	ADP
chd-130	27	36	presentation	presentation	NOUN
chd-130	27	37	with	with	ADP
chd-130	27	38	this	this	DET
chd-130	27	39	disease	disease	NOUN
chd-130	27	40	.	.	PUNCT
chd-130	28	1	it	it	PRON
chd-130	28	2	is	be	AUX
chd-130	28	3	important	important	ADJ
chd-130	28	4	to	to	PART
chd-130	28	5	note	note	VERB
chd-130	28	6	that	that	SCONJ
chd-130	28	7	in	in	ADP
chd-130	28	8	india	india	PROPN
chd-130	28	9	,	,	PUNCT
chd-130	28	10	almost	almost	ADV
chd-130	28	11	80	80	NUM
chd-130	28	12	%	%	NOUN
chd-130	28	13	patients	patient	NOUN
chd-130	28	14	with	with	ADP
chd-130	28	15	gbc	gbc	PROPN
chd-130	28	16	do	do	AUX
chd-130	28	17	also	also	ADV
chd-130	28	18	have	have	VERB
chd-130	28	19	gallstones	gallstone	NOUN
chd-130	28	20	and	and	CCONJ
chd-130	28	21	its	its	PRON
chd-130	28	22	presence	presence	NOUN
chd-130	28	23	increases	increase	VERB
chd-130	28	24	the	the	DET
chd-130	28	25	vulnerability	vulnerability	NOUN
chd-130	28	26	of	of	ADP
chd-130	28	27	the	the	DET
chd-130	28	28	gb	gb	NOUN
chd-130	28	29	to	to	ADP
chd-130	28	30	mucosal	mucosal	ADJ
chd-130	28	31	injury	injury	NOUN
chd-130	28	32	.	.	PUNCT
chd-130	29	1	the	the	DET
chd-130	29	2	incidence	incidence	NOUN
chd-130	29	3	of	of	ADP
chd-130	29	4	gbc	gbc	PROPN
chd-130	29	5	is	be	AUX
chd-130	29	6	out	out	ADP
chd-130	29	7	of	of	ADP
chd-130	29	8	proportion	proportion	NOUN
chd-130	29	9	to	to	ADP
chd-130	29	10	the	the	DET
chd-130	29	11	prevalence	prevalence	NOUN
chd-130	29	12	of	of	ADP
chd-130	29	13	gallstones	gallstone	NOUN
chd-130	29	14	in	in	ADP
chd-130	29	15	india	india	PROPN
chd-130	29	16	.	.	PUNCT
chd-130	30	1	on	on	ADP
chd-130	30	2	the	the	DET
chd-130	30	3	other	other	ADJ
chd-130	30	4	hand	hand	NOUN
chd-130	30	5	,	,	PUNCT
chd-130	30	6	in	in	ADP
chd-130	30	7	the	the	DET
chd-130	30	8	united	united	PROPN
chd-130	30	9	states	states	PROPN
chd-130	30	10	,	,	PUNCT
chd-130	30	11	it	it	PRON
chd-130	30	12	is	be	AUX
chd-130	30	13	one	one	NUM
chd-130	30	14	of	of	ADP
chd-130	30	15	the	the	DET
chd-130	30	16	few	few	ADJ
chd-130	30	17	cancers	cancer	NOUN
chd-130	30	18	that	that	PRON
chd-130	30	19	has	have	VERB
chd-130	30	20	a	a	DET
chd-130	30	21	low	low	ADJ
chd-130	30	22	incidence	incidence	NOUN
chd-130	30	23	in	in	ADP
chd-130	30	24	the	the	DET
chd-130	30	25	african	african	ADJ
chd-130	30	26	americans	americans	PROPN
chd-130	30	27	while	while	SCONJ
chd-130	30	28	the	the	DET
chd-130	30	29	disease	disease	NOUN
chd-130	30	30	has	have	VERB
chd-130	30	31	the	the	DET
chd-130	30	32	highest	high	ADJ
chd-130	30	33	incidence	incidence	NOUN
chd-130	30	34	rates	rate	NOUN
chd-130	30	35	in	in	ADP
chd-130	30	36	hispanics	hispanic	NOUN
chd-130	30	37	,	,	PUNCT
chd-130	30	38	alaskan	alaskan	ADJ
chd-130	30	39	native	native	ADJ
chd-130	30	40	(	(	PUNCT
chd-130	30	41	an	an	NOUN
chd-130	30	42	)	)	PUNCT
chd-130	30	43	and	and	CCONJ
chd-130	30	44	american	american	ADJ
chd-130	30	45	indians	indians	PROPN
chd-130	30	46	(	(	PUNCT
chd-130	30	47	ai	ai	VERB
chd-130	30	48	)	)	PUNCT
chd-130	30	49	and	and	CCONJ
chd-130	30	50	association	association	NOUN
chd-130	30	51	of	of	ADP
chd-130	30	52	gallstones	gallstone	NOUN
chd-130	30	53	with	with	ADP
chd-130	30	54	gbc	gbc	PROPN
chd-130	30	55	is	be	AUX
chd-130	30	56	not	not	PART
chd-130	30	57	so	so	ADV
chd-130	30	58	much	much	ADV
chd-130	30	59	common	common	ADJ
chd-130	30	60	as	as	SCONJ
chd-130	30	61	compared	compare	VERB
chd-130	30	62	to	to	ADP
chd-130	30	63	india	india	PROPN
chd-130	30	64	(	(	PUNCT
chd-130	30	65	henley	henley	PROPN
chd-130	30	66	et	et	PROPN
chd-130	30	67	al	al	PROPN
chd-130	30	68	.	.	PROPN
chd-130	30	69	,	,	PUNCT
chd-130	30	70	2015	2015	NUM
chd-130	30	71	)	)	PUNCT
chd-130	30	72	.	.	PUNCT
chd-130	31	1	often	often	ADV
chd-130	31	2	,	,	PUNCT
chd-130	31	3	patients	patient	NOUN
chd-130	31	4	with	with	ADP
chd-130	31	5	gbc	gbc	PROPN
chd-130	31	6	present	present	ADJ
chd-130	31	7	with	with	ADP
chd-130	31	8	severe	severe	ADJ
chd-130	31	9	,	,	PUNCT
chd-130	31	10	persistent	persistent	ADJ
chd-130	31	11	abdominal	abdominal	ADJ
chd-130	31	12	pain	pain	NOUN
chd-130	31	13	that	that	PRON
chd-130	31	14	can	can	AUX
chd-130	31	15	be	be	AUX
chd-130	31	16	diffuse	diffuse	ADJ
chd-130	31	17	or	or	CCONJ
chd-130	31	18	localized	localize	VERB
chd-130	31	19	to	to	ADP
chd-130	31	20	the	the	DET
chd-130	31	21	right	right	ADJ
chd-130	31	22	upper	upper	ADJ
chd-130	31	23	quadrant	quadrant	NOUN
chd-130	31	24	.	.	PUNCT
chd-130	32	1	more	more	ADV
chd-130	32	2	often	often	ADV
chd-130	32	3	than	than	ADP
chd-130	32	4	not	not	PART
chd-130	32	5	,	,	PUNCT
chd-130	32	6	however	however	ADV
chd-130	32	7	,	,	PUNCT
chd-130	32	8	the	the	DET
chd-130	32	9	disease	disease	NOUN
chd-130	32	10	is	be	AUX
chd-130	32	11	“	"	PUNCT
chd-130	32	12	masked	masked	ADJ
chd-130	32	13	”	"	PUNCT
chd-130	32	14	thereby	thereby	ADV
chd-130	32	15	presenting	present	VERB
chd-130	32	16	with	with	ADP
chd-130	32	17	no	no	DET
chd-130	32	18	clinical	clinical	ADJ
chd-130	32	19	symptoms	symptom	NOUN
chd-130	32	20	and	and	CCONJ
chd-130	32	21	as	as	ADP
chd-130	32	22	aforementioned	aforementione	VERB
chd-130	32	23	,	,	PUNCT
chd-130	32	24	detected	detect	VERB
chd-130	32	25	incidentally	incidentally	ADV
chd-130	32	26	on	on	ADP
chd-130	32	27	surgery	surgery	NOUN
chd-130	32	28	for	for	ADP
chd-130	32	29	gallstone	gallstone	NOUN
chd-130	32	30	disease	disease	NOUN
chd-130	32	31	.	.	PUNCT
chd-130	33	1	patients	patient	NOUN
chd-130	33	2	may	may	AUX
chd-130	33	3	also	also	ADV
chd-130	33	4	present	present	VERB
chd-130	33	5	with	with	ADP
chd-130	33	6	complaints	complaint	NOUN
chd-130	33	7	of	of	ADP
chd-130	33	8	weight	weight	NOUN
chd-130	33	9	loss	loss	NOUN
chd-130	33	10	and	and	CCONJ
chd-130	33	11	anorexia	anorexia	DET
chd-130	33	12	a	a	DET
chd-130	33	13	sign	sign	NOUN
chd-130	33	14	of	of	ADP
chd-130	33	15	late	late	ADJ
chd-130	33	16	stage	stage	NOUN
chd-130	33	17	disease	disease	NOUN
chd-130	33	18	.	.	PUNCT
chd-130	34	1	on	on	ADP
chd-130	34	2	examination	examination	NOUN
chd-130	34	3	,	,	PUNCT
chd-130	34	4	they	they	PRON
chd-130	34	5	may	may	AUX
chd-130	34	6	present	present	VERB
chd-130	34	7	with	with	ADP
chd-130	34	8	jaundice	jaundice	NOUN
chd-130	34	9	,	,	PUNCT
chd-130	34	10	abdominal	abdominal	ADJ
chd-130	34	11	pain	pain	NOUN
chd-130	34	12	in	in	ADP
chd-130	34	13	the	the	DET
chd-130	34	14	right	right	ADJ
chd-130	34	15	upper	upper	ADJ
chd-130	34	16	quadrant	quadrant	NOUN
chd-130	34	17	with	with	ADP
chd-130	34	18	or	or	CCONJ
chd-130	34	19	without	without	ADP
chd-130	34	20	associated	associated	ADJ
chd-130	34	21	tenderness	tenderness	NOUN
chd-130	34	22	.	.	PUNCT
chd-130	35	1	a	a	DET
chd-130	35	2	non	non	ADJ
chd-130	35	3	-	-	ADJ
chd-130	35	4	tender	tender	ADJ
chd-130	35	5	palpable	palpable	ADJ
chd-130	35	6	mass	mass	NOUN
chd-130	35	7	in	in	ADP
chd-130	35	8	the	the	DET
chd-130	35	9	same	same	ADJ
chd-130	35	10	region	region	NOUN
chd-130	35	11	(	(	PUNCT
chd-130	35	12	a	a	DET
chd-130	35	13	tenderness	tenderness	NOUN
chd-130	35	14	is	be	AUX
chd-130	35	15	more	more	ADV
chd-130	35	16	indicative	indicative	ADJ
chd-130	35	17	of	of	ADP
chd-130	35	18	gallstone	gallstone	NOUN
chd-130	35	19	disease	disease	NOUN
chd-130	35	20	)	)	PUNCT
chd-130	35	21	,	,	PUNCT
chd-130	35	22	periumbilical	periumbilical	ADJ
chd-130	35	23	lymphadenopathy	lymphadenopathy	ADJ
chd-130	35	24	,	,	PUNCT
chd-130	35	25	and	and	CCONJ
chd-130	35	26	palpable	palpable	ADJ
chd-130	35	27	left	leave	VERB
chd-130	35	28	supraclavicular	supraclavicular	ADJ
chd-130	35	29	lymph	lymph	NOUN
chd-130	35	30	nodes	node	NOUN
chd-130	35	31	are	be	AUX
chd-130	35	32	also	also	ADV
chd-130	35	33	found	find	VERB
chd-130	35	34	to	to	PART
chd-130	35	35	be	be	AUX
chd-130	35	36	associated	associate	VERB
chd-130	35	37	with	with	ADP
chd-130	35	38	advanced	advanced	ADJ
chd-130	35	39	gbc	gbc	PROPN
chd-130	35	40	.	.	PUNCT
chd-130	36	1	nausea	nausea	NOUN
chd-130	36	2	,	,	PUNCT
chd-130	36	3	vomiting	vomiting	NOUN
chd-130	36	4	and	and	CCONJ
chd-130	36	5	abdominal	abdominal	ADJ
chd-130	36	6	bloating	bloating	NOUN
chd-130	36	7	are	be	AUX
chd-130	36	8	some	some	PRON
chd-130	36	9	of	of	ADP
chd-130	36	10	the	the	DET
chd-130	36	11	other	other	ADJ
chd-130	36	12	vague	vague	ADJ
chd-130	36	13	accompanying	accompany	VERB
chd-130	36	14	symptoms	symptom	NOUN
chd-130	36	15	.	.	PUNCT
chd-130	37	1	prior	prior	ADV
chd-130	37	2	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-130	37	3	e3	e3	NOUN
chd-130	37	4	cancer	cancer	NOUN
chd-130	37	5	health	health	NOUN
chd-130	37	6	disparities	disparity	NOUN
chd-130	37	7	research	research	VERB
chd-130	37	8	to	to	ADP
chd-130	37	9	the	the	DET
chd-130	37	10	advent	advent	NOUN
chd-130	37	11	of	of	ADP
chd-130	37	12	radiographic	radiographic	ADJ
chd-130	37	13	techniques	technique	NOUN
chd-130	37	14	in	in	ADP
chd-130	37	15	diagnosing	diagnose	VERB
chd-130	37	16	gbc	gbc	PROPN
chd-130	37	17	,	,	PUNCT
chd-130	37	18	the	the	DET
chd-130	37	19	preoperative	preoperative	ADJ
chd-130	37	20	rate	rate	NOUN
chd-130	37	21	for	for	ADP
chd-130	37	22	detecting	detect	VERB
chd-130	37	23	the	the	DET
chd-130	37	24	disease	disease	NOUN
chd-130	37	25	was	be	AUX
chd-130	37	26	10	10	NUM
chd-130	37	27	-	-	SYM
chd-130	37	28	15	15	NUM
chd-130	37	29	%	%	NOUN
chd-130	37	30	.	.	PUNCT
chd-130	38	1	use	use	NOUN
chd-130	38	2	of	of	ADP
chd-130	38	3	abdominal	abdominal	ADJ
chd-130	38	4	ultrasound	ultrasound	NOUN
chd-130	38	5	and	and	CCONJ
chd-130	38	6	cross	cross	VERB
chd-130	38	7	sectional	sectional	ADJ
chd-130	38	8	imaging	imaging	NOUN
chd-130	38	9	with	with	ADP
chd-130	38	10	ct	ct	PROPN
chd-130	38	11	/	/	SYM
chd-130	38	12	mri	mri	NOUN
chd-130	38	13	,	,	PUNCT
chd-130	38	14	have	have	AUX
chd-130	38	15	become	become	VERB
chd-130	38	16	the	the	DET
chd-130	38	17	mainstay	mainstay	ADJ
chd-130	38	18	diagnostic	diagnostic	ADJ
chd-130	38	19	tools	tool	NOUN
chd-130	38	20	for	for	ADP
chd-130	38	21	detecting	detect	VERB
chd-130	38	22	gbc	gbc	PROPN
chd-130	38	23	.	.	PUNCT
chd-130	38	24	endoscopic	endoscopic	ADJ
chd-130	38	25	ultrasound	ultrasound	NOUN
chd-130	38	26	(	(	PUNCT
chd-130	38	27	eus	eus	PROPN
chd-130	38	28	)	)	PUNCT
chd-130	38	29	may	may	AUX
chd-130	38	30	also	also	ADV
chd-130	38	31	be	be	AUX
chd-130	38	32	employed	employ	VERB
chd-130	38	33	in	in	ADP
chd-130	38	34	detecting	detect	VERB
chd-130	38	35	pre	pre	ADJ
chd-130	38	36	-	-	ADJ
chd-130	38	37	cancerous	cancerous	ADJ
chd-130	38	38	lesions	lesion	NOUN
chd-130	38	39	.	.	PUNCT
chd-130	39	1	gallbladder	gallbladder	NOUN
chd-130	39	2	polyps	polyp	NOUN
chd-130	39	3	≥2	≥2	PRON
chd-130	39	4	cm	cm	NOUN
chd-130	39	5	in	in	ADP
chd-130	39	6	size	size	NOUN
chd-130	39	7	,	,	PUNCT
chd-130	39	8	or	or	CCONJ
chd-130	39	9	a	a	DET
chd-130	39	10	calcified	calcified	ADJ
chd-130	39	11	rim	rim	NOUN
chd-130	39	12	of	of	ADP
chd-130	39	13	the	the	DET
chd-130	39	14	gallbladder	gallbladder	NOUN
chd-130	39	15	termed	term	VERB
chd-130	39	16	“	"	PUNCT
chd-130	39	17	porcelain	porcelain	NOUN
chd-130	39	18	gallbladder	gallbladder	NOUN
chd-130	39	19	”	"	PUNCT
chd-130	39	20	are	be	AUX
chd-130	39	21	indications	indication	NOUN
chd-130	39	22	for	for	ADP
chd-130	39	23	surgical	surgical	ADJ
chd-130	39	24	resection	resection	NOUN
chd-130	39	25	as	as	SCONJ
chd-130	39	26	these	these	PRON
chd-130	39	27	are	be	AUX
chd-130	39	28	pre	pre	ADJ
chd-130	39	29	-	-	ADJ
chd-130	39	30	malignant	malignant	ADJ
chd-130	39	31	conditions	condition	NOUN
chd-130	39	32	.	.	PUNCT
chd-130	40	1	however	however	ADV
chd-130	40	2	,	,	PUNCT
chd-130	40	3	it	it	PRON
chd-130	40	4	is	be	AUX
chd-130	40	5	important	important	ADJ
chd-130	40	6	to	to	PART
chd-130	40	7	note	note	VERB
chd-130	40	8	that	that	SCONJ
chd-130	40	9	porcelain	porcelain	NOUN
chd-130	40	10	gallbladder	gallbladder	NOUN
chd-130	40	11	is	be	AUX
chd-130	40	12	no	no	ADV
chd-130	40	13	longer	long	ADV
chd-130	40	14	thought	think	VERB
chd-130	40	15	to	to	PART
chd-130	40	16	be	be	AUX
chd-130	40	17	as	as	ADV
chd-130	40	18	strongly	strongly	ADV
chd-130	40	19	associated	associate	VERB
chd-130	40	20	with	with	ADP
chd-130	40	21	gbc	gbc	NOUN
chd-130	40	22	as	as	SCONJ
chd-130	40	23	previously	previously	ADV
chd-130	40	24	reported	report	VERB
chd-130	40	25	,	,	PUNCT
chd-130	40	26	but	but	CCONJ
chd-130	40	27	this	this	DET
chd-130	40	28	belief	belief	NOUN
chd-130	40	29	continues	continue	VERB
chd-130	40	30	to	to	PART
chd-130	40	31	be	be	AUX
chd-130	40	32	propagated	propagate	VERB
chd-130	40	33	as	as	ADP
chd-130	40	34	dogma	dogma	NOUN
chd-130	40	35	in	in	ADP
chd-130	40	36	the	the	DET
chd-130	40	37	medical	medical	ADJ
chd-130	40	38	literature	literature	NOUN
chd-130	40	39	and	and	CCONJ
chd-130	40	40	textbooks	textbook	NOUN
chd-130	40	41	.	.	PUNCT
chd-130	41	1	several	several	ADJ
chd-130	41	2	large	large	ADJ
chd-130	41	3	studies	study	NOUN
chd-130	41	4	from	from	ADP
chd-130	41	5	the	the	DET
chd-130	41	6	united	united	PROPN
chd-130	41	7	states	states	PROPN
chd-130	41	8	(	(	PUNCT
chd-130	41	9	articles	article	NOUN
chd-130	41	10	attached	attach	VERB
chd-130	41	11	)	)	PUNCT
chd-130	41	12	have	have	AUX
chd-130	41	13	shown	show	VERB
chd-130	41	14	little	little	ADJ
chd-130	41	15	to	to	ADP
chd-130	41	16	no	no	DET
chd-130	41	17	association	association	NOUN
chd-130	41	18	between	between	ADP
chd-130	41	19	porcelain	porcelain	NOUN
chd-130	41	20	gallbladder	gallbladder	NOUN
chd-130	41	21	and	and	CCONJ
chd-130	41	22	gbc	gbc	PROPN
chd-130	41	23	(	(	PUNCT
chd-130	41	24	stephen	stephen	NOUN
chd-130	41	25	and	and	CCONJ
chd-130	41	26	berger	berger	PROPN
chd-130	41	27	,	,	PUNCT
chd-130	41	28	2001	2001	NUM
chd-130	41	29	;	;	PUNCT
chd-130	41	30	khan	khan	PROPN
chd-130	41	31	et	et	PROPN
chd-130	41	32	al	al	PROPN
chd-130	41	33	.	.	PROPN
chd-130	41	34	,	,	PUNCT
chd-130	41	35	2011	2011	NUM
chd-130	41	36	)	)	PUNCT
chd-130	41	37	.	.	PUNCT
chd-130	42	1	however	however	ADV
chd-130	42	2	,	,	PUNCT
chd-130	42	3	it	it	PRON
chd-130	42	4	is	be	AUX
chd-130	42	5	important	important	ADJ
chd-130	42	6	to	to	PART
chd-130	42	7	note	note	VERB
chd-130	42	8	that	that	SCONJ
chd-130	42	9	the	the	DET
chd-130	42	10	population	population	NOUN
chd-130	42	11	in	in	ADP
chd-130	42	12	the	the	DET
chd-130	42	13	united	united	PROPN
chd-130	42	14	states	states	PROPN
chd-130	42	15	is	be	AUX
chd-130	42	16	very	very	ADV
chd-130	42	17	different	different	ADJ
chd-130	42	18	from	from	ADP
chd-130	42	19	that	that	PRON
chd-130	42	20	of	of	ADP
chd-130	42	21	the	the	DET
chd-130	42	22	previous	previous	ADJ
chd-130	42	23	studies	study	NOUN
chd-130	42	24	from	from	ADP
chd-130	42	25	other	other	ADJ
chd-130	42	26	countries	country	NOUN
chd-130	42	27	which	which	PRON
chd-130	42	28	likely	likely	ADV
chd-130	42	29	included	include	VERB
chd-130	42	30	a	a	DET
chd-130	42	31	large	large	ADJ
chd-130	42	32	demographic	demographic	ADJ
chd-130	42	33	of	of	ADP
chd-130	42	34	amerindians	amerindian	NOUN
chd-130	42	35	and	and	CCONJ
chd-130	42	36	reported	report	VERB
chd-130	42	37	a	a	DET
chd-130	42	38	very	very	ADV
chd-130	42	39	high	high	ADJ
chd-130	42	40	incident	incident	NOUN
chd-130	42	41	of	of	ADP
chd-130	42	42	gbc	gbc	PROPN
chd-130	42	43	in	in	ADP
chd-130	42	44	patients	patient	NOUN
chd-130	42	45	with	with	ADP
chd-130	42	46	porcelain	porcelain	NOUN
chd-130	42	47	gallbladder	gallbladder	NOUN
chd-130	42	48	.	.	PUNCT
chd-130	43	1	geographical	geographical	ADJ
chd-130	43	2	variability	variability	NOUN
chd-130	43	3	in	in	ADP
chd-130	43	4	the	the	DET
chd-130	43	5	incidence	incidence	NOUN
chd-130	43	6	of	of	ADP
chd-130	43	7	gbc	gbc	PROPN
chd-130	43	8	is	be	AUX
chd-130	43	9	often	often	ADV
chd-130	43	10	found	find	VERB
chd-130	43	11	to	to	PART
chd-130	43	12	be	be	AUX
chd-130	43	13	associated	associate	VERB
chd-130	43	14	with	with	ADP
chd-130	43	15	the	the	DET
chd-130	43	16	prevalence	prevalence	NOUN
chd-130	43	17	of	of	ADP
chd-130	43	18	gallstone	gallstone	NOUN
chd-130	43	19	disease	disease	NOUN
chd-130	43	20	in	in	ADP
chd-130	43	21	the	the	DET
chd-130	43	22	same	same	ADJ
chd-130	43	23	population	population	NOUN
chd-130	43	24	.	.	PUNCT
chd-130	44	1	however	however	ADV
chd-130	44	2	,	,	PUNCT
chd-130	44	3	the	the	DET
chd-130	44	4	presence	presence	NOUN
chd-130	44	5	of	of	ADP
chd-130	44	6	gallstones	gallstone	NOUN
chd-130	44	7	alone	alone	ADV
chd-130	44	8	does	do	AUX
chd-130	44	9	not	not	PART
chd-130	44	10	appear	appear	VERB
chd-130	44	11	to	to	PART
chd-130	44	12	cause	cause	VERB
chd-130	44	13	cancer	cancer	NOUN
chd-130	44	14	in	in	ADP
chd-130	44	15	the	the	DET
chd-130	44	16	gallbladder	gallbladder	NOUN
chd-130	44	17	,	,	PUNCT
chd-130	44	18	as	as	SCONJ
chd-130	44	19	populations	population	NOUN
chd-130	44	20	that	that	PRON
chd-130	44	21	have	have	VERB
chd-130	44	22	high	high	ADJ
chd-130	44	23	incidence	incidence	NOUN
chd-130	44	24	of	of	ADP
chd-130	44	25	gallstones	gallstone	NOUN
chd-130	44	26	do	do	AUX
chd-130	44	27	not	not	PART
chd-130	44	28	necessarily	necessarily	ADV
chd-130	44	29	have	have	VERB
chd-130	44	30	high	high	ADJ
chd-130	44	31	incidence	incidence	NOUN
chd-130	44	32	of	of	ADP
chd-130	44	33	gbc	gbc	PROPN
chd-130	44	34	.	.	PUNCT
chd-130	45	1	chronic	chronic	ADJ
chd-130	45	2	infection	infection	NOUN
chd-130	45	3	with	with	ADP
chd-130	45	4	salmonella	salmonella	NOUN
chd-130	45	5	typhi	typhi	NOUN
chd-130	45	6	is	be	AUX
chd-130	45	7	another	another	DET
chd-130	45	8	recognized	recognize	VERB
chd-130	45	9	risk	risk	NOUN
chd-130	45	10	factor	factor	NOUN
chd-130	45	11	for	for	ADP
chd-130	45	12	gbc	gbc	PROPN
chd-130	45	13	(	(	PUNCT
chd-130	45	14	singh	singh	PROPN
chd-130	45	15	et	et	PROPN
chd-130	45	16	al	al	PROPN
chd-130	45	17	.	.	PROPN
chd-130	45	18	,	,	PUNCT
chd-130	45	19	2004b	2004b	NUM
chd-130	45	20	)	)	PUNCT
chd-130	45	21	.	.	PUNCT
chd-130	46	1	a	a	DET
chd-130	46	2	research	research	NOUN
chd-130	46	3	group	group	NOUN
chd-130	46	4	from	from	ADP
chd-130	46	5	varanasi	varanasi	PROPN
chd-130	46	6	,	,	PUNCT
chd-130	46	7	india	india	PROPN
chd-130	46	8	,	,	PUNCT
chd-130	46	9	in	in	ADP
chd-130	46	10	particular	particular	ADJ
chd-130	46	11	,	,	PUNCT
chd-130	46	12	has	have	AUX
chd-130	46	13	not	not	PART
chd-130	46	14	only	only	ADV
chd-130	46	15	shown	show	VERB
chd-130	46	16	the	the	DET
chd-130	46	17	association	association	NOUN
chd-130	46	18	of	of	ADP
chd-130	46	19	chronic	chronic	ADJ
chd-130	46	20	infection	infection	NOUN
chd-130	46	21	with	with	ADP
chd-130	46	22	gallbladder	gallbladder	NOUN
chd-130	46	23	cancer	cancer	NOUN
chd-130	46	24	but	but	CCONJ
chd-130	46	25	also	also	ADV
chd-130	46	26	has	have	AUX
chd-130	46	27	demonstrated	demonstrate	VERB
chd-130	46	28	underlying	underlying	ADJ
chd-130	46	29	mechanism	mechanism	NOUN
chd-130	46	30	as	as	ADP
chd-130	46	31	to	to	ADP
chd-130	46	32	how	how	SCONJ
chd-130	46	33	infection	infection	NOUN
chd-130	46	34	of	of	ADP
chd-130	46	35	salmonella	salmonella	NOUN
chd-130	46	36	species	specie	NOUN
chd-130	46	37	can	can	AUX
chd-130	46	38	help	help	VERB
chd-130	46	39	promote	promote	VERB
chd-130	46	40	transformation	transformation	NOUN
chd-130	46	41	of	of	ADP
chd-130	46	42	normal	normal	ADJ
chd-130	46	43	gallbladder	gallbladder	NOUN
chd-130	46	44	cells	cell	NOUN
chd-130	46	45	(	(	PUNCT
chd-130	46	46	sharma	sharma	PROPN
chd-130	46	47	et	et	PROPN
chd-130	46	48	al	al	PROPN
chd-130	46	49	.	.	PROPN
chd-130	46	50	,	,	PUNCT
chd-130	46	51	2007	2007	NUM
chd-130	46	52	;	;	PUNCT
chd-130	46	53	scanu	scanu	PROPN
chd-130	46	54	et	et	NOUN
chd-130	46	55	a.	a.	NOUN
chd-130	46	56	,	,	PUNCT
chd-130	46	57	2015	2015	NUM
chd-130	46	58	)	)	PUNCT
chd-130	46	59	.	.	PUNCT
chd-130	47	1	additionally	additionally	ADV
chd-130	47	2	,	,	PUNCT
chd-130	47	3	socioeconomic	socioeconomic	ADJ
chd-130	47	4	status	status	NOUN
chd-130	47	5	and	and	CCONJ
chd-130	47	6	genetic	genetic	ADJ
chd-130	47	7	elements	element	NOUN
chd-130	47	8	that	that	PRON
chd-130	47	9	impede	impede	VERB
chd-130	47	10	access	access	NOUN
chd-130	47	11	to	to	ADP
chd-130	47	12	early	early	ADJ
chd-130	47	13	detection	detection	NOUN
chd-130	47	14	and	and	CCONJ
chd-130	47	15	surgical	surgical	ADJ
chd-130	47	16	procedures	procedure	NOUN
chd-130	47	17	such	such	ADJ
chd-130	47	18	as	as	ADP
chd-130	47	19	cholecystectomy	cholecystectomy	NOUN
chd-130	47	20	are	be	AUX
chd-130	47	21	thought	think	VERB
chd-130	47	22	to	to	PART
chd-130	47	23	be	be	AUX
chd-130	47	24	contributory	contributory	ADJ
chd-130	47	25	to	to	ADP
chd-130	47	26	poor	poor	ADJ
chd-130	47	27	outcome	outcome	NOUN
chd-130	47	28	.	.	PUNCT
chd-130	48	1	in	in	ADP
chd-130	48	2	addition	addition	NOUN
chd-130	48	3	to	to	ADP
chd-130	48	4	varied	varied	ADJ
chd-130	48	5	geographical	geographical	ADJ
chd-130	48	6	incidences	incidence	NOUN
chd-130	48	7	,	,	PUNCT
chd-130	48	8	some	some	DET
chd-130	48	9	other	other	ADJ
chd-130	48	10	factors	factor	NOUN
chd-130	48	11	such	such	ADJ
chd-130	48	12	as	as	ADP
chd-130	48	13	the	the	DET
chd-130	48	14	differences	difference	NOUN
chd-130	48	15	in	in	ADP
chd-130	48	16	age	age	NOUN
chd-130	48	17	,	,	PUNCT
chd-130	48	18	race	race	NOUN
chd-130	48	19	and	and	CCONJ
chd-130	48	20	sex	sex	NOUN
chd-130	48	21	also	also	ADV
chd-130	48	22	contribute	contribute	VERB
chd-130	48	23	to	to	ADP
chd-130	48	24	the	the	DET
chd-130	48	25	occurrence	occurrence	NOUN
chd-130	48	26	of	of	ADP
chd-130	48	27	the	the	DET
chd-130	48	28	disease	disease	NOUN
chd-130	48	29	.	.	PUNCT
chd-130	49	1	figure	figure	NOUN
chd-130	49	2	1	1	NUM
chd-130	49	3	briefly	briefly	NOUN
chd-130	49	4	describes	describe	VERB
chd-130	49	5	some	some	DET
chd-130	49	6	characteristic	characteristic	ADJ
chd-130	49	7	features	feature	NOUN
chd-130	49	8	of	of	ADP
chd-130	49	9	gbc	gbc	PROPN
chd-130	49	10	.	.	PUNCT
chd-130	50	1	figure	figure	NOUN
chd-130	50	2	1	1	NUM
chd-130	50	3	:	:	PUNCT
chd-130	50	4	gallbladder	gallbladder	NOUN
chd-130	50	5	cancer	cancer	NOUN
chd-130	50	6	:	:	PUNCT
chd-130	50	7	basic	basic	ADJ
chd-130	50	8	features	feature	NOUN
chd-130	50	9	,	,	PUNCT
chd-130	50	10	risk	risk	NOUN
chd-130	50	11	factors	factor	NOUN
chd-130	50	12	,	,	PUNCT
chd-130	50	13	and	and	CCONJ
chd-130	50	14	therapeutic	therapeutic	ADJ
chd-130	50	15	options	option	NOUN
chd-130	50	16	.	.	PUNCT
chd-130	51	1	•	•	NUM
chd-130	51	2	risk	risk	NOUN
chd-130	51	3	factor	factor	NOUN
chd-130	51	4	:	:	PUNCT
chd-130	51	5	gallstones	gallstone	NOUN
chd-130	51	6	,	,	PUNCT
chd-130	51	7	gallbladder	gallbladder	NOUN
chd-130	51	8	polyps	polyp	NOUN
chd-130	51	9	,	,	PUNCT
chd-130	51	10	chronic	chronic	ADJ
chd-130	51	11	cholecystitis	cholecystitis	NOUN
chd-130	51	12	,	,	PUNCT
chd-130	51	13	chronic	chronic	ADJ
chd-130	51	14	typhoid	typhoid	NOUN
chd-130	51	15	carrier	carrier	NOUN
chd-130	51	16	state	state	NOUN
chd-130	51	17	,	,	PUNCT
chd-130	51	18	obesity	obesity	NOUN
chd-130	51	19	,	,	PUNCT
chd-130	51	20	diabetes	diabetes	NOUN
chd-130	51	21	•	•	NUM
chd-130	51	22	females	female	NOUN
chd-130	51	23	are	be	AUX
chd-130	51	24	at	at	ADP
chd-130	51	25	more	more	ADV
chd-130	51	26	at	at	ADP
chd-130	51	27	risk	risk	NOUN
chd-130	51	28	than	than	SCONJ
chd-130	51	29	their	their	PRON
chd-130	51	30	male	male	ADJ
chd-130	51	31	counterparts	counterpart	NOUN
chd-130	51	32	•	•	NOUN
chd-130	51	33	typically	typically	ADV
chd-130	51	34	presents	present	VERB
chd-130	51	35	as	as	ADP
chd-130	51	36	an	an	DET
chd-130	51	37	incidental	incidental	ADJ
chd-130	51	38	finding	finding	NOUN
chd-130	51	39	following	follow	VERB
chd-130	51	40	cholecystectomy	cholecystectomy	NOUN
chd-130	51	41	(	(	PUNCT
chd-130	51	42	localized	localized	ADJ
chd-130	51	43	stage	stage	NOUN
chd-130	51	44	)	)	PUNCT
chd-130	51	45	or	or	CCONJ
chd-130	51	46	with	with	ADP
chd-130	51	47	abdominal	abdominal	ADJ
chd-130	51	48	pain	pain	NOUN
chd-130	51	49	(	(	PUNCT
chd-130	51	50	advanced	advanced	ADJ
chd-130	51	51	stage	stage	NOUN
chd-130	51	52	)	)	PUNCT
chd-130	51	53	•	•	NUM
chd-130	51	54	majority	majority	NOUN
chd-130	51	55	of	of	ADP
chd-130	51	56	them	they	PRON
chd-130	51	57	are	be	AUX
chd-130	51	58	adenocarcinoma	adenocarcinoma	ADJ
chd-130	51	59	•	•	NOUN
chd-130	51	60	level	level	NOUN
chd-130	51	61	1	1	NUM
chd-130	51	62	evidence	evidence	NOUN
chd-130	51	63	for	for	ADP
chd-130	51	64	adjuvant	adjuvant	ADJ
chd-130	51	65	chemotherapy	chemotherapy	NOUN
chd-130	51	66	:	:	PUNCT
chd-130	51	67	capecitabine	capecitabine	VERB
chd-130	51	68	•	•	ADP
chd-130	51	69	palliative	palliative	ADJ
chd-130	51	70	1st	1st	ADJ
chd-130	51	71	line	line	NOUN
chd-130	51	72	chemotherapy	chemotherapy	NOUN
chd-130	51	73	:	:	PUNCT
chd-130	51	74	gemcitabine	gemcitabine	NOUN
chd-130	51	75	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	CCONJ
chd-130	51	76	e4	e4	PROPN
chd-130	51	77	cancer	cancer	NOUN
chd-130	51	78	health	health	NOUN
chd-130	51	79	disparities	disparity	NOUN
chd-130	51	80	research	research	VERB
chd-130	51	81	•	•	NOUN
chd-130	51	82	no	no	DET
chd-130	51	83	2nd	2nd	ADJ
chd-130	51	84	line	line	NOUN
chd-130	51	85	palliative	palliative	ADJ
chd-130	51	86	chemotherapy	chemotherapy	NOUN
chd-130	51	87	with	with	ADP
chd-130	51	88	a	a	DET
chd-130	51	89	demonstrated	demonstrate	VERB
chd-130	51	90	survival	survival	NOUN
chd-130	51	91	benefit	benefit	NOUN
chd-130	51	92	over	over	ADP
chd-130	51	93	active	active	ADJ
chd-130	51	94	symptom	symptom	NOUN
chd-130	51	95	control	control	NOUN
chd-130	51	96	•	•	ADJ
chd-130	51	97	median	median	ADJ
chd-130	51	98	overall	overall	ADJ
chd-130	51	99	survival	survival	NOUN
chd-130	51	100	:	:	PUNCT
chd-130	51	101	~12	~12	NUM
chd-130	51	102	months	month	NOUN
chd-130	51	103	molecular	molecular	ADJ
chd-130	51	104	pathogenesis	pathogenesis	NOUN
chd-130	51	105	late	late	ADJ
chd-130	51	106	70s	70	NOUN
chd-130	51	107	and	and	CCONJ
chd-130	51	108	early	early	ADJ
chd-130	51	109	80s	80	NOUN
chd-130	51	110	was	be	AUX
chd-130	51	111	an	an	DET
chd-130	51	112	exciting	exciting	ADJ
chd-130	51	113	time	time	NOUN
chd-130	51	114	in	in	ADP
chd-130	51	115	biomedical	biomedical	ADJ
chd-130	51	116	research	research	NOUN
chd-130	51	117	for	for	ADP
chd-130	51	118	cancer	cancer	NOUN
chd-130	51	119	researchers	researcher	NOUN
chd-130	51	120	who	who	PRON
chd-130	51	121	invested	invest	VERB
chd-130	51	122	their	their	PRON
chd-130	51	123	efforts	effort	NOUN
chd-130	51	124	in	in	ADP
chd-130	51	125	establishing	establish	VERB
chd-130	51	126	a	a	DET
chd-130	51	127	link	link	NOUN
chd-130	51	128	between	between	ADP
chd-130	51	129	cancer	cancer	NOUN
chd-130	51	130	and	and	CCONJ
chd-130	51	131	heredity	heredity	NOUN
chd-130	51	132	.	.	PUNCT
chd-130	52	1	the	the	DET
chd-130	52	2	role	role	NOUN
chd-130	52	3	of	of	ADP
chd-130	52	4	mutated	mutate	VERB
chd-130	52	5	genes	gene	NOUN
chd-130	52	6	in	in	ADP
chd-130	52	7	cancer	cancer	NOUN
chd-130	52	8	biology	biology	NOUN
chd-130	52	9	was	be	AUX
chd-130	52	10	beginning	begin	VERB
chd-130	52	11	to	to	PART
chd-130	52	12	be	be	AUX
chd-130	52	13	discovered	discover	VERB
chd-130	52	14	and	and	CCONJ
chd-130	52	15	explored	explore	VERB
chd-130	52	16	in	in	ADP
chd-130	52	17	various	various	ADJ
chd-130	52	18	types	type	NOUN
chd-130	52	19	of	of	ADP
chd-130	52	20	cancers	cancer	NOUN
chd-130	52	21	.	.	PUNCT
chd-130	53	1	mechanistic	mechanistic	ADJ
chd-130	53	2	insight	insight	NOUN
chd-130	53	3	into	into	ADP
chd-130	53	4	discovering	discover	VERB
chd-130	53	5	the	the	DET
chd-130	53	6	molecular	molecular	ADJ
chd-130	53	7	basis	basis	NOUN
chd-130	53	8	for	for	ADP
chd-130	53	9	the	the	DET
chd-130	53	10	development	development	NOUN
chd-130	53	11	of	of	ADP
chd-130	53	12	gbc	gbc	PROPN
chd-130	53	13	in	in	ADP
chd-130	53	14	the	the	DET
chd-130	53	15	western	western	ADJ
chd-130	53	16	world	world	NOUN
chd-130	53	17	started	start	VERB
chd-130	53	18	very	very	ADV
chd-130	53	19	early	early	ADV
chd-130	53	20	on	on	ADV
chd-130	53	21	and	and	CCONJ
chd-130	53	22	in	in	ADP
chd-130	53	23	full	full	ADJ
chd-130	53	24	force	force	NOUN
chd-130	53	25	.	.	PUNCT
chd-130	54	1	reports	report	NOUN
chd-130	54	2	implicating	implicate	VERB
chd-130	54	3	the	the	DET
chd-130	54	4	role	role	NOUN
chd-130	54	5	of	of	ADP
chd-130	54	6	genetic	genetic	ADJ
chd-130	54	7	/	/	SYM
chd-130	54	8	hereditary	hereditary	ADJ
chd-130	54	9	predisposition	predisposition	NOUN
chd-130	54	10	can	can	AUX
chd-130	54	11	be	be	AUX
chd-130	54	12	traced	trace	VERB
chd-130	54	13	back	back	ADV
chd-130	54	14	to	to	ADP
chd-130	54	15	as	as	ADV
chd-130	54	16	early	early	ADV
chd-130	54	17	as	as	ADP
chd-130	54	18	the	the	DET
chd-130	54	19	80s	80	NOUN
chd-130	54	20	(	(	PUNCT
chd-130	54	21	trajber	trajber	NOUN
chd-130	54	22	et	et	PROPN
chd-130	54	23	al	al	PROPN
chd-130	54	24	.	.	PROPN
chd-130	54	25	,	,	PUNCT
chd-130	54	26	1982	1982	NUM
chd-130	54	27	;	;	PUNCT
chd-130	54	28	weiss	weiss	PROPN
chd-130	54	29	et	et	PROPN
chd-130	54	30	al	al	PROPN
chd-130	54	31	.	.	PROPN
chd-130	54	32	,	,	PUNCT
chd-130	54	33	1984	1984	NUM
chd-130	54	34	)	)	PUNCT
chd-130	54	35	.	.	PUNCT
chd-130	55	1	karyotyping	karyotyping	NOUN
chd-130	55	2	techniques	technique	NOUN
chd-130	55	3	first	first	ADV
chd-130	55	4	were	be	AUX
chd-130	55	5	used	use	VERB
chd-130	55	6	by	by	ADP
chd-130	55	7	hecht	hecht	PROPN
chd-130	55	8	and	and	CCONJ
chd-130	55	9	his	his	PRON
chd-130	55	10	colleagues	colleague	NOUN
chd-130	55	11	in	in	ADP
chd-130	55	12	1983	1983	NUM
chd-130	55	13	to	to	PART
chd-130	55	14	demonstrate	demonstrate	VERB
chd-130	55	15	the	the	DET
chd-130	55	16	presence	presence	NOUN
chd-130	55	17	of	of	ADP
chd-130	55	18	a	a	DET
chd-130	55	19	high	high	ADJ
chd-130	55	20	level	level	NOUN
chd-130	55	21	of	of	ADP
chd-130	55	22	aneuploidy	aneuploidy	NOUN
chd-130	55	23	in	in	ADP
chd-130	55	24	the	the	DET
chd-130	55	25	form	form	NOUN
chd-130	55	26	of	of	ADP
chd-130	55	27	missing	missing	ADJ
chd-130	55	28	or	or	CCONJ
chd-130	55	29	extra	extra	ADJ
chd-130	55	30	chromosomes	chromosome	NOUN
chd-130	55	31	and/or	and/or	CCONJ
chd-130	55	32	chromosomal	chromosomal	ADJ
chd-130	55	33	rearrangement	rearrangement	NOUN
chd-130	55	34	in	in	ADP
chd-130	55	35	a	a	DET
chd-130	55	36	tissue	tissue	NOUN
chd-130	55	37	specimen	speciman	NOUN
chd-130	55	38	obtained	obtain	VERB
chd-130	55	39	from	from	ADP
chd-130	55	40	a	a	DET
chd-130	55	41	papago	papago	PROPN
chd-130	55	42	indian	indian	ADJ
chd-130	55	43	woman	woman	NOUN
chd-130	55	44	with	with	ADP
chd-130	55	45	gbc	gbc	PROPN
chd-130	55	46	in	in	ADP
chd-130	55	47	the	the	DET
chd-130	55	48	united	united	PROPN
chd-130	55	49	states	states	PROPN
chd-130	55	50	(	(	PUNCT
chd-130	55	51	hecht	hecht	PROPN
chd-130	55	52	et	et	PROPN
chd-130	55	53	al	al	PROPN
chd-130	55	54	.	.	PROPN
chd-130	55	55	,	,	PUNCT
chd-130	55	56	1983	1983	NUM
chd-130	55	57	)	)	PUNCT
chd-130	55	58	.	.	PUNCT
chd-130	56	1	this	this	DET
chd-130	56	2	study	study	NOUN
chd-130	56	3	reported	report	VERB
chd-130	56	4	the	the	DET
chd-130	56	5	presence	presence	NOUN
chd-130	56	6	of	of	ADP
chd-130	56	7	double	double	ADJ
chd-130	56	8	minute	minute	NOUN
chd-130	56	9	chromosomes	chromosome	NOUN
chd-130	56	10	as	as	ADV
chd-130	56	11	well	well	ADV
chd-130	56	12	as	as	ADP
chd-130	56	13	homogenously	homogenously	ADV
chd-130	56	14	stained	stain	VERB
chd-130	56	15	regions	region	NOUN
chd-130	56	16	on	on	ADP
chd-130	56	17	chromosomes	chromosome	NOUN
chd-130	56	18	in	in	ADP
chd-130	56	19	those	those	DET
chd-130	56	20	cancer	cancer	NOUN
chd-130	56	21	cells	cell	NOUN
chd-130	56	22	.	.	PUNCT
chd-130	57	1	a	a	DET
chd-130	57	2	decade	decade	NOUN
chd-130	57	3	later	later	ADV
chd-130	57	4	,	,	PUNCT
chd-130	57	5	another	another	DET
chd-130	57	6	group	group	NOUN
chd-130	57	7	explored	explore	VERB
chd-130	57	8	the	the	DET
chd-130	57	9	correlation	correlation	NOUN
chd-130	57	10	between	between	ADP
chd-130	57	11	the	the	DET
chd-130	57	12	dna	dna	PROPN
chd-130	57	13	content	content	NOUN
chd-130	57	14	and	and	CCONJ
chd-130	57	15	the	the	DET
chd-130	57	16	cytological	cytological	ADJ
chd-130	57	17	and	and	CCONJ
chd-130	57	18	histological	histological	ADJ
chd-130	57	19	features	feature	NOUN
chd-130	57	20	in	in	ADP
chd-130	57	21	the	the	DET
chd-130	57	22	tumor	tumor	NOUN
chd-130	57	23	cells	cell	NOUN
chd-130	57	24	obtained	obtain	VERB
chd-130	57	25	from	from	ADP
chd-130	57	26	the	the	DET
chd-130	57	27	patients	patient	NOUN
chd-130	57	28	with	with	ADP
chd-130	57	29	gbc	gbc	PROPN
chd-130	57	30	(	(	PUNCT
chd-130	57	31	roa	roa	PROPN
chd-130	57	32	et	et	PROPN
chd-130	57	33	al	al	PROPN
chd-130	57	34	.	.	PROPN
chd-130	57	35	,	,	PUNCT
chd-130	57	36	1993	1993	NUM
chd-130	57	37	)	)	PUNCT
chd-130	57	38	.	.	PUNCT
chd-130	58	1	these	these	DET
chd-130	58	2	reports	report	NOUN
chd-130	58	3	were	be	AUX
chd-130	58	4	the	the	PRON
chd-130	58	5	among	among	ADP
chd-130	58	6	the	the	DET
chd-130	58	7	first	first	ADJ
chd-130	58	8	ones	one	NOUN
chd-130	58	9	to	to	PART
chd-130	58	10	have	have	AUX
chd-130	58	11	used	use	VERB
chd-130	58	12	molecular	molecular	ADJ
chd-130	58	13	techniques	technique	NOUN
chd-130	58	14	to	to	PART
chd-130	58	15	decipher	decipher	VERB
chd-130	58	16	the	the	DET
chd-130	58	17	molecular	molecular	ADJ
chd-130	58	18	/	/	SYM
chd-130	58	19	genetic	genetic	ADJ
chd-130	58	20	basis	basis	NOUN
chd-130	58	21	for	for	ADP
chd-130	58	22	gbc	gbc	PROPN
chd-130	58	23	.	.	PUNCT
chd-130	59	1	the	the	DET
chd-130	59	2	following	following	ADJ
chd-130	59	3	year	year	NOUN
chd-130	59	4	,	,	PUNCT
chd-130	59	5	a	a	DET
chd-130	59	6	small	small	ADJ
chd-130	59	7	but	but	CCONJ
chd-130	59	8	an	an	DET
chd-130	59	9	important	important	ADJ
chd-130	59	10	study	study	NOUN
chd-130	59	11	conducted	conduct	VERB
chd-130	59	12	by	by	ADP
chd-130	59	13	japanese	japanese	ADJ
chd-130	59	14	researchers	researcher	NOUN
chd-130	59	15	,	,	PUNCT
chd-130	59	16	demonstrated	demonstrate	VERB
chd-130	59	17	mutations	mutation	NOUN
chd-130	59	18	in	in	ADP
chd-130	59	19	the	the	DET
chd-130	59	20	p53	p53	NOUN
chd-130	59	21	gene	gene	NOUN
chd-130	59	22	in	in	ADP
chd-130	59	23	almost	almost	ADV
chd-130	59	24	one	one	NUM
chd-130	59	25	-	-	PUNCT
chd-130	59	26	third	third	NOUN
chd-130	59	27	of	of	ADP
chd-130	59	28	the	the	DET
chd-130	59	29	patients	patient	NOUN
chd-130	59	30	with	with	ADP
chd-130	59	31	gbc	gbc	PROPN
chd-130	59	32	.	.	PUNCT
chd-130	60	1	they	they	PRON
chd-130	60	2	used	use	VERB
chd-130	60	3	pcr	pcr	ADJ
chd-130	60	4	-	-	ADJ
chd-130	60	5	single	single	ADJ
chd-130	60	6	strand	strand	NOUN
chd-130	60	7	conformation	conformation	NOUN
chd-130	60	8	polymorphism	polymorphism	NOUN
chd-130	60	9	(	(	PUNCT
chd-130	60	10	sscp	sscp	NOUN
chd-130	60	11	)	)	PUNCT
chd-130	60	12	for	for	ADP
chd-130	60	13	the	the	DET
chd-130	60	14	very	very	ADV
chd-130	60	15	first	first	ADJ
chd-130	60	16	time	time	NOUN
chd-130	60	17	to	to	PART
chd-130	60	18	discover	discover	VERB
chd-130	60	19	and	and	CCONJ
chd-130	60	20	establish	establish	VERB
chd-130	60	21	their	their	PRON
chd-130	60	22	findings	finding	NOUN
chd-130	60	23	(	(	PUNCT
chd-130	60	24	takagi	takagi	PROPN
chd-130	60	25	et	et	PROPN
chd-130	60	26	al	al	PROPN
chd-130	60	27	.	.	PROPN
chd-130	60	28	,	,	PUNCT
chd-130	60	29	1994	1994	NUM
chd-130	60	30	)	)	PUNCT
chd-130	60	31	.	.	PUNCT
chd-130	61	1	the	the	DET
chd-130	61	2	next	next	ADJ
chd-130	61	3	several	several	ADJ
chd-130	61	4	years	year	NOUN
chd-130	61	5	brought	bring	VERB
chd-130	61	6	about	about	ADP
chd-130	61	7	an	an	DET
chd-130	61	8	increase	increase	NOUN
chd-130	61	9	in	in	ADP
chd-130	61	10	the	the	DET
chd-130	61	11	number	number	NOUN
chd-130	61	12	of	of	ADP
chd-130	61	13	published	publish	VERB
chd-130	61	14	studies	study	NOUN
chd-130	61	15	mostly	mostly	ADV
chd-130	61	16	from	from	ADP
chd-130	61	17	the	the	DET
chd-130	61	18	japanese	japanese	ADJ
chd-130	61	19	investigators	investigator	NOUN
chd-130	61	20	.	.	PUNCT
chd-130	62	1	these	these	DET
chd-130	62	2	studies	study	NOUN
chd-130	62	3	involved	involve	VERB
chd-130	62	4	discovering	discover	VERB
chd-130	62	5	various	various	ADJ
chd-130	62	6	mutations	mutation	NOUN
chd-130	62	7	in	in	ADP
chd-130	62	8	k	k	PROPN
chd-130	62	9	-	-	PROPN
chd-130	62	10	ras	ras	X
chd-130	62	11	(	(	PUNCT
chd-130	62	12	watanabe	watanabe	PROPN
chd-130	62	13	et	et	PROPN
chd-130	62	14	al	al	PROPN
chd-130	62	15	.	.	PROPN
chd-130	62	16	,	,	PUNCT
chd-130	62	17	1994	1994	NUM
chd-130	62	18	;	;	PUNCT
chd-130	62	19	hanada	hanada	PROPN
chd-130	62	20	et	et	PROPN
chd-130	62	21	al	al	PROPN
chd-130	62	22	,	,	PUNCT
chd-130	62	23	1996	1996	NUM
chd-130	62	24	;	;	PUNCT
chd-130	62	25	matsubara	matsubara	PROPN
chd-130	62	26	et	et	PROPN
chd-130	62	27	al	al	PROPN
chd-130	62	28	.	.	PROPN
chd-130	62	29	,	,	PUNCT
chd-130	62	30	1996	1996	NUM
chd-130	62	31	;	;	PUNCT
chd-130	62	32	tomono	tomono	PROPN
chd-130	62	33	et	et	PROPN
chd-130	62	34	al	al	PROPN
chd-130	62	35	.	.	PROPN
chd-130	62	36	,	,	PUNCT
chd-130	62	37	1996	1996	NUM
chd-130	62	38	;	;	PUNCT
chd-130	62	39	saetta	saetta	PROPN
chd-130	62	40	et	et	PROPN
chd-130	62	41	al	al	PROPN
chd-130	62	42	.	.	PROPN
chd-130	62	43	,	,	PUNCT
chd-130	62	44	1996	1996	NUM
chd-130	62	45	;	;	PUNCT
chd-130	62	46	iwase	iwase	NOUN
chd-130	62	47	et	et	PROPN
chd-130	62	48	al	al	PROPN
chd-130	62	49	.	.	PROPN
chd-130	62	50	,	,	PUNCT
chd-130	62	51	1997	1997	NUM
chd-130	62	52	.	.	PUNCT
chd-130	63	1	,	,	PUNCT
chd-130	63	2	tanno	tanno	NOUN
chd-130	63	3	et	et	PROPN
chd-130	63	4	al	al	PROPN
chd-130	63	5	.	.	PROPN
chd-130	63	6	,	,	PUNCT
chd-130	63	7	1998	1998	NUM
chd-130	63	8	)	)	PUNCT
chd-130	63	9	and	and	CCONJ
chd-130	63	10	p53	p53	NOUN
chd-130	63	11	genes	gene	NOUN
chd-130	63	12	(	(	PUNCT
chd-130	63	13	hanada	hanada	NOUN
chd-130	63	14	et	et	PROPN
chd-130	63	15	al	al	PROPN
chd-130	63	16	,	,	PUNCT
chd-130	63	17	1996	1996	NUM
chd-130	63	18	;	;	PUNCT
chd-130	63	19	ajiki	ajiki	PROPN
chd-130	63	20	et	et	PROPN
chd-130	63	21	al	al	PROPN
chd-130	63	22	.	.	PROPN
chd-130	63	23	,	,	PUNCT
chd-130	63	24	1996	1996	NUM
chd-130	63	25	;	;	PUNCT
chd-130	63	26	fujii	fujii	PROPN
chd-130	63	27	et	et	PROPN
chd-130	63	28	al	al	PROPN
chd-130	63	29	.	.	PROPN
chd-130	63	30	,	,	PUNCT
chd-130	63	31	1996	1996	NUM
chd-130	63	32	;	;	PUNCT
chd-130	63	33	hanada	hanada	PROPN
chd-130	63	34	et	et	PROPN
chd-130	63	35	al	al	PROPN
chd-130	63	36	.	.	PROPN
chd-130	63	37	,	,	PUNCT
chd-130	63	38	1997	1997	NUM
chd-130	63	39	;	;	PUNCT
chd-130	63	40	jonas	jonas	PROPN
chd-130	63	41	et	et	PROPN
chd-130	63	42	al	al	PROPN
chd-130	63	43	.	.	PROPN
chd-130	63	44	,	,	PUNCT
chd-130	63	45	1997	1997	NUM
chd-130	63	46	;	;	PUNCT
chd-130	63	47	yokoyama	yokoyama	PROPN
chd-130	63	48	et	et	PROPN
chd-130	63	49	al	al	PROPN
chd-130	63	50	.	.	PROPN
chd-130	63	51	,	,	PUNCT
chd-130	63	52	1998	1998	NUM
chd-130	63	53	)	)	PUNCT
chd-130	63	54	in	in	ADP
chd-130	63	55	a	a	DET
chd-130	63	56	significant	significant	ADJ
chd-130	63	57	percentage	percentage	NOUN
chd-130	63	58	of	of	ADP
chd-130	63	59	patients	patient	NOUN
chd-130	63	60	presenting	present	VERB
chd-130	63	61	with	with	ADP
chd-130	63	62	gbc	gbc	PROPN
chd-130	63	63	.	.	PUNCT
chd-130	64	1	by	by	ADP
chd-130	64	2	late	late	ADJ
chd-130	64	3	1990s	1990	NOUN
chd-130	64	4	,	,	PUNCT
chd-130	64	5	many	many	ADJ
chd-130	64	6	studies	study	NOUN
chd-130	64	7	were	be	AUX
chd-130	64	8	able	able	ADJ
chd-130	64	9	to	to	PART
chd-130	64	10	detect	detect	VERB
chd-130	64	11	the	the	DET
chd-130	64	12	mutations	mutation	NOUN
chd-130	64	13	and/or	and/or	CCONJ
chd-130	64	14	the	the	DET
chd-130	64	15	altered	altered	ADJ
chd-130	64	16	expression	expression	NOUN
chd-130	64	17	of	of	ADP
chd-130	64	18	tumor	tumor	NOUN
chd-130	64	19	suppressor	suppressor	NOUN
chd-130	64	20	genes	gene	NOUN
chd-130	64	21	and	and	CCONJ
chd-130	64	22	oncogenes	oncogene	NOUN
chd-130	64	23	in	in	ADP
chd-130	64	24	the	the	DET
chd-130	64	25	patients	patient	NOUN
chd-130	64	26	with	with	ADP
chd-130	64	27	gbc	gbc	PROPN
chd-130	64	28	.	.	PUNCT
chd-130	65	1	however	however	ADV
chd-130	65	2	,	,	PUNCT
chd-130	65	3	most	most	ADJ
chd-130	65	4	of	of	ADP
chd-130	65	5	them	they	PRON
chd-130	65	6	lacked	lack	VERB
chd-130	65	7	mechanistic	mechanistic	ADJ
chd-130	65	8	explanations	explanation	NOUN
chd-130	65	9	for	for	ADP
chd-130	65	10	their	their	PRON
chd-130	65	11	findings	finding	NOUN
chd-130	65	12	.	.	PUNCT
chd-130	66	1	in	in	ADP
chd-130	66	2	1999	1999	NUM
chd-130	66	3	,	,	PUNCT
chd-130	66	4	a	a	DET
chd-130	66	5	study	study	NOUN
chd-130	66	6	was	be	AUX
chd-130	66	7	published	publish	VERB
chd-130	66	8	discussing	discuss	VERB
chd-130	66	9	the	the	DET
chd-130	66	10	molecular	molecular	ADJ
chd-130	66	11	mechanisms	mechanism	NOUN
chd-130	66	12	underlying	underlie	VERB
chd-130	66	13	tumorigenesis	tumorigenesis	NOUN
chd-130	66	14	of	of	ADP
chd-130	66	15	gallbladder	gallbladder	NOUN
chd-130	66	16	carcinomas	carcinoma	NOUN
chd-130	66	17	,	,	PUNCT
chd-130	66	18	the	the	DET
chd-130	66	19	first	first	ADJ
chd-130	66	20	of	of	ADP
chd-130	66	21	its	its	PRON
chd-130	66	22	kind	kind	NOUN
chd-130	66	23	(	(	PUNCT
chd-130	66	24	wistuba	wistuba	PROPN
chd-130	66	25	et	et	PROPN
chd-130	66	26	al	al	PROPN
chd-130	66	27	.	.	PROPN
chd-130	66	28	,	,	PUNCT
chd-130	66	29	1999	1999	NUM
chd-130	66	30	)	)	PUNCT
chd-130	66	31	.	.	PUNCT
chd-130	67	1	the	the	DET
chd-130	67	2	researchers	researcher	NOUN
chd-130	67	3	pointed	point	VERB
chd-130	67	4	out	out	ADP
chd-130	67	5	that	that	SCONJ
chd-130	67	6	while	while	SCONJ
chd-130	67	7	nearly	nearly	ADV
chd-130	67	8	all	all	PRON
chd-130	67	9	of	of	ADP
chd-130	67	10	the	the	DET
chd-130	67	11	gallbladder	gallbladder	NOUN
chd-130	67	12	carcinomas	carcinoma	NOUN
chd-130	67	13	evolved	evolve	VERB
chd-130	67	14	from	from	ADP
chd-130	67	15	dysplasia	dysplasia	NOUN
chd-130	67	16	and	and	CCONJ
chd-130	67	17	carcinoma	carcinoma	NOUN
chd-130	67	18	in	in	ADP
chd-130	67	19	situ	situ	NOUN
chd-130	67	20	,	,	PUNCT
chd-130	67	21	role	role	NOUN
chd-130	67	22	of	of	ADP
chd-130	67	23	pre	pre	ADJ
chd-130	67	24	-	-	ADJ
chd-130	67	25	cancerous	cancerous	ADJ
chd-130	67	26	lesions	lesion	NOUN
chd-130	67	27	such	such	ADJ
chd-130	67	28	as	as	ADP
chd-130	67	29	gallbladder	gallbladder	NOUN
chd-130	67	30	adenomas	adenoma	NOUN
chd-130	67	31	in	in	ADP
chd-130	67	32	the	the	DET
chd-130	67	33	pathogenesis	pathogenesis	NOUN
chd-130	67	34	of	of	ADP
chd-130	67	35	gbc	gbc	PROPN
chd-130	67	36	was	be	AUX
chd-130	67	37	still	still	ADV
chd-130	67	38	controversial	controversial	ADJ
chd-130	67	39	.	.	PUNCT
chd-130	68	1	they	they	PRON
chd-130	68	2	further	far	ADV
chd-130	68	3	analyzed	analyze	VERB
chd-130	68	4	dna	dna	PROPN
chd-130	68	5	obtained	obtain	VERB
chd-130	68	6	from	from	ADP
chd-130	68	7	micro	micro	ADJ
chd-130	68	8	-	-	ADJ
chd-130	68	9	dissected	dissected	ADJ
chd-130	68	10	tissue	tissue	NOUN
chd-130	68	11	samples	sample	NOUN
chd-130	68	12	of	of	ADP
chd-130	68	13	pyloric	pyloric	NOUN
chd-130	68	14	and	and	CCONJ
chd-130	68	15	intestinal	intestinal	ADJ
chd-130	68	16	-	-	PUNCT
chd-130	68	17	type	type	NOUN
chd-130	68	18	gallbladder	gallbladder	NOUN
chd-130	68	19	adenomas	adenoma	NOUN
chd-130	68	20	to	to	PART
chd-130	68	21	compare	compare	VERB
chd-130	68	22	the	the	DET
chd-130	68	23	molecular	molecular	ADJ
chd-130	68	24	abnormalities	abnormality	NOUN
chd-130	68	25	found	find	VERB
chd-130	68	26	in	in	ADP
chd-130	68	27	adenomas	adenoma	NOUN
chd-130	68	28	with	with	ADP
chd-130	68	29	the	the	DET
chd-130	68	30	ones	one	NOUN
chd-130	68	31	seen	see	VERB
chd-130	68	32	in	in	ADP
chd-130	68	33	carcinomas	carcinoma	NOUN
chd-130	68	34	.	.	PUNCT
chd-130	69	1	tissue	tissue	NOUN
chd-130	69	2	samples	sample	NOUN
chd-130	69	3	derived	derive	VERB
chd-130	69	4	from	from	ADP
chd-130	69	5	carcinoma	carcinoma	NOUN
chd-130	69	6	samples	sample	NOUN
chd-130	69	7	displayed	display	VERB
chd-130	69	8	tp53	tp53	PROPN
chd-130	69	9	mutations	mutation	NOUN
chd-130	69	10	alongside	alongside	ADP
chd-130	69	11	mutations	mutation	NOUN
chd-130	69	12	in	in	ADP
chd-130	69	13	both	both	CCONJ
chd-130	69	14	the	the	DET
chd-130	69	15	kas	kas	PROPN
chd-130	69	16	well	well	INTJ
chd-130	69	17	as	as	ADP
chd-130	69	18	n	n	CCONJ
chd-130	69	19	-	-	PUNCT
chd-130	69	20	ras	ras	NOUN
chd-130	69	21	genes	gene	NOUN
chd-130	69	22	.	.	PUNCT
chd-130	70	1	they	they	PRON
chd-130	70	2	also	also	ADV
chd-130	70	3	demonstrated	demonstrate	VERB
chd-130	70	4	loss	loss	NOUN
chd-130	70	5	of	of	ADP
chd-130	70	6	heterozygosity	heterozygosity	NOUN
chd-130	70	7	(	(	PUNCT
chd-130	70	8	loh	loh	PROPN
chd-130	70	9	)	)	PUNCT
chd-130	70	10	at	at	ADP
chd-130	70	11	chromosomal	chromosomal	ADJ
chd-130	70	12	regions	region	NOUN
chd-130	70	13	5q22	5q22	NUM
chd-130	70	14	apc	apc	PROPN
chd-130	70	15	-	-	PUNCT
chd-130	70	16	mcc	mcc	PROPN
chd-130	70	17	region	region	NOUN
chd-130	70	18	,	,	PUNCT
chd-130	70	19	9p21	9p21	NOUN
chd-130	70	20	-	-	PUNCT
chd-130	70	21	cdkn2a	cdkn2a	PROPN
chd-130	70	22	,	,	PUNCT
chd-130	70	23	tp53	tp53	PROPN
chd-130	70	24	,	,	PUNCT
chd-130	70	25	rb	rb	NOUN
chd-130	70	26	,	,	PUNCT
chd-130	70	27	and	and	CCONJ
chd-130	70	28	dcc	dcc	PROPN
chd-130	70	29	.	.	PUNCT
chd-130	71	1	these	these	DET
chd-130	71	2	genetic	genetic	ADJ
chd-130	71	3	aberrations	aberration	NOUN
chd-130	71	4	have	have	AUX
chd-130	71	5	been	be	AUX
chd-130	71	6	known	know	VERB
chd-130	71	7	to	to	PART
chd-130	71	8	be	be	AUX
chd-130	71	9	associated	associate	VERB
chd-130	71	10	with	with	ADP
chd-130	71	11	and	and	CCONJ
chd-130	71	12	play	play	VERB
chd-130	71	13	important	important	ADJ
chd-130	71	14	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	ADJ
chd-130	71	15	e5	e5	PROPN
chd-130	71	16	cancer	cancer	NOUN
chd-130	71	17	health	health	NOUN
chd-130	71	18	disparities	disparity	NOUN
chd-130	71	19	research	research	NOUN
chd-130	71	20	role	role	NOUN
chd-130	71	21	in	in	ADP
chd-130	71	22	tumor	tumor	NOUN
chd-130	71	23	initiation	initiation	NOUN
chd-130	71	24	and	and	CCONJ
chd-130	71	25	progression	progression	NOUN
chd-130	71	26	in	in	ADP
chd-130	71	27	several	several	ADJ
chd-130	71	28	other	other	ADJ
chd-130	71	29	cancer	cancer	NOUN
chd-130	71	30	types	type	NOUN
chd-130	71	31	.	.	PUNCT
chd-130	72	1	since	since	SCONJ
chd-130	72	2	these	these	DET
chd-130	72	3	mutations	mutation	NOUN
chd-130	72	4	/	/	SYM
chd-130	72	5	molecular	molecular	ADJ
chd-130	72	6	changes	change	NOUN
chd-130	72	7	were	be	AUX
chd-130	72	8	not	not	PART
chd-130	72	9	exhibited	exhibit	VERB
chd-130	72	10	by	by	ADP
chd-130	72	11	adenoma	adenoma	ADJ
chd-130	72	12	samples	sample	NOUN
chd-130	72	13	,	,	PUNCT
chd-130	72	14	the	the	DET
chd-130	72	15	researchers	researcher	NOUN
chd-130	72	16	concluded	conclude	VERB
chd-130	72	17	that	that	SCONJ
chd-130	72	18	adenomatous	adenomatous	ADJ
chd-130	72	19	changes	change	NOUN
chd-130	72	20	were	be	AUX
chd-130	72	21	not	not	PART
chd-130	72	22	similar	similar	ADJ
chd-130	72	23	to	to	ADP
chd-130	72	24	those	those	PRON
chd-130	72	25	seen	see	VERB
chd-130	72	26	in	in	ADP
chd-130	72	27	conditions	condition	NOUN
chd-130	72	28	of	of	ADP
chd-130	72	29	dysplasia	dysplasia	NOUN
chd-130	72	30	,	,	PUNCT
chd-130	72	31	carcinoma	carcinoma	NOUN
chd-130	72	32	in	in	ADP
chd-130	72	33	situ	situ	NOUN
chd-130	72	34	,	,	PUNCT
chd-130	72	35	and/or	and/or	CCONJ
chd-130	72	36	invasive	invasive	ADJ
chd-130	72	37	carcinoma	carcinoma	NOUN
chd-130	72	38	of	of	ADP
chd-130	72	39	the	the	DET
chd-130	72	40	gallbladder	gallbladder	NOUN
chd-130	72	41	.	.	PUNCT
chd-130	73	1	similarly	similarly	ADV
chd-130	73	2	,	,	PUNCT
chd-130	73	3	it	it	PRON
chd-130	73	4	was	be	AUX
chd-130	73	5	shown	show	VERB
chd-130	73	6	that	that	SCONJ
chd-130	73	7	in	in	ADP
chd-130	73	8	25	25	NUM
chd-130	73	9	%	%	NOUN
chd-130	73	10	of	of	ADP
chd-130	73	11	adenomas	adenoma	NOUN
chd-130	73	12	,	,	PUNCT
chd-130	73	13	there	there	PRON
chd-130	73	14	was	be	VERB
chd-130	73	15	a	a	DET
chd-130	73	16	mutation	mutation	NOUN
chd-130	73	17	in	in	ADP
chd-130	73	18	the	the	DET
chd-130	73	19	k	k	PROPN
chd-130	73	20	-	-	PUNCT
chd-130	73	21	ras	ras	ADJ
chd-130	73	22	oncogene	oncogene	NOUN
chd-130	73	23	at	at	ADP
chd-130	73	24	codons	codon	NOUN
chd-130	73	25	12	12	NUM
chd-130	73	26	and	and	CCONJ
chd-130	73	27	61	61	NUM
chd-130	73	28	,	,	PUNCT
chd-130	73	29	suggesting	suggest	VERB
chd-130	73	30	strongly	strongly	ADV
chd-130	73	31	that	that	SCONJ
chd-130	73	32	these	these	DET
chd-130	73	33	adenomas	adenoma	NOUN
chd-130	73	34	were	be	AUX
chd-130	73	35	not	not	PART
chd-130	73	36	forerunners	forerunner	NOUN
chd-130	73	37	of	of	ADP
chd-130	73	38	invasive	invasive	ADJ
chd-130	73	39	gbc	gbc	PROPN
chd-130	73	40	(	(	PUNCT
chd-130	73	41	wistuba	wistuba	PROPN
chd-130	73	42	et	et	PROPN
chd-130	73	43	al	al	PROPN
chd-130	73	44	.	.	PROPN
chd-130	73	45	,	,	PUNCT
chd-130	73	46	1999	1999	NUM
chd-130	73	47	)	)	PUNCT
chd-130	73	48	.	.	PUNCT
chd-130	74	1	later	later	ADV
chd-130	74	2	in	in	ADP
chd-130	74	3	2001	2001	NUM
chd-130	74	4	,	,	PUNCT
chd-130	74	5	a	a	DET
chd-130	74	6	japanese	japanese	ADJ
chd-130	74	7	study	study	NOUN
chd-130	74	8	confirmed	confirm	VERB
chd-130	74	9	this	this	DET
chd-130	74	10	hypothesis	hypothesis	NOUN
chd-130	74	11	by	by	ADP
chd-130	74	12	analyzing	analyze	VERB
chd-130	74	13	betacatenin	betacatenin	NOUN
chd-130	74	14	protein	protein	NOUN
chd-130	74	15	expression	expression	NOUN
chd-130	74	16	and	and	CCONJ
chd-130	74	17	mutation	mutation	NOUN
chd-130	74	18	in	in	ADP
chd-130	74	19	the	the	DET
chd-130	74	20	corresponding	corresponding	ADJ
chd-130	74	21	genes	gene	NOUN
chd-130	74	22	.	.	PUNCT
chd-130	75	1	beta	beta	ADJ
chd-130	75	2	catenin	catenin	NOUN
chd-130	75	3	is	be	AUX
chd-130	75	4	a	a	DET
chd-130	75	5	regulator	regulator	NOUN
chd-130	75	6	of	of	ADP
chd-130	75	7	cell	cell	NOUN
chd-130	75	8	-	-	PUNCT
chd-130	75	9	cell	cell	NOUN
chd-130	75	10	adhesion	adhesion	NOUN
chd-130	75	11	and	and	CCONJ
chd-130	75	12	intranuclear	intranuclear	NOUN
chd-130	75	13	transcription	transcription	NOUN
chd-130	75	14	in	in	ADP
chd-130	75	15	gallbladder	gallbladder	NOUN
chd-130	75	16	carcinogenesis	carcinogenesis	NOUN
chd-130	75	17	.	.	PUNCT
chd-130	76	1	the	the	DET
chd-130	76	2	authors	author	NOUN
chd-130	76	3	also	also	ADV
chd-130	76	4	observed	observe	VERB
chd-130	76	5	that	that	SCONJ
chd-130	76	6	the	the	DET
chd-130	76	7	gallbladder	gallbladder	NOUN
chd-130	76	8	adenomas	adenoma	NOUN
chd-130	76	9	,	,	PUNCT
chd-130	76	10	in	in	ADP
chd-130	76	11	comparison	comparison	NOUN
chd-130	76	12	to	to	ADP
chd-130	76	13	carcinomas	carcinoma	NOUN
chd-130	76	14	,	,	PUNCT
chd-130	76	15	showed	show	VERB
chd-130	76	16	a	a	DET
chd-130	76	17	remarkably	remarkably	ADV
chd-130	76	18	high	high	ADJ
chd-130	76	19	expression	expression	NOUN
chd-130	76	20	of	of	ADP
chd-130	76	21	beta	beta	NOUN
chd-130	76	22	-	-	PUNCT
chd-130	76	23	catenin	catenin	NOUN
chd-130	76	24	protein	protein	NOUN
chd-130	76	25	in	in	ADP
chd-130	76	26	both	both	CCONJ
chd-130	76	27	the	the	DET
chd-130	76	28	cytoplasm	cytoplasm	NOUN
chd-130	76	29	as	as	ADV
chd-130	76	30	well	well	ADV
chd-130	76	31	as	as	ADP
chd-130	76	32	the	the	DET
chd-130	76	33	nucleus	nucleus	NOUN
chd-130	76	34	(	(	PUNCT
chd-130	76	35	p	p	X
chd-130	76	36	<	<	X
chd-130	76	37	0.05	0.05	NUM
chd-130	76	38	and	and	CCONJ
chd-130	76	39	p	p	X
chd-130	76	40	<	<	X
chd-130	76	41	0.001	0.001	NUM
chd-130	76	42	respectively	respectively	ADV
chd-130	76	43	)	)	PUNCT
chd-130	76	44	.	.	PUNCT
chd-130	77	1	62.5	62.5	NUM
chd-130	77	2	%	%	NOUN
chd-130	77	3	of	of	ADP
chd-130	77	4	adenomas	adenoma	NOUN
chd-130	77	5	,	,	PUNCT
chd-130	77	6	while	while	SCONJ
chd-130	77	7	a	a	DET
chd-130	77	8	mere	mere	ADJ
chd-130	77	9	4.8	4.8	NUM
chd-130	77	10	%	%	NOUN
chd-130	77	11	of	of	ADP
chd-130	77	12	carcinomas	carcinoma	NOUN
chd-130	77	13	demonstrated	demonstrate	VERB
chd-130	77	14	exon	exon	PROPN
chd-130	77	15	3	3	NUM
chd-130	77	16	mutations	mutation	NOUN
chd-130	77	17	in	in	ADP
chd-130	77	18	the	the	DET
chd-130	77	19	beta	beta	NOUN
chd-130	77	20	-	-	PUNCT
chd-130	77	21	catenin	catenin	NOUN
chd-130	77	22	gene	gene	NOUN
chd-130	77	23	.	.	PUNCT
chd-130	78	1	it	it	PRON
chd-130	78	2	was	be	AUX
chd-130	78	3	further	far	ADV
chd-130	78	4	demonstrated	demonstrate	VERB
chd-130	78	5	that	that	SCONJ
chd-130	78	6	the	the	DET
chd-130	78	7	adenoma	adenoma	NOUN
chd-130	78	8	to	to	ADP
chd-130	78	9	carcinoma	carcinoma	NOUN
chd-130	78	10	sequence	sequence	NOUN
chd-130	78	11	was	be	AUX
chd-130	78	12	a	a	DET
chd-130	78	13	minor	minor	ADJ
chd-130	78	14	pathway	pathway	NOUN
chd-130	78	15	in	in	ADP
chd-130	78	16	the	the	DET
chd-130	78	17	pathogenesis	pathogenesis	NOUN
chd-130	78	18	of	of	ADP
chd-130	78	19	gbc	gbc	PROPN
chd-130	78	20	using	use	VERB
chd-130	78	21	beta	beta	NOUN
chd-130	78	22	-	-	PUNCT
chd-130	78	23	catenin	catenin	NOUN
chd-130	78	24	as	as	ADP
chd-130	78	25	a	a	DET
chd-130	78	26	molecular	molecular	ADJ
chd-130	78	27	marker	marker	NOUN
chd-130	78	28	)	)	PUNCT
chd-130	78	29	(	(	PUNCT
chd-130	78	30	yanagisawa	yanagisawa	PROPN
chd-130	78	31	et	et	PROPN
chd-130	78	32	al	al	PROPN
chd-130	78	33	.	.	PROPN
chd-130	78	34	,	,	PUNCT
chd-130	78	35	2001	2001	NUM
chd-130	78	36	)	)	PUNCT
chd-130	78	37	.	.	PUNCT
chd-130	79	1	besides	besides	SCONJ
chd-130	79	2	k	k	PROPN
chd-130	79	3	-	-	PUNCT
chd-130	79	4	ras	ras	NOUN
chd-130	79	5	and	and	CCONJ
chd-130	79	6	p53	p53	NOUN
chd-130	79	7	,	,	PUNCT
chd-130	79	8	role	role	NOUN
chd-130	79	9	of	of	ADP
chd-130	79	10	other	other	ADJ
chd-130	79	11	cancer	cancer	NOUN
chd-130	79	12	associated	associate	VERB
chd-130	79	13	proteins	protein	NOUN
chd-130	79	14	were	be	AUX
chd-130	79	15	also	also	ADV
chd-130	79	16	explored	explore	VERB
chd-130	79	17	in	in	ADP
chd-130	79	18	the	the	DET
chd-130	79	19	pathogenesis	pathogenesis	NOUN
chd-130	79	20	of	of	ADP
chd-130	79	21	gbc	gbc	PROPN
chd-130	79	22	.	.	PUNCT
chd-130	80	1	for	for	ADP
chd-130	80	2	example	example	NOUN
chd-130	80	3	,	,	PUNCT
chd-130	80	4	two	two	NUM
chd-130	80	5	mucin	mucin	NOUN
chd-130	80	6	proteins	protein	NOUN
chd-130	80	7	muc1	muc1	NOUN
chd-130	80	8	and	and	CCONJ
chd-130	80	9	muc2	muc2	ADJ
chd-130	80	10	expressions	expression	NOUN
chd-130	80	11	were	be	AUX
chd-130	80	12	examined	examine	VERB
chd-130	80	13	both	both	CCONJ
chd-130	80	14	at	at	ADP
chd-130	80	15	mrna	mrna	PROPN
chd-130	80	16	as	as	ADV
chd-130	80	17	well	well	ADV
chd-130	80	18	as	as	ADP
chd-130	80	19	at	at	ADP
chd-130	80	20	protein	protein	NOUN
chd-130	80	21	level	level	NOUN
chd-130	80	22	in	in	ADP
chd-130	80	23	carcinoma	carcinoma	NOUN
chd-130	80	24	(	(	PUNCT
chd-130	80	25	55	55	NUM
chd-130	80	26	cases	case	NOUN
chd-130	80	27	)	)	PUNCT
chd-130	80	28	,	,	PUNCT
chd-130	80	29	dysplasia	dysplasia	NOUN
chd-130	80	30	(	(	PUNCT
chd-130	80	31	20	20	NUM
chd-130	80	32	cases	case	NOUN
chd-130	80	33	)	)	PUNCT
chd-130	80	34	and	and	CCONJ
chd-130	80	35	non	non	ADJ
chd-130	80	36	-	-	ADJ
chd-130	80	37	dysplastic	dysplastic	ADJ
chd-130	80	38	epithelia	epithelia	NOUN
chd-130	80	39	of	of	ADP
chd-130	80	40	the	the	DET
chd-130	80	41	gallbladder	gallbladder	NOUN
chd-130	80	42	,	,	PUNCT
chd-130	80	43	in	in	ADP
chd-130	80	44	a	a	DET
chd-130	80	45	japanese	japanese	ADJ
chd-130	80	46	study	study	NOUN
chd-130	80	47	(	(	PUNCT
chd-130	80	48	yamato	yamato	PROPN
chd-130	80	49	et	et	PROPN
chd-130	80	50	al	al	PROPN
chd-130	80	51	.	.	PROPN
chd-130	80	52	,	,	PUNCT
chd-130	80	53	1999	1999	NUM
chd-130	80	54	)	)	PUNCT
chd-130	80	55	.	.	PUNCT
chd-130	81	1	based	base	VERB
chd-130	81	2	on	on	ADP
chd-130	81	3	their	their	PRON
chd-130	81	4	observation	observation	NOUN
chd-130	81	5	,	,	PUNCT
chd-130	81	6	the	the	DET
chd-130	81	7	authors	author	NOUN
chd-130	81	8	suggested	suggest	VERB
chd-130	81	9	that	that	SCONJ
chd-130	81	10	muc1	muc1	NOUN
chd-130	81	11	expression	expression	NOUN
chd-130	81	12	indicated	indicate	VERB
chd-130	81	13	histological	histological	ADJ
chd-130	81	14	dedifferentiation	dedifferentiation	NOUN
chd-130	81	15	,	,	PUNCT
chd-130	81	16	increased	increase	VERB
chd-130	81	17	proliferation	proliferation	NOUN
chd-130	81	18	and	and	CCONJ
chd-130	81	19	invasion	invasion	NOUN
chd-130	81	20	.	.	PUNCT
chd-130	82	1	muc2	muc2	ADJ
chd-130	82	2	expression	expression	NOUN
chd-130	82	3	,	,	PUNCT
chd-130	82	4	on	on	ADP
chd-130	82	5	the	the	DET
chd-130	82	6	other	other	ADJ
chd-130	82	7	hand	hand	NOUN
chd-130	82	8	,	,	PUNCT
chd-130	82	9	showed	show	VERB
chd-130	82	10	a	a	DET
chd-130	82	11	correlation	correlation	NOUN
chd-130	82	12	to	to	PART
chd-130	82	13	decreased	decrease	VERB
chd-130	82	14	proliferation	proliferation	NOUN
chd-130	82	15	with	with	ADP
chd-130	82	16	reflection	reflection	NOUN
chd-130	82	17	of	of	ADP
chd-130	82	18	some	some	DET
chd-130	82	19	differentiation	differentiation	NOUN
chd-130	82	20	into	into	ADP
chd-130	82	21	goblet	goblet	NOUN
chd-130	82	22	cells	cell	NOUN
chd-130	82	23	.	.	PUNCT
chd-130	83	1	it	it	PRON
chd-130	83	2	was	be	AUX
chd-130	83	3	further	far	ADV
chd-130	83	4	suggested	suggest	VERB
chd-130	83	5	that	that	SCONJ
chd-130	83	6	expression	expression	NOUN
chd-130	83	7	of	of	ADP
chd-130	83	8	muc1	muc1	PROPN
chd-130	83	9	in	in	ADP
chd-130	83	10	a	a	DET
chd-130	83	11	dysplastic	dysplastic	ADJ
chd-130	83	12	gallbladder	gallbladder	NOUN
chd-130	83	13	reflected	reflect	VERB
chd-130	83	14	the	the	DET
chd-130	83	15	potential	potential	NOUN
chd-130	83	16	to	to	ADP
chd-130	83	17	developing	develop	VERB
chd-130	83	18	into	into	ADP
chd-130	83	19	a	a	DET
chd-130	83	20	malignancy	malignancy	NOUN
chd-130	83	21	(	(	PUNCT
chd-130	83	22	yamato	yamato	PROPN
chd-130	83	23	et	et	PROPN
chd-130	83	24	al	al	PROPN
chd-130	83	25	.	.	PROPN
chd-130	83	26	,	,	PUNCT
chd-130	83	27	1999	1999	NUM
chd-130	83	28	)	)	PUNCT
chd-130	83	29	.	.	PUNCT
chd-130	84	1	in	in	ADP
chd-130	84	2	the	the	DET
chd-130	84	3	same	same	ADJ
chd-130	84	4	year	year	NOUN
chd-130	84	5	,	,	PUNCT
chd-130	84	6	another	another	DET
chd-130	84	7	study	study	NOUN
chd-130	84	8	from	from	ADP
chd-130	84	9	north	north	PROPN
chd-130	84	10	korea	korea	PROPN
chd-130	84	11	revealed	reveal	VERB
chd-130	84	12	the	the	DET
chd-130	84	13	role	role	NOUN
chd-130	84	14	of	of	ADP
chd-130	84	15	molecular	molecular	ADJ
chd-130	84	16	alterations	alteration	NOUN
chd-130	84	17	in	in	ADP
chd-130	84	18	the	the	DET
chd-130	84	19	carcinogenesis	carcinogenesis	NOUN
chd-130	84	20	of	of	ADP
chd-130	84	21	gallbladder	gallbladder	NOUN
chd-130	84	22	.	.	PUNCT
chd-130	85	1	they	they	PRON
chd-130	85	2	analyzed	analyze	VERB
chd-130	85	3	32	32	NUM
chd-130	85	4	carcinomatous	carcinomatous	ADJ
chd-130	85	5	cases	case	NOUN
chd-130	85	6	and	and	CCONJ
chd-130	85	7	11	11	NUM
chd-130	85	8	dysplastic	dysplastic	ADJ
chd-130	85	9	cases	case	NOUN
chd-130	85	10	for	for	ADP
chd-130	85	11	loh	loh	PROPN
chd-130	85	12	and	and	CCONJ
chd-130	85	13	microsatellite	microsatellite	ADJ
chd-130	85	14	instability	instability	NOUN
chd-130	85	15	(	(	PUNCT
chd-130	85	16	msi	msi	PROPN
chd-130	85	17	)	)	PUNCT
chd-130	85	18	using	use	VERB
chd-130	85	19	17	17	NUM
chd-130	85	20	microsatellite	microsatellite	ADJ
chd-130	85	21	markers	marker	NOUN
chd-130	85	22	,	,	PUNCT
chd-130	85	23	on	on	ADP
chd-130	85	24	chromosomal	chromosomal	ADJ
chd-130	85	25	3p	3p	NUM
chd-130	85	26	,	,	PUNCT
chd-130	85	27	5q	5q	NUM
chd-130	85	28	,	,	PUNCT
chd-130	85	29	8p	8p	NUM
chd-130	85	30	,	,	PUNCT
chd-130	85	31	9p	9p	NUM
chd-130	85	32	,	,	PUNCT
chd-130	85	33	13q	13q	NUM
chd-130	85	34	,	,	PUNCT
chd-130	85	35	17p	17p	NOUN
chd-130	85	36	,	,	PUNCT
chd-130	85	37	and	and	CCONJ
chd-130	85	38	18q	18q	NUM
chd-130	85	39	sites	site	NOUN
chd-130	85	40	(	(	PUNCT
chd-130	85	41	chang	chang	PROPN
chd-130	85	42	et	et	PROPN
chd-130	85	43	al	al	PROPN
chd-130	85	44	.	.	PROPN
chd-130	85	45	,	,	PUNCT
chd-130	85	46	1999	1999	NUM
chd-130	85	47	)	)	PUNCT
chd-130	85	48	.	.	PUNCT
chd-130	86	1	loh	loh	PROPN
chd-130	86	2	on	on	ADP
chd-130	86	3	5q	5q	NUM
chd-130	86	4	indicated	indicate	VERB
chd-130	86	5	a	a	DET
chd-130	86	6	premature	premature	ADJ
chd-130	86	7	transformation	transformation	NOUN
chd-130	86	8	to	to	ADP
chd-130	86	9	carcinogenesis	carcinogenesis	NOUN
chd-130	86	10	while	while	SCONJ
chd-130	86	11	presence	presence	NOUN
chd-130	86	12	of	of	ADP
chd-130	86	13	loh	loh	PROPN
chd-130	86	14	on	on	ADP
chd-130	86	15	chromosomal	chromosomal	ADJ
chd-130	86	16	sites	site	NOUN
chd-130	86	17	3p	3p	NUM
chd-130	86	18	and	and	CCONJ
chd-130	86	19	9p	9p	NUM
chd-130	86	20	showed	show	VERB
chd-130	86	21	an	an	DET
chd-130	86	22	association	association	NOUN
chd-130	86	23	to	to	ADP
chd-130	86	24	the	the	DET
chd-130	86	25	advancement	advancement	NOUN
chd-130	86	26	of	of	ADP
chd-130	86	27	gbc	gbc	PROPN
chd-130	86	28	.	.	PUNCT
chd-130	87	1	late	late	ADJ
chd-130	87	2	event	event	NOUN
chd-130	87	3	of	of	ADP
chd-130	87	4	the	the	DET
chd-130	87	5	disease	disease	NOUN
chd-130	87	6	was	be	AUX
chd-130	87	7	likely	likely	ADJ
chd-130	87	8	to	to	PART
chd-130	87	9	be	be	AUX
chd-130	87	10	due	due	ADJ
chd-130	87	11	to	to	ADP
chd-130	87	12	presence	presence	NOUN
chd-130	87	13	of	of	ADP
chd-130	87	14	loh	loh	PROPN
chd-130	87	15	on	on	ADP
chd-130	87	16	chromosomal	chromosomal	ADJ
chd-130	87	17	sites	site	NOUN
chd-130	87	18	of	of	ADP
chd-130	87	19	13q	13q	NUM
chd-130	87	20	and	and	CCONJ
chd-130	87	21	18q	18q	NOUN
chd-130	87	22	.	.	PUNCT
chd-130	88	1	they	they	PRON
chd-130	88	2	observed	observe	VERB
chd-130	88	3	that	that	SCONJ
chd-130	88	4	loh	loh	PROPN
chd-130	88	5	on	on	ADP
chd-130	88	6	17p	17p	NOUN
chd-130	88	7	was	be	AUX
chd-130	88	8	present	present	ADJ
chd-130	88	9	not	not	PART
chd-130	88	10	only	only	ADV
chd-130	88	11	in	in	ADP
chd-130	88	12	dysplastic	dysplastic	ADJ
chd-130	88	13	disease	disease	NOUN
chd-130	88	14	but	but	CCONJ
chd-130	88	15	also	also	ADV
chd-130	88	16	found	find	VERB
chd-130	88	17	to	to	PART
chd-130	88	18	be	be	AUX
chd-130	88	19	higher	high	ADJ
chd-130	88	20	in	in	ADP
chd-130	88	21	the	the	DET
chd-130	88	22	different	different	ADJ
chd-130	88	23	stages	stage	NOUN
chd-130	88	24	of	of	ADP
chd-130	88	25	tumor	tumor	NOUN
chd-130	88	26	development	development	NOUN
chd-130	88	27	.	.	PUNCT
chd-130	89	1	the	the	DET
chd-130	89	2	authors	author	NOUN
chd-130	89	3	further	far	ADV
chd-130	89	4	demonstrated	demonstrate	VERB
chd-130	89	5	that	that	SCONJ
chd-130	89	6	while	while	SCONJ
chd-130	89	7	accumulation	accumulation	NOUN
chd-130	89	8	of	of	ADP
chd-130	89	9	loh	loh	PROPN
chd-130	89	10	was	be	AUX
chd-130	89	11	associated	associate	VERB
chd-130	89	12	with	with	ADP
chd-130	89	13	carcinogenesis	carcinogenesis	NOUN
chd-130	89	14	of	of	ADP
chd-130	89	15	the	the	DET
chd-130	89	16	gallbladder	gallbladder	NOUN
chd-130	89	17	,	,	PUNCT
chd-130	89	18	role	role	NOUN
chd-130	89	19	of	of	ADP
chd-130	89	20	mi	mi	PROPN
chd-130	89	21	was	be	AUX
chd-130	89	22	not	not	PART
chd-130	89	23	of	of	ADP
chd-130	89	24	much	much	ADJ
chd-130	89	25	significance	significance	NOUN
chd-130	89	26	(	(	PUNCT
chd-130	89	27	chang	chang	PROPN
chd-130	89	28	et	et	PROPN
chd-130	89	29	al	al	PROPN
chd-130	89	30	.	.	PROPN
chd-130	89	31	,	,	PUNCT
chd-130	89	32	1999	1999	NUM
chd-130	89	33	)	)	PUNCT
chd-130	89	34	.	.	PUNCT
chd-130	90	1	a	a	DET
chd-130	90	2	subsequent	subsequent	ADJ
chd-130	90	3	japanese	japanese	ADJ
chd-130	90	4	study	study	NOUN
chd-130	90	5	then	then	ADV
chd-130	90	6	aimed	aim	VERB
chd-130	90	7	to	to	PART
chd-130	90	8	investigate	investigate	VERB
chd-130	90	9	the	the	DET
chd-130	90	10	various	various	ADJ
chd-130	90	11	genetic	genetic	ADJ
chd-130	90	12	changes	change	NOUN
chd-130	90	13	associated	associate	VERB
chd-130	90	14	with	with	ADP
chd-130	90	15	gallbladder	gallbladder	NOUN
chd-130	90	16	carcinogenesis	carcinogenesis	NOUN
chd-130	90	17	and	and	CCONJ
chd-130	90	18	thus	thus	ADV
chd-130	90	19	implied	imply	VERB
chd-130	90	20	that	that	SCONJ
chd-130	90	21	the	the	DET
chd-130	90	22	presence	presence	NOUN
chd-130	90	23	of	of	ADP
chd-130	90	24	loh	loh	PROPN
chd-130	90	25	on	on	ADP
chd-130	90	26	chromosome	chromosome	NOUN
chd-130	90	27	17p	17p	NOUN
chd-130	90	28	led	lead	VERB
chd-130	90	29	to	to	ADP
chd-130	90	30	the	the	DET
chd-130	90	31	progression	progression	NOUN
chd-130	90	32	of	of	ADP
chd-130	90	33	gbc	gbc	PROPN
chd-130	90	34	at	at	ADP
chd-130	90	35	a	a	DET
chd-130	90	36	fairly	fairly	ADV
chd-130	90	37	early	early	ADJ
chd-130	90	38	stage	stage	NOUN
chd-130	90	39	,	,	PUNCT
chd-130	90	40	while	while	SCONJ
chd-130	90	41	presence	presence	NOUN
chd-130	90	42	of	of	ADP
chd-130	90	43	loh	loh	PROPN
chd-130	90	44	on	on	ADP
chd-130	90	45	18q	18q	NOUN
chd-130	90	46	and	and	CCONJ
chd-130	90	47	9p	9p	NUM
chd-130	90	48	played	play	VERB
chd-130	90	49	a	a	DET
chd-130	90	50	crucial	crucial	ADJ
chd-130	90	51	role	role	NOUN
chd-130	90	52	in	in	ADP
chd-130	90	53	further	further	ADJ
chd-130	90	54	advancement	advancement	NOUN
chd-130	90	55	of	of	ADP
chd-130	90	56	the	the	DET
chd-130	90	57	disease	disease	NOUN
chd-130	90	58	(	(	PUNCT
chd-130	90	59	hidaka	hidaka	X
chd-130	90	60	et	et	PROPN
chd-130	90	61	al	al	PROPN
chd-130	90	62	.	.	PROPN
chd-130	90	63	,	,	PUNCT
chd-130	90	64	1999	1999	NUM
chd-130	90	65	)	)	PUNCT
chd-130	90	66	.	.	PUNCT
chd-130	91	1	another	another	DET
chd-130	91	2	study	study	NOUN
chd-130	91	3	from	from	ADP
chd-130	91	4	japan	japan	PROPN
chd-130	91	5	emphasizing	emphasize	VERB
chd-130	91	6	on	on	ADP
chd-130	91	7	the	the	DET
chd-130	91	8	etiologic	etiologic	ADJ
chd-130	91	9	context	context	NOUN
chd-130	91	10	of	of	ADP
chd-130	91	11	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	91	12	maljunction	maljunction	NOUN
chd-130	91	13	,	,	PUNCT
chd-130	91	14	a	a	DET
chd-130	91	15	unique	unique	ADJ
chd-130	91	16	yet	yet	ADV
chd-130	91	17	an	an	DET
chd-130	91	18	important	important	ADJ
chd-130	91	19	factor	factor	NOUN
chd-130	91	20	associated	associate	VERB
chd-130	91	21	with	with	ADP
chd-130	91	22	gbc	gbc	PROPN
chd-130	91	23	in	in	ADP
chd-130	91	24	japanese	japanese	ADJ
chd-130	91	25	patients	patient	NOUN
chd-130	91	26	,	,	PUNCT
chd-130	91	27	hypothesized	hypothesize	VERB
chd-130	91	28	that	that	SCONJ
chd-130	91	29	hyperplastic	hyperplastic	ADJ
chd-130	91	30	epithelium	epithelium	NOUN
chd-130	91	31	played	play	VERB
chd-130	91	32	an	an	DET
chd-130	91	33	important	important	ADJ
chd-130	91	34	role	role	NOUN
chd-130	91	35	in	in	ADP
chd-130	91	36	carcinogenesis	carcinogenesis	NOUN
chd-130	91	37	.	.	PUNCT
chd-130	92	1	based	base	VERB
chd-130	92	2	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-130	92	3	e6	e6	VERB
chd-130	92	4	cancer	cancer	NOUN
chd-130	92	5	health	health	NOUN
chd-130	92	6	disparities	disparity	NOUN
chd-130	92	7	research	research	VERB
chd-130	92	8	on	on	ADP
chd-130	92	9	their	their	PRON
chd-130	92	10	findings	finding	NOUN
chd-130	92	11	,	,	PUNCT
chd-130	92	12	they	they	PRON
chd-130	92	13	believed	believe	VERB
chd-130	92	14	that	that	SCONJ
chd-130	92	15	development	development	NOUN
chd-130	92	16	of	of	ADP
chd-130	92	17	neoplasia	neoplasia	NOUN
chd-130	92	18	in	in	ADP
chd-130	92	19	a	a	DET
chd-130	92	20	gallbladder	gallbladder	NOUN
chd-130	92	21	with	with	ADP
chd-130	92	22	this	this	DET
chd-130	92	23	anatomic	anatomic	ADJ
chd-130	92	24	anomaly	anomaly	NOUN
chd-130	92	25	,	,	PUNCT
chd-130	92	26	advanced	advance	VERB
chd-130	92	27	through	through	ADP
chd-130	92	28	the	the	DET
chd-130	92	29	processes	process	NOUN
chd-130	92	30	of	of	ADP
chd-130	92	31	hyperproliferation	hyperproliferation	NOUN
chd-130	92	32	and	and	CCONJ
chd-130	92	33	genetic	genetic	ADJ
chd-130	92	34	variations	variation	NOUN
chd-130	92	35	(	(	PUNCT
chd-130	92	36	obara	obara	NOUN
chd-130	92	37	et	et	PROPN
chd-130	92	38	al	al	PROPN
chd-130	92	39	.	.	PROPN
chd-130	92	40	,	,	PUNCT
chd-130	92	41	1999	1999	NUM
chd-130	92	42	)	)	PUNCT
chd-130	92	43	.	.	PUNCT
chd-130	93	1	while	while	SCONJ
chd-130	93	2	most	most	ADJ
chd-130	93	3	of	of	ADP
chd-130	93	4	the	the	DET
chd-130	93	5	early	early	ADJ
chd-130	93	6	research	research	NOUN
chd-130	93	7	in	in	ADP
chd-130	93	8	japan	japan	PROPN
chd-130	93	9	was	be	AUX
chd-130	93	10	primarily	primarily	ADV
chd-130	93	11	focused	focus	VERB
chd-130	93	12	on	on	ADP
chd-130	93	13	genetic	genetic	ADJ
chd-130	93	14	alterations	alteration	NOUN
chd-130	93	15	in	in	ADP
chd-130	93	16	gbc	gbc	PROPN
chd-130	93	17	,	,	PUNCT
chd-130	93	18	a	a	DET
chd-130	93	19	group	group	NOUN
chd-130	93	20	of	of	ADP
chd-130	93	21	medical	medical	ADJ
chd-130	93	22	researchers	researcher	NOUN
chd-130	93	23	in	in	ADP
chd-130	93	24	varanasi	varanasi	NOUN
chd-130	93	25	,	,	PUNCT
chd-130	93	26	a	a	DET
chd-130	93	27	city	city	NOUN
chd-130	93	28	in	in	ADP
chd-130	93	29	india	india	PROPN
chd-130	93	30	located	locate	VERB
chd-130	93	31	on	on	ADP
chd-130	93	32	the	the	DET
chd-130	93	33	banks	bank	NOUN
chd-130	93	34	of	of	ADP
chd-130	93	35	river	river	NOUN
chd-130	93	36	ganges	gange	NOUN
chd-130	93	37	where	where	SCONJ
chd-130	93	38	incidence	incidence	NOUN
chd-130	93	39	of	of	ADP
chd-130	93	40	gbc	gbc	PROPN
chd-130	93	41	is	be	AUX
chd-130	93	42	very	very	ADV
chd-130	93	43	high	high	ADJ
chd-130	93	44	,	,	PUNCT
chd-130	93	45	started	start	VERB
chd-130	93	46	exploring	explore	VERB
chd-130	93	47	association	association	NOUN
chd-130	93	48	of	of	ADP
chd-130	93	49	various	various	ADJ
chd-130	93	50	etiologic	etiologic	ADJ
chd-130	93	51	agents	agent	NOUN
chd-130	93	52	and	and	CCONJ
chd-130	93	53	their	their	PRON
chd-130	93	54	role	role	NOUN
chd-130	93	55	in	in	ADP
chd-130	93	56	the	the	DET
chd-130	93	57	pathogenesis	pathogenesis	NOUN
chd-130	93	58	of	of	ADP
chd-130	93	59	this	this	DET
chd-130	93	60	cancer	cancer	NOUN
chd-130	93	61	.	.	PUNCT
chd-130	94	1	they	they	PRON
chd-130	94	2	were	be	AUX
chd-130	94	3	first	first	ADJ
chd-130	94	4	research	research	NOUN
chd-130	94	5	group	group	NOUN
chd-130	94	6	from	from	ADP
chd-130	94	7	india	india	PROPN
chd-130	94	8	,	,	PUNCT
chd-130	94	9	which	which	PRON
chd-130	94	10	demonstrated	demonstrate	VERB
chd-130	94	11	the	the	DET
chd-130	94	12	presence	presence	NOUN
chd-130	94	13	of	of	ADP
chd-130	94	14	salmonella	salmonella	NOUN
chd-130	94	15	typhi	typhi	VERB
chd-130	94	16	in	in	ADP
chd-130	94	17	gallbladder	gallbladder	NOUN
chd-130	94	18	cancer	cancer	NOUN
chd-130	94	19	tissues	tissue	NOUN
chd-130	94	20	as	as	SCONJ
chd-130	94	21	compared	compare	VERB
chd-130	94	22	to	to	PART
chd-130	94	23	control	control	VERB
chd-130	94	24	subjects	subject	NOUN
chd-130	94	25	and	and	CCONJ
chd-130	94	26	established	establish	VERB
chd-130	94	27	the	the	DET
chd-130	94	28	etiopathogenic	etiopathogenic	ADJ
chd-130	94	29	role	role	NOUN
chd-130	94	30	of	of	ADP
chd-130	94	31	chronic	chronic	ADJ
chd-130	94	32	typhoid	typhoid	NOUN
chd-130	94	33	carriage	carriage	NOUN
chd-130	94	34	in	in	ADP
chd-130	94	35	gallbladder	gallbladder	NOUN
chd-130	94	36	carcinogenesis	carcinogenesis	NOUN
chd-130	94	37	(	(	PUNCT
chd-130	94	38	nath	nath	NOUN
chd-130	94	39	et	et	PROPN
chd-130	94	40	al	al	PROPN
chd-130	94	41	.	.	PROPN
chd-130	94	42	,	,	PUNCT
chd-130	94	43	1997	1997	NUM
chd-130	94	44	)	)	PUNCT
chd-130	94	45	.	.	PUNCT
chd-130	95	1	another	another	DET
chd-130	95	2	important	important	ADJ
chd-130	95	3	study	study	NOUN
chd-130	95	4	from	from	ADP
chd-130	95	5	this	this	DET
chd-130	95	6	group	group	NOUN
chd-130	95	7	in	in	ADP
chd-130	95	8	varanasi	varanasi	PROPN
chd-130	95	9	,	,	PUNCT
chd-130	95	10	india	india	PROPN
chd-130	95	11	,	,	PUNCT
chd-130	95	12	demonstrated	demonstrate	VERB
chd-130	95	13	significantly	significantly	ADV
chd-130	95	14	higher	high	ADJ
chd-130	95	15	level	level	NOUN
chd-130	95	16	of	of	ADP
chd-130	95	17	heavy	heavy	ADJ
chd-130	95	18	metals	metal	NOUN
chd-130	95	19	such	such	ADJ
chd-130	95	20	as	as	ADP
chd-130	95	21	cadmium	cadmium	NOUN
chd-130	95	22	,	,	PUNCT
chd-130	95	23	chromium	chromium	NOUN
chd-130	95	24	,	,	PUNCT
chd-130	95	25	and	and	CCONJ
chd-130	95	26	lead	lead	VERB
chd-130	95	27	in	in	ADP
chd-130	95	28	the	the	DET
chd-130	95	29	patients	patient	NOUN
chd-130	95	30	of	of	ADP
chd-130	95	31	gbc	gbc	PROPN
chd-130	95	32	than	than	ADP
chd-130	95	33	in	in	ADP
chd-130	95	34	those	those	PRON
chd-130	95	35	with	with	ADP
chd-130	95	36	gall	gall	NOUN
chd-130	95	37	stones	stone	NOUN
chd-130	95	38	(	(	PUNCT
chd-130	95	39	shukla	shukla	NOUN
chd-130	95	40	et	et	NOUN
chd-130	95	41	al	al	PROPN
chd-130	95	42	.	.	PROPN
chd-130	95	43	,	,	PUNCT
chd-130	95	44	1998	1998	NUM
chd-130	95	45	)	)	PUNCT
chd-130	95	46	.	.	PUNCT
chd-130	96	1	role	role	NOUN
chd-130	96	2	of	of	ADP
chd-130	96	3	these	these	DET
chd-130	96	4	well	well	ADV
chd-130	96	5	-	-	PUNCT
chd-130	96	6	known	know	VERB
chd-130	96	7	chemical	chemical	NOUN
chd-130	96	8	carcinogens	carcinogen	NOUN
chd-130	96	9	was	be	AUX
chd-130	96	10	further	far	ADV
chd-130	96	11	corroborated	corroborate	VERB
chd-130	96	12	by	by	ADP
chd-130	96	13	the	the	DET
chd-130	96	14	presence	presence	NOUN
chd-130	96	15	of	of	ADP
chd-130	96	16	dangerously	dangerously	ADV
chd-130	96	17	high	high	ADJ
chd-130	96	18	concentrations	concentration	NOUN
chd-130	96	19	of	of	ADP
chd-130	96	20	these	these	DET
chd-130	96	21	metals	metal	NOUN
chd-130	96	22	in	in	ADP
chd-130	96	23	drinking	drink	VERB
chd-130	96	24	water	water	NOUN
chd-130	96	25	in	in	ADP
chd-130	96	26	this	this	DET
chd-130	96	27	geographic	geographic	ADJ
chd-130	96	28	location	location	NOUN
chd-130	96	29	of	of	ADP
chd-130	96	30	india	india	PROPN
chd-130	96	31	.	.	PUNCT
chd-130	97	1	interestingly	interestingly	ADV
chd-130	97	2	,	,	PUNCT
chd-130	97	3	more	more	ADJ
chd-130	97	4	than	than	ADP
chd-130	97	5	a	a	PRON
chd-130	97	6	decade	decade	NOUN
chd-130	97	7	later	later	ADV
chd-130	97	8	a	a	DET
chd-130	97	9	comparative	comparative	ADJ
chd-130	97	10	study	study	NOUN
chd-130	97	11	using	use	VERB
chd-130	97	12	resected	resect	VERB
chd-130	97	13	gallbladder	gallbladder	NOUN
chd-130	97	14	samples	sample	NOUN
chd-130	97	15	obtained	obtain	VERB
chd-130	97	16	from	from	ADP
chd-130	97	17	india	india	PROPN
chd-130	97	18	and	and	CCONJ
chd-130	97	19	japan	japan	PROPN
chd-130	97	20	confirmed	confirm	VERB
chd-130	97	21	that	that	SCONJ
chd-130	97	22	indian	indian	ADJ
chd-130	97	23	patients	patient	NOUN
chd-130	97	24	with	with	ADP
chd-130	97	25	gbc	gbc	PROPN
chd-130	97	26	had	have	VERB
chd-130	97	27	significantly	significantly	ADV
chd-130	97	28	higher	high	ADJ
chd-130	97	29	level	level	NOUN
chd-130	97	30	of	of	ADP
chd-130	97	31	chromium	chromium	NOUN
chd-130	97	32	,	,	PUNCT
chd-130	97	33	lead	lead	NOUN
chd-130	97	34	,	,	PUNCT
chd-130	97	35	arsenic	arsenic	NOUN
chd-130	97	36	and	and	CCONJ
chd-130	97	37	zinc	zinc	NOUN
chd-130	97	38	compared	compare	VERB
chd-130	97	39	to	to	ADP
chd-130	97	40	their	their	PRON
chd-130	97	41	japanese	japanese	ADJ
chd-130	97	42	counterparts	counterpart	NOUN
chd-130	97	43	(	(	PUNCT
chd-130	97	44	chhabra	chhabra	NOUN
chd-130	97	45	et	et	PROPN
chd-130	97	46	al	al	PROPN
chd-130	97	47	.	.	PROPN
chd-130	97	48	,	,	PUNCT
chd-130	97	49	2012	2012	NUM
chd-130	97	50	)	)	PUNCT
chd-130	97	51	.	.	PUNCT
chd-130	98	1	this	this	DET
chd-130	98	2	finding	finding	NOUN
chd-130	98	3	indicates	indicate	VERB
chd-130	98	4	towards	towards	ADP
chd-130	98	5	a	a	DET
chd-130	98	6	need	need	NOUN
chd-130	98	7	for	for	ADP
chd-130	98	8	more	more	ADV
chd-130	98	9	focused	focused	ADJ
chd-130	98	10	study	study	NOUN
chd-130	98	11	to	to	PART
chd-130	98	12	explore	explore	VERB
chd-130	98	13	the	the	DET
chd-130	98	14	role	role	NOUN
chd-130	98	15	of	of	ADP
chd-130	98	16	heavy	heavy	ADJ
chd-130	98	17	metals	metal	NOUN
chd-130	98	18	derived	derive	VERB
chd-130	98	19	genetic	genetic	ADJ
chd-130	98	20	aberrations	aberration	NOUN
chd-130	98	21	and	and	CCONJ
chd-130	98	22	relevant	relevant	ADJ
chd-130	98	23	signaling	signal	VERB
chd-130	98	24	pathways	pathway	NOUN
chd-130	98	25	so	so	SCONJ
chd-130	98	26	as	as	SCONJ
chd-130	98	27	to	to	PART
chd-130	98	28	develop	develop	VERB
chd-130	98	29	targeted	targeted	ADJ
chd-130	98	30	therapeutics	therapeutic	NOUN
chd-130	98	31	.	.	PUNCT
chd-130	99	1	by	by	ADP
chd-130	99	2	the	the	DET
chd-130	99	3	end	end	NOUN
chd-130	99	4	of	of	ADP
chd-130	99	5	1990s	1990s	NUM
chd-130	99	6	,	,	PUNCT
chd-130	99	7	it	it	PRON
chd-130	99	8	was	be	AUX
chd-130	99	9	widely	widely	ADV
chd-130	99	10	believed	believe	VERB
chd-130	99	11	that	that	SCONJ
chd-130	99	12	abnormalities	abnormality	NOUN
chd-130	99	13	in	in	ADP
chd-130	99	14	tp53	tp53	PROPN
chd-130	99	15	(	(	PUNCT
chd-130	99	16	17p13	17p13	NUM
chd-130	99	17	)	)	PUNCT
chd-130	99	18	and	and	CCONJ
chd-130	99	19	p16(ink4)/cdkn2	p16(ink4)/cdkn2	NOUN
chd-130	99	20	(	(	PUNCT
chd-130	99	21	9p21	9p21	NOUN
chd-130	99	22	-	-	PUNCT
chd-130	99	23	22	22	NUM
chd-130	99	24	)	)	PUNCT
chd-130	99	25	loci	locus	NOUN
chd-130	99	26	were	be	AUX
chd-130	99	27	regularly	regularly	ADV
chd-130	99	28	encountered	encounter	VERB
chd-130	99	29	and	and	CCONJ
chd-130	99	30	frequently	frequently	ADV
chd-130	99	31	associated	associate	VERB
chd-130	99	32	with	with	ADP
chd-130	99	33	early	early	ADJ
chd-130	99	34	pathogenesis	pathogenesis	NOUN
chd-130	99	35	of	of	ADP
chd-130	99	36	the	the	DET
chd-130	99	37	neoplastic	neoplastic	ADJ
chd-130	99	38	disease	disease	NOUN
chd-130	99	39	of	of	ADP
chd-130	99	40	the	the	DET
chd-130	99	41	gallbladder	gallbladder	NOUN
chd-130	99	42	.	.	PUNCT
chd-130	100	1	mutations	mutation	NOUN
chd-130	100	2	in	in	ADP
chd-130	100	3	the	the	DET
chd-130	100	4	k	k	PROPN
chd-130	100	5	-	-	PUNCT
chd-130	100	6	ras	ras	ADJ
chd-130	100	7	genes	gene	NOUN
chd-130	100	8	appeared	appear	VERB
chd-130	100	9	to	to	PART
chd-130	100	10	be	be	AUX
chd-130	100	11	a	a	DET
chd-130	100	12	rare	rare	ADJ
chd-130	100	13	neoplastic	neoplastic	ADJ
chd-130	100	14	event	event	NOUN
chd-130	100	15	,	,	PUNCT
chd-130	100	16	the	the	DET
chd-130	100	17	exceptions	exception	NOUN
chd-130	100	18	of	of	ADP
chd-130	100	19	which	which	PRON
chd-130	100	20	included	include	VERB
chd-130	100	21	anomaly	anomaly	NOUN
chd-130	100	22	associated	associated	PROPN
chd-130	100	23	gbc	gbc	PROPN
chd-130	100	24	.	.	PUNCT
chd-130	101	1	the	the	DET
chd-130	101	2	sequence	sequence	NOUN
chd-130	101	3	of	of	ADP
chd-130	101	4	dysplasia	dysplasia	NOUN
chd-130	101	5	to	to	ADP
chd-130	101	6	carcinoma	carcinoma	NOUN
chd-130	101	7	(	(	PUNCT
chd-130	101	8	cis	cis	NOUN
chd-130	101	9	)	)	PUNCT
chd-130	101	10	was	be	AUX
chd-130	101	11	believed	believe	VERB
chd-130	101	12	to	to	PART
chd-130	101	13	be	be	AUX
chd-130	101	14	a	a	DET
chd-130	101	15	major	major	ADJ
chd-130	101	16	route	route	NOUN
chd-130	101	17	for	for	ADP
chd-130	101	18	the	the	DET
chd-130	101	19	development	development	NOUN
chd-130	101	20	of	of	ADP
chd-130	101	21	this	this	DET
chd-130	101	22	disease	disease	NOUN
chd-130	101	23	in	in	ADP
chd-130	101	24	gallbladders	gallbladder	NOUN
chd-130	101	25	with	with	ADP
chd-130	101	26	associated	associated	ADJ
chd-130	101	27	anomalies	anomaly	NOUN
chd-130	101	28	(	(	PUNCT
chd-130	101	29	wistuba	wistuba	PROPN
chd-130	101	30	et	et	PROPN
chd-130	101	31	al	al	PROPN
chd-130	101	32	.	.	PROPN
chd-130	101	33	,	,	PUNCT
chd-130	101	34	1999	1999	NUM
chd-130	101	35	)	)	PUNCT
chd-130	101	36	.	.	PUNCT
chd-130	102	1	in	in	ADP
chd-130	102	2	a	a	DET
chd-130	102	3	small	small	ADJ
chd-130	102	4	but	but	CCONJ
chd-130	102	5	significant	significant	ADJ
chd-130	102	6	study	study	NOUN
chd-130	102	7	that	that	PRON
chd-130	102	8	examined	examine	VERB
chd-130	102	9	the	the	DET
chd-130	102	10	role	role	NOUN
chd-130	102	11	of	of	ADP
chd-130	102	12	genetic	genetic	ADJ
chd-130	102	13	variation	variation	NOUN
chd-130	102	14	in	in	ADP
chd-130	102	15	tumorigenesis	tumorigenesis	NOUN
chd-130	102	16	and	and	CCONJ
chd-130	102	17	as	as	ADP
chd-130	102	18	to	to	ADP
chd-130	102	19	how	how	SCONJ
chd-130	102	20	these	these	DET
chd-130	102	21	variations	variation	NOUN
chd-130	102	22	were	be	AUX
chd-130	102	23	associated	associate	VERB
chd-130	102	24	with	with	ADP
chd-130	102	25	the	the	DET
chd-130	102	26	clinicopathological	clinicopathological	ADJ
chd-130	102	27	features	feature	NOUN
chd-130	102	28	of	of	ADP
chd-130	102	29	gbc	gbc	PROPN
chd-130	102	30	using	use	VERB
chd-130	102	31	multiple	multiple	ADJ
chd-130	102	32	markers	marker	NOUN
chd-130	102	33	to	to	PART
chd-130	102	34	study	study	VERB
chd-130	102	35	msi	msi	PROPN
chd-130	102	36	and	and	CCONJ
chd-130	102	37	loh	loh	PROPN
chd-130	102	38	,	,	PUNCT
chd-130	102	39	authors	author	NOUN
chd-130	102	40	observed	observe	VERB
chd-130	102	41	that	that	SCONJ
chd-130	102	42	there	there	PRON
chd-130	102	43	was	be	VERB
chd-130	102	44	one	one	NUM
chd-130	102	45	genetic	genetic	ADJ
chd-130	102	46	pathway	pathway	NOUN
chd-130	102	47	dependent	dependent	ADJ
chd-130	102	48	on	on	ADP
chd-130	102	49	the	the	DET
chd-130	102	50	msi	msi	PROPN
chd-130	102	51	pathway	pathway	NOUN
chd-130	102	52	and	and	CCONJ
chd-130	102	53	another	another	PRON
chd-130	102	54	on	on	ADP
chd-130	102	55	loh	loh	PROPN
chd-130	102	56	pathway	pathway	NOUN
chd-130	102	57	in	in	ADP
chd-130	102	58	gbc	gbc	PROPN
chd-130	103	1	[	[	X
chd-130	103	2	31	31	NUM
chd-130	103	3	]	]	PUNCT
chd-130	103	4	.	.	PUNCT
chd-130	104	1	interestingly	interestingly	ADV
chd-130	104	2	,	,	PUNCT
chd-130	104	3	metastasis	metastasis	NOUN
chd-130	104	4	to	to	ADP
chd-130	104	5	the	the	DET
chd-130	104	6	lymph	lymph	NOUN
chd-130	104	7	nodes	node	NOUN
chd-130	104	8	was	be	AUX
chd-130	104	9	not	not	PART
chd-130	104	10	seen	see	VERB
chd-130	104	11	in	in	ADP
chd-130	104	12	patients	patient	NOUN
chd-130	104	13	with	with	ADP
chd-130	104	14	msipositive	msipositive	ADJ
chd-130	104	15	tumors	tumor	NOUN
chd-130	104	16	.	.	PUNCT
chd-130	105	1	an	an	DET
chd-130	105	2	inverse	inverse	NOUN
chd-130	105	3	relationship	relationship	NOUN
chd-130	105	4	was	be	AUX
chd-130	105	5	also	also	ADV
chd-130	105	6	found	find	VERB
chd-130	105	7	between	between	ADP
chd-130	105	8	the	the	DET
chd-130	105	9	presence	presence	NOUN
chd-130	105	10	of	of	ADP
chd-130	105	11	loh	loh	PROPN
chd-130	105	12	and	and	CCONJ
chd-130	105	13	msi	msi	PROPN
chd-130	105	14	in	in	ADP
chd-130	105	15	gbc	gbc	PROPN
chd-130	105	16	(	(	PUNCT
chd-130	105	17	yoshida	yoshida	PROPN
chd-130	105	18	et	et	PROPN
chd-130	105	19	al	al	PROPN
chd-130	105	20	.	.	PROPN
chd-130	105	21	,	,	PUNCT
chd-130	105	22	2000	2000	NUM
chd-130	105	23	)	)	PUNCT
chd-130	105	24	.	.	PUNCT
chd-130	106	1	soon	soon	ADV
chd-130	106	2	,	,	PUNCT
chd-130	106	3	a	a	DET
chd-130	106	4	korean	korean	ADJ
chd-130	106	5	study	study	NOUN
chd-130	106	6	demonstrated	demonstrate	VERB
chd-130	106	7	that	that	SCONJ
chd-130	106	8	development	development	NOUN
chd-130	106	9	of	of	ADP
chd-130	106	10	dysplastic	dysplastic	ADJ
chd-130	106	11	and/or	and/or	CCONJ
chd-130	106	12	subsequent	subsequent	ADJ
chd-130	106	13	malignant	malignant	ADJ
chd-130	106	14	features	feature	NOUN
chd-130	106	15	in	in	ADP
chd-130	106	16	gbc	gbc	PROPN
chd-130	106	17	was	be	AUX
chd-130	106	18	associated	associate	VERB
chd-130	106	19	with	with	ADP
chd-130	106	20	the	the	DET
chd-130	106	21	presence	presence	NOUN
chd-130	106	22	of	of	ADP
chd-130	106	23	multiple	multiple	ADJ
chd-130	106	24	loh	loh	PROPN
chd-130	106	25	.	.	PUNCT
chd-130	107	1	malignant	malignant	ADJ
chd-130	107	2	changes	change	NOUN
chd-130	107	3	from	from	ADP
chd-130	107	4	dysplastic	dysplastic	ADJ
chd-130	107	5	gallbladder	gallbladder	NOUN
chd-130	107	6	was	be	AUX
chd-130	107	7	associated	associate	VERB
chd-130	107	8	with	with	ADP
chd-130	107	9	alterations	alteration	NOUN
chd-130	107	10	in	in	ADP
chd-130	107	11	k	k	PROPN
chd-130	107	12	-	-	PUNCT
chd-130	107	13	ras	ras	NOUN
chd-130	107	14	,	,	PUNCT
chd-130	107	15	p53	p53	NOUN
chd-130	107	16	and	and	CCONJ
chd-130	107	17	p16	p16	NOUN
chd-130	107	18	genes	gene	NOUN
chd-130	107	19	,	,	PUNCT
chd-130	107	20	while	while	SCONJ
chd-130	107	21	role	role	NOUN
chd-130	107	22	of	of	ADP
chd-130	107	23	msi	msi	PROPN
chd-130	107	24	is	be	AUX
chd-130	107	25	limited	limit	VERB
chd-130	107	26	in	in	ADP
chd-130	107	27	the	the	DET
chd-130	107	28	development	development	NOUN
chd-130	107	29	of	of	ADP
chd-130	107	30	gbc	gbc	PROPN
chd-130	107	31	(	(	PUNCT
chd-130	107	32	kim	kim	PROPN
chd-130	107	33	et	et	PROPN
chd-130	107	34	al	al	PROPN
chd-130	107	35	.	.	PROPN
chd-130	107	36	,	,	PUNCT
chd-130	107	37	2001	2001	NUM
chd-130	107	38	)	)	PUNCT
chd-130	107	39	.	.	PUNCT
chd-130	108	1	however	however	ADV
chd-130	108	2	,	,	PUNCT
chd-130	108	3	a	a	DET
chd-130	108	4	follow	follow	VERB
chd-130	108	5	up	up	ADP
chd-130	108	6	report	report	NOUN
chd-130	108	7	from	from	ADP
chd-130	108	8	chile	chile	PROPN
chd-130	108	9	which	which	PRON
chd-130	108	10	is	be	AUX
chd-130	108	11	another	another	DET
chd-130	108	12	geographic	geographic	ADJ
chd-130	108	13	area	area	NOUN
chd-130	108	14	almost	almost	ADV
chd-130	108	15	endemic	endemic	ADJ
chd-130	108	16	for	for	ADP
chd-130	108	17	gbc	gbc	PROPN
chd-130	108	18	,	,	PUNCT
chd-130	108	19	emphasized	emphasize	VERB
chd-130	108	20	the	the	DET
chd-130	108	21	role	role	NOUN
chd-130	108	22	of	of	ADP
chd-130	108	23	msi	msi	PROPN
chd-130	108	24	in	in	ADP
chd-130	108	25	gbc	gbc	PROPN
chd-130	108	26	(	(	PUNCT
chd-130	108	27	roa	roa	PROPN
chd-130	108	28	et	et	PROPN
chd-130	108	29	al	al	PROPN
chd-130	108	30	.	.	PROPN
chd-130	108	31	,	,	PUNCT
chd-130	108	32	2005	2005	NUM
chd-130	108	33	)	)	PUNCT
chd-130	108	34	.	.	PUNCT
chd-130	109	1	this	this	DET
chd-130	109	2	group	group	NOUN
chd-130	109	3	observed	observe	VERB
chd-130	109	4	msi	msi	NOUN
chd-130	109	5	in	in	ADP
chd-130	109	6	equal	equal	ADJ
chd-130	109	7	proportions	proportion	NOUN
chd-130	109	8	in	in	ADP
chd-130	109	9	early	early	ADV
chd-130	109	10	as	as	ADV
chd-130	109	11	well	well	ADV
chd-130	109	12	as	as	ADP
chd-130	109	13	late	late	ADJ
chd-130	109	14	stages	stage	NOUN
chd-130	109	15	of	of	ADP
chd-130	109	16	gbc	gbc	PROPN
chd-130	109	17	.	.	PUNCT
chd-130	110	1	they	they	PRON
chd-130	110	2	also	also	ADV
chd-130	110	3	demonstrated	demonstrate	VERB
chd-130	110	4	that	that	SCONJ
chd-130	110	5	msi	msi	PROPN
chd-130	110	6	was	be	AUX
chd-130	110	7	seen	see	VERB
chd-130	110	8	in	in	ADP
chd-130	110	9	premalignant	premalignant	ADJ
chd-130	110	10	lesions	lesion	NOUN
chd-130	110	11	and	and	CCONJ
chd-130	110	12	indicated	indicate	VERB
chd-130	110	13	that	that	SCONJ
chd-130	110	14	inactivation	inactivation	NOUN
chd-130	110	15	of	of	ADP
chd-130	110	16	hmlh1	hmlh1	PROPN
chd-130	110	17	,	,	PUNCT
chd-130	110	18	hmsh2	hmsh2	ADJ
chd-130	110	19	,	,	PUNCT
chd-130	110	20	and	and	CCONJ
chd-130	110	21	hmsh6	hmsh6	NOUN
chd-130	110	22	,	,	PUNCT
chd-130	110	23	genes	gene	NOUN
chd-130	110	24	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-130	110	25	e7	e7	PROPN
chd-130	110	26	cancer	cancer	NOUN
chd-130	110	27	health	health	NOUN
chd-130	110	28	disparities	disparity	NOUN
chd-130	110	29	research	research	NOUN
chd-130	110	30	were	be	AUX
chd-130	110	31	responsible	responsible	ADJ
chd-130	110	32	for	for	ADP
chd-130	110	33	mismatch	mismatch	ADJ
chd-130	110	34	repair	repair	NOUN
chd-130	110	35	,	,	PUNCT
chd-130	110	36	occurred	occur	VERB
chd-130	110	37	early	early	ADV
chd-130	110	38	in	in	ADP
chd-130	110	39	gallbladder	gallbladder	NOUN
chd-130	110	40	carcinogenesis	carcinogenesis	NOUN
chd-130	110	41	.	.	PUNCT
chd-130	111	1	in	in	ADP
chd-130	111	2	the	the	DET
chd-130	111	3	meantime	meantime	NOUN
chd-130	111	4	,	,	PUNCT
chd-130	111	5	contradicting	contradict	VERB
chd-130	111	6	reports	report	NOUN
chd-130	111	7	on	on	ADP
chd-130	111	8	the	the	DET
chd-130	111	9	role	role	NOUN
chd-130	111	10	of	of	ADP
chd-130	111	11	msi	msi	PROPN
chd-130	111	12	in	in	ADP
chd-130	111	13	gbc	gbc	PROPN
chd-130	111	14	kept	keep	VERB
chd-130	111	15	emerging	emerge	VERB
chd-130	111	16	from	from	ADP
chd-130	111	17	different	different	ADJ
chd-130	111	18	parts	part	NOUN
chd-130	111	19	of	of	ADP
chd-130	111	20	the	the	DET
chd-130	111	21	world	world	NOUN
chd-130	111	22	.	.	PUNCT
chd-130	112	1	a	a	DET
chd-130	112	2	greek	greek	ADJ
chd-130	112	3	study	study	NOUN
chd-130	112	4	in	in	ADP
chd-130	112	5	2006	2006	NUM
chd-130	112	6	asserted	assert	VERB
chd-130	112	7	the	the	DET
chd-130	112	8	role	role	NOUN
chd-130	112	9	of	of	ADP
chd-130	112	10	msi	msi	PROPN
chd-130	112	11	in	in	ADP
chd-130	112	12	gbc	gbc	PROPN
chd-130	112	13	was	be	AUX
chd-130	112	14	minor	minor	ADJ
chd-130	112	15	(	(	PUNCT
chd-130	112	16	saetta	saetta	PROPN
chd-130	112	17	et	et	PROPN
chd-130	112	18	al	al	PROPN
chd-130	112	19	.	.	PROPN
chd-130	112	20	,	,	PUNCT
chd-130	112	21	2001	2001	NUM
chd-130	112	22	)	)	PUNCT
chd-130	112	23	.	.	PUNCT
chd-130	113	1	however	however	ADV
chd-130	113	2	,	,	PUNCT
chd-130	113	3	it	it	PRON
chd-130	113	4	is	be	AUX
chd-130	113	5	vital	vital	ADJ
chd-130	113	6	to	to	PART
chd-130	113	7	make	make	VERB
chd-130	113	8	a	a	DET
chd-130	113	9	note	note	NOUN
chd-130	113	10	of	of	ADP
chd-130	113	11	the	the	DET
chd-130	113	12	differences	difference	NOUN
chd-130	113	13	in	in	ADP
chd-130	113	14	the	the	DET
chd-130	113	15	results	result	NOUN
chd-130	113	16	which	which	PRON
chd-130	113	17	could	could	AUX
chd-130	113	18	be	be	AUX
chd-130	113	19	due	due	ADJ
chd-130	113	20	to	to	ADP
chd-130	113	21	a	a	DET
chd-130	113	22	varied	varied	ADJ
chd-130	113	23	selection	selection	NOUN
chd-130	113	24	of	of	ADP
chd-130	113	25	markers	marker	NOUN
chd-130	113	26	required	require	VERB
chd-130	113	27	to	to	PART
chd-130	113	28	study	study	VERB
chd-130	113	29	msi	msi	NOUN
chd-130	113	30	.	.	PUNCT
chd-130	114	1	it	it	PRON
chd-130	114	2	is	be	AUX
chd-130	114	3	also	also	ADV
chd-130	114	4	imperative	imperative	ADJ
chd-130	114	5	to	to	PART
chd-130	114	6	note	note	VERB
chd-130	114	7	the	the	DET
chd-130	114	8	role	role	NOUN
chd-130	114	9	of	of	ADP
chd-130	114	10	different	different	ADJ
chd-130	114	11	mechanisms	mechanism	NOUN
chd-130	114	12	due	due	ADJ
chd-130	114	13	to	to	ADP
chd-130	114	14	varied	varied	ADJ
chd-130	114	15	etiologies	etiology	NOUN
chd-130	114	16	in	in	ADP
chd-130	114	17	a	a	DET
chd-130	114	18	diverse	diverse	ADJ
chd-130	114	19	patient	patient	ADJ
chd-130	114	20	population	population	NOUN
chd-130	114	21	,	,	PUNCT
chd-130	114	22	as	as	ADP
chd-130	114	23	a	a	DET
chd-130	114	24	possibility	possibility	NOUN
chd-130	114	25	.	.	PUNCT
chd-130	115	1	availability	availability	NOUN
chd-130	115	2	of	of	ADP
chd-130	115	3	newer	new	ADJ
chd-130	115	4	and	and	CCONJ
chd-130	115	5	more	more	ADV
chd-130	115	6	effective	effective	ADJ
chd-130	115	7	molecular	molecular	ADJ
chd-130	115	8	methods	method	NOUN
chd-130	115	9	in	in	ADP
chd-130	115	10	the	the	DET
chd-130	115	11	early	early	ADJ
chd-130	115	12	years	year	NOUN
chd-130	115	13	of	of	ADP
chd-130	115	14	the	the	DET
chd-130	115	15	21st	21st	ADJ
chd-130	115	16	century	century	NOUN
chd-130	115	17	made	make	VERB
chd-130	115	18	it	it	PRON
chd-130	115	19	possible	possible	ADJ
chd-130	115	20	for	for	SCONJ
chd-130	115	21	gallbladder	gallbladder	NOUN
chd-130	115	22	researchers	researcher	NOUN
chd-130	115	23	to	to	PART
chd-130	115	24	conduct	conduct	VERB
chd-130	115	25	more	more	ADJ
chd-130	115	26	studies	study	NOUN
chd-130	115	27	using	use	VERB
chd-130	115	28	sophisticated	sophisticated	ADJ
chd-130	115	29	analyses	analysis	NOUN
chd-130	115	30	to	to	PART
chd-130	115	31	detect	detect	VERB
chd-130	115	32	molecular	molecular	ADJ
chd-130	115	33	alterations	alteration	NOUN
chd-130	115	34	in	in	ADP
chd-130	115	35	gallbladder	gallbladder	NOUN
chd-130	115	36	carcinogenesis	carcinogenesis	NOUN
chd-130	115	37	.	.	PUNCT
chd-130	116	1	a	a	DET
chd-130	116	2	japanese	japanese	ADJ
chd-130	116	3	study	study	NOUN
chd-130	116	4	using	use	VERB
chd-130	116	5	allelotyping	allelotype	VERB
chd-130	116	6	analysis	analysis	NOUN
chd-130	116	7	demonstrated	demonstrate	VERB
chd-130	116	8	that	that	SCONJ
chd-130	116	9	gbc	gbc	PROPN
chd-130	116	10	associated	associate	VERB
chd-130	116	11	with	with	ADP
chd-130	116	12	anomalous	anomalous	ADJ
chd-130	116	13	junction	junction	NOUN
chd-130	116	14	of	of	ADP
chd-130	116	15	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	116	16	duct	duct	NOUN
chd-130	116	17	(	(	PUNCT
chd-130	116	18	ajpbd	ajpbd	NOUN
chd-130	116	19	)	)	PUNCT
chd-130	116	20	exhibited	exhibit	VERB
chd-130	116	21	a	a	DET
chd-130	116	22	high	high	ADJ
chd-130	116	23	frequency	frequency	NOUN
chd-130	116	24	of	of	ADP
chd-130	116	25	loss	loss	NOUN
chd-130	116	26	of	of	ADP
chd-130	116	27	alleles	allele	NOUN
chd-130	116	28	along	along	ADV
chd-130	116	29	with	with	ADP
chd-130	116	30	the	the	DET
chd-130	116	31	presence	presence	NOUN
chd-130	116	32	of	of	ADP
chd-130	116	33	two	two	NUM
chd-130	116	34	new	new	ADJ
chd-130	116	35	regions	region	NOUN
chd-130	116	36	,	,	PUNCT
chd-130	116	37	believed	believe	VERB
chd-130	116	38	to	to	PART
chd-130	116	39	harbor	harbor	VERB
chd-130	116	40	genes	gene	NOUN
chd-130	116	41	with	with	ADP
chd-130	116	42	putative	putative	ADJ
chd-130	116	43	tumor	tumor	NOUN
chd-130	116	44	suppressor	suppressor	NOUN
chd-130	116	45	function	function	NOUN
chd-130	116	46	(	(	PUNCT
chd-130	116	47	nakayama	nakayama	PROPN
chd-130	116	48	et	et	PROPN
chd-130	116	49	al	al	PROPN
chd-130	116	50	.	.	PROPN
chd-130	116	51	,	,	PUNCT
chd-130	116	52	2001	2001	NUM
chd-130	116	53	)	)	PUNCT
chd-130	116	54	.	.	PUNCT
chd-130	117	1	in	in	ADP
chd-130	117	2	the	the	DET
chd-130	117	3	same	same	ADJ
chd-130	117	4	year	year	NOUN
chd-130	117	5	,	,	PUNCT
chd-130	117	6	a	a	DET
chd-130	117	7	group	group	NOUN
chd-130	117	8	of	of	ADP
chd-130	117	9	investigators	investigator	NOUN
chd-130	117	10	from	from	ADP
chd-130	117	11	johns	johns	PROPN
chd-130	117	12	hopkins	hopkins	PROPN
chd-130	117	13	medical	medical	PROPN
chd-130	117	14	institute	institute	PROPN
chd-130	117	15	in	in	ADP
chd-130	117	16	the	the	DET
chd-130	117	17	usa	usa	PROPN
chd-130	117	18	developed	develop	VERB
chd-130	117	19	their	their	PRON
chd-130	117	20	interest	interest	NOUN
chd-130	117	21	in	in	ADP
chd-130	117	22	studying	study	VERB
chd-130	117	23	this	this	DET
chd-130	117	24	intriguing	intriguing	ADJ
chd-130	117	25	disease	disease	NOUN
chd-130	117	26	and	and	CCONJ
chd-130	117	27	used	use	VERB
chd-130	117	28	genome	genome	NOUN
chd-130	117	29	-	-	PUNCT
chd-130	117	30	wide	wide	ADJ
chd-130	117	31	allelotyping	allelotyping	NOUN
chd-130	117	32	analysis	analysis	NOUN
chd-130	117	33	,	,	PUNCT
chd-130	117	34	a	a	DET
chd-130	117	35	sophisticated	sophisticated	ADJ
chd-130	117	36	global	global	ADJ
chd-130	117	37	analytical	analytical	ADJ
chd-130	117	38	technique	technique	NOUN
chd-130	117	39	,	,	PUNCT
chd-130	117	40	to	to	PART
chd-130	117	41	reveal	reveal	VERB
chd-130	117	42	multiple	multiple	ADJ
chd-130	117	43	sites	site	NOUN
chd-130	117	44	of	of	ADP
chd-130	117	45	allelic	allelic	ADJ
chd-130	117	46	loss	loss	NOUN
chd-130	117	47	in	in	ADP
chd-130	117	48	gbc	gbc	PROPN
chd-130	117	49	(	(	PUNCT
chd-130	117	50	wistuba	wistuba	PROPN
chd-130	117	51	et	et	PROPN
chd-130	117	52	al	al	PROPN
chd-130	117	53	.	.	PROPN
chd-130	117	54	,	,	PUNCT
chd-130	117	55	2001	2001	NUM
chd-130	117	56	)	)	PUNCT
chd-130	117	57	.	.	PUNCT
chd-130	118	1	according	accord	VERB
chd-130	118	2	to	to	ADP
chd-130	118	3	this	this	DET
chd-130	118	4	study	study	NOUN
chd-130	118	5	,	,	PUNCT
chd-130	118	6	frequent	frequent	ADJ
chd-130	118	7	allele	allele	NOUN
chd-130	118	8	losses	loss	NOUN
chd-130	118	9	were	be	AUX
chd-130	118	10	seen	see	VERB
chd-130	118	11	in	in	ADP
chd-130	118	12	21	21	NUM
chd-130	118	13	chromosomal	chromosomal	ADJ
chd-130	118	14	regions	region	NOUN
chd-130	118	15	,	,	PUNCT
chd-130	118	16	thereby	thereby	ADV
chd-130	118	17	being	be	AUX
chd-130	118	18	suggestive	suggestive	ADJ
chd-130	118	19	of	of	ADP
chd-130	118	20	the	the	DET
chd-130	118	21	inactivation	inactivation	NOUN
chd-130	118	22	of	of	ADP
chd-130	118	23	the	the	DET
chd-130	118	24	supposed	suppose	VERB
chd-130	118	25	tumor	tumor	NOUN
chd-130	118	26	suppressor	suppressor	NOUN
chd-130	118	27	genes	gene	NOUN
chd-130	118	28	in	in	ADP
chd-130	118	29	the	the	DET
chd-130	118	30	pathogenesis	pathogenesis	NOUN
chd-130	118	31	of	of	ADP
chd-130	118	32	gbc	gbc	PROPN
chd-130	118	33	.	.	PUNCT
chd-130	119	1	this	this	DET
chd-130	119	2	study	study	NOUN
chd-130	119	3	was	be	AUX
chd-130	119	4	the	the	DET
chd-130	119	5	first	first	ADJ
chd-130	119	6	of	of	ADP
chd-130	119	7	its	its	PRON
chd-130	119	8	kind	kind	NOUN
chd-130	119	9	,	,	PUNCT
chd-130	119	10	that	that	SCONJ
chd-130	119	11	too	too	ADV
chd-130	119	12	from	from	ADP
chd-130	119	13	west	west	PROPN
chd-130	119	14	,	,	PUNCT
chd-130	119	15	where	where	SCONJ
chd-130	119	16	gbc	gbc	PROPN
chd-130	119	17	is	be	AUX
chd-130	119	18	a	a	DET
chd-130	119	19	rare	rare	ADJ
chd-130	119	20	disease	disease	NOUN
chd-130	119	21	,	,	PUNCT
chd-130	119	22	to	to	PART
chd-130	119	23	provide	provide	VERB
chd-130	119	24	a	a	DET
chd-130	119	25	global	global	ADJ
chd-130	119	26	estimate	estimate	NOUN
chd-130	119	27	of	of	ADP
chd-130	119	28	the	the	DET
chd-130	119	29	extent	extent	NOUN
chd-130	119	30	to	to	PART
chd-130	119	31	which	which	PRON
chd-130	119	32	genetic	genetic	ADJ
chd-130	119	33	changes	change	NOUN
chd-130	119	34	were	be	AUX
chd-130	119	35	involved	involve	VERB
chd-130	119	36	in	in	ADP
chd-130	119	37	gbc	gbc	PROPN
chd-130	119	38	development	development	NOUN
chd-130	119	39	and	and	CCONJ
chd-130	119	40	to	to	PART
chd-130	119	41	have	have	VERB
chd-130	119	42	the	the	DET
chd-130	119	43	potential	potential	NOUN
chd-130	119	44	to	to	PART
chd-130	119	45	identify	identify	VERB
chd-130	119	46	new	new	ADJ
chd-130	119	47	tumor	tumor	NOUN
chd-130	119	48	suppressor	suppressor	NOUN
chd-130	119	49	genes	gene	NOUN
chd-130	119	50	and	and	CCONJ
chd-130	119	51	thus	thus	ADV
chd-130	119	52	identifying	identify	VERB
chd-130	119	53	numerous	numerous	ADJ
chd-130	119	54	new	new	ADJ
chd-130	119	55	markers	marker	NOUN
chd-130	119	56	in	in	ADP
chd-130	119	57	translational	translational	ADJ
chd-130	119	58	research	research	NOUN
chd-130	119	59	.	.	PUNCT
chd-130	120	1	another	another	DET
chd-130	120	2	similar	similar	ADJ
chd-130	120	3	study	study	NOUN
chd-130	120	4	followed	follow	VERB
chd-130	120	5	up	up	ADP
chd-130	120	6	in	in	ADP
chd-130	120	7	the	the	DET
chd-130	120	8	the	the	DET
chd-130	120	9	same	same	ADJ
chd-130	120	10	year	year	NOUN
chd-130	120	11	from	from	ADP
chd-130	120	12	europe	europe	PROPN
chd-130	120	13	,	,	PUNCT
chd-130	120	14	also	also	ADV
chd-130	120	15	demonstrated	demonstrate	VERB
chd-130	120	16	that	that	SCONJ
chd-130	120	17	alterations	alteration	NOUN
chd-130	120	18	in	in	ADP
chd-130	120	19	the	the	DET
chd-130	120	20	p53	p53	NOUN
chd-130	120	21	gene	gene	NOUN
chd-130	120	22	had	have	VERB
chd-130	120	23	a	a	DET
chd-130	120	24	likely	likely	ADJ
chd-130	120	25	role	role	NOUN
chd-130	120	26	in	in	ADP
chd-130	120	27	the	the	DET
chd-130	120	28	new	new	ADJ
chd-130	120	29	pathway	pathway	NOUN
chd-130	120	30	of	of	ADP
chd-130	120	31	gallbladder	gallbladder	NOUN
chd-130	120	32	carcinogenesis	carcinogenesis	NOUN
chd-130	120	33	(	(	PUNCT
chd-130	120	34	saetta	saetta	PROPN
chd-130	120	35	et	et	PROPN
chd-130	120	36	al	al	PROPN
chd-130	120	37	.	.	PROPN
chd-130	120	38	,	,	PUNCT
chd-130	120	39	2001	2001	NUM
chd-130	120	40	)	)	PUNCT
chd-130	120	41	.	.	PUNCT
chd-130	121	1	one	one	NUM
chd-130	121	2	of	of	ADP
chd-130	121	3	the	the	DET
chd-130	121	4	most	most	ADV
chd-130	121	5	significant	significant	ADJ
chd-130	121	6	studies	study	NOUN
chd-130	121	7	reporting	report	VERB
chd-130	121	8	other	other	ADJ
chd-130	121	9	aberrated	aberrate	VERB
chd-130	121	10	molecular	molecular	ADJ
chd-130	121	11	lesions	lesion	NOUN
chd-130	121	12	(	(	PUNCT
chd-130	121	13	besides	besides	SCONJ
chd-130	121	14	p53	p53	NOUN
chd-130	121	15	and	and	CCONJ
chd-130	121	16	kras	kra	NOUN
chd-130	121	17	)	)	PUNCT
chd-130	121	18	in	in	ADP
chd-130	121	19	gbc	gbc	PROPN
chd-130	121	20	resulted	result	VERB
chd-130	121	21	from	from	ADP
chd-130	121	22	a	a	DET
chd-130	121	23	collaborative	collaborative	ADJ
chd-130	121	24	effort	effort	NOUN
chd-130	121	25	between	between	ADP
chd-130	121	26	chile	chile	PROPN
chd-130	121	27	and	and	CCONJ
chd-130	121	28	us	we	PRON
chd-130	121	29	based	base	VERB
chd-130	121	30	researchers	researcher	NOUN
chd-130	121	31	.	.	PUNCT
chd-130	122	1	presence	presence	NOUN
chd-130	122	2	of	of	ADP
chd-130	122	3	a	a	DET
chd-130	122	4	tumor	tumor	NOUN
chd-130	122	5	suppressor	suppressor	NOUN
chd-130	122	6	gene	gene	NOUN
chd-130	122	7	at	at	ADP
chd-130	122	8	chromosomal	chromosomal	ADJ
chd-130	122	9	location	location	NOUN
chd-130	122	10	3p14.2	3p14.2	NOUN
chd-130	122	11	containing	contain	VERB
chd-130	122	12	the	the	DET
chd-130	122	13	fragile	fragile	ADJ
chd-130	122	14	histidine	histidine	NOUN
chd-130	122	15	triad	triad	NOUN
chd-130	122	16	(	(	PUNCT
chd-130	122	17	fhit	fhit	PROPN
chd-130	122	18	)	)	PUNCT
chd-130	122	19	was	be	AUX
chd-130	122	20	shown	show	VERB
chd-130	122	21	to	to	PART
chd-130	122	22	be	be	AUX
chd-130	122	23	involved	involve	VERB
chd-130	122	24	in	in	ADP
chd-130	122	25	the	the	DET
chd-130	122	26	pathogenesis	pathogenesis	NOUN
chd-130	122	27	of	of	ADP
chd-130	122	28	this	this	DET
chd-130	122	29	disease	disease	NOUN
chd-130	122	30	(	(	PUNCT
chd-130	122	31	wistuba	wistuba	PROPN
chd-130	122	32	et	et	PROPN
chd-130	122	33	al	al	PROPN
chd-130	122	34	.	.	PROPN
chd-130	122	35	,	,	PUNCT
chd-130	122	36	2002	2002	NUM
chd-130	122	37	)	)	PUNCT
chd-130	122	38	.	.	PUNCT
chd-130	123	1	much	much	ADV
chd-130	123	2	later	later	ADV
chd-130	123	3	in	in	ADP
chd-130	123	4	2009	2009	NUM
chd-130	123	5	,	,	PUNCT
chd-130	123	6	another	another	DET
chd-130	123	7	us	us	PROPN
chd-130	123	8	based	base	VERB
chd-130	123	9	study	study	NOUN
chd-130	123	10	,	,	PUNCT
chd-130	123	11	demonstrated	demonstrate	VERB
chd-130	123	12	that	that	SCONJ
chd-130	123	13	the	the	DET
chd-130	123	14	loss	loss	NOUN
chd-130	123	15	of	of	ADP
chd-130	123	16	fhit	fhit	NOUN
chd-130	123	17	and	and	CCONJ
chd-130	123	18	a	a	DET
chd-130	123	19	fragile	fragile	ADJ
chd-130	123	20	gene	gene	NOUN
chd-130	123	21	product	product	NOUN
chd-130	123	22	wwox	wwox	NOUN
chd-130	123	23	expression	expression	NOUN
chd-130	123	24	were	be	AUX
chd-130	123	25	part	part	NOUN
chd-130	123	26	of	of	ADP
chd-130	123	27	an	an	DET
chd-130	123	28	earlier	early	ADJ
chd-130	123	29	events	event	NOUN
chd-130	123	30	underlying	underlie	VERB
chd-130	123	31	pathogenesis	pathogenesis	NOUN
chd-130	123	32	of	of	ADP
chd-130	123	33	gbc	gbc	PROPN
chd-130	123	34	(	(	PUNCT
chd-130	123	35	bloomston	bloomston	NOUN
chd-130	123	36	et	et	PROPN
chd-130	123	37	al	al	PROPN
chd-130	123	38	.	.	PROPN
chd-130	123	39	,	,	PUNCT
chd-130	123	40	2009	2009	NUM
chd-130	123	41	)	)	PUNCT
chd-130	123	42	.	.	PUNCT
chd-130	124	1	the	the	DET
chd-130	124	2	same	same	ADJ
chd-130	124	3	year	year	NOUN
chd-130	124	4	,	,	PUNCT
chd-130	124	5	a	a	DET
chd-130	124	6	group	group	NOUN
chd-130	124	7	based	base	VERB
chd-130	124	8	in	in	ADP
chd-130	124	9	india	india	PROPN
chd-130	124	10	analyzed	analyze	VERB
chd-130	124	11	loh	loh	PROPN
chd-130	124	12	and	and	CCONJ
chd-130	124	13	msi	msi	PROPN
chd-130	124	14	in	in	ADP
chd-130	124	15	fhit	fhit	ADJ
chd-130	124	16	gene	gene	NOUN
chd-130	124	17	(	(	PUNCT
chd-130	124	18	priya	priya	PROPN
chd-130	124	19	et	et	PROPN
chd-130	124	20	al	al	PROPN
chd-130	124	21	.	.	PROPN
chd-130	124	22	,	,	PUNCT
chd-130	124	23	2009	2009	NUM
chd-130	124	24	)	)	PUNCT
chd-130	124	25	.	.	PUNCT
chd-130	125	1	this	this	DET
chd-130	125	2	group	group	NOUN
chd-130	125	3	of	of	ADP
chd-130	125	4	investigators	investigator	NOUN
chd-130	125	5	from	from	ADP
chd-130	125	6	india	india	PROPN
chd-130	125	7	also	also	ADV
chd-130	125	8	looked	look	VERB
chd-130	125	9	for	for	ADP
chd-130	125	10	the	the	DET
chd-130	125	11	expression	expression	NOUN
chd-130	125	12	of	of	ADP
chd-130	125	13	the	the	DET
chd-130	125	14	p53	p53	NOUN
chd-130	125	15	gene	gene	NOUN
chd-130	125	16	in	in	ADP
chd-130	125	17	gbc	gbc	PROPN
chd-130	125	18	,	,	PUNCT
chd-130	125	19	chronic	chronic	ADJ
chd-130	125	20	cholecystitis	cholecystitis	NOUN
chd-130	125	21	(	(	PUNCT
chd-130	125	22	cc	cc	NOUN
chd-130	125	23	)	)	PUNCT
chd-130	125	24	,	,	PUNCT
chd-130	125	25	xanthogranulomatous	xanthogranulomatous	ADJ
chd-130	125	26	cholecystitis	cholecystitis	PROPN
chd-130	125	27	(	(	PUNCT
chd-130	125	28	xgc	xgc	PROPN
chd-130	125	29	)	)	PUNCT
chd-130	125	30	and	and	CCONJ
chd-130	125	31	the	the	DET
chd-130	125	32	normal	normal	ADJ
chd-130	125	33	gallbladder	gallbladder	NOUN
chd-130	125	34	to	to	PART
chd-130	125	35	establish	establish	VERB
chd-130	125	36	the	the	DET
chd-130	125	37	role	role	NOUN
chd-130	125	38	of	of	ADP
chd-130	125	39	the	the	DET
chd-130	125	40	fhit	fhit	ADJ
chd-130	125	41	gene	gene	NOUN
chd-130	125	42	in	in	ADP
chd-130	125	43	the	the	DET
chd-130	125	44	gallbladder	gallbladder	NOUN
chd-130	125	45	cancer	cancer	NOUN
chd-130	125	46	using	use	VERB
chd-130	125	47	microsatellite	microsatellite	ADJ
chd-130	125	48	markers	marker	NOUN
chd-130	125	49	such	such	ADJ
chd-130	125	50	as	as	ADP
chd-130	125	51	d3s1217	d3s1217	NOUN
chd-130	125	52	,	,	PUNCT
chd-130	125	53	d3s1300	d3s1300	NUM
chd-130	125	54	,	,	PUNCT
chd-130	125	55	d3s1313	d3s1313	NUM
chd-130	125	56	,	,	PUNCT
chd-130	125	57	d3s1600	d3s1600	NUM
chd-130	125	58	,	,	PUNCT
chd-130	125	59	and	and	CCONJ
chd-130	125	60	d3s2757	d3s2757	NOUN
chd-130	125	61	.	.	PUNCT
chd-130	126	1	this	this	DET
chd-130	126	2	study	study	NOUN
chd-130	126	3	reported	report	VERB
chd-130	126	4	17.5	17.5	NUM
chd-130	126	5	%	%	NOUN
chd-130	126	6	of	of	ADP
chd-130	126	7	msi	msi	NOUN
chd-130	126	8	and	and	CCONJ
chd-130	126	9	27.5	27.5	NUM
chd-130	126	10	%	%	NOUN
chd-130	126	11	of	of	ADP
chd-130	126	12	loh	loh	PROPN
chd-130	126	13	in	in	ADP
chd-130	126	14	the	the	DET
chd-130	126	15	gbc	gbc	PROPN
chd-130	126	16	cases	case	NOUN
chd-130	126	17	from	from	ADP
chd-130	126	18	india	india	PROPN
chd-130	126	19	.	.	PUNCT
chd-130	127	1	significant	significant	ADJ
chd-130	127	2	differences	difference	NOUN
chd-130	127	3	were	be	AUX
chd-130	127	4	also	also	ADV
chd-130	127	5	noted	note	VERB
chd-130	127	6	in	in	ADP
chd-130	127	7	loh	loh	PROPN
chd-130	127	8	between	between	ADP
chd-130	127	9	gbc	gbc	PROPN
chd-130	127	10	and	and	CCONJ
chd-130	127	11	cc	cc	PROPN
chd-130	127	12	(	(	PUNCT
chd-130	127	13	p=0.002	p=0.002	NOUN
chd-130	127	14	)	)	PUNCT
chd-130	127	15	and	and	CCONJ
chd-130	127	16	gbc	gbc	PROPN
chd-130	127	17	and	and	CCONJ
chd-130	127	18	normal	normal	ADJ
chd-130	127	19	gb	gb	NOUN
chd-130	127	20	(	(	PUNCT
chd-130	127	21	p=0.02	p=0.02	NOUN
chd-130	127	22	)	)	PUNCT
chd-130	127	23	.	.	PUNCT
chd-130	128	1	their	their	PRON
chd-130	128	2	results	result	NOUN
chd-130	128	3	suggested	suggest	VERB
chd-130	128	4	that	that	SCONJ
chd-130	128	5	cc	cc	PROPN
chd-130	128	6	acts	act	VERB
chd-130	128	7	as	as	ADP
chd-130	128	8	a	a	DET
chd-130	128	9	pre	pre	ADJ
chd-130	128	10	-	-	ADJ
chd-130	128	11	invasive	invasive	ADJ
chd-130	128	12	lesion	lesion	NOUN
chd-130	128	13	in	in	ADP
chd-130	128	14	the	the	DET
chd-130	128	15	pathogenesis	pathogenesis	NOUN
chd-130	128	16	of	of	ADP
chd-130	128	17	gbc	gbc	PROPN
chd-130	128	18	(	(	PUNCT
chd-130	128	19	priya	priya	PROPN
chd-130	128	20	et	et	PROPN
chd-130	128	21	al	al	PROPN
chd-130	128	22	.	.	PROPN
chd-130	128	23	,	,	PUNCT
chd-130	128	24	2009	2009	NUM
chd-130	128	25	.	.	PUNCT
chd-130	129	1	it	it	PRON
chd-130	129	2	is	be	AUX
chd-130	129	3	important	important	ADJ
chd-130	129	4	to	to	PART
chd-130	129	5	note	note	VERB
chd-130	129	6	that	that	SCONJ
chd-130	129	7	some	some	DET
chd-130	129	8	researchers	researcher	NOUN
chd-130	129	9	believe	believe	VERB
chd-130	129	10	that	that	SCONJ
chd-130	129	11	xgc	xgc	PROPN
chd-130	129	12	,	,	PUNCT
chd-130	129	13	an	an	DET
chd-130	129	14	uncommon	uncommon	ADJ
chd-130	129	15	variant	variant	NOUN
chd-130	129	16	of	of	ADP
chd-130	129	17	cc	cc	PROPN
chd-130	129	18	,	,	PUNCT
chd-130	129	19	is	be	AUX
chd-130	129	20	a	a	DET
chd-130	129	21	precursor	precursor	NOUN
chd-130	129	22	lesion	lesion	NOUN
chd-130	129	23	of	of	ADP
chd-130	129	24	gbc	gbc	PROPN
chd-130	129	25	.	.	PUNCT
chd-130	130	1	this	this	PRON
chd-130	130	2	was	be	AUX
chd-130	130	3	the	the	DET
chd-130	130	4	first	first	ADJ
chd-130	130	5	report	report	NOUN
chd-130	130	6	to	to	ADP
chd-130	130	7	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-130	130	8	e8	e8	PROPN
chd-130	130	9	cancer	cancer	NOUN
chd-130	130	10	health	health	NOUN
chd-130	130	11	disparities	disparity	NOUN
chd-130	130	12	research	research	NOUN
chd-130	130	13	study	study	NOUN
chd-130	130	14	and	and	CCONJ
chd-130	130	15	compare	compare	VERB
chd-130	130	16	genomic	genomic	ADJ
chd-130	130	17	instability	instability	NOUN
chd-130	130	18	in	in	ADP
chd-130	130	19	gbc	gbc	PROPN
chd-130	130	20	versus	versus	ADP
chd-130	130	21	different	different	ADJ
chd-130	130	22	variants	variant	NOUN
chd-130	130	23	of	of	ADP
chd-130	130	24	cc	cc	PROPN
chd-130	130	25	and	and	CCONJ
chd-130	130	26	normal	normal	ADJ
chd-130	130	27	gallbladder	gallbladder	NOUN
chd-130	130	28	from	from	ADP
chd-130	130	29	any	any	DET
chd-130	130	30	asian	asian	ADJ
chd-130	130	31	country	country	NOUN
chd-130	130	32	.	.	PUNCT
chd-130	131	1	however	however	ADV
chd-130	131	2	,	,	PUNCT
chd-130	131	3	an	an	DET
chd-130	131	4	earlier	early	ADJ
chd-130	131	5	report	report	NOUN
chd-130	131	6	in	in	ADP
chd-130	131	7	2001	2001	NUM
chd-130	131	8	had	have	AUX
chd-130	131	9	studied	study	VERB
chd-130	131	10	xgc	xgc	INTJ
chd-130	131	11	at	at	ADP
chd-130	131	12	molecular	molecular	ADJ
chd-130	131	13	level	level	NOUN
chd-130	131	14	and	and	CCONJ
chd-130	131	15	confirmed	confirm	VERB
chd-130	131	16	that	that	SCONJ
chd-130	131	17	while	while	SCONJ
chd-130	131	18	etiopathologic	etiopathologic	ADJ
chd-130	131	19	factors	factor	NOUN
chd-130	131	20	of	of	ADP
chd-130	131	21	xgc	xgc	PROPN
chd-130	131	22	could	could	AUX
chd-130	131	23	have	have	VERB
chd-130	131	24	a	a	DET
chd-130	131	25	correlation	correlation	NOUN
chd-130	131	26	to	to	ADP
chd-130	131	27	cancer	cancer	NOUN
chd-130	131	28	,	,	PUNCT
chd-130	131	29	xgc	xgc	PROPN
chd-130	131	30	might	might	AUX
chd-130	131	31	not	not	PART
chd-130	131	32	be	be	AUX
chd-130	131	33	an	an	DET
chd-130	131	34	immediate	immediate	ADJ
chd-130	131	35	cause	cause	NOUN
chd-130	131	36	of	of	ADP
chd-130	131	37	cancer	cancer	NOUN
chd-130	131	38	(	(	PUNCT
chd-130	131	39	takada	takada	NOUN
chd-130	131	40	et	et	PROPN
chd-130	131	41	al	al	PROPN
chd-130	131	42	.	.	PROPN
chd-130	131	43	,	,	PUNCT
chd-130	131	44	2002	2002	NUM
chd-130	131	45	)	)	PUNCT
chd-130	131	46	.	.	PUNCT
chd-130	132	1	in	in	ADP
chd-130	132	2	a	a	DET
chd-130	132	3	study	study	NOUN
chd-130	132	4	conducted	conduct	VERB
chd-130	132	5	in	in	ADP
chd-130	132	6	italy	italy	PROPN
chd-130	132	7	,	,	PUNCT
chd-130	132	8	expression	expression	NOUN
chd-130	132	9	of	of	ADP
chd-130	132	10	the	the	DET
chd-130	132	11	p53	p53	NOUN
chd-130	132	12	gene	gene	NOUN
chd-130	132	13	as	as	ADV
chd-130	132	14	well	well	ADV
chd-130	132	15	as	as	ADP
chd-130	132	16	microsatellite	microsatellite	ADJ
chd-130	132	17	instability	instability	NOUN
chd-130	132	18	(	(	PUNCT
chd-130	132	19	msi	msi	PROPN
chd-130	132	20	)	)	PUNCT
chd-130	132	21	status	status	NOUN
chd-130	132	22	were	be	AUX
chd-130	132	23	studied	study	VERB
chd-130	132	24	in	in	ADP
chd-130	132	25	tumor	tumor	NOUN
chd-130	132	26	tissues	tissue	NOUN
chd-130	132	27	obtained	obtain	VERB
chd-130	132	28	from	from	ADP
chd-130	132	29	71	71	NUM
chd-130	132	30	patients	patient	NOUN
chd-130	132	31	with	with	ADP
chd-130	132	32	gbc	gbc	PROPN
chd-130	132	33	.	.	PUNCT
chd-130	133	1	examination	examination	NOUN
chd-130	133	2	of	of	ADP
chd-130	133	3	all	all	DET
chd-130	133	4	neoplasms	neoplasm	NOUN
chd-130	133	5	were	be	AUX
chd-130	133	6	conducted	conduct	VERB
chd-130	133	7	using	use	VERB
chd-130	133	8	ihc	ihc	PROPN
chd-130	133	9	staining	stain	VERB
chd-130	133	10	for	for	ADP
chd-130	133	11	hmsh2	hmsh2	PROPN
chd-130	133	12	,	,	PUNCT
chd-130	133	13	hmlh1	hmlh1	PROPN
chd-130	133	14	,	,	PUNCT
chd-130	133	15	p53	p53	NOUN
chd-130	133	16	proteins	protein	NOUN
chd-130	133	17	and	and	CCONJ
chd-130	133	18	markers	marker	NOUN
chd-130	133	19	of	of	ADP
chd-130	133	20	gi	gi	NOUN
chd-130	133	21	differentiation	differentiation	NOUN
chd-130	133	22	along	along	ADP
chd-130	133	23	with	with	ADP
chd-130	133	24	a	a	DET
chd-130	133	25	microsatellite	microsatellite	ADJ
chd-130	133	26	analysis	analysis	NOUN
chd-130	133	27	at	at	ADP
chd-130	133	28	mononucleotide	mononucleotide	NOUN
chd-130	133	29	locus	locus	NOUN
chd-130	133	30	bat-26	bat-26	NOUN
chd-130	133	31	.	.	PUNCT
chd-130	134	1	the	the	DET
chd-130	134	2	authors	author	NOUN
chd-130	134	3	showed	show	VERB
chd-130	134	4	that	that	SCONJ
chd-130	134	5	although	although	SCONJ
chd-130	134	6	msi	msi	PROPN
chd-130	134	7	was	be	AUX
chd-130	134	8	not	not	PART
chd-130	134	9	a	a	DET
chd-130	134	10	key	key	ADJ
chd-130	134	11	factor	factor	NOUN
chd-130	134	12	in	in	ADP
chd-130	134	13	gbc	gbc	PROPN
chd-130	134	14	development	development	NOUN
chd-130	134	15	,	,	PUNCT
chd-130	134	16	alteration	alteration	NOUN
chd-130	134	17	in	in	ADP
chd-130	134	18	the	the	DET
chd-130	134	19	p53	p53	NOUN
chd-130	134	20	gene	gene	NOUN
chd-130	134	21	played	play	VERB
chd-130	134	22	a	a	DET
chd-130	134	23	critical	critical	ADJ
chd-130	134	24	role	role	NOUN
chd-130	134	25	in	in	ADP
chd-130	134	26	a	a	DET
chd-130	134	27	large	large	ADJ
chd-130	134	28	percent	percent	NOUN
chd-130	134	29	of	of	ADP
chd-130	134	30	cases	case	NOUN
chd-130	134	31	with	with	ADP
chd-130	134	32	the	the	DET
chd-130	134	33	exclusion	exclusion	NOUN
chd-130	134	34	of	of	ADP
chd-130	134	35	mucinous	mucinous	ADJ
chd-130	134	36	and	and	CCONJ
chd-130	134	37	squamous	squamous	ADJ
chd-130	134	38	gbc	gbc	PROPN
chd-130	134	39	(	(	PUNCT
chd-130	134	40	sessa	sessa	PROPN
chd-130	134	41	et	et	PROPN
chd-130	134	42	al	al	PROPN
chd-130	134	43	.	.	PROPN
chd-130	134	44	,	,	PUNCT
chd-130	134	45	2003	2003	NUM
chd-130	134	46	)	)	PUNCT
chd-130	134	47	.	.	PUNCT
chd-130	135	1	concurrently	concurrently	ADV
chd-130	135	2	,	,	PUNCT
chd-130	135	3	a	a	DET
chd-130	135	4	small	small	ADJ
chd-130	135	5	study	study	NOUN
chd-130	135	6	at	at	ADP
chd-130	135	7	johns	johns	PROPN
chd-130	135	8	hopkins	hopkins	PROPN
chd-130	135	9	medical	medical	PROPN
chd-130	135	10	institute	institute	PROPN
chd-130	135	11	,	,	PUNCT
chd-130	135	12	found	find	VERB
chd-130	135	13	hypermethylated	hypermethylate	VERB
chd-130	135	14	regions	region	NOUN
chd-130	135	15	at	at	ADP
chd-130	135	16	various	various	ADJ
chd-130	135	17	promoter	promoter	NOUN
chd-130	135	18	sites	site	NOUN
chd-130	135	19	of	of	ADP
chd-130	135	20	tumor	tumor	NOUN
chd-130	135	21	suppressor	suppressor	NOUN
chd-130	135	22	genes	gene	NOUN
chd-130	135	23	that	that	PRON
chd-130	135	24	contributed	contribute	VERB
chd-130	135	25	to	to	ADP
chd-130	135	26	the	the	DET
chd-130	135	27	formation	formation	NOUN
chd-130	135	28	of	of	ADP
chd-130	135	29	the	the	DET
chd-130	135	30	tumor	tumor	NOUN
chd-130	135	31	as	as	ADV
chd-130	135	32	well	well	ADV
chd-130	135	33	as	as	ADP
chd-130	135	34	its	its	PRON
chd-130	135	35	progression	progression	NOUN
chd-130	135	36	inside	inside	ADP
chd-130	135	37	a	a	DET
chd-130	135	38	gb	gb	NOUN
chd-130	135	39	that	that	PRON
chd-130	135	40	was	be	AUX
chd-130	135	41	chronically	chronically	ADV
chd-130	135	42	inflamed	inflame	VERB
chd-130	135	43	.	.	PUNCT
chd-130	136	1	since	since	SCONJ
chd-130	136	2	this	this	DET
chd-130	136	3	study	study	NOUN
chd-130	136	4	included	include	VERB
chd-130	136	5	a	a	DET
chd-130	136	6	large	large	ADJ
chd-130	136	7	cohort	cohort	NOUN
chd-130	136	8	of	of	ADP
chd-130	136	9	specimens	specimen	NOUN
chd-130	136	10	obtained	obtain	VERB
chd-130	136	11	from	from	ADP
chd-130	136	12	two	two	NUM
chd-130	136	13	different	different	ADJ
chd-130	136	14	populations	population	NOUN
chd-130	136	15	,	,	PUNCT
chd-130	136	16	chile	chile	PROPN
chd-130	136	17	and	and	CCONJ
chd-130	136	18	the	the	DET
chd-130	136	19	united	united	PROPN
chd-130	136	20	states	states	PROPN
chd-130	136	21	,	,	PUNCT
chd-130	136	22	plain	plain	ADJ
chd-130	136	23	disparities	disparity	NOUN
chd-130	136	24	in	in	ADP
chd-130	136	25	the	the	DET
chd-130	136	26	patterns	pattern	NOUN
chd-130	136	27	of	of	ADP
chd-130	136	28	methylation	methylation	NOUN
chd-130	136	29	between	between	ADP
chd-130	136	30	the	the	DET
chd-130	136	31	gallbladders	gallbladder	NOUN
chd-130	136	32	obtained	obtain	VERB
chd-130	136	33	from	from	ADP
chd-130	136	34	these	these	DET
chd-130	136	35	two	two	NUM
chd-130	136	36	countries	country	NOUN
chd-130	136	37	led	lead	VERB
chd-130	136	38	to	to	ADP
chd-130	136	39	the	the	DET
chd-130	136	40	hypothesis	hypothesis	NOUN
chd-130	136	41	that	that	PRON
chd-130	136	42	these	these	DET
chd-130	136	43	differences	difference	NOUN
chd-130	136	44	indicated	indicate	VERB
chd-130	136	45	a	a	DET
chd-130	136	46	varied	varied	ADJ
chd-130	136	47	and	and	CCONJ
chd-130	136	48	distinctive	distinctive	ADJ
chd-130	136	49	biology	biology	NOUN
chd-130	136	50	associated	associate	VERB
chd-130	136	51	with	with	ADP
chd-130	136	52	this	this	DET
chd-130	136	53	disease	disease	NOUN
chd-130	136	54	around	around	ADP
chd-130	136	55	the	the	DET
chd-130	136	56	world	world	NOUN
chd-130	136	57	(	(	PUNCT
chd-130	136	58	house	house	PROPN
chd-130	136	59	et	et	PROPN
chd-130	136	60	al	al	PROPN
chd-130	136	61	.	.	PROPN
chd-130	136	62	,	,	PUNCT
chd-130	136	63	2003	2003	NUM
chd-130	136	64	)	)	PUNCT
chd-130	136	65	.	.	PUNCT
chd-130	137	1	in	in	ADP
chd-130	137	2	a	a	DET
chd-130	137	3	subsequent	subsequent	ADJ
chd-130	137	4	chilean	chilean	ADJ
chd-130	137	5	study	study	NOUN
chd-130	137	6	,	,	PUNCT
chd-130	137	7	mutations	mutation	NOUN
chd-130	137	8	in	in	ADP
chd-130	137	9	mitochondrial	mitochondrial	ADJ
chd-130	137	10	dna	dna	NOUN
chd-130	137	11	(	(	PUNCT
chd-130	137	12	mtdna	mtdna	ADV
chd-130	137	13	)	)	PUNCT
chd-130	137	14	was	be	AUX
chd-130	137	15	observed	observe	VERB
chd-130	137	16	in	in	ADP
chd-130	137	17	gbc	gbc	PROPN
chd-130	137	18	which	which	PRON
chd-130	137	19	suggested	suggest	VERB
chd-130	137	20	that	that	SCONJ
chd-130	137	21	mtdna	mtdna	NOUN
chd-130	137	22	be	be	AUX
chd-130	137	23	additionally	additionally	ADV
chd-130	137	24	investigated	investigate	VERB
chd-130	137	25	in	in	ADP
chd-130	137	26	patients	patient	NOUN
chd-130	137	27	from	from	ADP
chd-130	137	28	different	different	ADJ
chd-130	137	29	geographical	geographical	ADJ
chd-130	137	30	regions	region	NOUN
chd-130	137	31	thus	thus	ADV
chd-130	137	32	including	include	VERB
chd-130	137	33	it	it	PRON
chd-130	137	34	in	in	ADP
chd-130	137	35	a	a	DET
chd-130	137	36	list	list	NOUN
chd-130	137	37	of	of	ADP
chd-130	137	38	molecular	molecular	ADJ
chd-130	137	39	biomarkers	biomarker	NOUN
chd-130	137	40	for	for	ADP
chd-130	137	41	early	early	ADJ
chd-130	137	42	detection	detection	NOUN
chd-130	137	43	of	of	ADP
chd-130	137	44	gbc	gbc	PROPN
chd-130	137	45	(	(	PUNCT
chd-130	137	46	tang	tang	PROPN
chd-130	137	47	et	et	PROPN
chd-130	137	48	al	al	PROPN
chd-130	137	49	.	.	PROPN
chd-130	137	50	,	,	PUNCT
chd-130	137	51	2004	2004	NUM
chd-130	137	52	)	)	PUNCT
chd-130	137	53	.	.	PUNCT
chd-130	138	1	same	same	ADJ
chd-130	138	2	year	year	NOUN
chd-130	138	3	,	,	PUNCT
chd-130	138	4	investigators	investigator	NOUN
chd-130	138	5	at	at	ADP
chd-130	138	6	johns	johns	PROPN
chd-130	138	7	hopkins	hopkins	PROPN
chd-130	138	8	demonstrated	demonstrate	VERB
chd-130	138	9	that	that	SCONJ
chd-130	138	10	gbc	gbc	PROPN
chd-130	138	11	had	have	VERB
chd-130	138	12	a	a	DET
chd-130	138	13	unique	unique	ADJ
chd-130	138	14	pattern	pattern	NOUN
chd-130	138	15	of	of	ADP
chd-130	138	16	abnormal	abnormal	ADJ
chd-130	138	17	gene	gene	NOUN
chd-130	138	18	methylation	methylation	NOUN
chd-130	138	19	in	in	ADP
chd-130	138	20	a	a	DET
chd-130	138	21	study	study	NOUN
chd-130	138	22	which	which	PRON
chd-130	138	23	encompassed	encompass	VERB
chd-130	138	24	the	the	DET
chd-130	138	25	most	most	ADV
chd-130	138	26	inclusive	inclusive	ADJ
chd-130	138	27	methylation	methylation	NOUN
chd-130	138	28	profiling	profiling	NOUN
chd-130	138	29	.	.	PUNCT
chd-130	139	1	the	the	DET
chd-130	139	2	finding	finding	NOUN
chd-130	139	3	of	of	ADP
chd-130	139	4	methylation	methylation	NOUN
chd-130	139	5	in	in	ADP
chd-130	139	6	gallbladders	gallbladder	NOUN
chd-130	139	7	with	with	ADP
chd-130	139	8	cc	cc	PROPN
chd-130	139	9	(	(	PUNCT
chd-130	139	10	and	and	CCONJ
chd-130	139	11	without	without	ADP
chd-130	139	12	cancer	cancer	NOUN
chd-130	139	13	)	)	PUNCT
chd-130	139	14	in	in	ADP
chd-130	139	15	healthy	healthy	ADJ
chd-130	139	16	individuals	individual	NOUN
chd-130	139	17	suggested	suggest	VERB
chd-130	139	18	that	that	SCONJ
chd-130	139	19	this	this	PRON
chd-130	139	20	was	be	AUX
chd-130	139	21	an	an	DET
chd-130	139	22	important	important	ADJ
chd-130	139	23	phenomenon	phenomenon	NOUN
chd-130	139	24	in	in	ADP
chd-130	139	25	the	the	DET
chd-130	139	26	early	early	ADJ
chd-130	139	27	pathogenesis	pathogenesis	NOUN
chd-130	139	28	of	of	ADP
chd-130	139	29	gbc	gbc	PROPN
chd-130	139	30	(	(	PUNCT
chd-130	139	31	takahashi	takahashi	PROPN
chd-130	139	32	et	et	PROPN
chd-130	139	33	al	al	PROPN
chd-130	139	34	.	.	PROPN
chd-130	139	35	,	,	PUNCT
chd-130	139	36	2004	2004	NUM
chd-130	139	37	)	)	PUNCT
chd-130	139	38	.	.	PUNCT
chd-130	140	1	subsequently	subsequently	ADV
chd-130	140	2	,	,	PUNCT
chd-130	140	3	a	a	DET
chd-130	140	4	group	group	NOUN
chd-130	140	5	from	from	ADP
chd-130	140	6	chile	chile	PROPN
chd-130	140	7	observed	observe	VERB
chd-130	140	8	that	that	SCONJ
chd-130	140	9	the	the	DET
chd-130	140	10	high	high	ADJ
chd-130	140	11	frequency	frequency	NOUN
chd-130	140	12	of	of	ADP
chd-130	140	13	methylation	methylation	NOUN
chd-130	140	14	of	of	ADP
chd-130	140	15	promoter	promoter	NOUN
chd-130	140	16	areas	area	NOUN
chd-130	140	17	for	for	ADP
chd-130	140	18	cdkn2a	cdkn2a	PROPN
chd-130	140	19	(	(	PUNCT
chd-130	140	20	p16	p16	NOUN
chd-130	140	21	)	)	PUNCT
chd-130	140	22	,	,	PUNCT
chd-130	140	23	fhit	fhit	PROPN
chd-130	140	24	,	,	PUNCT
chd-130	140	25	apc	apc	PROPN
chd-130	140	26	,	,	PUNCT
chd-130	140	27	and	and	CCONJ
chd-130	140	28	cdh1	cdh1	NOUN
chd-130	140	29	genes	gene	NOUN
chd-130	140	30	led	lead	VERB
chd-130	140	31	to	to	ADP
chd-130	140	32	the	the	DET
chd-130	140	33	inactivation	inactivation	NOUN
chd-130	140	34	of	of	ADP
chd-130	140	35	genes	gene	NOUN
chd-130	140	36	responsible	responsible	ADJ
chd-130	140	37	for	for	ADP
chd-130	140	38	tumor	tumor	NOUN
chd-130	140	39	suppression	suppression	NOUN
chd-130	140	40	and	and	CCONJ
chd-130	140	41	control	control	NOUN
chd-130	140	42	of	of	ADP
chd-130	140	43	cellular	cellular	ADJ
chd-130	140	44	proliferation	proliferation	NOUN
chd-130	140	45	in	in	ADP
chd-130	140	46	the	the	DET
chd-130	140	47	carcinogenesis	carcinogenesis	NOUN
chd-130	140	48	mechanism	mechanism	NOUN
chd-130	140	49	(	(	PUNCT
chd-130	140	50	roa	roa	NOUN
chd-130	140	51	et	et	PROPN
chd-130	140	52	al	al	PROPN
chd-130	140	53	.	.	PROPN
chd-130	140	54	,	,	PUNCT
chd-130	140	55	2006	2006	NUM
chd-130	140	56	)	)	PUNCT
chd-130	140	57	.	.	PUNCT
chd-130	141	1	another	another	DET
chd-130	141	2	chilean	chilean	ADJ
chd-130	141	3	study	study	NOUN
chd-130	141	4	then	then	ADV
chd-130	141	5	confirmed	confirm	VERB
chd-130	141	6	by	by	ADP
chd-130	141	7	epigenetic	epigenetic	ADJ
chd-130	141	8	inactivation	inactivation	NOUN
chd-130	141	9	that	that	SCONJ
chd-130	141	10	abnormal	abnormal	ADJ
chd-130	141	11	methylation	methylation	NOUN
chd-130	141	12	in	in	ADP
chd-130	141	13	the	the	DET
chd-130	141	14	promoter	promoter	NOUN
chd-130	141	15	regions	region	NOUN
chd-130	141	16	of	of	ADP
chd-130	141	17	tumor	tumor	NOUN
chd-130	141	18	suppressor	suppressor	NOUN
chd-130	141	19	genes	gene	NOUN
chd-130	141	20	such	such	ADJ
chd-130	141	21	as	as	ADP
chd-130	141	22	dutt1	dutt1	NOUN
chd-130	141	23	(	(	PUNCT
chd-130	141	24	3p12	3p12	NUM
chd-130	141	25	)	)	PUNCT
chd-130	141	26	,	,	PUNCT
chd-130	141	27	fhit	fhit	VERB
chd-130	141	28	(	(	PUNCT
chd-130	141	29	3p14.2	3p14.2	NUM
chd-130	141	30	)	)	PUNCT
chd-130	141	31	,	,	PUNCT
chd-130	141	32	blu	blu	NOUN
chd-130	141	33	,	,	PUNCT
chd-130	141	34	rassf1a	rassf1a	PROPN
chd-130	141	35	,	,	PUNCT
chd-130	141	36	sema3b	sema3b	NOUN
chd-130	141	37	and	and	CCONJ
chd-130	141	38	hmlh1	hmlh1	PROPN
chd-130	141	39	(	(	PUNCT
chd-130	141	40	3p21.3	3p21.3	NUM
chd-130	141	41	)	)	PUNCT
chd-130	141	42	on	on	ADP
chd-130	141	43	chromosome	chromosome	NOUN
chd-130	141	44	3p	3p	NUM
chd-130	141	45	was	be	AUX
chd-130	141	46	a	a	DET
chd-130	141	47	frequent	frequent	ADJ
chd-130	141	48	occurrence	occurrence	NOUN
chd-130	141	49	(	(	PUNCT
chd-130	141	50	riquelme	riquelme	PROPN
chd-130	141	51	et	et	PROPN
chd-130	141	52	al	al	PROPN
chd-130	141	53	.	.	PROPN
chd-130	141	54	,	,	PUNCT
chd-130	141	55	2007	2007	NUM
chd-130	141	56	)	)	PUNCT
chd-130	141	57	.	.	PUNCT
chd-130	142	1	a	a	DET
chd-130	142	2	small	small	ADJ
chd-130	142	3	study	study	NOUN
chd-130	142	4	from	from	ADP
chd-130	142	5	greece	greece	PROPN
chd-130	142	6	reported	report	VERB
chd-130	142	7	mutations	mutation	NOUN
chd-130	142	8	in	in	ADP
chd-130	142	9	the	the	DET
chd-130	142	10	b	b	NOUN
chd-130	142	11	-	-	PUNCT
chd-130	142	12	raf	raf	NOUN
chd-130	142	13	gene	gene	NOUN
chd-130	142	14	for	for	ADP
chd-130	142	15	the	the	DET
chd-130	142	16	first	first	ADJ
chd-130	142	17	time	time	NOUN
chd-130	142	18	,	,	PUNCT
chd-130	142	19	which	which	PRON
chd-130	142	20	is	be	AUX
chd-130	142	21	an	an	DET
chd-130	142	22	important	important	ADJ
chd-130	142	23	component	component	NOUN
chd-130	142	24	of	of	ADP
chd-130	142	25	ras	ras	X
chd-130	142	26	signaling	signal	VERB
chd-130	142	27	pathway	pathway	NOUN
chd-130	142	28	(	(	PUNCT
chd-130	142	29	ras	ras	NOUN
chd-130	142	30	/	/	SYM
chd-130	142	31	raf	raf	PROPN
chd-130	142	32	/	/	SYM
chd-130	142	33	mek	mek	PROPN
chd-130	142	34	/	/	SYM
chd-130	142	35	erk	erk	PROPN
chd-130	142	36	)	)	PUNCT
chd-130	142	37	.	.	PUNCT
chd-130	143	1	they	they	PRON
chd-130	143	2	reported	report	VERB
chd-130	143	3	that	that	SCONJ
chd-130	143	4	almost	almost	ADV
chd-130	143	5	one	one	NUM
chd-130	143	6	third	third	NOUN
chd-130	143	7	of	of	ADP
chd-130	143	8	all	all	DET
chd-130	143	9	patients	patient	NOUN
chd-130	143	10	with	with	ADP
chd-130	143	11	gbc	gbc	PROPN
chd-130	143	12	also	also	ADV
chd-130	143	13	presented	present	VERB
chd-130	143	14	with	with	ADP
chd-130	143	15	mutations	mutation	NOUN
chd-130	143	16	in	in	ADP
chd-130	143	17	the	the	DET
chd-130	143	18	b	b	NOUN
chd-130	143	19	-	-	PUNCT
chd-130	143	20	raf	raf	NOUN
chd-130	143	21	gene	gene	NOUN
chd-130	143	22	(	(	PUNCT
chd-130	143	23	saetta	saetta	PROPN
chd-130	143	24	et	et	PROPN
chd-130	143	25	al	al	PROPN
chd-130	143	26	.	.	PROPN
chd-130	143	27	,	,	PUNCT
chd-130	143	28	2004	2004	NUM
chd-130	143	29	)	)	PUNCT
chd-130	143	30	.	.	PUNCT
chd-130	144	1	it	it	PRON
chd-130	144	2	is	be	AUX
chd-130	144	3	imperative	imperative	ADJ
chd-130	144	4	to	to	PART
chd-130	144	5	note	note	VERB
chd-130	144	6	that	that	SCONJ
chd-130	144	7	the	the	DET
chd-130	144	8	ras	ras	PROPN
chd-130	144	9	pathway	pathway	NOUN
chd-130	144	10	is	be	AUX
chd-130	144	11	an	an	DET
chd-130	144	12	organized	organized	ADJ
chd-130	144	13	,	,	PUNCT
chd-130	144	14	downstream	downstream	ADJ
chd-130	144	15	pathway	pathway	NOUN
chd-130	144	16	in	in	ADP
chd-130	144	17	which	which	PRON
chd-130	144	18	raf	raf	NOUN
chd-130	144	19	proteins	protein	NOUN
chd-130	144	20	are	be	AUX
chd-130	144	21	activated	activate	VERB
chd-130	144	22	in	in	ADP
chd-130	144	23	a	a	DET
chd-130	144	24	ras	ras	X
chd-130	144	25	dependent	dependent	ADJ
chd-130	144	26	manner	manner	NOUN
chd-130	144	27	.	.	PUNCT
chd-130	145	1	considering	consider	VERB
chd-130	145	2	the	the	DET
chd-130	145	3	fact	fact	NOUN
chd-130	145	4	that	that	SCONJ
chd-130	145	5	ras	ra	VERB
chd-130	145	6	signaling	signal	VERB
chd-130	145	7	pathway	pathway	NOUN
chd-130	145	8	could	could	AUX
chd-130	145	9	be	be	AUX
chd-130	145	10	activated	activate	VERB
chd-130	145	11	by	by	ADP
chd-130	145	12	mutations	mutation	NOUN
chd-130	145	13	at	at	ADP
chd-130	145	14	various	various	ADJ
chd-130	145	15	levels	level	NOUN
chd-130	145	16	including	include	VERB
chd-130	145	17	b	b	NOUN
chd-130	145	18	-	-	PUNCT
chd-130	145	19	raf	raf	NOUN
chd-130	145	20	,	,	PUNCT
chd-130	145	21	it	it	PRON
chd-130	145	22	was	be	AUX
chd-130	145	23	an	an	DET
chd-130	145	24	important	important	ADJ
chd-130	145	25	finding	finding	NOUN
chd-130	145	26	of	of	ADP
chd-130	145	27	reemphasizing	reemphasize	VERB
chd-130	145	28	the	the	DET
chd-130	145	29	role	role	NOUN
chd-130	145	30	of	of	ADP
chd-130	145	31	ras	ras	NOUN
chd-130	145	32	pathway	pathway	NOUN
chd-130	145	33	in	in	ADP
chd-130	145	34	those	those	DET
chd-130	145	35	gbc	gbc	PROPN
chd-130	145	36	cases	case	NOUN
chd-130	145	37	where	where	SCONJ
chd-130	145	38	no	no	DET
chd-130	145	39	mutation	mutation	NOUN
chd-130	145	40	was	be	AUX
chd-130	145	41	detected	detect	VERB
chd-130	145	42	in	in	ADP
chd-130	145	43	the	the	DET
chd-130	145	44	k	k	PROPN
chd-130	145	45	-	-	PUNCT
chd-130	145	46	ras	ras	X
chd-130	145	47	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-130	145	48	e9	e9	PROPN
chd-130	145	49	cancer	cancer	NOUN
chd-130	145	50	health	health	NOUN
chd-130	145	51	disparities	disparity	NOUN
chd-130	145	52	research	research	NOUN
chd-130	145	53	oncogene	oncogene	NOUN
chd-130	145	54	(	(	PUNCT
chd-130	145	55	saetta	saetta	PROPN
chd-130	145	56	et	et	PROPN
chd-130	145	57	al	al	PROPN
chd-130	145	58	.	.	PROPN
chd-130	145	59	,	,	PUNCT
chd-130	145	60	2004	2004	NUM
chd-130	145	61	)	)	PUNCT
chd-130	145	62	.	.	PUNCT
chd-130	146	1	same	same	ADJ
chd-130	146	2	year	year	NOUN
chd-130	146	3	,	,	PUNCT
chd-130	146	4	our	our	PRON
chd-130	146	5	group	group	NOUN
chd-130	146	6	demonstrated	demonstrate	VERB
chd-130	146	7	that	that	SCONJ
chd-130	146	8	almost	almost	ADV
chd-130	146	9	one	one	NUM
chd-130	146	10	third	third	NOUN
chd-130	146	11	of	of	ADP
chd-130	146	12	all	all	DET
chd-130	146	13	the	the	DET
chd-130	146	14	patients	patient	NOUN
chd-130	146	15	with	with	ADP
chd-130	146	16	gbc	gbc	PROPN
chd-130	146	17	has	have	VERB
chd-130	146	18	mutations	mutation	NOUN
chd-130	146	19	in	in	ADP
chd-130	146	20	codon	codon	NOUN
chd-130	146	21	12	12	NUM
chd-130	146	22	of	of	ADP
chd-130	146	23	the	the	DET
chd-130	146	24	k	k	PROPN
chd-130	146	25	-	-	PUNCT
chd-130	146	26	ras	ras	ADJ
chd-130	146	27	oncogene	oncogene	NOUN
chd-130	146	28	(	(	PUNCT
chd-130	146	29	singh	singh	PROPN
chd-130	146	30	et	et	PROPN
chd-130	146	31	al	al	PROPN
chd-130	146	32	.	.	PROPN
chd-130	146	33	,	,	PUNCT
chd-130	146	34	2004b	2004b	NUM
chd-130	146	35	)	)	PUNCT
chd-130	146	36	.	.	PUNCT
chd-130	147	1	while	while	SCONJ
chd-130	147	2	this	this	DET
chd-130	147	3	study	study	NOUN
chd-130	147	4	was	be	AUX
chd-130	147	5	the	the	DET
chd-130	147	6	first	first	ADJ
chd-130	147	7	of	of	ADP
chd-130	147	8	its	its	PRON
chd-130	147	9	kind	kind	NOUN
chd-130	147	10	from	from	ADP
chd-130	147	11	india	india	PROPN
chd-130	147	12	to	to	PART
chd-130	147	13	use	use	VERB
chd-130	147	14	methods	method	NOUN
chd-130	147	15	to	to	PART
chd-130	147	16	detect	detect	VERB
chd-130	147	17	changes	change	NOUN
chd-130	147	18	at	at	ADP
chd-130	147	19	a	a	DET
chd-130	147	20	molecular	molecular	ADJ
chd-130	147	21	level	level	NOUN
chd-130	147	22	in	in	ADP
chd-130	147	23	an	an	DET
chd-130	147	24	oncogene	oncogene	NOUN
chd-130	147	25	,	,	PUNCT
chd-130	147	26	it	it	PRON
chd-130	147	27	also	also	ADV
chd-130	147	28	demonstrated	demonstrate	VERB
chd-130	147	29	that	that	SCONJ
chd-130	147	30	detection	detection	NOUN
chd-130	147	31	of	of	ADP
chd-130	147	32	such	such	ADJ
chd-130	147	33	molecular	molecular	ADJ
chd-130	147	34	aberration	aberration	NOUN
chd-130	147	35	in	in	ADP
chd-130	147	36	an	an	DET
chd-130	147	37	oncogene	oncogene	NOUN
chd-130	147	38	could	could	AUX
chd-130	147	39	be	be	AUX
chd-130	147	40	performed	perform	VERB
chd-130	147	41	on	on	ADP
chd-130	147	42	a	a	DET
chd-130	147	43	small	small	ADJ
chd-130	147	44	number	number	NOUN
chd-130	147	45	of	of	ADP
chd-130	147	46	tumor	tumor	NOUN
chd-130	147	47	cells	cell	NOUN
chd-130	147	48	retrieved	retrieve	VERB
chd-130	147	49	from	from	ADP
chd-130	147	50	fine	fine	ADJ
chd-130	147	51	-	-	PUNCT
chd-130	147	52	needle	needle	NOUN
chd-130	147	53	aspirates	aspirate	NOUN
chd-130	147	54	.	.	PUNCT
chd-130	148	1	additionally	additionally	ADV
chd-130	148	2	,	,	PUNCT
chd-130	148	3	together	together	ADV
chd-130	148	4	with	with	ADP
chd-130	148	5	cytological	cytological	ADJ
chd-130	148	6	examination	examination	NOUN
chd-130	148	7	,	,	PUNCT
chd-130	148	8	this	this	DET
chd-130	148	9	work	work	NOUN
chd-130	148	10	showed	show	VERB
chd-130	148	11	a	a	DET
chd-130	148	12	possibility	possibility	NOUN
chd-130	148	13	to	to	PART
chd-130	148	14	help	help	VERB
chd-130	148	15	making	make	VERB
chd-130	148	16	a	a	DET
chd-130	148	17	definitive	definitive	ADJ
chd-130	148	18	diagnosis	diagnosis	NOUN
chd-130	148	19	in	in	ADP
chd-130	148	20	patients	patient	NOUN
chd-130	148	21	with	with	ADP
chd-130	148	22	other	other	ADJ
chd-130	148	23	risk	risk	NOUN
chd-130	148	24	factors	factor	NOUN
chd-130	148	25	,	,	PUNCT
chd-130	148	26	at	at	ADP
chd-130	148	27	least	least	ADJ
chd-130	148	28	in	in	ADP
chd-130	148	29	a	a	DET
chd-130	148	30	sub	sub	NOUN
chd-130	148	31	-	-	ADJ
chd-130	148	32	set	set	ADJ
chd-130	148	33	of	of	ADP
chd-130	148	34	patients	patient	NOUN
chd-130	148	35	harboring	harbor	VERB
chd-130	148	36	k	k	PROPN
chd-130	148	37	-	-	PUNCT
chd-130	148	38	ras	ras	ADJ
chd-130	148	39	mutations	mutation	NOUN
chd-130	148	40	.	.	PUNCT
chd-130	149	1	besides	besides	SCONJ
chd-130	149	2	,	,	PUNCT
chd-130	149	3	this	this	DET
chd-130	149	4	work	work	NOUN
chd-130	149	5	also	also	ADV
chd-130	149	6	suggested	suggest	VERB
chd-130	149	7	the	the	DET
chd-130	149	8	role	role	NOUN
chd-130	149	9	of	of	ADP
chd-130	149	10	chronic	chronic	ADJ
chd-130	149	11	inflammation	inflammation	NOUN
chd-130	149	12	in	in	ADP
chd-130	149	13	the	the	DET
chd-130	149	14	etiology	etiology	NOUN
chd-130	149	15	of	of	ADP
chd-130	149	16	gallbladder	gallbladder	NOUN
chd-130	149	17	carcinogenesis	carcinogenesis	NOUN
chd-130	149	18	(	(	PUNCT
chd-130	149	19	singh	singh	PROPN
chd-130	149	20	et	et	PROPN
chd-130	149	21	al	al	PROPN
chd-130	149	22	.	.	PROPN
chd-130	149	23	,	,	PUNCT
chd-130	149	24	2004b	2004b	NUM
chd-130	149	25	)	)	PUNCT
chd-130	149	26	.	.	PUNCT
chd-130	150	1	in	in	ADP
chd-130	150	2	the	the	DET
chd-130	150	3	dawn	dawn	NOUN
chd-130	150	4	of	of	ADP
chd-130	150	5	21st	21st	ADJ
chd-130	150	6	century	century	NOUN
chd-130	150	7	,	,	PUNCT
chd-130	150	8	with	with	ADP
chd-130	150	9	growing	grow	VERB
chd-130	150	10	realization	realization	NOUN
chd-130	150	11	of	of	ADP
chd-130	150	12	cancer	cancer	NOUN
chd-130	150	13	being	be	AUX
chd-130	150	14	a	a	DET
chd-130	150	15	much	much	ADV
chd-130	150	16	more	more	ADV
chd-130	150	17	complex	complex	ADJ
chd-130	150	18	disease	disease	NOUN
chd-130	150	19	,	,	PUNCT
chd-130	150	20	than	than	SCONJ
chd-130	150	21	it	it	PRON
chd-130	150	22	was	be	AUX
chd-130	150	23	thought	think	VERB
chd-130	150	24	to	to	PART
chd-130	150	25	be	be	AUX
chd-130	150	26	earlier	early	ADJ
chd-130	150	27	,	,	PUNCT
chd-130	150	28	cancer	cancer	NOUN
chd-130	150	29	researchers	researcher	NOUN
chd-130	150	30	working	work	VERB
chd-130	150	31	on	on	ADP
chd-130	150	32	gbc	gbc	PROPN
chd-130	150	33	initiated	initiate	VERB
chd-130	150	34	pathwaymechanism	pathwaymechanism	NOUN
chd-130	150	35	oriented	orient	VERB
chd-130	150	36	studies	study	NOUN
chd-130	150	37	in	in	ADP
chd-130	150	38	various	various	ADJ
chd-130	150	39	parts	part	NOUN
chd-130	150	40	of	of	ADP
chd-130	150	41	the	the	DET
chd-130	150	42	world	world	NOUN
chd-130	150	43	.	.	PUNCT
chd-130	151	1	one	one	NUM
chd-130	151	2	such	such	ADJ
chd-130	151	3	study	study	NOUN
chd-130	151	4	conducted	conduct	VERB
chd-130	151	5	in	in	ADP
chd-130	151	6	japan	japan	PROPN
chd-130	151	7	cited	cite	VERB
chd-130	151	8	factors	factor	NOUN
chd-130	151	9	such	such	ADJ
chd-130	151	10	as	as	ADP
chd-130	151	11	homozygous	homozygous	ADJ
chd-130	151	12	deletions	deletion	NOUN
chd-130	151	13	,	,	PUNCT
chd-130	151	14	promoter	promoter	NOUN
chd-130	151	15	and	and	CCONJ
chd-130	151	16	loh	loh	PROPN
chd-130	151	17	hypermethylations	hypermethylation	NOUN
chd-130	151	18	and	and	CCONJ
chd-130	151	19	multiple	multiple	ADJ
chd-130	151	20	loh	loh	PROPN
chd-130	151	21	to	to	PART
chd-130	151	22	be	be	AUX
chd-130	151	23	the	the	DET
chd-130	151	24	major	major	ADJ
chd-130	151	25	mechanisms	mechanism	NOUN
chd-130	151	26	involved	involve	VERB
chd-130	151	27	in	in	ADP
chd-130	151	28	inactivation	inactivation	NOUN
chd-130	151	29	of	of	ADP
chd-130	151	30	the	the	DET
chd-130	151	31	p16	p16	NOUN
chd-130	151	32	gene	gene	NOUN
chd-130	151	33	in	in	ADP
chd-130	151	34	gbc	gbc	PROPN
chd-130	151	35	(	(	PUNCT
chd-130	151	36	tadokoro	tadokoro	ADP
chd-130	151	37	et	et	PROPN
chd-130	151	38	al	al	PROPN
chd-130	151	39	.	.	PROPN
chd-130	151	40	,	,	PUNCT
chd-130	151	41	2007	2007	NUM
chd-130	151	42	)	)	PUNCT
chd-130	151	43	.	.	PUNCT
chd-130	152	1	another	another	DET
chd-130	152	2	such	such	ADJ
chd-130	152	3	study	study	NOUN
chd-130	152	4	to	to	PART
chd-130	152	5	understand	understand	VERB
chd-130	152	6	geographical	geographical	ADJ
chd-130	152	7	differences	difference	NOUN
chd-130	152	8	in	in	ADP
chd-130	152	9	genetic	genetic	ADJ
chd-130	152	10	changes	change	NOUN
chd-130	152	11	involved	involve	VERB
chd-130	152	12	in	in	ADP
chd-130	152	13	gbc	gbc	PROPN
chd-130	152	14	between	between	ADP
chd-130	152	15	japan	japan	PROPN
chd-130	152	16	and	and	CCONJ
chd-130	152	17	hungary	hungary	PROPN
chd-130	152	18	,	,	PUNCT
chd-130	152	19	was	be	AUX
chd-130	152	20	conducted	conduct	VERB
chd-130	152	21	in	in	ADP
chd-130	152	22	a	a	DET
chd-130	152	23	collaborative	collaborative	ADJ
chd-130	152	24	effort	effort	NOUN
chd-130	152	25	by	by	ADP
chd-130	152	26	collecting	collect	VERB
chd-130	152	27	specimens	specimen	NOUN
chd-130	152	28	obtained	obtain	VERB
chd-130	152	29	from	from	ADP
chd-130	152	30	patients	patient	NOUN
chd-130	152	31	living	live	VERB
chd-130	152	32	in	in	ADP
chd-130	152	33	these	these	DET
chd-130	152	34	two	two	NUM
chd-130	152	35	countries	country	NOUN
chd-130	152	36	.	.	PUNCT
chd-130	153	1	a	a	DET
chd-130	153	2	considerable	considerable	ADJ
chd-130	153	3	difference	difference	NOUN
chd-130	153	4	between	between	ADP
chd-130	153	5	the	the	DET
chd-130	153	6	two	two	NUM
chd-130	153	7	populations	population	NOUN
chd-130	153	8	was	be	AUX
chd-130	153	9	attributed	attribute	VERB
chd-130	153	10	to	to	ADP
chd-130	153	11	the	the	DET
chd-130	153	12	presence	presence	NOUN
chd-130	153	13	of	of	ADP
chd-130	153	14	high	high	ADJ
chd-130	153	15	msi	msi	NOUN
chd-130	153	16	seen	see	VERB
chd-130	153	17	in	in	ADP
chd-130	153	18	japanese	japanese	ADJ
chd-130	153	19	patients	patient	NOUN
chd-130	153	20	as	as	SCONJ
chd-130	153	21	opposed	oppose	VERB
chd-130	153	22	to	to	ADP
chd-130	153	23	just	just	ADV
chd-130	153	24	one	one	NUM
chd-130	153	25	high	high	ADJ
chd-130	153	26	msi	msi	NOUN
chd-130	153	27	patient	patient	NOUN
chd-130	153	28	in	in	ADP
chd-130	153	29	hungary	hungary	PROPN
chd-130	153	30	.	.	PUNCT
chd-130	154	1	this	this	PRON
chd-130	154	2	further	far	ADV
chd-130	154	3	affirmed	affirm	VERB
chd-130	154	4	the	the	DET
chd-130	154	5	notion	notion	NOUN
chd-130	154	6	that	that	SCONJ
chd-130	154	7	geographic	geographic	ADJ
chd-130	154	8	variation	variation	NOUN
chd-130	154	9	could	could	AUX
chd-130	154	10	play	play	VERB
chd-130	154	11	a	a	DET
chd-130	154	12	significant	significant	ADJ
chd-130	154	13	role	role	NOUN
chd-130	154	14	in	in	ADP
chd-130	154	15	the	the	DET
chd-130	154	16	process	process	NOUN
chd-130	154	17	of	of	ADP
chd-130	154	18	gallbladder	gallbladder	NOUN
chd-130	154	19	carcinogenesis	carcinogenesis	NOUN
chd-130	154	20	at	at	ADP
chd-130	154	21	mechanistic	mechanistic	ADJ
chd-130	154	22	level	level	NOUN
chd-130	154	23	(	(	PUNCT
chd-130	154	24	nagahashi	nagahashi	PROPN
chd-130	154	25	et	et	PROPN
chd-130	154	26	al	al	PROPN
chd-130	154	27	.	.	PROPN
chd-130	154	28	,	,	PUNCT
chd-130	154	29	2008	2008	NUM
chd-130	154	30	)	)	PUNCT
chd-130	154	31	.	.	PUNCT
chd-130	155	1	investigators	investigator	NOUN
chd-130	155	2	in	in	ADP
chd-130	155	3	the	the	DET
chd-130	155	4	united	united	PROPN
chd-130	155	5	states	states	PROPN
chd-130	155	6	relying	rely	VERB
chd-130	155	7	on	on	ADP
chd-130	155	8	serial	serial	ADJ
chd-130	155	9	analysis	analysis	NOUN
chd-130	155	10	of	of	ADP
chd-130	155	11	gene	gene	NOUN
chd-130	155	12	expression	expression	NOUN
chd-130	155	13	(	(	PUNCT
chd-130	155	14	sage	sage	NOUN
chd-130	155	15	)	)	PUNCT
chd-130	155	16	created	create	VERB
chd-130	155	17	cdna	cdna	PROPN
chd-130	155	18	libraries	library	NOUN
chd-130	155	19	from	from	ADP
chd-130	155	20	the	the	DET
chd-130	155	21	tumor	tumor	NOUN
chd-130	155	22	tissues	tissue	NOUN
chd-130	155	23	of	of	ADP
chd-130	155	24	stage	stage	NOUN
chd-130	155	25	matched	match	VERB
chd-130	155	26	gbc	gbc	PROPN
chd-130	155	27	patients	patient	NOUN
chd-130	155	28	of	of	ADP
chd-130	155	29	native	native	ADJ
chd-130	155	30	american	american	PROPN
chd-130	155	31	,	,	PUNCT
chd-130	155	32	caucasian	caucasian	ADJ
chd-130	155	33	and	and	CCONJ
chd-130	155	34	hispanic	hispanic	ADJ
chd-130	155	35	/	/	SYM
chd-130	155	36	latino	latino	ADJ
chd-130	155	37	descent	descent	NOUN
chd-130	155	38	,	,	PUNCT
chd-130	155	39	along	along	ADP
chd-130	155	40	with	with	ADP
chd-130	155	41	the	the	DET
chd-130	155	42	tissues	tissue	NOUN
chd-130	155	43	from	from	ADP
chd-130	155	44	normal	normal	ADJ
chd-130	155	45	gallbladder	gallbladder	NOUN
chd-130	155	46	.	.	PUNCT
chd-130	156	1	rt	rt	VERB
chd-130	156	2	-	-	PUNCT
chd-130	156	3	qpcr	qpcr	ADV
chd-130	156	4	analysis	analysis	NOUN
chd-130	156	5	was	be	AUX
chd-130	156	6	performed	perform	VERB
chd-130	156	7	on	on	ADP
chd-130	156	8	the	the	DET
chd-130	156	9	microdissected	microdissecte	VERB
chd-130	156	10	epithelia	epithelia	NOUN
chd-130	156	11	extracted	extract	VERB
chd-130	156	12	from	from	ADP
chd-130	156	13	both	both	DET
chd-130	156	14	gbc	gbc	PROPN
chd-130	156	15	as	as	ADV
chd-130	156	16	well	well	ADV
chd-130	156	17	as	as	ADP
chd-130	156	18	their	their	PRON
chd-130	156	19	corresponding	corresponding	ADJ
chd-130	156	20	non	non	ADJ
chd-130	156	21	-	-	ADJ
chd-130	156	22	neoplastic	neoplastic	ADJ
chd-130	156	23	mucosae	mucosa	NOUN
chd-130	156	24	.	.	PUNCT
chd-130	157	1	to	to	PART
chd-130	157	2	further	far	ADV
chd-130	157	3	understand	understand	VERB
chd-130	157	4	the	the	DET
chd-130	157	5	complexity	complexity	NOUN
chd-130	157	6	of	of	ADP
chd-130	157	7	the	the	DET
chd-130	157	8	disease	disease	NOUN
chd-130	157	9	,	,	PUNCT
chd-130	157	10	immunohistochemistry	immunohistochemistry	NOUN
chd-130	157	11	on	on	ADP
chd-130	157	12	the	the	DET
chd-130	157	13	gbcs	gbc	NOUN
chd-130	157	14	was	be	AUX
chd-130	157	15	done	do	VERB
chd-130	157	16	in	in	ADP
chd-130	157	17	a	a	DET
chd-130	157	18	complex	complex	ADJ
chd-130	157	19	tissue	tissue	NOUN
chd-130	157	20	microarray	microarray	NOUN
chd-130	157	21	format	format	NOUN
chd-130	157	22	.	.	PUNCT
chd-130	158	1	the	the	DET
chd-130	158	2	hallmark	hallmark	NOUN
chd-130	158	3	of	of	ADP
chd-130	158	4	this	this	DET
chd-130	158	5	study	study	NOUN
chd-130	158	6	was	be	AUX
chd-130	158	7	using	use	VERB
chd-130	158	8	sage	sage	NOUN
chd-130	158	9	to	to	PART
chd-130	158	10	make	make	VERB
chd-130	158	11	an	an	DET
chd-130	158	12	impartial	impartial	ADJ
chd-130	158	13	assessment	assessment	NOUN
chd-130	158	14	of	of	ADP
chd-130	158	15	the	the	DET
chd-130	158	16	transcriptome	transcriptome	NOUN
chd-130	158	17	in	in	ADP
chd-130	158	18	gbc	gbc	PROPN
chd-130	158	19	,	,	PUNCT
chd-130	158	20	and	and	CCONJ
chd-130	158	21	identifying	identify	VERB
chd-130	158	22	a	a	DET
chd-130	158	23	new	new	ADJ
chd-130	158	24	positive	positive	ADJ
chd-130	158	25	prognostic	prognostic	ADJ
chd-130	158	26	marker	marker	NOUN
chd-130	158	27	expression	expression	NOUN
chd-130	158	28	of	of	ADP
chd-130	158	29	connective	connective	ADJ
chd-130	158	30	tissue	tissue	NOUN
chd-130	158	31	growth	growth	NOUN
chd-130	158	32	factor	factor	NOUN
chd-130	158	33	(	(	PUNCT
chd-130	158	34	ctgf	ctgf	NOUN
chd-130	158	35	)	)	PUNCT
chd-130	158	36	.	.	PUNCT
chd-130	159	1	gbc	gbc	PROPN
chd-130	159	2	and	and	CCONJ
chd-130	159	3	non	non	ADJ
chd-130	159	4	-	-	ADJ
chd-130	159	5	neoplastic	neoplastic	ADJ
chd-130	159	6	mucosae	mucosa	NOUN
chd-130	159	7	from	from	ADP
chd-130	159	8	the	the	DET
chd-130	159	9	gallbladder	gallbladder	NOUN
chd-130	159	10	have	have	VERB
chd-130	159	11	sage	sage	NOUN
chd-130	159	12	libraries	library	NOUN
chd-130	159	13	which	which	PRON
chd-130	159	14	are	be	AUX
chd-130	159	15	available	available	ADJ
chd-130	159	16	publicly	publicly	ADV
chd-130	159	17	at	at	ADP
chd-130	159	18	the	the	DET
chd-130	159	19	cancer	cancer	NOUN
chd-130	159	20	genome	genome	NOUN
chd-130	159	21	anatomy	anatomy	NOUN
chd-130	159	22	project	project	NOUN
chd-130	159	23	that	that	PRON
chd-130	159	24	would	would	AUX
chd-130	159	25	help	help	VERB
chd-130	159	26	facilitate	facilitate	VERB
chd-130	159	27	the	the	DET
chd-130	159	28	research	research	NOUN
chd-130	159	29	needed	need	VERB
chd-130	159	30	for	for	ADP
chd-130	159	31	this	this	DET
chd-130	159	32	deadly	deadly	ADJ
chd-130	159	33	cancer	cancer	NOUN
chd-130	159	34	(	(	PUNCT
chd-130	159	35	alvarez	alvarez	PROPN
chd-130	159	36	et	et	PROPN
chd-130	159	37	al	al	PROPN
chd-130	159	38	.	.	PROPN
chd-130	159	39	,	,	PUNCT
chd-130	159	40	2008	2008	NUM
chd-130	159	41	)	)	PUNCT
chd-130	159	42	.	.	PUNCT
chd-130	160	1	in	in	ADP
chd-130	160	2	another	another	DET
chd-130	160	3	small	small	ADJ
chd-130	160	4	attempt	attempt	NOUN
chd-130	160	5	to	to	PART
chd-130	160	6	identify	identify	VERB
chd-130	160	7	metastasis	metastasis	NOUN
chd-130	160	8	-	-	PUNCT
chd-130	160	9	associated	associate	VERB
chd-130	160	10	proteins	protein	NOUN
chd-130	160	11	in	in	ADP
chd-130	160	12	gbc	gbc	PROPN
chd-130	160	13	,	,	PUNCT
chd-130	160	14	a	a	DET
chd-130	160	15	chinese	chinese	ADJ
chd-130	160	16	study	study	NOUN
chd-130	160	17	demonstrated	demonstrate	VERB
chd-130	160	18	that	that	SCONJ
chd-130	160	19	overexpression	overexpression	NOUN
chd-130	160	20	of	of	ADP
chd-130	160	21	chloride	chloride	NOUN
chd-130	160	22	intracellular	intracellular	ADJ
chd-130	160	23	channel	channel	NOUN
chd-130	160	24	1	1	NUM
chd-130	160	25	(	(	PUNCT
chd-130	160	26	clic1	clic1	NOUN
chd-130	160	27	)	)	PUNCT
chd-130	160	28	encouraged	encourage	VERB
chd-130	160	29	cell	cell	NOUN
chd-130	160	30	motility	motility	NOUN
chd-130	160	31	and	and	CCONJ
chd-130	160	32	inundation	inundation	NOUN
chd-130	160	33	of	of	ADP
chd-130	160	34	gbc	gbc	NOUN
chd-130	160	35	-	-	PUNCT
chd-130	160	36	sd18l	sd18l	X
chd-130	160	37	(	(	PUNCT
chd-130	160	38	cell	cell	NOUN
chd-130	160	39	line	line	NOUN
chd-130	160	40	with	with	ADP
chd-130	160	41	a	a	DET
chd-130	160	42	low	low	ADJ
chd-130	160	43	potential	potential	NOUN
chd-130	160	44	for	for	ADP
chd-130	160	45	metastasis	metastasis	NOUN
chd-130	160	46	)	)	PUNCT
chd-130	160	47	in	in	ADP
chd-130	160	48	vitro	vitro	VERB
chd-130	160	49	.	.	PUNCT
chd-130	161	1	it	it	PRON
chd-130	161	2	was	be	AUX
chd-130	161	3	interesting	interesting	ADJ
chd-130	161	4	to	to	PART
chd-130	161	5	note	note	VERB
chd-130	161	6	that	that	SCONJ
chd-130	161	7	inhibition	inhibition	NOUN
chd-130	161	8	of	of	ADP
chd-130	161	9	clic1	clic1	NOUN
chd-130	161	10	expression	expression	NOUN
chd-130	161	11	by	by	ADP
chd-130	161	12	rnai	rnai	PROPN
chd-130	161	13	significantly	significantly	ADV
chd-130	161	14	decreased	decrease	VERB
chd-130	161	15	the	the	DET
chd-130	161	16	cell	cell	NOUN
chd-130	161	17	motility	motility	NOUN
chd-130	161	18	as	as	ADV
chd-130	161	19	well	well	ADV
chd-130	161	20	as	as	ADP
chd-130	161	21	the	the	DET
chd-130	161	22	invasiveness	invasiveness	NOUN
chd-130	161	23	of	of	ADP
chd-130	161	24	gbc	gbc	NOUN
chd-130	161	25	-	-	PUNCT
chd-130	161	26	sd18h	sd18h	NOUN
chd-130	161	27	(	(	PUNCT
chd-130	161	28	a	a	DET
chd-130	161	29	cell	cell	NOUN
chd-130	161	30	line	line	NOUN
chd-130	161	31	with	with	ADP
chd-130	161	32	a	a	DET
chd-130	161	33	high	high	ADJ
chd-130	161	34	potential	potential	NOUN
chd-130	161	35	for	for	ADP
chd-130	161	36	metastasis	metastasis	NOUN
chd-130	161	37	)	)	PUNCT
chd-130	161	38	.	.	PUNCT
chd-130	162	1	this	this	DET
chd-130	162	2	study	study	NOUN
chd-130	162	3	thus	thus	ADV
chd-130	162	4	demonstrated	demonstrate	VERB
chd-130	162	5	that	that	SCONJ
chd-130	162	6	clic1	clic1	NOUN
chd-130	162	7	could	could	AUX
chd-130	162	8	play	play	VERB
chd-130	162	9	a	a	DET
chd-130	162	10	crucial	crucial	ADJ
chd-130	162	11	role	role	NOUN
chd-130	162	12	in	in	ADP
chd-130	162	13	gbc	gbc	PROPN
chd-130	162	14	metastasis	metastasis	NOUN
chd-130	162	15	,	,	PUNCT
chd-130	162	16	and	and	CCONJ
chd-130	162	17	was	be	AUX
chd-130	162	18	hence	hence	ADV
chd-130	162	19	identified	identify	VERB
chd-130	162	20	to	to	PART
chd-130	162	21	be	be	AUX
chd-130	162	22	a	a	DET
chd-130	162	23	regulator	regulator	NOUN
chd-130	162	24	of	of	ADP
chd-130	162	25	metastasis	metastasis	NOUN
chd-130	162	26	in	in	ADP
chd-130	162	27	gbc	gbc	PROPN
chd-130	162	28	(	(	PUNCT
chd-130	162	29	wang	wang	PROPN
chd-130	162	30	et	et	PROPN
chd-130	162	31	al	al	PROPN
chd-130	162	32	.	.	PROPN
chd-130	162	33	,	,	PUNCT
chd-130	162	34	2009	2009	NUM
chd-130	162	35	)	)	PUNCT
chd-130	162	36	.	.	PUNCT
chd-130	163	1	an	an	DET
chd-130	163	2	overview	overview	NOUN
chd-130	163	3	of	of	ADP
chd-130	163	4	some	some	DET
chd-130	163	5	such	such	ADJ
chd-130	163	6	key	key	ADJ
chd-130	163	7	studies	study	NOUN
chd-130	163	8	reporting	report	VERB
chd-130	163	9	mutational	mutational	ADJ
chd-130	163	10	spectrum	spectrum	NOUN
chd-130	163	11	in	in	ADP
chd-130	163	12	gbc	gbc	PROPN
chd-130	163	13	is	be	AUX
chd-130	163	14	provided	provide	VERB
chd-130	163	15	in	in	ADP
chd-130	163	16	table	table	NOUN
chd-130	163	17	1	1	NUM
chd-130	163	18	.	.	PUNCT
chd-130	164	1	in	in	ADP
chd-130	164	2	another	another	PRON
chd-130	164	3	such	such	ADJ
chd-130	164	4	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-130	164	5	e10	e10	NUM
chd-130	164	6	cancer	cancer	NOUN
chd-130	164	7	health	health	NOUN
chd-130	164	8	disparities	disparity	NOUN
chd-130	164	9	research	research	VERB
chd-130	164	10	interesting	interesting	ADJ
chd-130	164	11	study	study	NOUN
chd-130	164	12	from	from	ADP
chd-130	164	13	india	india	PROPN
chd-130	164	14	,	,	PUNCT
chd-130	164	15	investigators	investigator	NOUN
chd-130	164	16	identified	identify	VERB
chd-130	164	17	e	e	NOUN
chd-130	164	18	-	-	NOUN
chd-130	164	19	cadherin	cadherin	NOUN
chd-130	164	20	(	(	PUNCT
chd-130	164	21	cdh1	cdh1	NOUN
chd-130	164	22	)	)	PUNCT
chd-130	164	23	genomic	genomic	NOUN
chd-130	164	24	instability	instability	NOUN
chd-130	164	25	and	and	CCONJ
chd-130	164	26	demonstrated	demonstrate	VERB
chd-130	164	27	a	a	DET
chd-130	164	28	correlation	correlation	NOUN
chd-130	164	29	between	between	ADP
chd-130	164	30	their	their	PRON
chd-130	164	31	findings	finding	NOUN
chd-130	164	32	with	with	ADP
chd-130	164	33	cdh1	cdh1	NOUN
chd-130	164	34	protein	protein	NOUN
chd-130	164	35	expression	expression	NOUN
chd-130	164	36	in	in	ADP
chd-130	164	37	conditions	condition	NOUN
chd-130	164	38	of	of	ADP
chd-130	164	39	gbc	gbc	PROPN
chd-130	164	40	and	and	CCONJ
chd-130	164	41	other	other	ADJ
chd-130	164	42	non	non	ADJ
chd-130	164	43	-	-	ADJ
chd-130	164	44	neoplastic	neoplastic	ADJ
chd-130	164	45	conditions	condition	NOUN
chd-130	164	46	of	of	ADP
chd-130	164	47	cc	cc	PROPN
chd-130	164	48	,	,	PUNCT
chd-130	164	49	xgc	xgc	PROPN
chd-130	164	50	,	,	PUNCT
chd-130	164	51	as	as	ADV
chd-130	164	52	well	well	ADV
chd-130	164	53	as	as	ADP
chd-130	164	54	with	with	ADP
chd-130	164	55	normal	normal	ADJ
chd-130	164	56	gb	gb	NOUN
chd-130	164	57	,	,	PUNCT
chd-130	164	58	to	to	PART
chd-130	164	59	define	define	VERB
chd-130	164	60	its	its	PRON
chd-130	164	61	role	role	NOUN
chd-130	164	62	in	in	ADP
chd-130	164	63	gbc	gbc	PROPN
chd-130	164	64	carcinogenesis	carcinogenesis	NOUN
chd-130	164	65	.	.	PUNCT
chd-130	165	1	more	more	ADV
chd-130	165	2	importantly	importantly	ADV
chd-130	165	3	this	this	DET
chd-130	165	4	study	study	NOUN
chd-130	165	5	provided	provide	VERB
chd-130	165	6	solid	solid	ADJ
chd-130	165	7	evidence	evidence	NOUN
chd-130	165	8	as	as	ADP
chd-130	165	9	to	to	ADP
chd-130	165	10	how	how	SCONJ
chd-130	165	11	cc	cc	NOUN
chd-130	165	12	acts	act	VERB
chd-130	165	13	as	as	ADP
chd-130	165	14	precursor	precursor	NOUN
chd-130	165	15	lesion	lesion	NOUN
chd-130	165	16	to	to	ADP
chd-130	165	17	gbc	gbc	PROPN
chd-130	165	18	(	(	PUNCT
chd-130	165	19	priya	priya	PROPN
chd-130	165	20	et	et	PROPN
chd-130	165	21	al	al	PROPN
chd-130	165	22	.	.	PROPN
chd-130	165	23	,	,	PUNCT
chd-130	165	24	2010	2010	NUM
chd-130	165	25	)	)	PUNCT
chd-130	165	26	.	.	PUNCT
chd-130	166	1	table	table	NOUN
chd-130	166	2	1	1	NUM
chd-130	166	3	.	.	PUNCT
chd-130	166	4	important	important	ADJ
chd-130	166	5	mutations	mutation	NOUN
chd-130	166	6	during	during	ADP
chd-130	166	7	various	various	ADJ
chd-130	166	8	stages	stage	NOUN
chd-130	166	9	of	of	ADP
chd-130	166	10	gallbladder	gallbladder	NOUN
chd-130	166	11	cancer	cancer	NOUN
chd-130	166	12	development	development	NOUN
chd-130	166	13	.	.	PUNCT
chd-130	167	1	gene	gene	NOUN
chd-130	167	2	and	and	CCONJ
chd-130	167	3	reference	reference	NOUN
chd-130	167	4	adenoma	adenoma	ADV
chd-130	167	5	(	(	PUNCT
chd-130	167	6	%	%	INTJ
chd-130	167	7	)	)	PUNCT
chd-130	167	8	dysplasia	dysplasia	NOUN
chd-130	167	9	(	(	PUNCT
chd-130	167	10	%	%	INTJ
chd-130	167	11	)	)	PUNCT
chd-130	167	12	carcinoma	carcinoma	NOUN
chd-130	167	13	(	(	PUNCT
chd-130	167	14	%	%	NOUN
chd-130	167	15	)	)	PUNCT
chd-130	167	16	k	k	PROPN
chd-130	167	17	-	-	PUNCT
chd-130	167	18	ras	ras	X
chd-130	167	19	hanada	hanada	X
chd-130	167	20	et	et	PROPN
chd-130	167	21	al	al	PROPN
chd-130	167	22	.	.	PROPN
chd-130	167	23	,	,	PUNCT
chd-130	167	24	1999	1999	NUM
chd-130	167	25	watanabe	watanabe	PROPN
chd-130	167	26	et	et	PROPN
chd-130	167	27	al	al	PROPN
chd-130	167	28	.	.	PROPN
chd-130	167	29	,	,	PUNCT
chd-130	167	30	1999	1999	NUM
chd-130	167	31	kim	kim	PROPN
chd-130	167	32	et	et	PROPN
chd-130	167	33	al	al	PROPN
chd-130	167	34	.	.	PROPN
chd-130	167	35	,	,	PUNCT
chd-130	167	36	2001	2001	NUM
chd-130	167	37	wistua	wistua	NOUN
chd-130	167	38	et	et	PROPN
chd-130	167	39	al	al	PROPN
chd-130	167	40	.	.	PROPN
chd-130	167	41	,	,	PUNCT
chd-130	167	42	1999	1999	NUM
chd-130	167	43	singh	singh	PROPN
chd-130	167	44	et	et	PROPN
chd-130	167	45	al	al	PROPN
chd-130	167	46	.	.	PROPN
chd-130	167	47	,	,	PUNCT
chd-130	167	48	2004	2004	NUM
chd-130	167	49	li	li	PROPN
chd-130	167	50	et	et	PROPN
chd-130	167	51	al	al	PROPN
chd-130	167	52	.	.	PROPN
chd-130	167	53	,	,	PUNCT
chd-130	167	54	2014	2014	NUM
chd-130	167	55	17	17	NUM
chd-130	167	56	0	0	SYM
chd-130	167	57	0	0	NUM
chd-130	167	58	25	25	NUM
chd-130	167	59	15	15	NUM
chd-130	167	60	0	0	NUM
chd-130	167	61	38	38	NUM
chd-130	167	62	19	19	NUM
chd-130	167	63	20	20	NUM
chd-130	167	64	38	38	NUM
chd-130	167	65	8	8	NUM
chd-130	167	66	beta	beta	NOUN
chd-130	167	67	-	-	PUNCT
chd-130	167	68	catenin	catenin	NOUN
chd-130	167	69	yanagisawa	yanagisawa	NOUN
chd-130	167	70	et	et	PROPN
chd-130	167	71	al	al	PROPN
chd-130	167	72	.	.	PROPN
chd-130	167	73	,	,	PUNCT
chd-130	167	74	2001	2001	NUM
chd-130	167	75	rashid	rashid	PROPN
chd-130	167	76	et	et	PROPN
chd-130	167	77	al	al	PROPN
chd-130	167	78	.	.	PROPN
chd-130	167	79	,	,	PUNCT
chd-130	167	80	2001	2001	NUM
chd-130	167	81	chang	chang	PROPN
chd-130	167	82	et	et	PROPN
chd-130	167	83	al	al	PROPN
chd-130	167	84	.	.	PROPN
chd-130	167	85	,	,	PUNCT
chd-130	167	86	2002	2002	NUM
chd-130	167	87	kumari	kumari	X
chd-130	167	88	et	et	PROPN
chd-130	167	89	al	al	PROPN
chd-130	167	90	.	.	PROPN
chd-130	167	91	,	,	PUNCT
chd-130	167	92	2014	2014	NUM
chd-130	167	93	63	63	NUM
chd-130	167	94	57	57	NUM
chd-130	167	95	58	58	NUM
chd-130	167	96	0	0	NUM
chd-130	167	97	5	5	NUM
chd-130	167	98	9	9	NUM
chd-130	167	99	0	0	NUM
chd-130	167	100	4	4	NUM
chd-130	167	101	egfr	egfr	X
chd-130	167	102	/	/	SYM
chd-130	167	103	erbb2	erbb2	PROPN
chd-130	167	104	/	/	SYM
chd-130	167	105	erbb3	erbb3	NOUN
chd-130	167	106	nakazawa	nakazawa	PROPN
chd-130	167	107	et	et	PROPN
chd-130	167	108	al	al	PROPN
chd-130	167	109	.	.	PROPN
chd-130	167	110	,	,	PUNCT
chd-130	167	111	2005	2005	NUM
chd-130	167	112	leone	leone	NOUN
chd-130	167	113	et	et	PROPN
chd-130	167	114	al	al	PROPN
chd-130	167	115	.	.	PROPN
chd-130	167	116	,	,	PUNCT
chd-130	167	117	2006	2006	NUM
chd-130	167	118	pignochino	pignochino	NOUN
chd-130	167	119	et	et	PROPN
chd-130	167	120	al	al	PROPN
chd-130	167	121	.	.	PROPN
chd-130	167	122	,	,	PUNCT
chd-130	167	123	2010	2010	NUM
chd-130	167	124	li	li	X
chd-130	167	125	et	et	PROPN
chd-130	167	126	al	al	PROPN
chd-130	167	127	.	.	PROPN
chd-130	167	128	,	,	PUNCT
chd-130	167	129	2014	2014	NUM
chd-130	167	130	16	16	NUM
chd-130	167	131	15	15	NUM
chd-130	167	132	10	10	NUM
chd-130	167	133	37	37	NUM
chd-130	167	134	p161nk4a	p161nk4a	NOUN
chd-130	167	135	kim	kim	PROPN
chd-130	167	136	et	et	PROPN
chd-130	167	137	al	al	PROPN
chd-130	167	138	.	.	PROPN
chd-130	167	139	,	,	PUNCT
chd-130	167	140	2001	2001	NUM
chd-130	167	141	ueki	ueki	PROPN
chd-130	167	142	et	et	PROPN
chd-130	167	143	al	al	PROPN
chd-130	167	144	.	.	PROPN
chd-130	167	145	,	,	PUNCT
chd-130	167	146	2004	2004	NUM
chd-130	167	147	0	0	SYM
chd-130	167	148	0	0	NUM
chd-130	167	149	31	31	NUM
chd-130	167	150	62	62	NUM
chd-130	167	151	tp53	tp53	PROPN
chd-130	167	152	wistua	wistua	NOUN
chd-130	167	153	et	et	PROPN
chd-130	167	154	al	al	PROPN
chd-130	167	155	.	.	PROPN
chd-130	167	156	,	,	PUNCT
chd-130	167	157	1999	1999	NUM
chd-130	167	158	kim	kim	PROPN
chd-130	167	159	et	et	PROPN
chd-130	167	160	al	al	PROPN
chd-130	167	161	.	.	PROPN
chd-130	167	162	,	,	PUNCT
chd-130	167	163	2001	2001	NUM
chd-130	167	164	li	li	X
chd-130	167	165	et	et	PROPN
chd-130	167	166	al	al	PROPN
chd-130	167	167	.	.	PROPN
chd-130	167	168	,	,	PUNCT
chd-130	167	169	2014	2014	NUM
chd-130	167	170	kumari	kumari	X
chd-130	167	171	et	et	PROPN
chd-130	167	172	al	al	PROPN
chd-130	167	173	.	.	PROPN
chd-130	167	174	,	,	PUNCT
chd-130	167	175	2014	2014	NUM
chd-130	167	176	noguchietal	noguchietal	ADJ
chd-130	167	177	.	.	PROPN
chd-130	167	178	,	,	PUNCT
chd-130	167	179	2017	2017	NUM
chd-130	167	180	0	0	NUM
chd-130	167	181	0	0	NUM
chd-130	167	182	0	0	NUM
chd-130	167	183	36	36	NUM
chd-130	167	184	47	47	NUM
chd-130	167	185	18	18	NUM
chd-130	167	186	64	64	NUM
chd-130	167	187	abovementioned	abovementione	VERB
chd-130	167	188	studies	study	NOUN
chd-130	167	189	to	to	PART
chd-130	167	190	identify	identify	VERB
chd-130	167	191	genetic	genetic	ADJ
chd-130	167	192	alterations	alteration	NOUN
chd-130	167	193	in	in	ADP
chd-130	167	194	the	the	DET
chd-130	167	195	gbc	gbc	PROPN
chd-130	167	196	were	be	AUX
chd-130	167	197	based	base	VERB
chd-130	167	198	on	on	ADP
chd-130	167	199	conventional	conventional	ADJ
chd-130	167	200	sequencing	sequencing	NOUN
chd-130	167	201	methods	method	NOUN
chd-130	167	202	such	such	ADJ
chd-130	167	203	as	as	ADP
chd-130	167	204	sanger	sanger	PROPN
chd-130	167	205	sequencing	sequencing	NOUN
chd-130	167	206	,	,	PUNCT
chd-130	167	207	which	which	PRON
chd-130	167	208	had	have	VERB
chd-130	167	209	its	its	PRON
chd-130	167	210	own	own	ADJ
chd-130	167	211	limitations	limitation	NOUN
chd-130	167	212	.	.	PUNCT
chd-130	168	1	in	in	ADP
chd-130	168	2	the	the	DET
chd-130	168	3	recent	recent	ADJ
chd-130	168	4	past	past	NOUN
chd-130	168	5	,	,	PUNCT
chd-130	168	6	altered	alter	VERB
chd-130	168	7	genetic	genetic	ADJ
chd-130	168	8	pathways	pathway	NOUN
chd-130	168	9	involved	involve	VERB
chd-130	168	10	in	in	ADP
chd-130	168	11	human	human	ADJ
chd-130	168	12	cancer	cancer	NOUN
chd-130	168	13	are	be	AUX
chd-130	168	14	being	be	AUX
chd-130	168	15	studied	study	VERB
chd-130	168	16	using	use	VERB
chd-130	168	17	next	next	ADJ
chd-130	168	18	-	-	PUNCT
chd-130	168	19	generation	generation	NOUN
chd-130	168	20	sequencing	sequencing	NOUN
chd-130	168	21	(	(	PUNCT
chd-130	168	22	ngs	ng	NOUN
chd-130	168	23	)	)	PUNCT
chd-130	168	24	technologies	technology	NOUN
chd-130	168	25	which	which	PRON
chd-130	168	26	has	have	AUX
chd-130	168	27	really	really	ADV
chd-130	168	28	helped	help	VERB
chd-130	168	29	in	in	ADP
chd-130	168	30	understanding	understand	VERB
chd-130	168	31	the	the	DET
chd-130	168	32	disease	disease	NOUN
chd-130	168	33	mechanism	mechanism	NOUN
chd-130	168	34	.	.	PUNCT
chd-130	169	1	ngs	ng	NOUN
chd-130	169	2	has	have	VERB
chd-130	169	3	numerous	numerous	ADJ
chd-130	169	4	advantages	advantage	NOUN
chd-130	169	5	when	when	SCONJ
chd-130	169	6	compared	compare	VERB
chd-130	169	7	to	to	ADP
chd-130	169	8	the	the	DET
chd-130	169	9	conventional	conventional	ADJ
chd-130	169	10	sequencing	sequence	VERB
chd-130	169	11	methods	method	NOUN
chd-130	169	12	in	in	ADP
chd-130	169	13	that	that	SCONJ
chd-130	169	14	it	it	PRON
chd-130	169	15	is	be	AUX
chd-130	169	16	a	a	DET
chd-130	169	17	highly	highly	ADV
chd-130	169	18	throughput	throughput	NOUN
chd-130	169	19	method	method	NOUN
chd-130	169	20	.	.	PUNCT
chd-130	170	1	it	it	PRON
chd-130	170	2	permits	permit	VERB
chd-130	170	3	a	a	DET
chd-130	170	4	large	large	ADJ
chd-130	170	5	number	number	NOUN
chd-130	170	6	of	of	ADP
chd-130	170	7	parallel	parallel	ADJ
chd-130	170	8	sequencing	sequencing	NOUN
chd-130	170	9	simultaneously	simultaneously	ADV
chd-130	170	10	in	in	ADP
chd-130	170	11	multiple	multiple	ADJ
chd-130	170	12	genomic	genomic	ADJ
chd-130	170	13	regions	region	NOUN
chd-130	170	14	of	of	ADP
chd-130	170	15	many	many	ADJ
chd-130	170	16	samples	sample	NOUN
chd-130	170	17	to	to	PART
chd-130	170	18	identify	identify	VERB
chd-130	170	19	any	any	DET
chd-130	170	20	associated	associated	ADJ
chd-130	170	21	mutations	mutation	NOUN
chd-130	170	22	in	in	ADP
chd-130	170	23	the	the	DET
chd-130	170	24	same	same	ADJ
chd-130	170	25	run	run	NOUN
chd-130	170	26	sequence	sequence	NOUN
chd-130	170	27	.	.	PUNCT
chd-130	171	1	another	another	DET
chd-130	171	2	crucial	crucial	ADJ
chd-130	171	3	benefit	benefit	NOUN
chd-130	171	4	to	to	ADP
chd-130	171	5	using	use	VERB
chd-130	171	6	ngs	ng	NOUN
chd-130	171	7	is	be	AUX
chd-130	171	8	the	the	DET
chd-130	171	9	reduction	reduction	NOUN
chd-130	171	10	in	in	ADP
chd-130	171	11	the	the	DET
chd-130	171	12	turnaround	turnaround	NOUN
chd-130	171	13	analysis	analysis	NOUN
chd-130	171	14	time	time	NOUN
chd-130	171	15	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	CCONJ
chd-130	171	16	e11	e11	ADJ
chd-130	171	17	cancer	cancer	NOUN
chd-130	171	18	health	health	NOUN
chd-130	171	19	disparities	disparity	NOUN
chd-130	171	20	research	research	NOUN
chd-130	171	21	during	during	ADP
chd-130	171	22	routine	routine	ADJ
chd-130	171	23	tumor	tumor	NOUN
chd-130	171	24	sequencing	sequencing	NOUN
chd-130	171	25	,	,	PUNCT
chd-130	171	26	which	which	PRON
chd-130	171	27	ultimately	ultimately	ADV
chd-130	171	28	will	will	AUX
chd-130	171	29	lead	lead	VERB
chd-130	171	30	to	to	ADP
chd-130	171	31	short	short	ADJ
chd-130	171	32	clinical	clinical	ADJ
chd-130	171	33	reporting	reporting	NOUN
chd-130	171	34	time	time	NOUN
chd-130	171	35	.	.	PUNCT
chd-130	172	1	in	in	ADP
chd-130	172	2	addition	addition	NOUN
chd-130	172	3	,	,	PUNCT
chd-130	172	4	the	the	DET
chd-130	172	5	amount	amount	NOUN
chd-130	172	6	of	of	ADP
chd-130	172	7	rna	rna	NOUN
chd-130	172	8	/	/	SYM
chd-130	172	9	dna	dna	PROPN
chd-130	172	10	required	require	VERB
chd-130	172	11	for	for	ADP
chd-130	172	12	analysis	analysis	NOUN
chd-130	172	13	is	be	AUX
chd-130	172	14	very	very	ADV
chd-130	172	15	low	low	ADJ
chd-130	172	16	in	in	ADP
chd-130	172	17	comparison	comparison	NOUN
chd-130	172	18	to	to	ADP
chd-130	172	19	traditional	traditional	ADJ
chd-130	172	20	methods	method	NOUN
chd-130	172	21	.	.	PUNCT
chd-130	173	1	genomic	genomic	ADJ
chd-130	173	2	aberrations	aberration	NOUN
chd-130	173	3	such	such	ADJ
chd-130	173	4	as	as	ADP
chd-130	173	5	single	single	ADJ
chd-130	173	6	/	/	SYM
chd-130	173	7	multiple	multiple	ADJ
chd-130	173	8	nucleotide	nucleotide	ADJ
chd-130	173	9	variants	variant	NOUN
chd-130	173	10	,	,	PUNCT
chd-130	173	11	copy	copy	VERB
chd-130	173	12	number	number	NOUN
chd-130	173	13	variations	variation	NOUN
chd-130	173	14	(	(	PUNCT
chd-130	173	15	cnvs	cnvs	NOUN
chd-130	173	16	)	)	PUNCT
chd-130	173	17	,	,	PUNCT
chd-130	173	18	fusion	fusion	NOUN
chd-130	173	19	transcripts	transcript	NOUN
chd-130	173	20	,	,	PUNCT
chd-130	173	21	and	and	CCONJ
chd-130	173	22	small	small	ADJ
chd-130	173	23	and	and	CCONJ
chd-130	173	24	large	large	ADJ
chd-130	173	25	insertions	insertion	NOUN
chd-130	173	26	and	and	CCONJ
chd-130	173	27	deletions	deletion	NOUN
chd-130	173	28	can	can	AUX
chd-130	173	29	be	be	AUX
chd-130	173	30	detected	detect	VERB
chd-130	173	31	simultaneously	simultaneously	ADV
chd-130	173	32	with	with	ADP
chd-130	173	33	high	high	ADJ
chd-130	173	34	sensitivity	sensitivity	NOUN
chd-130	173	35	and	and	CCONJ
chd-130	173	36	rate	rate	NOUN
chd-130	173	37	of	of	ADP
chd-130	173	38	accuracy	accuracy	NOUN
chd-130	173	39	.	.	PUNCT
chd-130	174	1	the	the	DET
chd-130	174	2	highlight	highlight	NOUN
chd-130	174	3	of	of	ADP
chd-130	174	4	ngs	ng	NOUN
chd-130	174	5	is	be	AUX
chd-130	174	6	the	the	DET
chd-130	174	7	high	high	ADJ
chd-130	174	8	rate	rate	NOUN
chd-130	174	9	of	of	ADP
chd-130	174	10	sensitivity	sensitivity	NOUN
chd-130	174	11	and	and	CCONJ
chd-130	174	12	quantitative	quantitative	ADJ
chd-130	174	13	evaluation	evaluation	NOUN
chd-130	174	14	of	of	ADP
chd-130	174	15	the	the	DET
chd-130	174	16	mutated	mutate	VERB
chd-130	174	17	allele	allele	NOUN
chd-130	174	18	that	that	PRON
chd-130	174	19	is	be	AUX
chd-130	174	20	significantly	significantly	ADV
chd-130	174	21	better	well	ADJ
chd-130	174	22	than	than	ADP
chd-130	174	23	sanger	sanger	PROPN
chd-130	174	24	sequencing	sequence	VERB
chd-130	174	25	(	(	PUNCT
chd-130	174	26	2	2	NUM
chd-130	174	27	-	-	SYM
chd-130	174	28	10	10	NUM
chd-130	174	29	%	%	NOUN
chd-130	174	30	vs	vs	ADP
chd-130	174	31	15	15	NUM
chd-130	174	32	-	-	SYM
chd-130	174	33	25	25	NUM
chd-130	174	34	%	%	NOUN
chd-130	174	35	)	)	PUNCT
chd-130	174	36	.	.	PUNCT
chd-130	175	1	a	a	DET
chd-130	175	2	group	group	NOUN
chd-130	175	3	of	of	ADP
chd-130	175	4	investigators	investigator	NOUN
chd-130	175	5	from	from	ADP
chd-130	175	6	china	china	PROPN
chd-130	175	7	were	be	AUX
chd-130	175	8	the	the	DET
chd-130	175	9	first	first	ADJ
chd-130	175	10	to	to	PART
chd-130	175	11	take	take	VERB
chd-130	175	12	advantage	advantage	NOUN
chd-130	175	13	of	of	ADP
chd-130	175	14	the	the	DET
chd-130	175	15	newly	newly	ADV
chd-130	175	16	available	available	ADJ
chd-130	175	17	ngs	ng	NOUN
chd-130	175	18	technique	technique	NOUN
chd-130	175	19	to	to	PART
chd-130	175	20	identify	identify	VERB
chd-130	175	21	new	new	ADJ
chd-130	175	22	mutations	mutation	NOUN
chd-130	175	23	in	in	ADP
chd-130	175	24	gbc	gbc	PROPN
chd-130	175	25	(	(	PUNCT
chd-130	175	26	li	li	PROPN
chd-130	175	27	et	et	PROPN
chd-130	175	28	al	al	PROPN
chd-130	175	29	.	.	PROPN
chd-130	175	30	,	,	PUNCT
chd-130	175	31	2014	2014	NUM
chd-130	175	32	)	)	PUNCT
chd-130	175	33	.	.	PUNCT
chd-130	176	1	here	here	ADV
chd-130	176	2	,	,	PUNCT
chd-130	176	3	they	they	PRON
chd-130	176	4	studied	study	VERB
chd-130	176	5	57	57	NUM
chd-130	176	6	pairs	pair	NOUN
chd-130	176	7	of	of	ADP
chd-130	176	8	tumornormal	tumornormal	ADJ
chd-130	176	9	tissues	tissue	NOUN
chd-130	176	10	and	and	CCONJ
chd-130	176	11	subjected	subject	VERB
chd-130	176	12	them	they	PRON
chd-130	176	13	to	to	ADP
chd-130	176	14	a	a	DET
chd-130	176	15	combination	combination	NOUN
chd-130	176	16	of	of	ADP
chd-130	176	17	exome	exome	NOUN
chd-130	176	18	as	as	ADV
chd-130	176	19	well	well	ADV
chd-130	176	20	as	as	ADP
chd-130	176	21	ultra	ultra	ADJ
chd-130	176	22	deep	deep	ADJ
chd-130	176	23	targeted	targeted	ADJ
chd-130	176	24	sequencing	sequencing	NOUN
chd-130	176	25	of	of	ADP
chd-130	176	26	cancerrelated	cancerrelate	VERB
chd-130	176	27	genes	gene	NOUN
chd-130	176	28	[	[	X
chd-130	176	29	54	54	NUM
chd-130	176	30	]	]	PUNCT
chd-130	176	31	.	.	PUNCT
chd-130	177	1	they	they	PRON
chd-130	177	2	found	find	VERB
chd-130	177	3	that	that	SCONJ
chd-130	177	4	there	there	PRON
chd-130	177	5	was	be	VERB
chd-130	177	6	an	an	DET
chd-130	177	7	increase	increase	NOUN
chd-130	177	8	in	in	ADP
chd-130	177	9	c	c	PROPN
chd-130	177	10	>	>	X
chd-130	177	11	t	t	PROPN
chd-130	177	12	/	/	SYM
chd-130	177	13	g	g	PROPN
chd-130	177	14	>	>	X
chd-130	177	15	a	a	DET
chd-130	177	16	transition	transition	NOUN
chd-130	177	17	in	in	ADP
chd-130	177	18	gbc	gbc	PROPN
chd-130	177	19	.	.	PUNCT
chd-130	178	1	this	this	DET
chd-130	178	2	identification	identification	NOUN
chd-130	178	3	of	of	ADP
chd-130	178	4	somatic	somatic	ADJ
chd-130	178	5	mutation	mutation	NOUN
chd-130	178	6	framework	framework	NOUN
chd-130	178	7	of	of	ADP
chd-130	178	8	gbc	gbc	PROPN
chd-130	178	9	was	be	AUX
chd-130	178	10	done	do	VERB
chd-130	178	11	in	in	ADP
chd-130	178	12	a	a	DET
chd-130	178	13	systematic	systematic	ADJ
chd-130	178	14	manner	manner	NOUN
chd-130	178	15	,	,	PUNCT
chd-130	178	16	discovering	discover	VERB
chd-130	178	17	gbc	gbc	NOUN
chd-130	178	18	driver	driver	NOUN
chd-130	178	19	genes	gene	NOUN
chd-130	178	20	in	in	ADP
chd-130	178	21	the	the	DET
chd-130	178	22	c	c	PROPN
chd-130	178	23	>	>	X
chd-130	178	24	t	t	PROPN
chd-130	178	25	/	/	SYM
chd-130	178	26	g	g	PROPN
chd-130	178	27	>	>	X
chd-130	178	28	a	a	DET
chd-130	178	29	transition	transition	NOUN
chd-130	178	30	along	along	ADP
chd-130	178	31	with	with	ADP
chd-130	178	32	studying	study	VERB
chd-130	178	33	a	a	DET
chd-130	178	34	pathway	pathway	NOUN
chd-130	178	35	centered	center	VERB
chd-130	178	36	around	around	ADP
chd-130	178	37	erbb	erbb	NOUN
chd-130	178	38	signaling	signal	VERB
chd-130	178	39	.	.	PUNCT
chd-130	179	1	they	they	PRON
chd-130	179	2	also	also	ADV
chd-130	179	3	pointed	point	VERB
chd-130	179	4	out	out	ADP
chd-130	179	5	that	that	SCONJ
chd-130	179	6	genetic	genetic	ADJ
chd-130	179	7	mutations	mutation	NOUN
chd-130	179	8	in	in	ADP
chd-130	179	9	the	the	DET
chd-130	179	10	erbb	erbb	NOUN
chd-130	179	11	pathway	pathway	NOUN
chd-130	179	12	was	be	AUX
chd-130	179	13	a	a	DET
chd-130	179	14	poor	poor	ADJ
chd-130	179	15	prognostic	prognostic	ADJ
chd-130	179	16	indicator	indicator	NOUN
chd-130	179	17	of	of	ADP
chd-130	179	18	the	the	DET
chd-130	179	19	disease	disease	NOUN
chd-130	179	20	.	.	PUNCT
chd-130	180	1	this	this	DET
chd-130	180	2	study	study	NOUN
chd-130	180	3	also	also	ADV
chd-130	180	4	went	go	VERB
chd-130	180	5	on	on	ADP
chd-130	180	6	to	to	PART
chd-130	180	7	suggest	suggest	VERB
chd-130	180	8	that	that	SCONJ
chd-130	180	9	patients	patient	NOUN
chd-130	180	10	exhibiting	exhibit	VERB
chd-130	180	11	genetic	genetic	ADJ
chd-130	180	12	mutations	mutation	NOUN
chd-130	180	13	in	in	ADP
chd-130	180	14	the	the	DET
chd-130	180	15	erbb	erbb	NOUN
chd-130	180	16	pathway	pathway	NOUN
chd-130	180	17	could	could	AUX
chd-130	180	18	potentially	potentially	ADV
chd-130	180	19	benefit	benefit	VERB
chd-130	180	20	from	from	ADP
chd-130	180	21	therapies	therapy	NOUN
chd-130	180	22	already	already	ADV
chd-130	180	23	available	available	ADJ
chd-130	180	24	or	or	CCONJ
chd-130	180	25	in	in	ADP
chd-130	180	26	the	the	DET
chd-130	180	27	process	process	NOUN
chd-130	180	28	of	of	ADP
chd-130	180	29	development	development	NOUN
chd-130	180	30	(	(	PUNCT
chd-130	180	31	li	li	PROPN
chd-130	180	32	et	et	PROPN
chd-130	180	33	al	al	PROPN
chd-130	180	34	.	.	PROPN
chd-130	180	35	,	,	PUNCT
chd-130	180	36	2014	2014	NUM
chd-130	180	37	)	)	PUNCT
chd-130	180	38	.	.	PUNCT
chd-130	181	1	in	in	ADP
chd-130	181	2	a	a	DET
chd-130	181	3	similar	similar	ADJ
chd-130	181	4	kind	kind	NOUN
chd-130	181	5	of	of	ADP
chd-130	181	6	study	study	NOUN
chd-130	181	7	using	use	VERB
chd-130	181	8	ngs	ng	NOUN
chd-130	181	9	techniques	technique	NOUN
chd-130	181	10	,	,	PUNCT
chd-130	181	11	a	a	DET
chd-130	181	12	japanese	japanese	ADJ
chd-130	181	13	group	group	NOUN
chd-130	181	14	analyzed	analyze	VERB
chd-130	181	15	29	29	NUM
chd-130	181	16	tissues	tissue	NOUN
chd-130	181	17	obtained	obtain	VERB
chd-130	181	18	from	from	ADP
chd-130	181	19	japanese	japanese	ADJ
chd-130	181	20	patients	patient	NOUN
chd-130	181	21	with	with	ADP
chd-130	181	22	gbc	gbc	PROPN
chd-130	181	23	,	,	PUNCT
chd-130	181	24	using	use	VERB
chd-130	181	25	an	an	DET
chd-130	181	26	integration	integration	NOUN
chd-130	181	27	of	of	ADP
chd-130	181	28	wholeexome	wholeexome	NOUN
chd-130	181	29	and	and	CCONJ
chd-130	181	30	transcriptome	transcriptome	ADJ
chd-130	181	31	sequencing	sequence	VERB
chd-130	181	32	techniques	technique	NOUN
chd-130	181	33	to	to	PART
chd-130	181	34	uncover	uncover	VERB
chd-130	181	35	molecular	molecular	ADJ
chd-130	181	36	variations	variation	NOUN
chd-130	181	37	and	and	CCONJ
chd-130	181	38	thus	thus	ADV
chd-130	181	39	,	,	PUNCT
chd-130	181	40	prospective	prospective	ADJ
chd-130	181	41	therapeutic	therapeutic	ADJ
chd-130	181	42	targets	target	NOUN
chd-130	181	43	(	(	PUNCT
chd-130	181	44	nakamura	nakamura	NOUN
chd-130	181	45	et	et	PROPN
chd-130	181	46	al	al	PROPN
chd-130	181	47	.	.	PROPN
chd-130	181	48	,	,	PUNCT
chd-130	181	49	2015	2015	NUM
chd-130	181	50	)	)	PUNCT
chd-130	181	51	.	.	PUNCT
chd-130	182	1	it	it	PRON
chd-130	182	2	was	be	AUX
chd-130	182	3	suggested	suggest	VERB
chd-130	182	4	in	in	ADP
chd-130	182	5	this	this	DET
chd-130	182	6	study	study	NOUN
chd-130	182	7	that	that	PRON
chd-130	182	8	apobecmediated	apobecmediate	VERB
chd-130	182	9	somatic	somatic	ADJ
chd-130	182	10	mutational	mutational	ADJ
chd-130	182	11	signature	signature	NOUN
chd-130	182	12	,	,	PUNCT
chd-130	182	13	associated	associate	VERB
chd-130	182	14	with	with	ADP
chd-130	182	15	apobec3b	apobec3b	NOUN
chd-130	182	16	expression	expression	NOUN
chd-130	182	17	and	and	CCONJ
chd-130	182	18	a	a	DET
chd-130	182	19	higher	high	ADJ
chd-130	182	20	number	number	NOUN
chd-130	182	21	of	of	ADP
chd-130	182	22	mutations	mutation	NOUN
chd-130	182	23	,	,	PUNCT
chd-130	182	24	selectively	selectively	ADV
chd-130	182	25	contributed	contribute	VERB
chd-130	182	26	to	to	ADP
chd-130	182	27	gbc	gbc	PROPN
chd-130	182	28	initiation	initiation	NOUN
chd-130	182	29	and	and	CCONJ
chd-130	182	30	progression	progression	NOUN
chd-130	182	31	.	.	PUNCT
chd-130	183	1	the	the	DET
chd-130	183	2	japanese	japanese	ADJ
chd-130	183	3	authors	author	NOUN
chd-130	183	4	also	also	ADV
chd-130	183	5	reaffirmed	reaffirm	VERB
chd-130	183	6	the	the	DET
chd-130	183	7	findings	finding	NOUN
chd-130	183	8	in	in	ADP
chd-130	183	9	the	the	DET
chd-130	183	10	previous	previous	ADJ
chd-130	183	11	study	study	NOUN
chd-130	183	12	(	(	PUNCT
chd-130	183	13	nakamura	nakamura	PROPN
chd-130	183	14	et	et	PROPN
chd-130	183	15	al	al	PROPN
chd-130	183	16	.	.	PROPN
chd-130	183	17	,	,	PUNCT
chd-130	183	18	2015	2015	NUM
chd-130	183	19	)	)	PUNCT
chd-130	183	20	and	and	CCONJ
chd-130	183	21	suggested	suggest	VERB
chd-130	183	22	that	that	SCONJ
chd-130	183	23	activation	activation	NOUN
chd-130	183	24	of	of	ADP
chd-130	183	25	the	the	DET
chd-130	183	26	egfr	egfr	ADJ
chd-130	183	27	family	family	NOUN
chd-130	183	28	of	of	ADP
chd-130	183	29	genes	gene	NOUN
chd-130	183	30	(	(	PUNCT
chd-130	183	31	egfr	egfr	X
chd-130	183	32	,	,	PUNCT
chd-130	183	33	erbb2	erbb2	PROPN
chd-130	183	34	,	,	PUNCT
chd-130	183	35	erbb3	erbb3	PROPN
chd-130	183	36	)	)	PUNCT
chd-130	183	37	was	be	AUX
chd-130	183	38	seen	see	VERB
chd-130	183	39	frequently	frequently	ADV
chd-130	183	40	in	in	ADP
chd-130	183	41	gbc	gbc	PROPN
chd-130	183	42	and	and	CCONJ
chd-130	183	43	could	could	AUX
chd-130	183	44	be	be	AUX
chd-130	183	45	clinical	clinical	ADJ
chd-130	183	46	important	important	ADJ
chd-130	183	47	as	as	SCONJ
chd-130	183	48	they	they	PRON
chd-130	183	49	could	could	AUX
chd-130	183	50	be	be	AUX
chd-130	183	51	used	use	VERB
chd-130	183	52	as	as	ADP
chd-130	183	53	potential	potential	ADJ
chd-130	183	54	targets	target	NOUN
chd-130	183	55	.	.	PUNCT
chd-130	184	1	a	a	DET
chd-130	184	2	recent	recent	ADJ
chd-130	184	3	study	study	NOUN
chd-130	184	4	by	by	ADP
chd-130	184	5	one	one	NUM
chd-130	184	6	of	of	ADP
chd-130	184	7	the	the	DET
chd-130	184	8	authors	author	NOUN
chd-130	184	9	(	(	PUNCT
chd-130	184	10	bm	bm	PROPN
chd-130	184	11	)	)	PUNCT
chd-130	184	12	of	of	ADP
chd-130	184	13	this	this	DET
chd-130	184	14	article	article	NOUN
chd-130	184	15	,	,	PUNCT
chd-130	184	16	determined	determine	VERB
chd-130	184	17	the	the	DET
chd-130	184	18	presence	presence	NOUN
chd-130	184	19	of	of	ADP
chd-130	184	20	184	184	NUM
chd-130	184	21	non	non	X
chd-130	184	22	synonymous	synonymous	ADJ
chd-130	184	23	somatic	somatic	ADJ
chd-130	184	24	mutations	mutation	NOUN
chd-130	184	25	and	and	CCONJ
chd-130	184	26	60	60	NUM
chd-130	184	27	rare	rare	ADJ
chd-130	184	28	germline	germline	NOUN
chd-130	184	29	mutations	mutation	NOUN
chd-130	184	30	in	in	ADP
chd-130	184	31	smad	smad	PROPN
chd-130	184	32	family	family	NOUN
chd-130	184	33	member	member	NOUN
chd-130	184	34	4	4	NUM
chd-130	184	35	(	(	PUNCT
chd-130	184	36	smad4	smad4	NOUN
chd-130	184	37	)	)	PUNCT
chd-130	184	38	,	,	PUNCT
chd-130	184	39	lysine	lysine	NOUN
chd-130	184	40	methyltransferase	methyltransferase	NOUN
chd-130	184	41	2c	2c	NOUN
chd-130	184	42	(	(	PUNCT
chd-130	184	43	kmt2c	kmt2c	X
chd-130	184	44	)	)	PUNCT
chd-130	184	45	and	and	CCONJ
chd-130	184	46	tp53	tp53	PROPN
chd-130	184	47	genes	gene	NOUN
chd-130	184	48	using	use	VERB
chd-130	184	49	ultra	ultra	ADJ
chd-130	184	50	deep	deep	ADJ
chd-130	184	51	sequencing	sequencing	NOUN
chd-130	184	52	across	across	ADP
chd-130	184	53	409	409	NUM
chd-130	184	54	cancer	cancer	NOUN
chd-130	184	55	related	relate	VERB
chd-130	184	56	genes	gene	NOUN
chd-130	184	57	in	in	ADP
chd-130	184	58	gbc	gbc	NOUN
chd-130	184	59	patients	patient	NOUN
chd-130	184	60	of	of	ADP
chd-130	184	61	northern	northern	ADJ
chd-130	184	62	india	india	PROPN
chd-130	184	63	(	(	PUNCT
chd-130	184	64	yadav	yadav	PROPN
chd-130	184	65	et	et	PROPN
chd-130	184	66	al	al	PROPN
chd-130	184	67	.	.	PROPN
chd-130	184	68	,	,	PUNCT
chd-130	184	69	2017	2017	NUM
chd-130	184	70	)	)	PUNCT
chd-130	184	71	.	.	PUNCT
chd-130	185	1	of	of	ADP
chd-130	185	2	note	note	NOUN
chd-130	185	3	,	,	PUNCT
chd-130	185	4	somatic	somatic	ADJ
chd-130	185	5	mutations	mutation	NOUN
chd-130	185	6	of	of	ADP
chd-130	185	7	high	high	ADJ
chd-130	185	8	significance	significance	NOUN
chd-130	185	9	within	within	ADP
chd-130	185	10	9	9	NUM
chd-130	185	11	novel	novel	NOUN
chd-130	185	12	genes	gene	NOUN
chd-130	185	13	in	in	ADP
chd-130	185	14	gbc	gbc	PROPN
chd-130	185	15	were	be	AUX
chd-130	185	16	identified	identify	VERB
chd-130	185	17	.	.	PUNCT
chd-130	186	1	the	the	DET
chd-130	186	2	results	result	NOUN
chd-130	186	3	in	in	ADP
chd-130	186	4	study	study	NOUN
chd-130	186	5	hinted	hint	VERB
chd-130	186	6	at	at	ADP
chd-130	186	7	the	the	DET
chd-130	186	8	presence	presence	NOUN
chd-130	186	9	and	and	CCONJ
chd-130	186	10	significance	significance	NOUN
chd-130	186	11	of	of	ADP
chd-130	186	12	rare	rare	ADJ
chd-130	186	13	,	,	PUNCT
chd-130	186	14	inherited	inherit	VERB
chd-130	186	15	germline	germline	NOUN
chd-130	186	16	mutations	mutation	NOUN
chd-130	186	17	in	in	ADP
chd-130	186	18	the	the	DET
chd-130	186	19	genes	gene	NOUN
chd-130	186	20	of	of	ADP
chd-130	186	21	the	the	DET
chd-130	186	22	dna	dna	NOUN
chd-130	186	23	-	-	PUNCT
chd-130	186	24	repair	repair	NOUN
chd-130	186	25	pathway	pathway	NOUN
chd-130	186	26	in	in	ADP
chd-130	186	27	addition	addition	NOUN
chd-130	186	28	to	to	ADP
chd-130	186	29	acquired	acquire	VERB
chd-130	186	30	somatic	somatic	ADJ
chd-130	186	31	mutations	mutation	NOUN
chd-130	186	32	in	in	ADP
chd-130	186	33	the	the	DET
chd-130	186	34	carcinogenesis	carcinogenesis	NOUN
chd-130	186	35	of	of	ADP
chd-130	186	36	gbc	gbc	PROPN
chd-130	186	37	.	.	PUNCT
chd-130	187	1	a	a	DET
chd-130	187	2	high	high	ADJ
chd-130	187	3	throughput	throughput	NOUN
chd-130	187	4	sequencing	sequence	VERB
chd-130	187	5	based	base	VERB
chd-130	187	6	analysis	analysis	NOUN
chd-130	187	7	of	of	ADP
chd-130	187	8	the	the	DET
chd-130	187	9	mutation	mutation	NOUN
chd-130	187	10	profile	profile	NOUN
chd-130	187	11	in	in	ADP
chd-130	187	12	gbc	gbc	PROPN
chd-130	187	13	was	be	AUX
chd-130	187	14	carried	carry	VERB
chd-130	187	15	out	out	ADP
chd-130	187	16	for	for	ADP
chd-130	187	17	the	the	DET
chd-130	187	18	very	very	ADV
chd-130	187	19	first	first	ADJ
chd-130	187	20	time	time	NOUN
chd-130	187	21	by	by	ADP
chd-130	187	22	an	an	DET
chd-130	187	23	indian	indian	ADJ
chd-130	187	24	group	group	NOUN
chd-130	187	25	from	from	ADP
chd-130	187	26	the	the	DET
chd-130	187	27	northern	northern	ADJ
chd-130	187	28	part	part	NOUN
chd-130	187	29	of	of	ADP
chd-130	187	30	the	the	DET
chd-130	187	31	country	country	NOUN
chd-130	187	32	.	.	PUNCT
chd-130	188	1	this	this	DET
chd-130	188	2	study	study	NOUN
chd-130	188	3	was	be	AUX
chd-130	188	4	different	different	ADJ
chd-130	188	5	in	in	ADP
chd-130	188	6	the	the	DET
chd-130	188	7	sense	sense	NOUN
chd-130	188	8	that	that	SCONJ
chd-130	188	9	they	they	PRON
chd-130	188	10	restricted	restrict	VERB
chd-130	188	11	the	the	DET
chd-130	188	12	study	study	NOUN
chd-130	188	13	to	to	ADP
chd-130	188	14	regions	region	NOUN
chd-130	188	15	of	of	ADP
chd-130	188	16	common	common	ADJ
chd-130	188	17	genetic	genetic	ADJ
chd-130	188	18	aberrations	aberration	NOUN
chd-130	188	19	so	so	SCONJ
chd-130	188	20	as	as	SCONJ
chd-130	188	21	to	to	PART
chd-130	188	22	take	take	VERB
chd-130	188	23	advantage	advantage	NOUN
chd-130	188	24	of	of	ADP
chd-130	188	25	targeting	target	VERB
chd-130	188	26	sequencing	sequence	VERB
chd-130	188	27	approaches	approach	NOUN
chd-130	188	28	and	and	CCONJ
chd-130	188	29	covering	cover	VERB
chd-130	188	30	rare	rare	ADJ
chd-130	188	31	mutations	mutation	NOUN
chd-130	188	32	high	high	ADJ
chd-130	188	33	confidence	confidence	NOUN
chd-130	188	34	.	.	PUNCT
chd-130	189	1	cancer	cancer	NOUN
chd-130	189	2	initiating	initiate	VERB
chd-130	189	3	as	as	ADV
chd-130	189	4	well	well	ADV
chd-130	189	5	as	as	ADP
chd-130	189	6	progressing	progress	VERB
chd-130	189	7	events	event	NOUN
chd-130	189	8	were	be	AUX
chd-130	189	9	tagged	tag	VERB
chd-130	189	10	with	with	ADP
chd-130	189	11	biological	biological	ADJ
chd-130	189	12	pathways	pathway	NOUN
chd-130	189	13	associated	associate	VERB
chd-130	189	14	with	with	ADP
chd-130	189	15	409	409	NUM
chd-130	189	16	cancer	cancer	NOUN
chd-130	189	17	genes	gene	NOUN
chd-130	189	18	which	which	PRON
chd-130	189	19	were	be	AUX
chd-130	189	20	analyzed	analyze	VERB
chd-130	189	21	in	in	ADP
chd-130	189	22	the	the	DET
chd-130	189	23	study	study	NOUN
chd-130	189	24	(	(	PUNCT
chd-130	189	25	yadav	yadav	PROPN
chd-130	189	26	et	et	PROPN
chd-130	189	27	al	al	PROPN
chd-130	189	28	.	.	PROPN
chd-130	189	29	,	,	PUNCT
chd-130	189	30	2017	2017	NUM
chd-130	189	31	)	)	PUNCT
chd-130	189	32	.	.	PUNCT
chd-130	190	1	the	the	DET
chd-130	190	2	somatic	somatic	ADJ
chd-130	190	3	mutation	mutation	NOUN
chd-130	190	4	spectrum	spectrum	NOUN
chd-130	190	5	in	in	ADP
chd-130	190	6	this	this	DET
chd-130	190	7	study	study	NOUN
chd-130	190	8	was	be	AUX
chd-130	190	9	found	find	VERB
chd-130	190	10	to	to	PART
chd-130	190	11	be	be	AUX
chd-130	190	12	dominated	dominate	VERB
chd-130	190	13	by	by	ADP
chd-130	190	14	substitution	substitution	NOUN
chd-130	190	15	of	of	ADP
chd-130	190	16	the	the	DET
chd-130	190	17	c	c	PROPN
chd-130	190	18	>	>	X
chd-130	190	19	t	t	PROPN
chd-130	190	20	/	/	SYM
chd-130	190	21	g	g	PROPN
chd-130	190	22	>	>	X
chd-130	190	23	a	a	DET
chd-130	190	24	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-130	190	25	e12	e12	NOUN
chd-130	190	26	cancer	cancer	NOUN
chd-130	190	27	health	health	NOUN
chd-130	190	28	disparities	disparity	NOUN
chd-130	190	29	research	research	NOUN
chd-130	190	30	transition	transition	NOUN
chd-130	190	31	,	,	PUNCT
chd-130	190	32	consistent	consistent	ADJ
chd-130	190	33	with	with	ADP
chd-130	190	34	other	other	ADJ
chd-130	190	35	gbc	gbc	PROPN
chd-130	190	36	sequencing	sequence	VERB
chd-130	190	37	studies	study	NOUN
chd-130	190	38	(	(	PUNCT
chd-130	190	39	li	li	PROPN
chd-130	190	40	et	et	PROPN
chd-130	190	41	al	al	PROPN
chd-130	190	42	.	.	PROPN
chd-130	190	43	,	,	PUNCT
chd-130	190	44	2014	2014	NUM
chd-130	190	45	;	;	PUNCT
chd-130	191	1	nakamura	nakamura	PROPN
chd-130	191	2	et	et	PROPN
chd-130	191	3	al	al	PROPN
chd-130	191	4	.	.	PROPN
chd-130	191	5	,	,	PUNCT
chd-130	191	6	2015	2015	NUM
chd-130	191	7	)	)	PUNCT
chd-130	191	8	.	.	PUNCT
chd-130	192	1	this	this	DET
chd-130	192	2	study	study	NOUN
chd-130	192	3	from	from	ADP
chd-130	192	4	india	india	PROPN
chd-130	192	5	(	(	PUNCT
chd-130	192	6	yadav	yadav	PROPN
chd-130	192	7	et	et	PROPN
chd-130	192	8	al	al	PROPN
chd-130	192	9	.	.	PROPN
chd-130	192	10	,	,	PUNCT
chd-130	192	11	2017	2017	NUM
chd-130	192	12	)	)	PUNCT
chd-130	192	13	holds	hold	VERB
chd-130	192	14	promises	promise	NOUN
chd-130	192	15	for	for	ADP
chd-130	192	16	its	its	PRON
chd-130	192	17	possible	possible	ADJ
chd-130	192	18	role	role	NOUN
chd-130	192	19	in	in	ADP
chd-130	192	20	future	future	ADJ
chd-130	192	21	precision	precision	NOUN
chd-130	192	22	medicine	medicine	NOUN
chd-130	192	23	practice	practice	NOUN
chd-130	192	24	in	in	ADP
chd-130	192	25	gbc	gbc	PROPN
chd-130	192	26	,	,	PUNCT
chd-130	192	27	as	as	SCONJ
chd-130	192	28	it	it	PRON
chd-130	192	29	suggests	suggest	VERB
chd-130	192	30	that	that	SCONJ
chd-130	192	31	both	both	CCONJ
chd-130	192	32	the	the	DET
chd-130	192	33	somatic	somatic	ADJ
chd-130	192	34	mutation	mutation	NOUN
chd-130	192	35	profile	profile	NOUN
chd-130	192	36	as	as	ADV
chd-130	192	37	well	well	ADV
chd-130	192	38	as	as	ADP
chd-130	192	39	the	the	DET
chd-130	192	40	information	information	NOUN
chd-130	192	41	regarding	regard	VERB
chd-130	192	42	various	various	ADJ
chd-130	192	43	germline	germline	NOUN
chd-130	192	44	mutations	mutation	NOUN
chd-130	192	45	could	could	AUX
chd-130	192	46	be	be	AUX
chd-130	192	47	beneficial	beneficial	ADJ
chd-130	192	48	for	for	ADP
chd-130	192	49	understanding	understand	VERB
chd-130	192	50	the	the	DET
chd-130	192	51	disease	disease	NOUN
chd-130	192	52	pathology	pathology	NOUN
chd-130	192	53	as	as	ADV
chd-130	192	54	well	well	ADV
chd-130	192	55	as	as	ADP
chd-130	192	56	for	for	ADP
chd-130	192	57	developing	develop	VERB
chd-130	192	58	novel	novel	ADJ
chd-130	192	59	therapeutic	therapeutic	ADJ
chd-130	192	60	strategies	strategy	NOUN
chd-130	192	61	.	.	PUNCT
chd-130	193	1	genetic	genetic	ADJ
chd-130	193	2	polymorphism	polymorphism	NOUN
chd-130	193	3	and	and	CCONJ
chd-130	193	4	risk	risk	NOUN
chd-130	193	5	of	of	ADP
chd-130	193	6	gbc	gbc	PROPN
chd-130	193	7	it	it	PRON
chd-130	193	8	is	be	AUX
chd-130	193	9	believed	believe	VERB
chd-130	193	10	that	that	SCONJ
chd-130	193	11	majority	majority	NOUN
chd-130	193	12	of	of	ADP
chd-130	193	13	the	the	DET
chd-130	193	14	cancers	cancer	NOUN
chd-130	193	15	are	be	AUX
chd-130	193	16	derived	derive	VERB
chd-130	193	17	from	from	ADP
chd-130	193	18	single	single	ADJ
chd-130	193	19	somatic	somatic	ADJ
chd-130	193	20	cells	cell	NOUN
chd-130	193	21	along	along	ADP
chd-130	193	22	with	with	ADP
chd-130	193	23	the	the	DET
chd-130	193	24	cells	cell	NOUN
chd-130	193	25	derived	derive	VERB
chd-130	193	26	by	by	ADP
chd-130	193	27	the	the	DET
chd-130	193	28	rapid	rapid	ADJ
chd-130	193	29	division	division	NOUN
chd-130	193	30	of	of	ADP
chd-130	193	31	those	those	DET
chd-130	193	32	parent	parent	NOUN
chd-130	193	33	cells	cell	NOUN
chd-130	193	34	.	.	PUNCT
chd-130	194	1	these	these	DET
chd-130	194	2	new	new	ADJ
chd-130	194	3	cells	cell	NOUN
chd-130	194	4	acquire	acquire	VERB
chd-130	194	5	various	various	ADJ
chd-130	194	6	genetic	genetic	ADJ
chd-130	194	7	or	or	CCONJ
chd-130	194	8	epigenetic	epigenetic	ADJ
chd-130	194	9	changes	change	NOUN
chd-130	194	10	within	within	ADP
chd-130	194	11	them	they	PRON
chd-130	194	12	that	that	PRON
chd-130	194	13	lead	lead	VERB
chd-130	194	14	to	to	PART
chd-130	194	15	altered	alter	VERB
chd-130	194	16	genetic	genetic	ADJ
chd-130	194	17	and	and	CCONJ
chd-130	194	18	thus	thus	ADV
chd-130	194	19	to	to	ADP
chd-130	194	20	phenotypic	phenotypic	ADJ
chd-130	194	21	variants	variant	NOUN
chd-130	194	22	.	.	PUNCT
chd-130	195	1	however	however	ADV
chd-130	195	2	,	,	PUNCT
chd-130	195	3	with	with	ADP
chd-130	195	4	the	the	DET
chd-130	195	5	advent	advent	NOUN
chd-130	195	6	of	of	ADP
chd-130	195	7	the	the	DET
chd-130	195	8	human	human	ADJ
chd-130	195	9	genome	genome	NOUN
chd-130	195	10	project	project	NOUN
chd-130	195	11	in	in	ADP
chd-130	195	12	early	early	ADJ
chd-130	195	13	2000s	2000s	NUM
chd-130	195	14	and	and	CCONJ
chd-130	195	15	published	publish	VERB
chd-130	195	16	evidences	evidence	NOUN
chd-130	195	17	started	start	VERB
chd-130	195	18	supporting	support	VERB
chd-130	195	19	the	the	DET
chd-130	195	20	theory	theory	NOUN
chd-130	195	21	that	that	SCONJ
chd-130	195	22	common	common	ADJ
chd-130	195	23	genetic	genetic	ADJ
chd-130	195	24	variations	variation	NOUN
chd-130	195	25	play	play	VERB
chd-130	195	26	important	important	ADJ
chd-130	195	27	role	role	NOUN
chd-130	195	28	in	in	ADP
chd-130	195	29	determining	determine	VERB
chd-130	195	30	the	the	DET
chd-130	195	31	range	range	NOUN
chd-130	195	32	of	of	ADP
chd-130	195	33	individual	individual	ADJ
chd-130	195	34	susceptibility	susceptibility	NOUN
chd-130	195	35	to	to	ADP
chd-130	195	36	neoplastic	neoplastic	ADJ
chd-130	195	37	diseases	disease	NOUN
chd-130	195	38	within	within	ADP
chd-130	195	39	a	a	DET
chd-130	195	40	particular	particular	ADJ
chd-130	195	41	population	population	NOUN
chd-130	195	42	.	.	PUNCT
chd-130	196	1	it	it	PRON
chd-130	196	2	was	be	AUX
chd-130	196	3	thought	think	VERB
chd-130	196	4	that	that	SCONJ
chd-130	196	5	they	they	PRON
chd-130	196	6	may	may	AUX
chd-130	196	7	result	result	VERB
chd-130	196	8	,	,	PUNCT
chd-130	196	9	among	among	ADP
chd-130	196	10	others	other	NOUN
chd-130	196	11	,	,	PUNCT
chd-130	196	12	from	from	ADP
chd-130	196	13	the	the	DET
chd-130	196	14	differences	difference	NOUN
chd-130	196	15	in	in	ADP
chd-130	196	16	the	the	DET
chd-130	196	17	metabolism	metabolism	NOUN
chd-130	196	18	of	of	ADP
chd-130	196	19	environmental	environmental	ADJ
chd-130	196	20	carcinogens	carcinogen	NOUN
chd-130	196	21	and	and	CCONJ
chd-130	196	22	mechanisms	mechanism	NOUN
chd-130	196	23	of	of	ADP
chd-130	196	24	dna	dna	PROPN
chd-130	196	25	repair	repair	NOUN
chd-130	196	26	and	and	CCONJ
chd-130	196	27	the	the	DET
chd-130	196	28	kind	kind	NOUN
chd-130	196	29	and	and	CCONJ
chd-130	196	30	rate	rate	NOUN
chd-130	196	31	of	of	ADP
chd-130	196	32	metabolism	metabolism	NOUN
chd-130	196	33	is	be	AUX
chd-130	196	34	genetically	genetically	ADV
chd-130	196	35	determined	determine	VERB
chd-130	196	36	by	by	ADP
chd-130	196	37	polymorphic	polymorphic	ADJ
chd-130	196	38	enzyme	enzyme	NOUN
chd-130	196	39	coding	code	VERB
chd-130	196	40	genes	gene	NOUN
chd-130	196	41	participating	participate	VERB
chd-130	196	42	in	in	ADP
chd-130	196	43	the	the	DET
chd-130	196	44	process	process	NOUN
chd-130	196	45	of	of	ADP
chd-130	196	46	xenobiotic	xenobiotic	ADJ
chd-130	196	47	transformation	transformation	NOUN
chd-130	196	48	.	.	PUNCT
chd-130	197	1	a	a	DET
chd-130	197	2	large	large	ADJ
chd-130	197	3	number	number	NOUN
chd-130	197	4	of	of	ADP
chd-130	197	5	enzymes	enzyme	NOUN
chd-130	197	6	involved	involve	VERB
chd-130	197	7	in	in	ADP
chd-130	197	8	the	the	DET
chd-130	197	9	reaction	reaction	NOUN
chd-130	197	10	of	of	ADP
chd-130	197	11	oxidation	oxidation	NOUN
chd-130	197	12	or	or	CCONJ
chd-130	197	13	conjugation	conjugation	NOUN
chd-130	197	14	of	of	ADP
chd-130	197	15	exo	exo	NOUN
chd-130	197	16	-	-	PUNCT
chd-130	197	17	endogenous	endogenous	ADJ
chd-130	197	18	xenobioties	xenobiotie	NOUN
chd-130	197	19	have	have	AUX
chd-130	197	20	shown	show	VERB
chd-130	197	21	genetic	genetic	ADJ
chd-130	197	22	polymorphism	polymorphism	NOUN
chd-130	197	23	.	.	PUNCT
chd-130	198	1	gene	gene	NOUN
chd-130	198	2	variability	variability	NOUN
chd-130	198	3	may	may	AUX
chd-130	198	4	alter	alter	VERB
chd-130	198	5	the	the	DET
chd-130	198	6	expression	expression	NOUN
chd-130	198	7	or	or	CCONJ
chd-130	198	8	enzymatic	enzymatic	ADJ
chd-130	198	9	activity	activity	NOUN
chd-130	198	10	of	of	ADP
chd-130	198	11	coded	code	VERB
chd-130	198	12	enzymes	enzyme	NOUN
chd-130	198	13	.	.	PUNCT
chd-130	199	1	first	first	ADV
chd-130	199	2	such	such	ADJ
chd-130	199	3	study	study	NOUN
chd-130	199	4	in	in	ADP
chd-130	199	5	gbc	gbc	PROPN
chd-130	199	6	was	be	AUX
chd-130	199	7	conducted	conduct	VERB
chd-130	199	8	in	in	ADP
chd-130	199	9	japan	japan	PROPN
chd-130	199	10	in	in	ADP
chd-130	199	11	which	which	PRON
chd-130	199	12	authors	author	NOUN
chd-130	199	13	investigated	investigate	VERB
chd-130	199	14	the	the	DET
chd-130	199	15	correlation	correlation	NOUN
chd-130	199	16	between	between	ADP
chd-130	199	17	the	the	DET
chd-130	199	18	genetic	genetic	ADJ
chd-130	199	19	polymorphisms	polymorphism	NOUN
chd-130	199	20	in	in	ADP
chd-130	199	21	cytochrome	cytochrome	ADJ
chd-130	199	22	p4501a1	p4501a1	NOUN
chd-130	199	23	(	(	PUNCT
chd-130	199	24	cyp1a1	cyp1a1	NOUN
chd-130	199	25	)	)	PUNCT
chd-130	199	26	gene	gene	NOUN
chd-130	199	27	and	and	CCONJ
chd-130	199	28	the	the	DET
chd-130	199	29	risk	risk	NOUN
chd-130	199	30	of	of	ADP
chd-130	199	31	development	development	NOUN
chd-130	199	32	of	of	ADP
chd-130	199	33	gbc	gbc	PROPN
chd-130	199	34	.	.	PUNCT
chd-130	200	1	the	the	DET
chd-130	200	2	frequency	frequency	NOUN
chd-130	200	3	and	and	CCONJ
chd-130	200	4	relationship	relationship	NOUN
chd-130	200	5	between	between	ADP
chd-130	200	6	the	the	DET
chd-130	200	7	cyp1a1	cyp1a1	ADJ
chd-130	200	8	genetic	genetic	ADJ
chd-130	200	9	polymorphisms	polymorphism	NOUN
chd-130	200	10	and	and	CCONJ
chd-130	200	11	the	the	DET
chd-130	200	12	development	development	NOUN
chd-130	200	13	of	of	ADP
chd-130	200	14	gbc	gbc	PROPN
chd-130	200	15	was	be	AUX
chd-130	200	16	closely	closely	ADV
chd-130	200	17	examined	examine	VERB
chd-130	200	18	in	in	ADP
chd-130	200	19	order	order	NOUN
chd-130	200	20	to	to	PART
chd-130	200	21	determine	determine	VERB
chd-130	200	22	the	the	DET
chd-130	200	23	differences	difference	NOUN
chd-130	200	24	in	in	ADP
chd-130	200	25	susceptibility	susceptibility	NOUN
chd-130	200	26	to	to	ADP
chd-130	200	27	developing	develop	VERB
chd-130	200	28	the	the	DET
chd-130	200	29	disease	disease	NOUN
chd-130	200	30	.	.	PUNCT
chd-130	201	1	they	they	PRON
chd-130	201	2	demonstrated	demonstrate	VERB
chd-130	201	3	that	that	SCONJ
chd-130	201	4	females	female	NOUN
chd-130	201	5	with	with	ADP
chd-130	201	6	genotypes	genotype	NOUN
chd-130	201	7	c	c	NOUN
chd-130	201	8	and/or	and/or	CCONJ
chd-130	201	9	ile	ile	PROPN
chd-130	201	10	/	/	SYM
chd-130	201	11	val	val	NOUN
chd-130	201	12	in	in	ADP
chd-130	201	13	cyp1a1	cyp1a1	NOUN
chd-130	201	14	gene	gene	NOUN
chd-130	201	15	were	be	AUX
chd-130	201	16	potentially	potentially	ADV
chd-130	201	17	more	more	ADV
chd-130	201	18	susceptible	susceptible	ADJ
chd-130	201	19	to	to	ADP
chd-130	201	20	developing	develop	VERB
chd-130	201	21	gbc	gbc	PROPN
chd-130	201	22	(	(	PUNCT
chd-130	201	23	tsuchiya	tsuchiya	PROPN
chd-130	201	24	et	et	PROPN
chd-130	201	25	al	al	PROPN
chd-130	201	26	.	.	PROPN
chd-130	201	27	,	,	PUNCT
chd-130	201	28	2002	2002	NUM
chd-130	201	29	)	)	PUNCT
chd-130	201	30	.	.	PUNCT
chd-130	202	1	next	next	ADJ
chd-130	202	2	was	be	AUX
chd-130	202	3	our	our	PRON
chd-130	202	4	own	own	ADJ
chd-130	202	5	study	study	NOUN
chd-130	202	6	that	that	PRON
chd-130	202	7	was	be	AUX
chd-130	202	8	performed	perform	VERB
chd-130	202	9	on	on	ADP
chd-130	202	10	a	a	DET
chd-130	202	11	large	large	ADJ
chd-130	202	12	cohort	cohort	NOUN
chd-130	202	13	of	of	ADP
chd-130	202	14	153	153	NUM
chd-130	202	15	patients	patient	NOUN
chd-130	202	16	with	with	ADP
chd-130	202	17	gbc	gbc	PROPN
chd-130	202	18	from	from	ADP
chd-130	202	19	north	north	PROPN
chd-130	202	20	india	india	PROPN
chd-130	202	21	(	(	PUNCT
chd-130	202	22	singh	singh	PROPN
chd-130	202	23	et	et	PROPN
chd-130	202	24	al	al	PROPN
chd-130	202	25	.	.	PROPN
chd-130	202	26	,	,	PUNCT
chd-130	202	27	2004a	2004a	NUM
chd-130	202	28	)	)	PUNCT
chd-130	202	29	.	.	PUNCT
chd-130	203	1	we	we	PRON
chd-130	203	2	reported	report	VERB
chd-130	203	3	that	that	SCONJ
chd-130	203	4	the	the	DET
chd-130	203	5	frequency	frequency	NOUN
chd-130	203	6	of	of	ADP
chd-130	203	7	the	the	DET
chd-130	203	8	xallele	xallele	PROPN
chd-130	203	9	of	of	ADP
chd-130	203	10	apolipoprotein	apolipoprotein	PROPN
chd-130	203	11	b	b	PROPN
chd-130	203	12	(	(	PUNCT
chd-130	203	13	apob	apob	PROPN
chd-130	203	14	)	)	PUNCT
chd-130	203	15	was	be	AUX
chd-130	203	16	significantly	significantly	ADV
chd-130	203	17	increased	increase	VERB
chd-130	203	18	in	in	ADP
chd-130	203	19	gbc	gbc	NOUN
chd-130	203	20	patients	patient	NOUN
chd-130	203	21	irrespective	irrespective	ADV
chd-130	203	22	of	of	ADP
chd-130	203	23	the	the	DET
chd-130	203	24	presence	presence	NOUN
chd-130	203	25	or	or	CCONJ
chd-130	203	26	absence	absence	NOUN
chd-130	203	27	of	of	ADP
chd-130	203	28	gallstones	gallstone	NOUN
chd-130	203	29	(	(	PUNCT
chd-130	203	30	gs	gs	NOUN
chd-130	203	31	)	)	PUNCT
chd-130	203	32	.	.	PUNCT
chd-130	204	1	the	the	DET
chd-130	204	2	odds	odd	NOUN
chd-130	204	3	ratio	ratio	NOUN
chd-130	204	4	was	be	AUX
chd-130	204	5	found	find	VERB
chd-130	204	6	to	to	PART
chd-130	204	7	be	be	AUX
chd-130	204	8	2.3	2.3	NUM
chd-130	204	9	and	and	CCONJ
chd-130	204	10	1.7	1.7	NUM
chd-130	204	11	respectively	respectively	ADV
chd-130	204	12	.	.	PUNCT
chd-130	205	1	apolipoprotein	apolipoprotein	PROPN
chd-130	205	2	b	b	PROPN
chd-130	205	3	(	(	PUNCT
chd-130	205	4	apob	apob	PROPN
chd-130	205	5	)	)	PUNCT
chd-130	205	6	is	be	AUX
chd-130	205	7	a	a	DET
chd-130	205	8	gene	gene	NOUN
chd-130	205	9	that	that	PRON
chd-130	205	10	is	be	AUX
chd-130	205	11	widely	widely	ADV
chd-130	205	12	known	know	VERB
chd-130	205	13	to	to	PART
chd-130	205	14	be	be	AUX
chd-130	205	15	associated	associate	VERB
chd-130	205	16	with	with	ADP
chd-130	205	17	alteration	alteration	NOUN
chd-130	205	18	in	in	ADP
chd-130	205	19	serum	serum	NOUN
chd-130	205	20	lipid	lipid	NOUN
chd-130	205	21	levels	level	NOUN
chd-130	205	22	and	and	CCONJ
chd-130	205	23	susceptibility	susceptibility	NOUN
chd-130	205	24	to	to	ADP
chd-130	205	25	gallstone	gallstone	NOUN
chd-130	205	26	(	(	PUNCT
chd-130	205	27	gs	gs	NOUN
chd-130	205	28	)	)	PUNCT
chd-130	205	29	disease	disease	NOUN
chd-130	205	30	.	.	PUNCT
chd-130	206	1	by	by	ADP
chd-130	206	2	the	the	DET
chd-130	206	3	abovementioned	abovementioned	ADJ
chd-130	206	4	findings	finding	NOUN
chd-130	206	5	,	,	PUNCT
chd-130	206	6	we	we	PRON
chd-130	206	7	suggested	suggest	VERB
chd-130	206	8	that	that	SCONJ
chd-130	206	9	a	a	DET
chd-130	206	10	polymorphism	polymorphism	NOUN
chd-130	206	11	in	in	ADP
chd-130	206	12	the	the	DET
chd-130	206	13	apob	apob	PROPN
chd-130	206	14	-	-	PUNCT
chd-130	206	15	xbai	xbai	PROPN
chd-130	206	16	gene	gene	NOUN
chd-130	206	17	results	result	NOUN
chd-130	206	18	in	in	ADP
chd-130	206	19	increased	increase	VERB
chd-130	206	20	susceptibility	susceptibility	NOUN
chd-130	206	21	to	to	ADP
chd-130	206	22	gbc	gbc	PROPN
chd-130	206	23	in	in	ADP
chd-130	206	24	a	a	DET
chd-130	206	25	favorable	favorable	ADJ
chd-130	206	26	environment	environment	NOUN
chd-130	206	27	(	(	PUNCT
chd-130	206	28	singh	singh	PROPN
chd-130	206	29	et	et	PROPN
chd-130	206	30	al	al	PROPN
chd-130	206	31	.	.	PROPN
chd-130	206	32	,	,	PUNCT
chd-130	206	33	2004a	2004a	NUM
chd-130	206	34	)	)	PUNCT
chd-130	206	35	.	.	PUNCT
chd-130	207	1	with	with	ADP
chd-130	207	2	time	time	NOUN
chd-130	207	3	many	many	ADJ
chd-130	207	4	other	other	ADJ
chd-130	207	5	similar	similar	ADJ
chd-130	207	6	studies	study	NOUN
chd-130	207	7	started	start	VERB
chd-130	207	8	appearing	appear	VERB
chd-130	207	9	looking	look	VERB
chd-130	207	10	for	for	ADP
chd-130	207	11	polymorphic	polymorphic	ADJ
chd-130	207	12	variants	variant	NOUN
chd-130	207	13	associated	associate	VERB
chd-130	207	14	with	with	ADP
chd-130	207	15	risk	risk	NOUN
chd-130	207	16	of	of	ADP
chd-130	207	17	developing	develop	VERB
chd-130	207	18	gbc	gbc	NOUN
chd-130	207	19	in	in	ADP
chd-130	207	20	endemic	endemic	ADJ
chd-130	207	21	areas	area	NOUN
chd-130	207	22	.	.	PUNCT
chd-130	208	1	in	in	ADP
chd-130	208	2	2006	2006	NUM
chd-130	208	3	,	,	PUNCT
chd-130	208	4	a	a	DET
chd-130	208	5	chinese	chinese	ADJ
chd-130	208	6	study	study	NOUN
chd-130	208	7	investigated	investigate	VERB
chd-130	208	8	the	the	DET
chd-130	208	9	potential	potential	ADJ
chd-130	208	10	risk	risk	NOUN
chd-130	208	11	associated	associate	VERB
chd-130	208	12	with	with	ADP
chd-130	208	13	polymorphisms	polymorphism	NOUN
chd-130	208	14	in	in	ADP
chd-130	208	15	the	the	DET
chd-130	208	16	cytochrome	cytochrome	NOUN
chd-130	208	17	p450	p450	PROPN
chd-130	208	18	17alpha	17alpha	PROPN
chd-130	208	19	-	-	PUNCT
chd-130	208	20	hydroxylases	hydroxylase	NOUN
chd-130	208	21	-	-	PUNCT
chd-130	208	22	c-(17,20)lyase	c-(17,20)lyase	NOUN
chd-130	208	23	(	(	PUNCT
chd-130	208	24	cyp17	cyp17	NOUN
chd-130	208	25	)	)	PUNCT
chd-130	208	26	enzyme	enzyme	NOUN
chd-130	208	27	(	(	PUNCT
chd-130	208	28	involved	involve	VERB
chd-130	208	29	in	in	ADP
chd-130	208	30	synthesis	synthesis	NOUN
chd-130	208	31	of	of	ADP
chd-130	208	32	sex	sex	NOUN
chd-130	208	33	hormones	hormone	NOUN
chd-130	208	34	)	)	PUNCT
chd-130	208	35	in	in	ADP
chd-130	208	36	gbc	gbc	PROPN
chd-130	208	37	.	.	PUNCT
chd-130	209	1	it	it	PRON
chd-130	209	2	was	be	AUX
chd-130	209	3	found	find	VERB
chd-130	209	4	that	that	SCONJ
chd-130	209	5	cyp17	cyp17	NOUN
chd-130	209	6	mspa1	mspa1	NOUN
chd-130	209	7	polymorphism	polymorphism	NOUN
chd-130	209	8	was	be	AUX
chd-130	209	9	associated	associate	VERB
chd-130	209	10	with	with	ADP
chd-130	209	11	an	an	DET
chd-130	209	12	exaggerated	exaggerated	ADJ
chd-130	209	13	increase	increase	NOUN
chd-130	209	14	in	in	ADP
chd-130	209	15	gbc	gbc	PROPN
chd-130	209	16	development	development	NOUN
chd-130	209	17	and	and	CCONJ
chd-130	209	18	was	be	AUX
chd-130	209	19	also	also	ADV
chd-130	209	20	contributory	contributory	ADJ
chd-130	209	21	to	to	ADP
chd-130	209	22	the	the	DET
chd-130	209	23	development	development	NOUN
chd-130	209	24	of	of	ADP
chd-130	209	25	biliary	biliary	ADJ
chd-130	209	26	stones	stone	NOUN
chd-130	209	27	among	among	ADP
chd-130	209	28	the	the	DET
chd-130	209	29	overweight	overweight	ADJ
chd-130	209	30	and	and	CCONJ
chd-130	209	31	diabetic	diabetic	ADJ
chd-130	209	32	individuals	individual	NOUN
chd-130	209	33	.	.	PUNCT
chd-130	210	1	this	this	DET
chd-130	210	2	finding	finding	NOUN
chd-130	210	3	led	lead	VERB
chd-130	210	4	to	to	ADP
chd-130	210	5	the	the	DET
chd-130	210	6	study	study	NOUN
chd-130	210	7	of	of	ADP
chd-130	210	8	an	an	DET
chd-130	210	9	intertwining	intertwine	VERB
chd-130	210	10	relationship	relationship	NOUN
chd-130	210	11	between	between	ADP
chd-130	210	12	the	the	DET
chd-130	210	13	genetic	genetic	ADJ
chd-130	210	14	and	and	CCONJ
chd-130	210	15	hormonal	hormonal	ADJ
chd-130	210	16	risk	risk	NOUN
chd-130	210	17	factors	factor	NOUN
chd-130	210	18	associated	associate	VERB
chd-130	210	19	with	with	ADP
chd-130	210	20	gallbladder	gallbladder	NOUN
chd-130	210	21	disease	disease	NOUN
chd-130	210	22	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-130	210	23	e13	e13	PROPN
chd-130	210	24	cancer	cancer	NOUN
chd-130	210	25	health	health	NOUN
chd-130	210	26	disparities	disparity	NOUN
chd-130	210	27	research	research	NOUN
chd-130	210	28	(	(	PUNCT
chd-130	210	29	hou	hou	NOUN
chd-130	210	30	et	et	PROPN
chd-130	210	31	al	al	PROPN
chd-130	210	32	.	.	PROPN
chd-130	210	33	,	,	PUNCT
chd-130	210	34	2006	2006	NUM
chd-130	210	35	)	)	PUNCT
chd-130	210	36	.	.	PUNCT
chd-130	211	1	same	same	ADJ
chd-130	211	2	year	year	NOUN
chd-130	211	3	,	,	PUNCT
chd-130	211	4	a	a	DET
chd-130	211	5	study	study	NOUN
chd-130	211	6	conducted	conduct	VERB
chd-130	211	7	by	by	ADP
chd-130	211	8	one	one	NUM
chd-130	211	9	of	of	ADP
chd-130	211	10	the	the	DET
chd-130	211	11	authors	author	NOUN
chd-130	211	12	(	(	PUNCT
chd-130	211	13	bm	bm	PROPN
chd-130	211	14	)	)	PUNCT
chd-130	211	15	in	in	ADP
chd-130	211	16	india	india	PROPN
chd-130	211	17	reported	report	VERB
chd-130	211	18	an	an	DET
chd-130	211	19	association	association	NOUN
chd-130	211	20	between	between	ADP
chd-130	211	21	glutathione	glutathione	NOUN
chd-130	211	22	s	s	NOUN
chd-130	211	23	-	-	NOUN
chd-130	211	24	transferase	transferase	NOUN
chd-130	211	25	(	(	PUNCT
chd-130	211	26	gst	gst	NOUN
chd-130	211	27	)	)	PUNCT
chd-130	211	28	polymorphic	polymorphic	ADJ
chd-130	211	29	variants	variant	NOUN
chd-130	211	30	(	(	PUNCT
chd-130	211	31	gstt1	gstt1	NOUN
chd-130	211	32	,	,	PUNCT
chd-130	211	33	gstm1	gstm1	NOUN
chd-130	211	34	,	,	PUNCT
chd-130	211	35	gstp1	gstp1	NOUN
chd-130	211	36	,	,	PUNCT
chd-130	211	37	and	and	CCONJ
chd-130	211	38	gstm3	gstm3	NOUN
chd-130	211	39	)	)	PUNCT
chd-130	211	40	with	with	ADP
chd-130	211	41	risk	risk	NOUN
chd-130	211	42	of	of	ADP
chd-130	211	43	gallbladder	gallbladder	NOUN
chd-130	211	44	cancer	cancer	NOUN
chd-130	211	45	(	(	PUNCT
chd-130	211	46	pandey	pandey	PROPN
chd-130	211	47	et	et	PROPN
chd-130	211	48	al	al	PROPN
chd-130	211	49	.	.	PROPN
chd-130	211	50	,	,	PUNCT
chd-130	211	51	2006	2006	NUM
chd-130	211	52	)	)	PUNCT
chd-130	211	53	.	.	PUNCT
chd-130	212	1	these	these	DET
chd-130	212	2	gsts	gst	NOUN
chd-130	212	3	are	be	AUX
chd-130	212	4	a	a	DET
chd-130	212	5	family	family	NOUN
chd-130	212	6	of	of	ADP
chd-130	212	7	detoxifying	detoxify	VERB
chd-130	212	8	enzymes	enzyme	NOUN
chd-130	212	9	and	and	CCONJ
chd-130	212	10	are	be	AUX
chd-130	212	11	thus	thus	ADV
chd-130	212	12	intricately	intricately	ADV
chd-130	212	13	involved	involve	VERB
chd-130	212	14	in	in	ADP
chd-130	212	15	the	the	DET
chd-130	212	16	metabolism	metabolism	NOUN
chd-130	212	17	of	of	ADP
chd-130	212	18	many	many	ADJ
chd-130	212	19	known	known	ADJ
chd-130	212	20	and	and	CCONJ
chd-130	212	21	potential	potential	ADJ
chd-130	212	22	carcinogens	carcinogen	NOUN
chd-130	212	23	.	.	PUNCT
chd-130	213	1	various	various	ADJ
chd-130	213	2	allelic	allelic	ADJ
chd-130	213	3	variants	variant	NOUN
chd-130	213	4	of	of	ADP
chd-130	213	5	these	these	DET
chd-130	213	6	polymorphic	polymorphic	ADJ
chd-130	213	7	gsts	gst	NOUN
chd-130	213	8	show	show	VERB
chd-130	213	9	deformed	deform	VERB
chd-130	213	10	enzymatic	enzymatic	ADJ
chd-130	213	11	activity	activity	NOUN
chd-130	213	12	and	and	CCONJ
chd-130	213	13	thus	thus	ADV
chd-130	213	14	are	be	AUX
chd-130	213	15	reckoned	reckon	VERB
chd-130	213	16	to	to	PART
chd-130	213	17	increase	increase	VERB
chd-130	213	18	cancer	cancer	NOUN
chd-130	213	19	risk	risk	NOUN
chd-130	213	20	and	and	CCONJ
chd-130	213	21	susceptibility	susceptibility	NOUN
chd-130	213	22	.	.	PUNCT
chd-130	214	1	this	this	PRON
chd-130	214	2	was	be	AUX
chd-130	214	3	first	first	ADJ
chd-130	214	4	study	study	NOUN
chd-130	214	5	to	to	PART
chd-130	214	6	show	show	VERB
chd-130	214	7	a	a	DET
chd-130	214	8	correlation	correlation	NOUN
chd-130	214	9	between	between	ADP
chd-130	214	10	val	val	ADJ
chd-130	214	11	allele	allele	NOUN
chd-130	214	12	of	of	ADP
chd-130	214	13	gstp1	gstp1	NOUN
chd-130	214	14	and	and	CCONJ
chd-130	214	15	an	an	DET
chd-130	214	16	increased	increase	VERB
chd-130	214	17	risk	risk	NOUN
chd-130	214	18	of	of	ADP
chd-130	214	19	gbc	gbc	PROPN
chd-130	214	20	in	in	ADP
chd-130	214	21	the	the	DET
chd-130	214	22	indian	indian	ADJ
chd-130	214	23	population	population	NOUN
chd-130	214	24	(	(	PUNCT
chd-130	214	25	pandey	pandey	PROPN
chd-130	214	26	et	et	PROPN
chd-130	214	27	al	al	PROPN
chd-130	214	28	.	.	PROPN
chd-130	214	29	,	,	PUNCT
chd-130	214	30	2006	2006	NUM
chd-130	214	31	)	)	PUNCT
chd-130	214	32	.	.	PUNCT
chd-130	215	1	following	follow	VERB
chd-130	215	2	year	year	NOUN
chd-130	215	3	,	,	PUNCT
chd-130	215	4	same	same	ADJ
chd-130	215	5	group	group	NOUN
chd-130	215	6	including	include	VERB
chd-130	215	7	one	one	NUM
chd-130	215	8	of	of	ADP
chd-130	215	9	authors	author	NOUN
chd-130	215	10	of	of	ADP
chd-130	215	11	this	this	DET
chd-130	215	12	article	article	NOUN
chd-130	215	13	[	[	X
chd-130	215	14	bm	bm	X
chd-130	215	15	]	]	X
chd-130	215	16	went	go	VERB
chd-130	215	17	on	on	ADP
chd-130	215	18	to	to	PART
chd-130	215	19	show	show	VERB
chd-130	215	20	that	that	SCONJ
chd-130	215	21	a	a	DET
chd-130	215	22	polymorphic	polymorphic	ADJ
chd-130	215	23	variant	variant	NOUN
chd-130	215	24	of	of	ADP
chd-130	215	25	n	n	CCONJ
chd-130	215	26	-	-	PUNCT
chd-130	215	27	acetyl	acetyl	NOUN
chd-130	215	28	transferase2	transferase2	NOUN
chd-130	215	29	(	(	PUNCT
chd-130	215	30	nat2	nat2	PROPN
chd-130	215	31	)	)	PUNCT
chd-130	215	32	which	which	PRON
chd-130	215	33	is	be	AUX
chd-130	215	34	also	also	ADV
chd-130	215	35	known	know	VERB
chd-130	215	36	as	as	ADP
chd-130	215	37	slow	slow	ADJ
chd-130	215	38	acetylator	acetylator	NOUN
chd-130	215	39	phenotype	phenotype	NOUN
chd-130	215	40	,	,	PUNCT
chd-130	215	41	influenced	influence	VERB
chd-130	215	42	the	the	DET
chd-130	215	43	susceptibility	susceptibility	NOUN
chd-130	215	44	of	of	ADP
chd-130	215	45	gbc	gbc	PROPN
chd-130	215	46	(	(	PUNCT
chd-130	215	47	pandey	pandey	PROPN
chd-130	215	48	et	et	PROPN
chd-130	215	49	al	al	PROPN
chd-130	215	50	.	.	PROPN
chd-130	215	51	,	,	PUNCT
chd-130	215	52	2007	2007	NUM
chd-130	215	53	)	)	PUNCT
chd-130	215	54	.	.	PUNCT
chd-130	216	1	that	that	DET
chd-130	216	2	same	same	ADJ
chd-130	216	3	year	year	NOUN
chd-130	216	4	a	a	DET
chd-130	216	5	study	study	NOUN
chd-130	216	6	from	from	ADP
chd-130	216	7	china	china	PROPN
chd-130	216	8	demonstrated	demonstrate	VERB
chd-130	216	9	that	that	SCONJ
chd-130	216	10	ser326cys	ser326cy	VERB
chd-130	216	11	polymorphism	polymorphism	NOUN
chd-130	216	12	in	in	ADP
chd-130	216	13	human	human	ADJ
chd-130	216	14	oxoguanine	oxoguanine	NOUN
chd-130	216	15	glycosylase	glycosylase	NOUN
chd-130	216	16	1	1	NUM
chd-130	216	17	(	(	PUNCT
chd-130	216	18	hogg1	hogg1	ADJ
chd-130	216	19	)	)	PUNCT
chd-130	216	20	,	,	PUNCT
chd-130	216	21	a	a	DET
chd-130	216	22	gene	gene	NOUN
chd-130	216	23	involved	involve	VERB
chd-130	216	24	in	in	ADP
chd-130	216	25	the	the	DET
chd-130	216	26	excision	excision	NOUN
chd-130	216	27	repair	repair	NOUN
chd-130	216	28	mechanism	mechanism	NOUN
chd-130	216	29	for	for	ADP
chd-130	216	30	damaged	damaged	ADJ
chd-130	216	31	dna	dna	NOUN
chd-130	216	32	,	,	PUNCT
chd-130	216	33	has	have	VERB
chd-130	216	34	an	an	DET
chd-130	216	35	association	association	NOUN
chd-130	216	36	with	with	ADP
chd-130	216	37	gbc	gbc	PROPN
chd-130	216	38	(	(	PUNCT
chd-130	216	39	jiao	jiao	PROPN
chd-130	216	40	et	et	PROPN
chd-130	216	41	al	al	PROPN
chd-130	216	42	.	.	PROPN
chd-130	216	43	,	,	PUNCT
chd-130	216	44	2007	2007	NUM
chd-130	216	45	)	)	PUNCT
chd-130	216	46	.	.	PUNCT
chd-130	217	1	another	another	DET
chd-130	217	2	casecontrol	casecontrol	NOUN
chd-130	217	3	study	study	NOUN
chd-130	217	4	was	be	AUX
chd-130	217	5	undertaken	undertake	VERB
chd-130	217	6	in	in	ADP
chd-130	217	7	japan	japan	PROPN
chd-130	217	8	in	in	ADP
chd-130	217	9	order	order	NOUN
chd-130	217	10	to	to	PART
chd-130	217	11	examine	examine	VERB
chd-130	217	12	and	and	CCONJ
chd-130	217	13	determine	determine	VERB
chd-130	217	14	the	the	DET
chd-130	217	15	relationship	relationship	NOUN
chd-130	217	16	between	between	ADP
chd-130	217	17	the	the	DET
chd-130	217	18	various	various	ADJ
chd-130	217	19	genetic	genetic	ADJ
chd-130	217	20	polymorphisms	polymorphism	NOUN
chd-130	217	21	of	of	ADP
chd-130	217	22	genetic	genetic	ADJ
chd-130	217	23	polymorphisms	polymorphism	NOUN
chd-130	217	24	of	of	ADP
chd-130	217	25	cytochrome	cytochrome	NOUN
chd-130	217	26	p450	p450	PROPN
chd-130	217	27	1a1	1a1	NUM
chd-130	217	28	(	(	PUNCT
chd-130	217	29	cyp1a1	cyp1a1	NOUN
chd-130	217	30	)	)	PUNCT
chd-130	217	31	,	,	PUNCT
chd-130	217	32	glutathione	glutathione	NOUN
chd-130	217	33	s	s	NOUN
chd-130	217	34	-	-	PUNCT
chd-130	217	35	transferase	transferase	NOUN
chd-130	217	36	class	class	NOUN
chd-130	217	37	mu	mu	NOUN
chd-130	217	38	(	(	PUNCT
chd-130	217	39	gstm1	gstm1	PROPN
chd-130	217	40	)	)	PUNCT
chd-130	217	41	,	,	PUNCT
chd-130	217	42	and	and	CCONJ
chd-130	217	43	tumor	tumor	NOUN
chd-130	217	44	protein	protein	NOUN
chd-130	217	45	p53	p53	NOUN
chd-130	217	46	(	(	PUNCT
chd-130	217	47	tp53	tp53	PROPN
chd-130	217	48	)	)	PUNCT
chd-130	217	49	genes	gene	NOUN
chd-130	217	50	,	,	PUNCT
chd-130	217	51	and	and	CCONJ
chd-130	217	52	gbc	gbc	PROPN
chd-130	217	53	risk	risk	NOUN
chd-130	217	54	,	,	PUNCT
chd-130	217	55	observed	observe	VERB
chd-130	217	56	that	that	SCONJ
chd-130	217	57	the	the	DET
chd-130	217	58	val	val	ADJ
chd-130	217	59	allele	allele	NOUN
chd-130	217	60	of	of	ADP
chd-130	217	61	cyp1a1	cyp1a1	PROPN
chd-130	217	62	ile462val	ile462val	PROPN
chd-130	217	63	and	and	CCONJ
chd-130	217	64	the	the	DET
chd-130	217	65	pro	pro	ADJ
chd-130	217	66	allele	allele	NOUN
chd-130	217	67	of	of	ADP
chd-130	217	68	tp53	tp53	PROPN
chd-130	217	69	arg72pro	arg72pro	ADJ
chd-130	217	70	polymorphisms	polymorphism	NOUN
chd-130	217	71	aided	aid	VERB
chd-130	217	72	in	in	ADP
chd-130	217	73	a	a	DET
chd-130	217	74	heightened	heightened	ADJ
chd-130	217	75	incidence	incidence	NOUN
chd-130	217	76	of	of	ADP
chd-130	217	77	gbc	gbc	PROPN
chd-130	217	78	among	among	ADP
chd-130	217	79	japanese	japanese	ADJ
chd-130	217	80	women	woman	NOUN
chd-130	217	81	and	and	CCONJ
chd-130	217	82	men	man	NOUN
chd-130	217	83	,	,	PUNCT
chd-130	217	84	respectively	respectively	ADV
chd-130	217	85	(	(	PUNCT
chd-130	217	86	tsuchiya	tsuchiya	PROPN
chd-130	217	87	et	et	PROPN
chd-130	217	88	al	al	PROPN
chd-130	217	89	.	.	PROPN
chd-130	217	90	,	,	PUNCT
chd-130	217	91	2007	2007	NUM
chd-130	217	92	)	)	PUNCT
chd-130	217	93	.	.	PUNCT
chd-130	218	1	another	another	DET
chd-130	218	2	collaborative	collaborative	ADJ
chd-130	218	3	study	study	NOUN
chd-130	218	4	demonstrated	demonstrate	VERB
chd-130	218	5	that	that	SCONJ
chd-130	218	6	val	val	ADJ
chd-130	218	7	allele	allele	NOUN
chd-130	218	8	of	of	ADP
chd-130	218	9	cytochrome	cytochrome	ADJ
chd-130	218	10	p4501a1	p4501a1	NOUN
chd-130	218	11	(	(	PUNCT
chd-130	218	12	cyp1a1	cyp1a1	NOUN
chd-130	218	13	)	)	PUNCT
chd-130	218	14	gene	gene	NOUN
chd-130	218	15	contributes	contribute	VERB
chd-130	218	16	to	to	ADP
chd-130	218	17	the	the	DET
chd-130	218	18	development	development	NOUN
chd-130	218	19	of	of	ADP
chd-130	218	20	gbc	gbc	PROPN
chd-130	218	21	in	in	ADP
chd-130	218	22	women	woman	NOUN
chd-130	218	23	of	of	ADP
chd-130	218	24	two	two	NUM
chd-130	218	25	different	different	ADJ
chd-130	218	26	populations	population	NOUN
chd-130	218	27	of	of	ADP
chd-130	218	28	japan	japan	PROPN
chd-130	218	29	and	and	CCONJ
chd-130	218	30	hungary	hungary	PROPN
chd-130	218	31	(	(	PUNCT
chd-130	218	32	kimura	kimura	NOUN
chd-130	218	33	et	et	NOUN
chd-130	218	34	al	al	PROPN
chd-130	218	35	.	.	PROPN
chd-130	218	36	,	,	PUNCT
chd-130	218	37	2008	2008	NUM
chd-130	218	38	)	)	PUNCT
chd-130	218	39	.	.	PUNCT
chd-130	219	1	last	last	ADJ
chd-130	219	2	decade	decade	NOUN
chd-130	219	3	has	have	AUX
chd-130	219	4	seen	see	VERB
chd-130	219	5	a	a	DET
chd-130	219	6	growing	grow	VERB
chd-130	219	7	body	body	NOUN
chd-130	219	8	of	of	ADP
chd-130	219	9	data	datum	NOUN
chd-130	219	10	to	to	PART
chd-130	219	11	demonstrate	demonstrate	VERB
chd-130	219	12	an	an	DET
chd-130	219	13	association	association	NOUN
chd-130	219	14	between	between	ADP
chd-130	219	15	various	various	ADJ
chd-130	219	16	polymorphic	polymorphic	ADJ
chd-130	219	17	variants	variant	NOUN
chd-130	219	18	of	of	ADP
chd-130	219	19	many	many	ADJ
chd-130	219	20	cancers	cancer	NOUN
chd-130	219	21	associated	associate	VERB
chd-130	219	22	genes	gene	NOUN
chd-130	219	23	with	with	ADP
chd-130	219	24	risk	risk	NOUN
chd-130	219	25	of	of	ADP
chd-130	219	26	gbc	gbc	PROPN
chd-130	219	27	.	.	PUNCT
chd-130	220	1	majority	majority	NOUN
chd-130	220	2	of	of	ADP
chd-130	220	3	these	these	DET
chd-130	220	4	studies	study	NOUN
chd-130	220	5	came	come	VERB
chd-130	220	6	from	from	ADP
chd-130	220	7	researchers	researcher	NOUN
chd-130	220	8	including	include	VERB
chd-130	220	9	one	one	NUM
chd-130	220	10	of	of	ADP
chd-130	220	11	the	the	DET
chd-130	220	12	authors	author	NOUN
chd-130	220	13	of	of	ADP
chd-130	220	14	this	this	DET
chd-130	220	15	article	article	NOUN
chd-130	220	16	(	(	PUNCT
chd-130	220	17	bm	bm	PROPN
chd-130	220	18	)	)	PUNCT
chd-130	220	19	from	from	ADP
chd-130	220	20	north	north	PROPN
chd-130	220	21	india	india	PROPN
chd-130	220	22	.	.	PUNCT
chd-130	221	1	some	some	PRON
chd-130	221	2	of	of	ADP
chd-130	221	3	the	the	DET
chd-130	221	4	important	important	ADJ
chd-130	221	5	ones	one	NOUN
chd-130	221	6	are	be	AUX
chd-130	221	7	those	those	PRON
chd-130	221	8	that	that	PRON
chd-130	221	9	report	report	VERB
chd-130	221	10	a	a	DET
chd-130	221	11	strong	strong	ADJ
chd-130	221	12	link	link	NOUN
chd-130	221	13	between	between	ADP
chd-130	221	14	genetic	genetic	ADJ
chd-130	221	15	variants	variant	NOUN
chd-130	221	16	of	of	ADP
chd-130	221	17	signaling	signal	VERB
chd-130	221	18	molecules	molecule	NOUN
chd-130	221	19	such	such	ADJ
chd-130	221	20	as	as	ADP
chd-130	221	21	tumor	tumor	NOUN
chd-130	221	22	necrosis	necrosis	NOUN
chd-130	221	23	factor	factor	NOUN
chd-130	221	24	alpha	alpha	NOUN
chd-130	221	25	(	(	PUNCT
chd-130	221	26	tnfa	tnfa	NOUN
chd-130	221	27	)	)	PUNCT
chd-130	221	28	and	and	CCONJ
chd-130	221	29	interleukin	interleukin	NOUN
chd-130	221	30	6	6	NUM
chd-130	221	31	(	(	PUNCT
chd-130	221	32	il6	il6	NOUN
chd-130	221	33	)	)	PUNCT
chd-130	221	34	(	(	PUNCT
chd-130	221	35	vishnoi	vishnoi	NOUN
chd-130	221	36	et	et	PROPN
chd-130	221	37	al	al	PROPN
chd-130	221	38	.	.	PROPN
chd-130	221	39	,	,	PUNCT
chd-130	221	40	2007	2007	NUM
chd-130	221	41	)	)	PUNCT
chd-130	221	42	,	,	PUNCT
chd-130	221	43	a-204c	a-204c	NOUN
chd-130	221	44	of	of	ADP
chd-130	221	45	cholesterol	cholesterol	NOUN
chd-130	221	46	7alpha	7alpha	PROPN
chd-130	221	47	-	-	PUNCT
chd-130	221	48	hydroxylase	hydroxylase	NOUN
chd-130	221	49	(	(	PUNCT
chd-130	221	50	cyp7a1	cyp7a1	NOUN
chd-130	221	51	)	)	PUNCT
chd-130	221	52	(	(	PUNCT
chd-130	221	53	srivastava	srivastava	PROPN
chd-130	221	54	et	et	PROPN
chd-130	221	55	al	al	PROPN
chd-130	221	56	.	.	PROPN
chd-130	221	57	,	,	PUNCT
chd-130	221	58	2008a	2008a	NUM
chd-130	221	59	)	)	PUNCT
chd-130	221	60	,	,	PUNCT
chd-130	221	61	cholecystokinin	cholecystokinin	NOUN
chd-130	221	62	receptor	receptor	NOUN
chd-130	221	63	a	a	DET
chd-130	221	64	gene	gene	NOUN
chd-130	221	65	polymorphism	polymorphism	NOUN
chd-130	221	66	(	(	PUNCT
chd-130	221	67	srivastava	srivastava	PROPN
chd-130	221	68	et	et	PROPN
chd-130	221	69	al	al	PROPN
chd-130	221	70	.	.	PROPN
chd-130	221	71	,	,	PUNCT
chd-130	221	72	2008b	2008b	NUM
chd-130	221	73	)	)	PUNCT
chd-130	221	74	,	,	PUNCT
chd-130	221	75	interleukin-1	interleukin-1	NOUN
chd-130	221	76	gene	gene	NOUN
chd-130	221	77	polymorphism	polymorphism	NOUN
chd-130	221	78	(	(	PUNCT
chd-130	221	79	vishnoi	vishnoi	NOUN
chd-130	221	80	et	et	PROPN
chd-130	221	81	al	al	PROPN
chd-130	221	82	.	.	PROPN
chd-130	221	83	,	,	PUNCT
chd-130	221	84	2008	2008	NUM
chd-130	221	85	)	)	PUNCT
chd-130	221	86	,	,	PUNCT
chd-130	221	87	single	single	ADJ
chd-130	221	88	nucleotide	nucleotide	ADJ
chd-130	221	89	polymorphism	polymorphism	NOUN
chd-130	221	90	in	in	ADP
chd-130	221	91	abcg8	abcg8	NOUN
chd-130	221	92	transporter	transporter	NOUN
chd-130	221	93	gene	gene	NOUN
chd-130	221	94	(	(	PUNCT
chd-130	221	95	srivastava	srivastava	PROPN
chd-130	221	96	et	et	PROPN
chd-130	221	97	al	al	PROPN
chd-130	221	98	.	.	PROPN
chd-130	221	99	,	,	PUNCT
chd-130	221	100	2009	2009	NUM
chd-130	221	101	)	)	PUNCT
chd-130	221	102	,	,	PUNCT
chd-130	221	103	toll	toll	NOUN
chd-130	221	104	-	-	PUNCT
chd-130	221	105	like	like	ADJ
chd-130	221	106	receptor	receptor	NOUN
chd-130	221	107	gene	gene	NOUN
chd-130	221	108	polymorphisms	polymorphism	NOUN
chd-130	221	109	(	(	PUNCT
chd-130	221	110	srivastava	srivastava	PROPN
chd-130	221	111	et	et	PROPN
chd-130	221	112	al	al	PROPN
chd-130	221	113	.	.	PROPN
chd-130	221	114	,	,	PUNCT
chd-130	221	115	2010a	2010a	NUM
chd-130	221	116	)	)	PUNCT
chd-130	221	117	,	,	PUNCT
chd-130	221	118	and	and	CCONJ
chd-130	221	119	caspase-8	caspase-8	NUM
chd-130	221	120	gene	gene	NOUN
chd-130	221	121	polymorphisms	polymorphism	NOUN
chd-130	221	122	-	-	PUNCT
chd-130	221	123	genes	gene	NOUN
chd-130	221	124	that	that	PRON
chd-130	221	125	regulate	regulate	VERB
chd-130	221	126	apoptosis	apoptosis	NOUN
chd-130	221	127	in	in	ADP
chd-130	221	128	cancer	cancer	NOUN
chd-130	221	129	cells	cell	NOUN
chd-130	221	130	(	(	PUNCT
chd-130	221	131	srivastava	srivastava	PROPN
chd-130	221	132	et	et	PROPN
chd-130	221	133	al	al	PROPN
chd-130	221	134	.	.	PROPN
chd-130	221	135	,	,	PUNCT
chd-130	221	136	2010b	2010b	NUM
chd-130	221	137	)	)	PUNCT
chd-130	221	138	.	.	PUNCT
chd-130	222	1	in	in	ADP
chd-130	222	2	another	another	DET
chd-130	222	3	significant	significant	ADJ
chd-130	222	4	study	study	NOUN
chd-130	222	5	on	on	ADP
chd-130	222	6	larger	large	ADJ
chd-130	222	7	sample	sample	NOUN
chd-130	222	8	size	size	NOUN
chd-130	222	9	obtained	obtain	VERB
chd-130	222	10	from	from	ADP
chd-130	222	11	northern	northern	ADJ
chd-130	222	12	india	india	PROPN
chd-130	222	13	from	from	ADP
chd-130	222	14	the	the	DET
chd-130	222	15	same	same	ADJ
chd-130	222	16	group	group	NOUN
chd-130	222	17	led	lead	VERB
chd-130	222	18	by	by	ADP
chd-130	222	19	one	one	NUM
chd-130	222	20	of	of	ADP
chd-130	222	21	us	we	PRON
chd-130	222	22	(	(	PUNCT
chd-130	222	23	bm	bm	PROPN
chd-130	222	24	)	)	PUNCT
chd-130	222	25	,	,	PUNCT
chd-130	222	26	strong	strong	ADJ
chd-130	222	27	association	association	NOUN
chd-130	222	28	of	of	ADP
chd-130	222	29	a	a	DET
chd-130	222	30	haplotype	haplotype	NOUN
chd-130	222	31	of	of	ADP
chd-130	222	32	tumor	tumor	NOUN
chd-130	222	33	suppressor	suppressor	NOUN
chd-130	222	34	gene	gene	NOUN
chd-130	222	35	dcc	dcc	PROPN
chd-130	222	36	,	,	PUNCT
chd-130	222	37	grs2229080ars4078288	grs2229080ars4078288	ADJ
chd-130	222	38	-	-	PUNCT
chd-130	222	39	crs7504990	crs7504990	NOUN
chd-130	222	40	-	-	PUNCT
chd-130	222	41	ars714	ars714	PROPN
chd-130	222	42	was	be	AUX
chd-130	222	43	reported	report	VERB
chd-130	222	44	to	to	PART
chd-130	222	45	confer	confer	VERB
chd-130	222	46	high	high	ADJ
chd-130	222	47	risk	risk	NOUN
chd-130	222	48	of	of	ADP
chd-130	222	49	gbc	gbc	PROPN
chd-130	222	50	in	in	ADP
chd-130	222	51	northern	northern	ADJ
chd-130	222	52	indian	indian	ADJ
chd-130	222	53	population	population	NOUN
chd-130	222	54	(	(	PUNCT
chd-130	222	55	rai	rai	X
chd-130	222	56	et	et	PROPN
chd-130	222	57	al	al	PROPN
chd-130	222	58	.	.	PROPN
chd-130	222	59	,	,	PUNCT
chd-130	222	60	2013a	2013a	NUM
chd-130	222	61	)	)	PUNCT
chd-130	222	62	.	.	PUNCT
chd-130	223	1	in	in	ADP
chd-130	223	2	a	a	DET
chd-130	223	3	follow	follow	NOUN
chd-130	223	4	up	up	ADP
chd-130	223	5	genome	genome	NOUN
chd-130	223	6	wide	wide	ADJ
chd-130	223	7	association	association	NOUN
chd-130	223	8	study	study	NOUN
chd-130	223	9	(	(	PUNCT
chd-130	223	10	gwas	gwas	PROPN
chd-130	223	11	)	)	PUNCT
chd-130	223	12	using	use	VERB
chd-130	223	13	same	same	ADJ
chd-130	223	14	patients	patient	NOUN
chd-130	223	15	’	'	PUNCT
chd-130	223	16	cohort	cohort	NOUN
chd-130	223	17	,	,	PUNCT
chd-130	223	18	this	this	DET
chd-130	223	19	group	group	NOUN
chd-130	223	20	also	also	ADV
chd-130	223	21	identified	identify	VERB
chd-130	223	22	that	that	SCONJ
chd-130	223	23	some	some	DET
chd-130	223	24	polymorphic	polymorphic	ADJ
chd-130	223	25	variants	variant	NOUN
chd-130	223	26	of	of	ADP
chd-130	223	27	phospholipase	phospholipase	PROPN
chd-130	223	28	c	c	PROPN
chd-130	223	29	epsilon	epsilon	PROPN
chd-130	223	30	1	1	NUM
chd-130	223	31	(	(	PUNCT
chd-130	223	32	plce1	plce1	NOUN
chd-130	223	33	)	)	PUNCT
chd-130	223	34	gene	gene	NOUN
chd-130	223	35	which	which	PRON
chd-130	223	36	is	be	AUX
chd-130	223	37	known	know	VERB
chd-130	223	38	to	to	PART
chd-130	223	39	play	play	VERB
chd-130	223	40	a	a	DET
chd-130	223	41	critical	critical	ADJ
chd-130	223	42	role	role	NOUN
chd-130	223	43	in	in	ADP
chd-130	223	44	both	both	CCONJ
chd-130	223	45	formation	formation	NOUN
chd-130	223	46	and	and	CCONJ
chd-130	223	47	progression	progression	NOUN
chd-130	223	48	of	of	ADP
chd-130	223	49	esophageal	esophageal	ADJ
chd-130	223	50	and	and	CCONJ
chd-130	223	51	gastric	gastric	ADJ
chd-130	223	52	cancers	cancer	NOUN
chd-130	223	53	and	and	CCONJ
chd-130	223	54	psca	psca	NOUN
chd-130	223	55	gene	gene	NOUN
chd-130	223	56	which	which	PRON
chd-130	223	57	plays	play	VERB
chd-130	223	58	an	an	DET
chd-130	223	59	important	important	ADJ
chd-130	223	60	role	role	NOUN
chd-130	223	61	in	in	ADP
chd-130	223	62	inhibition	inhibition	NOUN
chd-130	223	63	of	of	ADP
chd-130	223	64	cell	cell	NOUN
chd-130	223	65	proliferation	proliferation	NOUN
chd-130	223	66	and/or	and/or	CCONJ
chd-130	223	67	inhibition	inhibition	NOUN
chd-130	223	68	of	of	ADP
chd-130	223	69	cell	cell	NOUN
chd-130	223	70	death	death	NOUN
chd-130	223	71	.	.	PUNCT
chd-130	224	1	this	this	DET
chd-130	224	2	study	study	NOUN
chd-130	224	3	showed	show	VERB
chd-130	224	4	that	that	SCONJ
chd-130	224	5	these	these	DET
chd-130	224	6	polymorphic	polymorphic	ADJ
chd-130	224	7	variants	variant	NOUN
chd-130	224	8	confer	confer	VERB
chd-130	224	9	susceptibility	susceptibility	NOUN
chd-130	224	10	to	to	ADP
chd-130	224	11	gbc	gbc	PROPN
chd-130	224	12	through	through	ADP
chd-130	224	13	gallstone	gallstone	NOUN
chd-130	224	14	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PART
chd-130	224	15	e14	e14	NOUN
chd-130	224	16	cancer	cancer	NOUN
chd-130	224	17	health	health	NOUN
chd-130	224	18	disparities	disparity	NOUN
chd-130	224	19	research	research	NOUN
chd-130	224	20	mediated	mediate	VERB
chd-130	224	21	inflammatory	inflammatory	ADJ
chd-130	224	22	pathway	pathway	NOUN
chd-130	224	23	and	and	CCONJ
chd-130	224	24	in	in	ADP
chd-130	224	25	a	a	DET
chd-130	224	26	gender	gender	NOUN
chd-130	224	27	specific	specific	ADJ
chd-130	224	28	manner	manner	NOUN
chd-130	224	29	respectively	respectively	ADV
chd-130	224	30	(	(	PUNCT
chd-130	224	31	sharma	sharma	PROPN
chd-130	224	32	et	et	PROPN
chd-130	224	33	al	al	PROPN
chd-130	224	34	.	.	PROPN
chd-130	224	35	,	,	PUNCT
chd-130	224	36	2013	2013	NUM
chd-130	224	37	;	;	PUNCT
chd-130	224	38	rai	rai	PROPN
chd-130	224	39	et	et	PROPN
chd-130	224	40	al	al	PROPN
chd-130	224	41	.	.	PROPN
chd-130	224	42	,	,	PUNCT
chd-130	224	43	2013b	2013b	NUM
chd-130	224	44	)	)	PUNCT
chd-130	224	45	.	.	PUNCT
chd-130	225	1	one	one	NUM
chd-130	225	2	of	of	ADP
chd-130	225	3	the	the	DET
chd-130	225	4	authors	author	NOUN
chd-130	225	5	(	(	PUNCT
chd-130	225	6	bm	bm	PROPN
chd-130	225	7	)	)	PUNCT
chd-130	225	8	of	of	ADP
chd-130	225	9	this	this	DET
chd-130	225	10	article	article	NOUN
chd-130	225	11	,	,	PUNCT
chd-130	225	12	recently	recently	ADV
chd-130	225	13	published	publish	VERB
chd-130	225	14	a	a	DET
chd-130	225	15	gwas	gwas	NOUN
chd-130	225	16	study	study	NOUN
chd-130	225	17	which	which	PRON
chd-130	225	18	to	to	ADP
chd-130	225	19	our	our	PRON
chd-130	225	20	knowledge	knowledge	NOUN
chd-130	225	21	is	be	AUX
chd-130	225	22	the	the	DET
chd-130	225	23	largest	large	ADJ
chd-130	225	24	study	study	NOUN
chd-130	225	25	worldwide	worldwide	ADV
chd-130	225	26	as	as	SCONJ
chd-130	225	27	it	it	PRON
chd-130	225	28	comprised	comprise	VERB
chd-130	225	29	of	of	ADP
chd-130	225	30	523	523	NUM
chd-130	225	31	gbc	gbc	NOUN
chd-130	225	32	patients	patient	NOUN
chd-130	225	33	and	and	CCONJ
chd-130	225	34	274	274	NUM
chd-130	225	35	controls	control	NOUN
chd-130	225	36	all	all	ADV
chd-130	225	37	from	from	ADP
chd-130	225	38	northern	northern	ADJ
chd-130	225	39	india	india	PROPN
chd-130	225	40	(	(	PUNCT
chd-130	225	41	yadav	yadav	PROPN
chd-130	225	42	et	et	PROPN
chd-130	225	43	al	al	PROPN
chd-130	225	44	.	.	PROPN
chd-130	225	45	,	,	PUNCT
chd-130	225	46	2018	2018	NUM
chd-130	225	47	)	)	PUNCT
chd-130	225	48	.	.	PUNCT
chd-130	226	1	this	this	DET
chd-130	226	2	study	study	NOUN
chd-130	226	3	reaffirms	reaffirm	VERB
chd-130	226	4	the	the	DET
chd-130	226	5	fact	fact	NOUN
chd-130	226	6	that	that	SCONJ
chd-130	226	7	the	the	DET
chd-130	226	8	link	link	NOUN
chd-130	226	9	between	between	ADP
chd-130	226	10	genetic	genetic	ADJ
chd-130	226	11	polymorphism	polymorphism	NOUN
chd-130	226	12	and	and	CCONJ
chd-130	226	13	disease	disease	NOUN
chd-130	226	14	risk	risk	NOUN
chd-130	226	15	may	may	AUX
chd-130	226	16	be	be	AUX
chd-130	226	17	very	very	ADV
chd-130	226	18	specific	specific	ADJ
chd-130	226	19	with	with	ADP
chd-130	226	20	regards	regard	NOUN
chd-130	226	21	to	to	ADP
chd-130	226	22	directional	directional	ADJ
chd-130	226	23	effect	effect	NOUN
chd-130	226	24	and	and	CCONJ
chd-130	226	25	histology	histology	NOUN
chd-130	226	26	/	/	SYM
chd-130	226	27	ethnicity	ethnicity	NOUN
chd-130	226	28	by	by	ADP
chd-130	226	29	demonstrating	demonstrate	VERB
chd-130	226	30	that	that	SCONJ
chd-130	226	31	genetic	genetic	ADJ
chd-130	226	32	variants	variant	NOUN
chd-130	226	33	on	on	ADP
chd-130	226	34	tert	tert	NOUN
chd-130	226	35	-	-	PUNCT
chd-130	226	36	clptm1l	clptm1l	ADJ
chd-130	226	37	and	and	CCONJ
chd-130	226	38	8q24.21	8q24.21	NUM
chd-130	226	39	loci	locus	NOUN
chd-130	226	40	affect	affect	VERB
chd-130	226	41	gbc	gbc	PROPN
chd-130	226	42	prognosis	prognosis	NOUN
chd-130	226	43	and	and	CCONJ
chd-130	226	44	predisposition	predisposition	NOUN
chd-130	226	45	.	.	PUNCT
chd-130	227	1	in	in	ADP
chd-130	227	2	order	order	NOUN
chd-130	227	3	to	to	PART
chd-130	227	4	describe	describe	VERB
chd-130	227	5	the	the	DET
chd-130	227	6	inter	inter	NOUN
chd-130	227	7	-	-	NOUN
chd-130	227	8	relationship	relationship	NOUN
chd-130	227	9	between	between	ADP
chd-130	227	10	genetic	genetic	ADJ
chd-130	227	11	variants	variant	NOUN
chd-130	227	12	and	and	CCONJ
chd-130	227	13	gbc	gbc	NOUN
chd-130	227	14	susceptibility	susceptibility	NOUN
chd-130	227	15	in	in	ADP
chd-130	227	16	populations	population	NOUN
chd-130	227	17	at	at	ADP
chd-130	227	18	risk	risk	NOUN
chd-130	227	19	,	,	PUNCT
chd-130	227	20	the	the	DET
chd-130	227	21	study	study	NOUN
chd-130	227	22	stressed	stress	VERB
chd-130	227	23	on	on	ADP
chd-130	227	24	the	the	DET
chd-130	227	25	need	need	NOUN
chd-130	227	26	to	to	PART
chd-130	227	27	perform	perform	VERB
chd-130	227	28	complete	complete	ADJ
chd-130	227	29	gene	gene	NOUN
chd-130	227	30	sequencing	sequencing	NOUN
chd-130	227	31	of	of	ADP
chd-130	227	32	the	the	DET
chd-130	227	33	5p15.33	5p15.33	NUM
chd-130	227	34	and	and	CCONJ
chd-130	227	35	8q24.21	8q24.21	NUM
chd-130	227	36	loci	locus	NOUN
chd-130	227	37	.	.	PUNCT
chd-130	228	1	however	however	ADV
chd-130	228	2	,	,	PUNCT
chd-130	228	3	it	it	PRON
chd-130	228	4	is	be	AUX
chd-130	228	5	important	important	ADJ
chd-130	228	6	to	to	PART
chd-130	228	7	note	note	VERB
chd-130	228	8	that	that	SCONJ
chd-130	228	9	in	in	ADP
chd-130	228	10	spite	spite	NOUN
chd-130	228	11	of	of	ADP
chd-130	228	12	huge	huge	ADJ
chd-130	228	13	amount	amount	NOUN
chd-130	228	14	of	of	ADP
chd-130	228	15	efforts	effort	NOUN
chd-130	228	16	involved	involve	VERB
chd-130	228	17	in	in	ADP
chd-130	228	18	these	these	DET
chd-130	228	19	studies	study	NOUN
chd-130	228	20	to	to	PART
chd-130	228	21	study	study	VERB
chd-130	228	22	genetic	genetic	ADJ
chd-130	228	23	risk	risk	NOUN
chd-130	228	24	factors	factor	NOUN
chd-130	228	25	,	,	PUNCT
chd-130	228	26	it	it	PRON
chd-130	228	27	is	be	AUX
chd-130	228	28	still	still	ADV
chd-130	228	29	unclear	unclear	ADJ
chd-130	228	30	that	that	SCONJ
chd-130	228	31	which	which	DET
chd-130	228	32	genetic	genetic	ADJ
chd-130	228	33	pathways	pathway	NOUN
chd-130	228	34	are	be	AUX
chd-130	228	35	actually	actually	ADV
chd-130	228	36	important	important	ADJ
chd-130	228	37	in	in	ADP
chd-130	228	38	order	order	NOUN
chd-130	228	39	to	to	PART
chd-130	228	40	make	make	VERB
chd-130	228	41	a	a	DET
chd-130	228	42	person	person	NOUN
chd-130	228	43	susceptible	susceptible	ADJ
chd-130	228	44	living	live	VERB
chd-130	228	45	in	in	ADP
chd-130	228	46	a	a	DET
chd-130	228	47	geographically	geographically	ADV
chd-130	228	48	prone	prone	ADJ
chd-130	228	49	area	area	NOUN
chd-130	228	50	for	for	ADP
chd-130	228	51	gbc	gbc	NOUN
chd-130	228	52	such	such	ADJ
chd-130	228	53	as	as	ADP
chd-130	228	54	north	north	PROPN
chd-130	228	55	india	india	PROPN
chd-130	228	56	.	.	PUNCT
chd-130	229	1	all	all	DET
chd-130	229	2	these	these	DET
chd-130	229	3	genes	gene	NOUN
chd-130	229	4	demonstrated	demonstrate	VERB
chd-130	229	5	above	above	ADP
chd-130	229	6	which	which	PRON
chd-130	229	7	have	have	AUX
chd-130	229	8	been	be	AUX
chd-130	229	9	shown	show	VERB
chd-130	229	10	to	to	PART
chd-130	229	11	be	be	AUX
chd-130	229	12	associated	associate	VERB
chd-130	229	13	with	with	ADP
chd-130	229	14	gbc	gbc	PROPN
chd-130	229	15	as	as	ADP
chd-130	229	16	risk	risk	NOUN
chd-130	229	17	factor	factor	NOUN
chd-130	229	18	belong	belong	VERB
chd-130	229	19	to	to	ADP
chd-130	229	20	different	different	ADJ
chd-130	229	21	signaling	signal	VERB
chd-130	229	22	pathways	pathway	NOUN
chd-130	229	23	,	,	PUNCT
chd-130	229	24	which	which	PRON
chd-130	229	25	further	far	ADV
chd-130	229	26	complicates	complicate	VERB
chd-130	229	27	the	the	DET
chd-130	229	28	issue	issue	NOUN
chd-130	229	29	of	of	ADP
chd-130	229	30	making	make	VERB
chd-130	229	31	a	a	DET
chd-130	229	32	coherent	coherent	ADJ
chd-130	229	33	picture	picture	NOUN
chd-130	229	34	of	of	ADP
chd-130	229	35	all	all	DET
chd-130	229	36	these	these	DET
chd-130	229	37	genetic	genetic	ADJ
chd-130	229	38	susceptibility	susceptibility	NOUN
chd-130	229	39	factors	factor	NOUN
chd-130	229	40	.	.	PUNCT
chd-130	230	1	many	many	ADJ
chd-130	230	2	more	more	ADJ
chd-130	230	3	studies	study	NOUN
chd-130	230	4	have	have	AUX
chd-130	230	5	been	be	AUX
chd-130	230	6	published	publish	VERB
chd-130	230	7	in	in	ADP
chd-130	230	8	recent	recent	ADJ
chd-130	230	9	past	past	NOUN
chd-130	230	10	from	from	ADP
chd-130	230	11	different	different	ADJ
chd-130	230	12	parts	part	NOUN
chd-130	230	13	of	of	ADP
chd-130	230	14	the	the	DET
chd-130	230	15	world	world	NOUN
chd-130	230	16	showing	show	VERB
chd-130	230	17	one	one	NUM
chd-130	230	18	or	or	CCONJ
chd-130	230	19	other	other	ADJ
chd-130	230	20	type	type	NOUN
chd-130	230	21	of	of	ADP
chd-130	230	22	polymorphic	polymorphic	ADJ
chd-130	230	23	variants	variant	NOUN
chd-130	230	24	of	of	ADP
chd-130	230	25	different	different	ADJ
chd-130	230	26	genes	gene	NOUN
chd-130	230	27	involves	involve	VERB
chd-130	230	28	in	in	ADP
chd-130	230	29	metabolism	metabolism	NOUN
chd-130	230	30	,	,	PUNCT
chd-130	230	31	signal	signal	ADJ
chd-130	230	32	transduction	transduction	NOUN
chd-130	230	33	,	,	PUNCT
chd-130	230	34	drugmetabolizing	drugmetabolize	VERB
chd-130	230	35	enzymes	enzyme	NOUN
chd-130	230	36	related	relate	VERB
chd-130	230	37	pathways	pathway	NOUN
chd-130	230	38	,	,	PUNCT
chd-130	230	39	however	however	ADV
chd-130	230	40	,	,	PUNCT
chd-130	230	41	most	most	ADJ
chd-130	230	42	of	of	ADP
chd-130	230	43	them	they	PRON
chd-130	230	44	are	be	AUX
chd-130	230	45	actually	actually	ADV
chd-130	230	46	adding	add	VERB
chd-130	230	47	more	more	ADJ
chd-130	230	48	complexity	complexity	NOUN
chd-130	230	49	to	to	ADP
chd-130	230	50	the	the	DET
chd-130	230	51	existing	exist	VERB
chd-130	230	52	mechanistic	mechanistic	ADJ
chd-130	230	53	insights	insight	NOUN
chd-130	230	54	about	about	ADP
chd-130	230	55	gbc	gbc	PROPN
chd-130	230	56	.	.	PUNCT
chd-130	231	1	interestingly	interestingly	ADV
chd-130	231	2	,	,	PUNCT
chd-130	231	3	genetic	genetic	ADJ
chd-130	231	4	aberrations	aberration	NOUN
chd-130	231	5	in	in	ADP
chd-130	231	6	genes	gene	NOUN
chd-130	231	7	associated	associate	VERB
chd-130	231	8	with	with	ADP
chd-130	231	9	inflammation	inflammation	NOUN
chd-130	231	10	which	which	PRON
chd-130	231	11	is	be	AUX
chd-130	231	12	an	an	DET
chd-130	231	13	important	important	ADJ
chd-130	231	14	aspect	aspect	NOUN
chd-130	231	15	of	of	ADP
chd-130	231	16	gallbladder	gallbladder	NOUN
chd-130	231	17	carcinogenesis	carcinogenesis	NOUN
chd-130	231	18	has	have	AUX
chd-130	231	19	not	not	PART
chd-130	231	20	been	be	AUX
chd-130	231	21	much	much	ADV
chd-130	231	22	explored	explore	VERB
chd-130	231	23	in	in	ADP
chd-130	231	24	these	these	DET
chd-130	231	25	gwas	gwas	PROPN
chd-130	231	26	studies	study	NOUN
chd-130	231	27	.	.	PUNCT
chd-130	232	1	foxm1	foxm1	ADJ
chd-130	232	2	,	,	PUNCT
chd-130	232	3	nf	nf	PROPN
chd-130	232	4	-	-	PUNCT
chd-130	232	5	kb	kb	PROPN
chd-130	232	6	,	,	PUNCT
chd-130	232	7	stat3	stat3	PROPN
chd-130	232	8	,	,	PUNCT
chd-130	232	9	wnt	wnt	PROPN
chd-130	232	10	/	/	SYM
chd-130	232	11	βcatenin	βcatenin	PROPN
chd-130	232	12	,	,	PUNCT
chd-130	232	13	hif-1α	hif-1α	PROPN
chd-130	232	14	,	,	PUNCT
chd-130	232	15	nrf2	nrf2	NOUN
chd-130	232	16	,	,	PUNCT
chd-130	232	17	androgen	androgen	NOUN
chd-130	232	18	and	and	CCONJ
chd-130	232	19	estrogen	estrogen	NOUN
chd-130	232	20	receptors	receptor	NOUN
chd-130	232	21	are	be	AUX
chd-130	232	22	some	some	DET
chd-130	232	23	examples	example	NOUN
chd-130	232	24	of	of	ADP
chd-130	232	25	the	the	DET
chd-130	232	26	tumor	tumor	NOUN
chd-130	232	27	suppressive	suppressive	NOUN
chd-130	232	28	as	as	ADV
chd-130	232	29	well	well	ADV
chd-130	232	30	as	as	ADP
chd-130	232	31	oncogenic	oncogenic	ADJ
chd-130	232	32	transcription	transcription	NOUN
chd-130	232	33	factors	factor	NOUN
chd-130	232	34	,	,	PUNCT
chd-130	232	35	the	the	DET
chd-130	232	36	interaction	interaction	NOUN
chd-130	232	37	between	between	ADP
chd-130	232	38	which	which	PRON
chd-130	232	39	,	,	PUNCT
chd-130	232	40	results	result	NOUN
chd-130	232	41	in	in	ADP
chd-130	232	42	chronic	chronic	ADJ
chd-130	232	43	inflammation	inflammation	NOUN
chd-130	232	44	of	of	ADP
chd-130	232	45	the	the	DET
chd-130	232	46	gallbladder	gallbladder	NOUN
chd-130	232	47	.	.	PUNCT
chd-130	233	1	the	the	DET
chd-130	233	2	chronic	chronic	ADJ
chd-130	233	3	inflammation	inflammation	NOUN
chd-130	233	4	may	may	AUX
chd-130	233	5	be	be	AUX
chd-130	233	6	either	either	CCONJ
chd-130	233	7	due	due	ADJ
chd-130	233	8	to	to	ADP
chd-130	233	9	stones	stone	NOUN
chd-130	233	10	or	or	CCONJ
chd-130	233	11	a	a	DET
chd-130	233	12	long	long	ADJ
chd-130	233	13	standing	stand	VERB
chd-130	233	14	infection	infection	NOUN
chd-130	233	15	of	of	ADP
chd-130	233	16	the	the	DET
chd-130	233	17	organ	organ	NOUN
chd-130	233	18	.	.	PUNCT
chd-130	234	1	studies	study	NOUN
chd-130	234	2	conducted	conduct	VERB
chd-130	234	3	in	in	ADP
chd-130	234	4	various	various	ADJ
chd-130	234	5	clinical	clinical	ADJ
chd-130	234	6	models	model	NOUN
chd-130	234	7	,	,	PUNCT
chd-130	234	8	pre	pre	ADJ
chd-130	234	9	-	-	ADJ
chd-130	234	10	clinical	clinical	ADJ
chd-130	234	11	samples	sample	NOUN
chd-130	234	12	as	as	ADV
chd-130	234	13	well	well	ADV
chd-130	234	14	as	as	ADP
chd-130	234	15	cell	cell	NOUN
chd-130	234	16	lines	line	NOUN
chd-130	234	17	,	,	PUNCT
chd-130	234	18	show	show	VERB
chd-130	234	19	that	that	SCONJ
chd-130	234	20	numerous	numerous	ADJ
chd-130	234	21	products	product	NOUN
chd-130	234	22	obtained	obtain	VERB
chd-130	234	23	from	from	ADP
chd-130	234	24	natural	natural	ADJ
chd-130	234	25	resources	resource	NOUN
chd-130	234	26	namely	namely	ADV
chd-130	234	27	,	,	PUNCT
chd-130	234	28	polyphenols	polyphenol	NOUN
chd-130	234	29	,	,	PUNCT
chd-130	234	30	alter	alter	VERB
chd-130	234	31	the	the	DET
chd-130	234	32	expression	expression	NOUN
chd-130	234	33	and	and	CCONJ
chd-130	234	34	activity	activity	NOUN
chd-130	234	35	of	of	ADP
chd-130	234	36	many	many	ADJ
chd-130	234	37	transcription	transcription	NOUN
chd-130	234	38	factors	factor	NOUN
chd-130	234	39	in	in	ADP
chd-130	234	40	various	various	ADJ
chd-130	234	41	tumor	tumor	NOUN
chd-130	234	42	models	model	NOUN
chd-130	234	43	(	(	PUNCT
chd-130	234	44	agrawal	agrawal	PROPN
chd-130	234	45	et	et	PROPN
chd-130	234	46	al	al	PROPN
chd-130	234	47	.	.	PROPN
chd-130	234	48	,	,	PUNCT
chd-130	234	49	2015	2015	NUM
chd-130	234	50	)	)	PUNCT
chd-130	234	51	.	.	PUNCT
chd-130	235	1	additional	additional	ADJ
chd-130	235	2	information	information	NOUN
chd-130	235	3	regarding	regard	VERB
chd-130	235	4	alterations	alteration	NOUN
chd-130	235	5	in	in	ADP
chd-130	235	6	the	the	DET
chd-130	235	7	aforementioned	aforementioned	ADJ
chd-130	235	8	genes	gene	NOUN
chd-130	235	9	and	and	CCONJ
chd-130	235	10	their	their	PRON
chd-130	235	11	regulator	regulator	NOUN
chd-130	235	12	pathways	pathway	NOUN
chd-130	235	13	could	could	AUX
chd-130	235	14	help	help	VERB
chd-130	235	15	design	design	VERB
chd-130	235	16	a	a	DET
chd-130	235	17	new	new	ADJ
chd-130	235	18	and	and	CCONJ
chd-130	235	19	improved	improved	ADJ
chd-130	235	20	form	form	NOUN
chd-130	235	21	of	of	ADP
chd-130	235	22	therapy	therapy	NOUN
chd-130	235	23	combining	combine	VERB
chd-130	235	24	these	these	DET
chd-130	235	25	natural	natural	ADJ
chd-130	235	26	products	product	NOUN
chd-130	235	27	along	along	ADP
chd-130	235	28	with	with	ADP
chd-130	235	29	the	the	DET
chd-130	235	30	standard	standard	NOUN
chd-130	235	31	currently	currently	ADV
chd-130	235	32	approved	approve	VERB
chd-130	235	33	chemotherapeutic	chemotherapeutic	ADJ
chd-130	235	34	regimen	regiman	NOUN
chd-130	235	35	.	.	PUNCT
chd-130	236	1	the	the	DET
chd-130	236	2	combined	combine	VERB
chd-130	236	3	therapy	therapy	NOUN
chd-130	236	4	has	have	AUX
chd-130	236	5	been	be	AUX
chd-130	236	6	considered	consider	VERB
chd-130	236	7	promising	promising	ADJ
chd-130	236	8	and	and	CCONJ
chd-130	236	9	the	the	DET
chd-130	236	10	hope	hope	NOUN
chd-130	236	11	is	be	AUX
chd-130	236	12	to	to	PART
chd-130	236	13	be	be	AUX
chd-130	236	14	able	able	ADJ
chd-130	236	15	to	to	PART
chd-130	236	16	not	not	PART
chd-130	236	17	only	only	ADV
chd-130	236	18	treat	treat	VERB
chd-130	236	19	the	the	DET
chd-130	236	20	inflammation	inflammation	NOUN
chd-130	236	21	and	and	CCONJ
chd-130	236	22	cancer	cancer	NOUN
chd-130	236	23	but	but	CCONJ
chd-130	236	24	also	also	ADV
chd-130	236	25	prevent	prevent	VERB
chd-130	236	26	the	the	DET
chd-130	236	27	two	two	NUM
chd-130	236	28	conditions	condition	NOUN
chd-130	236	29	.	.	PUNCT
chd-130	237	1	targeted	target	VERB
chd-130	237	2	therapy	therapy	NOUN
chd-130	237	3	in	in	ADP
chd-130	237	4	gbc	gbc	PROPN
chd-130	237	5	while	while	SCONJ
chd-130	237	6	there	there	PRON
chd-130	237	7	were	be	VERB
chd-130	237	8	a	a	DET
chd-130	237	9	multitude	multitude	NOUN
chd-130	237	10	of	of	ADP
chd-130	237	11	studies	study	NOUN
chd-130	237	12	by	by	ADP
chd-130	237	13	mid	mid	ADJ
chd-130	237	14	2000s	2000	NOUN
chd-130	237	15	that	that	PRON
chd-130	237	16	demonstrated	demonstrate	VERB
chd-130	237	17	that	that	SCONJ
chd-130	237	18	overexpression	overexpression	NOUN
chd-130	237	19	of	of	ADP
chd-130	237	20	tyrosine	tyrosine	NOUN
chd-130	237	21	kinase	kinase	PROPN
chd-130	237	22	growth	growth	NOUN
chd-130	237	23	factor	factor	NOUN
chd-130	237	24	receptors	receptor	NOUN
chd-130	237	25	such	such	ADJ
chd-130	237	26	as	as	ADP
chd-130	237	27	erbb-2	erbb-2	PROPN
chd-130	237	28	,	,	PUNCT
chd-130	237	29	epidermal	epidermal	ADJ
chd-130	237	30	growth	growth	NOUN
chd-130	237	31	factor	factor	NOUN
chd-130	237	32	receptor	receptor	NOUN
chd-130	237	33	(	(	PUNCT
chd-130	237	34	egfr	egfr	NOUN
chd-130	237	35	)	)	PUNCT
chd-130	237	36	,	,	PUNCT
chd-130	237	37	and	and	CCONJ
chd-130	237	38	met	meet	VERB
chd-130	237	39	could	could	AUX
chd-130	237	40	potentially	potentially	ADV
chd-130	237	41	lead	lead	VERB
chd-130	237	42	to	to	ADP
chd-130	237	43	the	the	DET
chd-130	237	44	formation	formation	NOUN
chd-130	237	45	of	of	ADP
chd-130	237	46	solid	solid	ADJ
chd-130	237	47	tumors	tumor	NOUN
chd-130	237	48	,	,	PUNCT
chd-130	237	49	there	there	PRON
chd-130	237	50	were	be	VERB
chd-130	237	51	a	a	DET
chd-130	237	52	group	group	NOUN
chd-130	237	53	of	of	ADP
chd-130	237	54	investigators	investigator	NOUN
chd-130	237	55	in	in	ADP
chd-130	237	56	japan	japan	PROPN
chd-130	237	57	who	who	PRON
chd-130	237	58	studied	study	VERB
chd-130	237	59	biliary	biliary	ADJ
chd-130	237	60	tract	tract	NOUN
chd-130	237	61	carcinomas	carcinoma	NOUN
chd-130	237	62	.	.	PUNCT
chd-130	238	1	the	the	DET
chd-130	238	2	investigators	investigator	NOUN
chd-130	238	3	,	,	PUNCT
chd-130	238	4	with	with	ADP
chd-130	238	5	the	the	DET
chd-130	238	6	intention	intention	NOUN
chd-130	238	7	of	of	ADP
chd-130	238	8	assessing	assess	VERB
chd-130	238	9	novel	novel	ADJ
chd-130	238	10	chemotherapies	chemotherapy	NOUN
chd-130	238	11	,	,	PUNCT
chd-130	238	12	focused	focus	VERB
chd-130	238	13	on	on	ADP
chd-130	238	14	these	these	DET
chd-130	238	15	receptors	receptor	NOUN
chd-130	238	16	in	in	ADP
chd-130	238	17	gbc	gbc	NOUN
chd-130	238	18	and	and	CCONJ
chd-130	238	19	demonstrated	demonstrate	VERB
chd-130	238	20	overexpression	overexpression	NOUN
chd-130	238	21	of	of	ADP
chd-130	238	22	the	the	DET
chd-130	238	23	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-130	238	24	e15	e15	PROPN
chd-130	238	25	cancer	cancer	NOUN
chd-130	238	26	health	health	NOUN
chd-130	238	27	disparities	disparity	NOUN
chd-130	238	28	research	research	PROPN
chd-130	238	29	tyrosine	tyrosine	PROPN
chd-130	238	30	kinase	kinase	PROPN
chd-130	238	31	receptor	receptor	NOUN
chd-130	238	32	proteins	protein	NOUN
chd-130	238	33	by	by	ADP
chd-130	238	34	ihc	ihc	PROPN
chd-130	238	35	in	in	ADP
chd-130	238	36	tumor	tumor	NOUN
chd-130	238	37	tissues	tissue	NOUN
chd-130	238	38	obtained	obtain	VERB
chd-130	238	39	from	from	ADP
chd-130	238	40	89	89	NUM
chd-130	238	41	gbc	gbc	PROPN
chd-130	238	42	patients	patient	NOUN
chd-130	238	43	.	.	PUNCT
chd-130	239	1	another	another	DET
chd-130	239	2	technique	technique	NOUN
chd-130	239	3	,	,	PUNCT
chd-130	239	4	fluorescence	fluorescence	NOUN
chd-130	239	5	in	in	ADP
chd-130	239	6	situ	situ	ADJ
chd-130	239	7	hybridization	hybridization	NOUN
chd-130	239	8	was	be	AUX
chd-130	239	9	used	use	VERB
chd-130	239	10	for	for	ADP
chd-130	239	11	gene	gene	NOUN
chd-130	239	12	amplification	amplification	NOUN
chd-130	239	13	in	in	ADP
chd-130	239	14	tumor	tumor	NOUN
chd-130	239	15	tissues	tissue	NOUN
chd-130	239	16	that	that	PRON
chd-130	239	17	stained	stain	VERB
chd-130	239	18	positive	positive	ADJ
chd-130	239	19	.	.	PUNCT
chd-130	240	1	there	there	PRON
chd-130	240	2	was	be	VERB
chd-130	240	3	an	an	DET
chd-130	240	4	overexpression	overexpression	NOUN
chd-130	240	5	of	of	ADP
chd-130	240	6	the	the	DET
chd-130	240	7	erbb-2	erbb-2	PROPN
chd-130	240	8	and	and	CCONJ
chd-130	240	9	the	the	DET
chd-130	240	10	egfr	egfr	ADJ
chd-130	240	11	genes	gene	NOUN
chd-130	240	12	in	in	ADP
chd-130	240	13	15.7	15.7	NUM
chd-130	240	14	and	and	CCONJ
chd-130	240	15	8.1	8.1	NUM
chd-130	240	16	%	%	NOUN
chd-130	240	17	of	of	ADP
chd-130	240	18	gbc	gbc	PROPN
chd-130	240	19	cases	case	NOUN
chd-130	240	20	with	with	ADP
chd-130	240	21	gbc	gbc	NOUN
chd-130	240	22	gene	gene	NOUN
chd-130	240	23	amplification	amplification	NOUN
chd-130	240	24	of	of	ADP
chd-130	240	25	79	79	NUM
chd-130	240	26	%	%	NOUN
chd-130	240	27	.	.	PUNCT
chd-130	241	1	this	this	DET
chd-130	241	2	study	study	NOUN
chd-130	241	3	suggested	suggest	VERB
chd-130	241	4	the	the	DET
chd-130	241	5	new	new	ADJ
chd-130	241	6	adjuvant	adjuvant	ADJ
chd-130	241	7	chemotherapies	chemotherapy	NOUN
chd-130	241	8	could	could	AUX
chd-130	241	9	be	be	AUX
chd-130	241	10	used	use	VERB
chd-130	241	11	in	in	ADP
chd-130	241	12	gbc	gbc	PROPN
chd-130	241	13	in	in	ADP
chd-130	241	14	which	which	PRON
chd-130	241	15	erbb-2	erbb-2	PROPN
chd-130	241	16	and	and	CCONJ
chd-130	241	17	egfr	egfr	NOUN
chd-130	241	18	are	be	AUX
chd-130	241	19	overexpressed	overexpresse	VERB
chd-130	241	20	(	(	PUNCT
chd-130	241	21	nakazawa	nakazawa	PROPN
chd-130	241	22	et	et	PROPN
chd-130	241	23	al	al	PROPN
chd-130	241	24	.	.	PROPN
chd-130	241	25	,	,	PUNCT
chd-130	241	26	2005	2005	NUM
chd-130	241	27	)	)	PUNCT
chd-130	241	28	.	.	PUNCT
chd-130	242	1	later	later	ADV
chd-130	242	2	,	,	PUNCT
chd-130	242	3	an	an	DET
chd-130	242	4	italian	italian	ADJ
chd-130	242	5	study	study	NOUN
chd-130	242	6	observed	observe	VERB
chd-130	242	7	that	that	SCONJ
chd-130	242	8	in	in	ADP
chd-130	242	9	a	a	DET
chd-130	242	10	subgroup	subgroup	NOUN
chd-130	242	11	of	of	ADP
chd-130	242	12	patients	patient	NOUN
chd-130	242	13	with	with	ADP
chd-130	242	14	gbc	gbc	PROPN
chd-130	242	15	,	,	PUNCT
chd-130	242	16	somatic	somatic	ADJ
chd-130	242	17	mutations	mutation	NOUN
chd-130	242	18	of	of	ADP
chd-130	242	19	the	the	DET
chd-130	242	20	egfr	egfr	ADJ
chd-130	242	21	gene	gene	NOUN
chd-130	242	22	in	in	ADP
chd-130	242	23	the	the	DET
chd-130	242	24	tyrosine	tyrosine	NOUN
chd-130	242	25	kinase	kinase	PROPN
chd-130	242	26	domain	domain	PROPN
chd-130	242	27	exhibited	exhibit	VERB
chd-130	242	28	cell	cell	NOUN
chd-130	242	29	signals	signal	NOUN
chd-130	242	30	maintaining	maintain	VERB
chd-130	242	31	proliferation	proliferation	NOUN
chd-130	242	32	and	and	CCONJ
chd-130	242	33	survival	survival	NOUN
chd-130	242	34	.	.	PUNCT
chd-130	243	1	further	far	ADV
chd-130	243	2	these	these	DET
chd-130	243	3	investigators	investigator	NOUN
chd-130	243	4	suggested	suggest	VERB
chd-130	243	5	a	a	DET
chd-130	243	6	small	small	ADJ
chd-130	243	7	molecule	molecule	NOUN
chd-130	243	8	inhibitor	inhibitor	NOUN
chd-130	243	9	of	of	ADP
chd-130	243	10	egfr	egfr	NOUN
chd-130	243	11	for	for	ADP
chd-130	243	12	treatment	treatment	NOUN
chd-130	243	13	(	(	PUNCT
chd-130	243	14	leone	leone	NOUN
chd-130	243	15	et	et	PROPN
chd-130	243	16	al	al	PROPN
chd-130	243	17	.	.	PROPN
chd-130	243	18	,	,	PUNCT
chd-130	243	19	2006	2006	NUM
chd-130	243	20	)	)	PUNCT
chd-130	243	21	.	.	PUNCT
chd-130	244	1	that	that	DET
chd-130	244	2	same	same	ADJ
chd-130	244	3	year	year	NOUN
chd-130	244	4	,	,	PUNCT
chd-130	244	5	a	a	DET
chd-130	244	6	chinese	chinese	ADJ
chd-130	244	7	study	study	NOUN
chd-130	244	8	reported	report	VERB
chd-130	244	9	that	that	SCONJ
chd-130	244	10	p53	p53	NOUN
chd-130	244	11	vascular	vascular	ADJ
chd-130	244	12	endothelial	endothelial	ADJ
chd-130	244	13	growth	growth	NOUN
chd-130	244	14	factor	factor	NOUN
chd-130	244	15	(	(	PUNCT
chd-130	244	16	vegf	vegf	PROPN
chd-130	244	17	)	)	PUNCT
chd-130	244	18	,	,	PUNCT
chd-130	244	19	a	a	DET
chd-130	244	20	marker	marker	NOUN
chd-130	244	21	for	for	ADP
chd-130	244	22	angiogenesis	angiogenesis	NOUN
chd-130	244	23	)	)	PUNCT
chd-130	244	24	pathway	pathway	NOUN
chd-130	244	25	potentially	potentially	ADV
chd-130	244	26	played	play	VERB
chd-130	244	27	a	a	DET
chd-130	244	28	role	role	NOUN
chd-130	244	29	in	in	ADP
chd-130	244	30	regulating	regulate	VERB
chd-130	244	31	tumor	tumor	NOUN
chd-130	244	32	angiogenesis	angiogenesis	NOUN
chd-130	244	33	in	in	ADP
chd-130	244	34	gbc	gbc	PROPN
chd-130	244	35	(	(	PUNCT
chd-130	244	36	tian	tian	PROPN
chd-130	244	37	et	et	PROPN
chd-130	244	38	al	al	PROPN
chd-130	244	39	.	.	PROPN
chd-130	244	40	,	,	PUNCT
chd-130	244	41	2006	2006	NUM
chd-130	244	42	)	)	PUNCT
chd-130	244	43	.	.	PUNCT
chd-130	245	1	this	this	DET
chd-130	245	2	study	study	NOUN
chd-130	245	3	suggested	suggest	VERB
chd-130	245	4	that	that	SCONJ
chd-130	245	5	analyzing	analyze	VERB
chd-130	245	6	the	the	DET
chd-130	245	7	expressions	expression	NOUN
chd-130	245	8	of	of	ADP
chd-130	245	9	the	the	DET
chd-130	245	10	p53	p53	NOUN
chd-130	245	11	as	as	ADV
chd-130	245	12	well	well	ADV
chd-130	245	13	as	as	ADP
chd-130	245	14	the	the	DET
chd-130	245	15	vegf	vegf	NOUN
chd-130	245	16	genes	gene	NOUN
chd-130	245	17	could	could	AUX
chd-130	245	18	be	be	AUX
chd-130	245	19	useful	useful	ADJ
chd-130	245	20	in	in	ADP
chd-130	245	21	predicting	predict	VERB
chd-130	245	22	the	the	DET
chd-130	245	23	tumor	tumor	NOUN
chd-130	245	24	vascularity	vascularity	NOUN
chd-130	245	25	in	in	ADP
chd-130	245	26	gbc	gbc	PROPN
chd-130	245	27	and	and	CCONJ
chd-130	245	28	targeting	target	VERB
chd-130	245	29	advanced	advanced	ADJ
chd-130	245	30	tumors	tumor	NOUN
chd-130	245	31	with	with	ADP
chd-130	245	32	anti	anti	ADJ
chd-130	245	33	-	-	ADJ
chd-130	245	34	vegf	vegf	ADJ
chd-130	245	35	inhibitors	inhibitor	NOUN
chd-130	245	36	could	could	AUX
chd-130	245	37	be	be	AUX
chd-130	245	38	a	a	DET
chd-130	245	39	good	good	ADJ
chd-130	245	40	therapeutic	therapeutic	ADJ
chd-130	245	41	strategy	strategy	NOUN
chd-130	245	42	.	.	PUNCT
chd-130	246	1	in	in	ADP
chd-130	246	2	order	order	NOUN
chd-130	246	3	to	to	PART
chd-130	246	4	better	well	ADV
chd-130	246	5	understand	understand	VERB
chd-130	246	6	the	the	DET
chd-130	246	7	underlying	underlying	ADJ
chd-130	246	8	mechanisms	mechanism	NOUN
chd-130	246	9	of	of	ADP
chd-130	246	10	tumor	tumor	NOUN
chd-130	246	11	development	development	NOUN
chd-130	246	12	and	and	CCONJ
chd-130	246	13	progression	progression	NOUN
chd-130	246	14	and	and	CCONJ
chd-130	246	15	to	to	PART
chd-130	246	16	improve	improve	VERB
chd-130	246	17	the	the	DET
chd-130	246	18	prognosis	prognosis	NOUN
chd-130	246	19	of	of	ADP
chd-130	246	20	gbc	gbc	PROPN
chd-130	246	21	patients	patient	NOUN
chd-130	246	22	,	,	PUNCT
chd-130	246	23	an	an	DET
chd-130	246	24	austrian	austrian	ADJ
chd-130	246	25	study	study	NOUN
chd-130	246	26	observed	observe	VERB
chd-130	246	27	an	an	DET
chd-130	246	28	increased	increase	VERB
chd-130	246	29	expression	expression	NOUN
chd-130	246	30	in	in	ADP
chd-130	246	31	the	the	DET
chd-130	246	32	her2	her2	PROPN
chd-130	246	33	/	/	SYM
chd-130	246	34	neu	neu	PROPN
chd-130	246	35	gene	gene	NOUN
chd-130	246	36	which	which	PRON
chd-130	246	37	clinically	clinically	ADV
chd-130	246	38	and	and	CCONJ
chd-130	246	39	statistically	statistically	ADV
chd-130	246	40	correlated	correlate	VERB
chd-130	246	41	with	with	ADP
chd-130	246	42	advanced	advanced	ADJ
chd-130	246	43	disease	disease	NOUN
chd-130	246	44	(	(	PUNCT
chd-130	246	45	puhalla	puhalla	NOUN
chd-130	246	46	et	et	NOUN
chd-130	246	47	al	al	PROPN
chd-130	246	48	.	.	PROPN
chd-130	246	49	,	,	PUNCT
chd-130	246	50	2007	2007	NUM
chd-130	246	51	)	)	PUNCT
chd-130	246	52	.	.	PUNCT
chd-130	247	1	in	in	ADP
chd-130	247	2	various	various	ADJ
chd-130	247	3	cancer	cancer	NOUN
chd-130	247	4	types	type	NOUN
chd-130	247	5	,	,	PUNCT
chd-130	247	6	it	it	PRON
chd-130	247	7	has	have	AUX
chd-130	247	8	been	be	AUX
chd-130	247	9	shown	show	VERB
chd-130	247	10	that	that	SCONJ
chd-130	247	11	p110alpha	p110alpha	ADJ
chd-130	247	12	catalytic	catalytic	ADJ
chd-130	247	13	subunit	subunit	NOUN
chd-130	247	14	of	of	ADP
chd-130	247	15	phosphatidylinositol	phosphatidylinositol	NOUN
chd-130	247	16	3	3	NUM
chd-130	247	17	-	-	PUNCT
chd-130	247	18	kinase	kinase	NOUN
chd-130	247	19	(	(	PUNCT
chd-130	247	20	pi3k	pi3k	PROPN
chd-130	247	21	)	)	PUNCT
chd-130	247	22	,	,	PUNCT
chd-130	247	23	encoded	encode	VERB
chd-130	247	24	by	by	ADP
chd-130	247	25	the	the	DET
chd-130	247	26	pik3ca	pik3ca	PROPN
chd-130	247	27	gene	gene	NOUN
chd-130	247	28	harbor	harbor	NOUN
chd-130	247	29	somatic	somatic	ADJ
chd-130	247	30	mutations	mutation	NOUN
chd-130	247	31	.	.	PUNCT
chd-130	248	1	exons	exon	NOUN
chd-130	248	2	9	9	NUM
chd-130	248	3	and	and	CCONJ
chd-130	248	4	20	20	NUM
chd-130	248	5	which	which	PRON
chd-130	248	6	encode	encode	VERB
chd-130	248	7	the	the	DET
chd-130	248	8	helical	helical	ADJ
chd-130	248	9	and	and	CCONJ
chd-130	248	10	kinase	kinase	NOUN
chd-130	248	11	domains	domain	NOUN
chd-130	248	12	of	of	ADP
chd-130	248	13	the	the	DET
chd-130	248	14	p110alpha	p110alpha	NOUN
chd-130	248	15	are	be	AUX
chd-130	248	16	the	the	DET
chd-130	248	17	major	major	ADJ
chd-130	248	18	hotspots	hotspot	NOUN
chd-130	248	19	for	for	ADP
chd-130	248	20	clusters	cluster	NOUN
chd-130	248	21	of	of	ADP
chd-130	248	22	genetic	genetic	ADJ
chd-130	248	23	mutations	mutation	NOUN
chd-130	248	24	.	.	PUNCT
chd-130	249	1	another	another	DET
chd-130	249	2	group	group	NOUN
chd-130	249	3	based	base	VERB
chd-130	249	4	in	in	ADP
chd-130	249	5	switzerland	switzerland	PROPN
chd-130	249	6	also	also	ADV
chd-130	249	7	reported	report	VERB
chd-130	249	8	that	that	SCONJ
chd-130	249	9	somatic	somatic	ADJ
chd-130	249	10	mutations	mutation	NOUN
chd-130	249	11	in	in	ADP
chd-130	249	12	the	the	DET
chd-130	249	13	pik3ca	pik3ca	PROPN
chd-130	249	14	gene	gene	NOUN
chd-130	249	15	resulted	result	VERB
chd-130	249	16	in	in	ADP
chd-130	249	17	recurrent	recurrent	ADJ
chd-130	249	18	activations	activation	NOUN
chd-130	249	19	of	of	ADP
chd-130	249	20	the	the	DET
chd-130	249	21	pi3k	pi3k	PROPN
chd-130	249	22	/	/	SYM
chd-130	249	23	akt	akt	PROPN
chd-130	249	24	pathway	pathway	NOUN
chd-130	249	25	in	in	ADP
chd-130	249	26	a	a	DET
chd-130	249	27	very	very	ADV
chd-130	249	28	small	small	ADJ
chd-130	249	29	sub	sub	NOUN
chd-130	249	30	-	-	ADJ
chd-130	249	31	set	set	ADJ
chd-130	249	32	of	of	ADP
chd-130	249	33	carcinomas	carcinoma	NOUN
chd-130	249	34	of	of	ADP
chd-130	249	35	the	the	DET
chd-130	249	36	gallbladder	gallbladder	NOUN
chd-130	249	37	(	(	PUNCT
chd-130	249	38	riener	riener	PROPN
chd-130	249	39	et	et	PROPN
chd-130	249	40	al	al	PROPN
chd-130	249	41	.	.	PROPN
chd-130	249	42	,	,	PUNCT
chd-130	249	43	2008	2008	NUM
chd-130	249	44	)	)	PUNCT
chd-130	249	45	.	.	PUNCT
chd-130	250	1	having	having	AUX
chd-130	250	2	realized	realize	VERB
chd-130	250	3	the	the	DET
chd-130	250	4	limitations	limitation	NOUN
chd-130	250	5	in	in	ADP
chd-130	250	6	treatment	treatment	NOUN
chd-130	250	7	options	option	NOUN
chd-130	250	8	other	other	ADJ
chd-130	250	9	than	than	ADP
chd-130	250	10	surgical	surgical	ADJ
chd-130	250	11	resection	resection	NOUN
chd-130	250	12	(	(	PUNCT
chd-130	250	13	which	which	PRON
chd-130	250	14	was	be	AUX
chd-130	250	15	an	an	DET
chd-130	250	16	unfavorable	unfavorable	ADJ
chd-130	250	17	prognostic	prognostic	ADJ
chd-130	250	18	marker	marker	NOUN
chd-130	250	19	)	)	PUNCT
chd-130	250	20	,	,	PUNCT
chd-130	250	21	a	a	DET
chd-130	250	22	group	group	NOUN
chd-130	250	23	of	of	ADP
chd-130	250	24	surgeons	surgeon	NOUN
chd-130	250	25	in	in	ADP
chd-130	250	26	japan	japan	PROPN
chd-130	250	27	identified	identify	VERB
chd-130	250	28	cellular	cellular	ADJ
chd-130	250	29	targets	target	NOUN
chd-130	250	30	that	that	PRON
chd-130	250	31	were	be	AUX
chd-130	250	32	gbc	gbc	NOUN
chd-130	250	33	specific	specific	ADJ
chd-130	250	34	and	and	CCONJ
chd-130	250	35	which	which	PRON
chd-130	250	36	could	could	AUX
chd-130	250	37	potentially	potentially	ADV
chd-130	250	38	be	be	AUX
chd-130	250	39	used	use	VERB
chd-130	250	40	as	as	ADP
chd-130	250	41	a	a	DET
chd-130	250	42	therapeutic	therapeutic	ADJ
chd-130	250	43	approach	approach	NOUN
chd-130	250	44	for	for	ADP
chd-130	250	45	the	the	DET
chd-130	250	46	disease	disease	NOUN
chd-130	250	47	.	.	PUNCT
chd-130	251	1	they	they	PRON
chd-130	251	2	identified	identify	VERB
chd-130	251	3	a	a	DET
chd-130	251	4	cell	cell	NOUN
chd-130	251	5	cycle	cycle	NOUN
chd-130	251	6	-	-	PUNCT
chd-130	251	7	related	relate	VERB
chd-130	251	8	gene	gene	NOUN
chd-130	251	9	,	,	PUNCT
chd-130	251	10	topoisomerase	topoisomerase	NOUN
chd-130	251	11	iialpha	iialpha	NOUN
chd-130	251	12	(	(	PUNCT
chd-130	251	13	topo	topo	PROPN
chd-130	251	14	iialpha	iialpha	PROPN
chd-130	251	15	)	)	PUNCT
chd-130	251	16	as	as	ADP
chd-130	251	17	one	one	NUM
chd-130	251	18	of	of	ADP
chd-130	251	19	the	the	DET
chd-130	251	20	highly	highly	ADV
chd-130	251	21	upregulated	upregulated	ADJ
chd-130	251	22	gene	gene	NOUN
chd-130	251	23	in	in	ADP
chd-130	251	24	gbc	gbc	NOUN
chd-130	251	25	tissue	tissue	NOUN
chd-130	251	26	which	which	PRON
chd-130	251	27	they	they	PRON
chd-130	251	28	further	far	ADV
chd-130	251	29	confirmed	confirm	VERB
chd-130	251	30	as	as	ADP
chd-130	251	31	a	a	DET
chd-130	251	32	potential	potential	ADJ
chd-130	251	33	chemotherapeutic	chemotherapeutic	ADJ
chd-130	251	34	target	target	NOUN
chd-130	251	35	,	,	PUNCT
chd-130	251	36	because	because	SCONJ
chd-130	251	37	those	those	DET
chd-130	251	38	cells	cell	NOUN
chd-130	251	39	strongly	strongly	ADV
chd-130	251	40	positive	positive	ADJ
chd-130	251	41	for	for	ADP
chd-130	251	42	topo	topo	PROPN
chd-130	251	43	iialpha	iialpha	PROPN
chd-130	251	44	had	have	AUX
chd-130	251	45	shown	show	VERB
chd-130	251	46	increased	increase	VERB
chd-130	251	47	sensitivity	sensitivity	NOUN
chd-130	251	48	against	against	ADP
chd-130	251	49	etoposide	etoposide	NOUN
chd-130	251	50	,	,	PUNCT
chd-130	251	51	as	as	ADV
chd-130	251	52	well	well	ADV
chd-130	251	53	as	as	ADP
chd-130	251	54	doxorubicin	doxorubicin	PROPN
chd-130	251	55	and	and	CCONJ
chd-130	251	56	idarubicin	idarubicin	PROPN
chd-130	251	57	(	(	PUNCT
chd-130	251	58	washiro	washiro	NOUN
chd-130	251	59	et	et	PROPN
chd-130	251	60	al	al	PROPN
chd-130	251	61	.	.	PROPN
chd-130	251	62	,	,	PUNCT
chd-130	251	63	2008	2008	NUM
chd-130	251	64	)	)	PUNCT
chd-130	251	65	.	.	PUNCT
chd-130	252	1	in	in	ADP
chd-130	252	2	the	the	DET
chd-130	252	3	subsequent	subsequent	ADJ
chd-130	252	4	year	year	NOUN
chd-130	252	5	,	,	PUNCT
chd-130	252	6	another	another	DET
chd-130	252	7	japanese	japanese	ADJ
chd-130	252	8	group	group	NOUN
chd-130	252	9	demonstrated	demonstrate	VERB
chd-130	252	10	genomic	genomic	ADJ
chd-130	252	11	instability	instability	NOUN
chd-130	252	12	due	due	ADP
chd-130	252	13	to	to	ADP
chd-130	252	14	amplification	amplification	NOUN
chd-130	252	15	in	in	ADP
chd-130	252	16	myc	myc	PROPN
chd-130	252	17	oncogene	oncogene	NOUN
chd-130	252	18	which	which	PRON
chd-130	252	19	resulted	result	VERB
chd-130	252	20	in	in	ADP
chd-130	252	21	specific	specific	ADJ
chd-130	252	22	amplification	amplification	NOUN
chd-130	252	23	of	of	ADP
chd-130	252	24	egfr	egfr	NOUN
chd-130	252	25	and/or	and/or	CCONJ
chd-130	252	26	erbb2	erbb2	NOUN
chd-130	252	27	in	in	ADP
chd-130	252	28	gbc	gbc	PROPN
chd-130	252	29	(	(	PUNCT
chd-130	252	30	ooi	ooi	PROPN
chd-130	252	31	et	et	PROPN
chd-130	252	32	al	al	PROPN
chd-130	252	33	.	.	PROPN
chd-130	252	34	,	,	PUNCT
chd-130	252	35	2009	2009	NUM
chd-130	252	36	)	)	PUNCT
chd-130	252	37	.	.	PUNCT
chd-130	253	1	another	another	DET
chd-130	253	2	in	in	ADP
chd-130	253	3	-	-	PUNCT
chd-130	253	4	vitro	vitro	X
chd-130	253	5	study	study	NOUN
chd-130	253	6	used	use	VERB
chd-130	253	7	a	a	DET
chd-130	253	8	combination	combination	NOUN
chd-130	253	9	of	of	ADP
chd-130	253	10	a	a	DET
chd-130	253	11	histone	histone	NOUN
chd-130	253	12	deacetylase	deacetylase	NOUN
chd-130	253	13	inhibitor	inhibitor	NOUN
chd-130	253	14	(	(	PUNCT
chd-130	253	15	saha	saha	PROPN
chd-130	253	16	)	)	PUNCT
chd-130	253	17	with	with	ADP
chd-130	253	18	repression	repression	NOUN
chd-130	253	19	of	of	ADP
chd-130	253	20	ezh2	ezh2	NOUN
chd-130	253	21	by	by	ADP
chd-130	253	22	sirna	sirna	PROPN
chd-130	253	23	treatment	treatment	NOUN
chd-130	253	24	which	which	PRON
chd-130	253	25	revealed	reveal	VERB
chd-130	253	26	an	an	DET
chd-130	253	27	increased	increase	VERB
chd-130	253	28	sensitivity	sensitivity	NOUN
chd-130	253	29	of	of	ADP
chd-130	253	30	the	the	DET
chd-130	253	31	gbc	gbc	PROPN
chd-130	253	32	cells	cell	NOUN
chd-130	253	33	to	to	AUX
chd-130	253	34	saha	saha	PROPN
chd-130	253	35	as	as	SCONJ
chd-130	253	36	opposed	oppose	VERB
chd-130	253	37	to	to	ADP
chd-130	253	38	the	the	DET
chd-130	253	39	normal	normal	ADJ
chd-130	253	40	cells	cell	NOUN
chd-130	253	41	.	.	PUNCT
chd-130	254	1	this	this	PRON
chd-130	254	2	was	be	AUX
chd-130	254	3	then	then	ADV
chd-130	254	4	considered	consider	VERB
chd-130	254	5	to	to	PART
chd-130	254	6	be	be	AUX
chd-130	254	7	indicative	indicative	ADJ
chd-130	254	8	of	of	ADP
chd-130	254	9	the	the	DET
chd-130	254	10	efficacy	efficacy	NOUN
chd-130	254	11	of	of	ADP
chd-130	254	12	the	the	DET
chd-130	254	13	new	new	ADJ
chd-130	254	14	anticancer	anticancer	NOUN
chd-130	254	15	agent	agent	NOUN
chd-130	254	16	(	(	PUNCT
chd-130	254	17	yamaguchi	yamaguchi	PROPN
chd-130	254	18	et	et	PROPN
chd-130	254	19	al	al	PROPN
chd-130	254	20	.	.	PROPN
chd-130	254	21	,	,	PUNCT
chd-130	254	22	2010	2010	NUM
chd-130	254	23	)	)	PUNCT
chd-130	254	24	.	.	PUNCT
chd-130	255	1	in	in	ADP
chd-130	255	2	a	a	DET
chd-130	255	3	significant	significant	ADJ
chd-130	255	4	study	study	NOUN
chd-130	255	5	to	to	PART
chd-130	255	6	evaluate	evaluate	VERB
chd-130	255	7	the	the	DET
chd-130	255	8	response	response	NOUN
chd-130	255	9	rate	rate	NOUN
chd-130	255	10	by	by	ADP
chd-130	255	11	response	response	NOUN
chd-130	255	12	evaluation	evaluation	NOUN
chd-130	255	13	criteria	criterion	NOUN
chd-130	255	14	in	in	ADP
chd-130	255	15	solid	solid	ADJ
chd-130	255	16	tumors	tumor	NOUN
chd-130	255	17	(	(	PUNCT
chd-130	255	18	recist	recist	NOUN
chd-130	255	19	)	)	PUNCT
chd-130	255	20	of	of	ADP
chd-130	255	21	targeted	target	VERB
chd-130	255	22	therapy	therapy	NOUN
chd-130	255	23	in	in	ADP
chd-130	255	24	biliary	biliary	ADJ
chd-130	255	25	cancers	cancer	NOUN
chd-130	255	26	which	which	PRON
chd-130	255	27	included	include	VERB
chd-130	255	28	gbc	gbc	PROPN
chd-130	255	29	,	,	PUNCT
chd-130	255	30	eligible	eligible	ADJ
chd-130	255	31	patients	patient	NOUN
chd-130	255	32	(	(	PUNCT
chd-130	255	33	10	10	NUM
chd-130	255	34	patients	patient	NOUN
chd-130	255	35	with	with	ADP
chd-130	255	36	gbc	gbc	PROPN
chd-130	255	37	)	)	PUNCT
chd-130	255	38	were	be	AUX
chd-130	255	39	treated	treat	VERB
chd-130	255	40	with	with	ADP
chd-130	255	41	bevacizumab	bevacizumab	NOUN
chd-130	255	42	(	(	PUNCT
chd-130	255	43	a	a	DET
chd-130	255	44	vegf	vegf	PROPN
chd-130	255	45	inhibitor	inhibitor	NOUN
chd-130	255	46	)	)	PUNCT
chd-130	255	47	and	and	CCONJ
chd-130	255	48	erlotinib	erlotinib	NOUN
chd-130	255	49	(	(	PUNCT
chd-130	255	50	egfr	egfr	ADJ
chd-130	255	51	inhibitor	inhibitor	NOUN
chd-130	255	52	)	)	PUNCT
chd-130	255	53	in	in	ADP
chd-130	255	54	combination	combination	NOUN
chd-130	255	55	with	with	ADP
chd-130	255	56	chemotherapy	chemotherapy	NOUN
chd-130	255	57	.	.	PUNCT
chd-130	256	1	using	use	VERB
chd-130	256	2	a	a	DET
chd-130	256	3	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PUNCT
chd-130	256	4	e16	e16	NOUN
chd-130	256	5	cancer	cancer	NOUN
chd-130	256	6	health	health	NOUN
chd-130	256	7	disparities	disparity	NOUN
chd-130	256	8	research	research	NOUN
chd-130	256	9	combination	combination	NOUN
chd-130	256	10	chemotherapy	chemotherapy	NOUN
chd-130	256	11	of	of	ADP
chd-130	256	12	bevacizumab	bevacizumab	NOUN
chd-130	256	13	with	with	ADP
chd-130	256	14	erlotinib	erlotinib	NOUN
chd-130	256	15	resulted	result	VERB
chd-130	256	16	in	in	ADP
chd-130	256	17	clinical	clinical	ADJ
chd-130	256	18	activity	activity	NOUN
chd-130	256	19	with	with	ADP
chd-130	256	20	infrequent	infrequent	ADJ
chd-130	256	21	grade	grade	NOUN
chd-130	256	22	3	3	NUM
chd-130	256	23	and	and	CCONJ
chd-130	256	24	4	4	NUM
chd-130	256	25	adverse	adverse	ADJ
chd-130	256	26	effects	effect	NOUN
chd-130	256	27	in	in	ADP
chd-130	256	28	advanced	advanced	ADJ
chd-130	256	29	gbc	gbc	PROPN
chd-130	256	30	cases	case	NOUN
chd-130	256	31	.	.	PUNCT
chd-130	257	1	preliminary	preliminary	ADJ
chd-130	257	2	molecular	molecular	ADJ
chd-130	257	3	analysis	analysis	NOUN
chd-130	257	4	showed	show	VERB
chd-130	257	5	that	that	SCONJ
chd-130	257	6	presence	presence	NOUN
chd-130	257	7	of	of	ADP
chd-130	257	8	a	a	DET
chd-130	257	9	mutation	mutation	NOUN
chd-130	257	10	in	in	ADP
chd-130	257	11	the	the	DET
chd-130	257	12	k	k	PROPN
chd-130	257	13	-	-	PUNCT
chd-130	257	14	ras	ras	ADJ
chd-130	257	15	oncogene	oncogene	NOUN
chd-130	257	16	altered	alter	VERB
chd-130	257	17	the	the	DET
chd-130	257	18	efficacy	efficacy	NOUN
chd-130	257	19	of	of	ADP
chd-130	257	20	erlotinib	erlotinib	PROPN
chd-130	257	21	.	.	PUNCT
chd-130	258	1	though	though	SCONJ
chd-130	258	2	a	a	DET
chd-130	258	3	small	small	ADJ
chd-130	258	4	study	study	NOUN
chd-130	258	5	in	in	ADP
chd-130	258	6	sample	sample	NOUN
chd-130	258	7	size	size	NOUN
chd-130	258	8	(	(	PUNCT
chd-130	258	9	only	only	ADV
chd-130	258	10	10	10	NUM
chd-130	258	11	cases	case	NOUN
chd-130	258	12	of	of	ADP
chd-130	258	13	gbc	gbc	NOUN
chd-130	258	14	)	)	PUNCT
chd-130	258	15	,	,	PUNCT
chd-130	258	16	results	result	VERB
chd-130	258	17	clearly	clearly	ADV
chd-130	258	18	warrant	warrant	VERB
chd-130	258	19	a	a	DET
chd-130	258	20	larger	large	ADJ
chd-130	258	21	study	study	NOUN
chd-130	258	22	in	in	ADP
chd-130	258	23	future	future	NOUN
chd-130	258	24	on	on	ADP
chd-130	258	25	a	a	DET
chd-130	258	26	bigger	big	ADJ
chd-130	258	27	cohort	cohort	NOUN
chd-130	258	28	of	of	ADP
chd-130	258	29	gbc	gbc	PROPN
chd-130	258	30	patients	patient	NOUN
chd-130	258	31	to	to	PART
chd-130	258	32	investigate	investigate	VERB
chd-130	258	33	the	the	DET
chd-130	258	34	efficacious	efficacious	ADJ
chd-130	258	35	performance	performance	NOUN
chd-130	258	36	of	of	ADP
chd-130	258	37	bevacizumab	bevacizumab	NOUN
chd-130	258	38	and	and	CCONJ
chd-130	258	39	erlotinib	erlotinib	PROPN
chd-130	258	40	when	when	SCONJ
chd-130	258	41	used	use	VERB
chd-130	258	42	together	together	ADV
chd-130	258	43	,	,	PUNCT
chd-130	258	44	as	as	ADP
chd-130	258	45	an	an	DET
chd-130	258	46	alternative	alternative	ADJ
chd-130	258	47	treatment	treatment	NOUN
chd-130	258	48	option	option	NOUN
chd-130	258	49	for	for	ADP
chd-130	258	50	patients	patient	NOUN
chd-130	258	51	with	with	ADP
chd-130	258	52	advanced	advanced	ADJ
chd-130	258	53	gbc	gbc	PROPN
chd-130	258	54	(	(	PUNCT
chd-130	258	55	lubner	lubner	NOUN
chd-130	258	56	et	et	PROPN
chd-130	258	57	al	al	PROPN
chd-130	258	58	.	.	PROPN
chd-130	258	59	,	,	PUNCT
chd-130	258	60	2010	2010	NUM
chd-130	258	61	)	)	PUNCT
chd-130	258	62	.	.	PUNCT
chd-130	259	1	in	in	ADP
chd-130	259	2	an	an	DET
chd-130	259	3	independent	independent	ADJ
chd-130	259	4	but	but	CCONJ
chd-130	259	5	encouraging	encourage	VERB
chd-130	259	6	small	small	ADJ
chd-130	259	7	case	case	NOUN
chd-130	259	8	report	report	NOUN
chd-130	259	9	,	,	PUNCT
chd-130	259	10	the	the	DET
chd-130	259	11	idea	idea	NOUN
chd-130	259	12	of	of	ADP
chd-130	259	13	using	use	VERB
chd-130	259	14	egfr	egfr	ADJ
chd-130	259	15	-	-	PUNCT
chd-130	259	16	tyrosine	tyrosine	NOUN
chd-130	259	17	kinase	kinase	PROPN
chd-130	259	18	inhibitor	inhibitor	PROPN
chd-130	259	19	(	(	PUNCT
chd-130	259	20	tki	tki	NOUN
chd-130	259	21	)	)	PUNCT
chd-130	259	22	in	in	ADP
chd-130	259	23	combination	combination	NOUN
chd-130	259	24	with	with	ADP
chd-130	259	25	conventional	conventional	ADJ
chd-130	259	26	chemotherapy	chemotherapy	NOUN
chd-130	259	27	was	be	AUX
chd-130	259	28	tested	test	VERB
chd-130	259	29	to	to	PART
chd-130	259	30	treat	treat	VERB
chd-130	259	31	gallbladder	gallbladder	NOUN
chd-130	259	32	cancer	cancer	NOUN
chd-130	259	33	in	in	ADP
chd-130	259	34	the	the	DET
chd-130	259	35	us	us	PROPN
chd-130	259	36	based	base	VERB
chd-130	259	37	hospital	hospital	NOUN
chd-130	259	38	(	(	PUNCT
chd-130	259	39	mody	mody	NOUN
chd-130	259	40	et	et	PROPN
chd-130	259	41	al	al	PROPN
chd-130	259	42	.	.	PROPN
chd-130	259	43	,	,	PUNCT
chd-130	259	44	2010	2010	NUM
chd-130	259	45	)	)	PUNCT
chd-130	259	46	.	.	PUNCT
chd-130	260	1	in	in	ADP
chd-130	260	2	this	this	DET
chd-130	260	3	case	case	NOUN
chd-130	260	4	report	report	NOUN
chd-130	260	5	,	,	PUNCT
chd-130	260	6	a	a	DET
chd-130	260	7	patient	patient	NOUN
chd-130	260	8	with	with	ADP
chd-130	260	9	stage	stage	NOUN
chd-130	260	10	iv	iv	NUM
chd-130	260	11	gbc	gbc	PROPN
chd-130	260	12	was	be	AUX
chd-130	260	13	shown	show	VERB
chd-130	260	14	to	to	PART
chd-130	260	15	have	have	VERB
chd-130	260	16	complete	complete	ADJ
chd-130	260	17	and	and	CCONJ
chd-130	260	18	prolonged	prolonged	ADJ
chd-130	260	19	response	response	NOUN
chd-130	260	20	,	,	PUNCT
chd-130	260	21	a	a	PRON
chd-130	260	22	not	not	PART
chd-130	260	23	so	so	ADV
chd-130	260	24	common	common	ADJ
chd-130	260	25	observation	observation	NOUN
chd-130	260	26	in	in	ADP
chd-130	260	27	gbc	gbc	PROPN
chd-130	260	28	,	,	PUNCT
chd-130	260	29	to	to	PART
chd-130	260	30	oral	oral	ADJ
chd-130	260	31	egfr	egfr	ADJ
chd-130	260	32	-	-	PUNCT
chd-130	260	33	tki	tki	NOUN
chd-130	260	34	plus	plus	CCONJ
chd-130	260	35	chemotherapy	chemotherapy	NOUN
chd-130	260	36	regimen	regiman	NOUN
chd-130	260	37	.	.	PUNCT
chd-130	261	1	of	of	ADP
chd-130	261	2	note	note	NOUN
chd-130	261	3	,	,	PUNCT
chd-130	261	4	this	this	DET
chd-130	261	5	study	study	NOUN
chd-130	261	6	mentions	mention	VERB
chd-130	261	7	that	that	SCONJ
chd-130	261	8	this	this	DET
chd-130	261	9	rare	rare	ADJ
chd-130	261	10	response	response	NOUN
chd-130	261	11	to	to	ADP
chd-130	261	12	the	the	DET
chd-130	261	13	treatment	treatment	NOUN
chd-130	261	14	for	for	ADP
chd-130	261	15	this	this	DET
chd-130	261	16	patient	patient	NOUN
chd-130	261	17	with	with	ADP
chd-130	261	18	gbc	gbc	PROPN
chd-130	261	19	was	be	AUX
chd-130	261	20	due	due	ADJ
chd-130	261	21	to	to	ADP
chd-130	261	22	an	an	DET
chd-130	261	23	absence	absence	NOUN
chd-130	261	24	of	of	ADP
chd-130	261	25	a	a	DET
chd-130	261	26	mutation	mutation	NOUN
chd-130	261	27	in	in	ADP
chd-130	261	28	the	the	DET
chd-130	261	29	egfr	egfr	ADJ
chd-130	261	30	gene	gene	NOUN
chd-130	261	31	.	.	PUNCT
chd-130	262	1	this	this	DET
chd-130	262	2	discovery	discovery	NOUN
chd-130	262	3	should	should	AUX
chd-130	262	4	again	again	ADV
chd-130	262	5	reiterate	reiterate	VERB
chd-130	262	6	the	the	DET
chd-130	262	7	need	need	NOUN
chd-130	262	8	for	for	ADP
chd-130	262	9	clinical	clinical	ADJ
chd-130	262	10	trials	trial	NOUN
chd-130	262	11	using	use	VERB
chd-130	262	12	egfr	egfr	NOUN
chd-130	262	13	-	-	PUNCT
chd-130	262	14	tkis	tkis	NOUN
chd-130	262	15	to	to	PART
chd-130	262	16	treat	treat	VERB
chd-130	262	17	gbc	gbc	PROPN
chd-130	262	18	.	.	PUNCT
chd-130	263	1	this	this	DET
chd-130	263	2	study	study	NOUN
chd-130	263	3	also	also	ADV
chd-130	263	4	suggest	suggest	VERB
chd-130	263	5	that	that	SCONJ
chd-130	263	6	future	future	ADJ
chd-130	263	7	clinical	clinical	ADJ
chd-130	263	8	trials	trial	NOUN
chd-130	263	9	should	should	AUX
chd-130	263	10	not	not	PART
chd-130	263	11	always	always	ADV
chd-130	263	12	consider	consider	VERB
chd-130	263	13	the	the	DET
chd-130	263	14	mutation	mutation	NOUN
chd-130	263	15	status	status	NOUN
chd-130	263	16	of	of	ADP
chd-130	263	17	the	the	DET
chd-130	263	18	egfr	egfr	ADJ
chd-130	263	19	gene	gene	NOUN
chd-130	263	20	as	as	ADP
chd-130	263	21	inclusion	inclusion	NOUN
chd-130	263	22	criteria	criterion	NOUN
chd-130	263	23	(	(	PUNCT
chd-130	263	24	mody	mody	NOUN
chd-130	263	25	et	et	NOUN
chd-130	263	26	al	al	PROPN
chd-130	263	27	.	.	PROPN
chd-130	263	28	,	,	PUNCT
chd-130	263	29	2010	2010	NUM
chd-130	263	30	)	)	PUNCT
chd-130	263	31	.	.	PUNCT
chd-130	264	1	in	in	ADP
chd-130	264	2	an	an	DET
chd-130	264	3	italian	italian	ADJ
chd-130	264	4	study	study	NOUN
chd-130	264	5	,	,	PUNCT
chd-130	264	6	investigators	investigator	NOUN
chd-130	264	7	analyzed	analyze	VERB
chd-130	264	8	mutations	mutation	NOUN
chd-130	264	9	,	,	PUNCT
chd-130	264	10	amplifications	amplification	NOUN
chd-130	264	11	and	and	CCONJ
chd-130	264	12	over	over	ADP
chd-130	264	13	-	-	PUNCT
chd-130	264	14	expression	expression	NOUN
chd-130	264	15	of	of	ADP
chd-130	264	16	egfr	egfr	NOUN
chd-130	264	17	,	,	PUNCT
chd-130	264	18	her2	her2	PROPN
chd-130	264	19	,	,	PUNCT
chd-130	264	20	and	and	CCONJ
chd-130	264	21	their	their	PRON
chd-130	264	22	molecular	molecular	ADJ
chd-130	264	23	transducers	transducer	NOUN
chd-130	264	24	in	in	ADP
chd-130	264	25	biliary	biliary	ADJ
chd-130	264	26	tract	tract	NOUN
chd-130	264	27	cancers	cancer	NOUN
chd-130	264	28	so	so	SCONJ
chd-130	264	29	that	that	SCONJ
chd-130	264	30	they	they	PRON
chd-130	264	31	could	could	AUX
chd-130	264	32	explore	explore	VERB
chd-130	264	33	possibilities	possibility	NOUN
chd-130	264	34	of	of	ADP
chd-130	264	35	combining	combine	VERB
chd-130	264	36	standard	standard	ADJ
chd-130	264	37	therapies	therapy	NOUN
chd-130	264	38	with	with	ADP
chd-130	264	39	or	or	CCONJ
chd-130	264	40	without	without	ADP
chd-130	264	41	molecular	molecular	ADJ
chd-130	264	42	targeting	targeting	NOUN
chd-130	264	43	(	(	PUNCT
chd-130	264	44	pignochino	pignochino	NOUN
chd-130	264	45	et	et	PROPN
chd-130	264	46	al	al	PROPN
chd-130	264	47	.	.	PROPN
chd-130	264	48	,	,	PUNCT
chd-130	264	49	2010	2010	NUM
chd-130	264	50	)	)	PUNCT
chd-130	264	51	.	.	PUNCT
chd-130	265	1	they	they	PRON
chd-130	265	2	reported	report	VERB
chd-130	265	3	that	that	SCONJ
chd-130	265	4	egfr	egfr	PROPN
chd-130	265	5	was	be	AUX
chd-130	265	6	expressed	express	VERB
chd-130	265	7	in	in	ADP
chd-130	265	8	~38	~38	NUM
chd-130	265	9	%	%	NOUN
chd-130	265	10	of	of	ADP
chd-130	265	11	patients	patient	NOUN
chd-130	265	12	with	with	ADP
chd-130	265	13	gbc	gbc	PROPN
chd-130	265	14	.	.	PUNCT
chd-130	266	1	activated	activate	VERB
chd-130	266	2	forms	form	NOUN
chd-130	266	3	of	of	ADP
chd-130	266	4	cancer	cancer	NOUN
chd-130	266	5	relevant	relevant	ADJ
chd-130	266	6	signaling	signal	VERB
chd-130	266	7	proteins	protein	NOUN
chd-130	266	8	such	such	ADJ
chd-130	266	9	as	as	ADP
chd-130	266	10	p	p	NOUN
chd-130	266	11	-	-	PUNCT
chd-130	266	12	mapk	mapk	NOUN
chd-130	266	13	and	and	CCONJ
chd-130	266	14	p	p	PROPN
chd-130	266	15	-	-	PUNCT
chd-130	266	16	akt	akt	PROPN
chd-130	266	17	were	be	AUX
chd-130	266	18	also	also	ADV
chd-130	266	19	highly	highly	ADV
chd-130	266	20	expressed	express	VERB
chd-130	266	21	in	in	ADP
chd-130	266	22	little	little	ADJ
chd-130	266	23	less	less	ADJ
chd-130	266	24	than	than	ADP
chd-130	266	25	46	46	NUM
chd-130	266	26	%	%	NOUN
chd-130	266	27	of	of	ADP
chd-130	266	28	gbc	gbc	PROPN
chd-130	266	29	,	,	PUNCT
chd-130	266	30	hinting	hint	VERB
chd-130	266	31	at	at	ADP
chd-130	266	32	an	an	DET
chd-130	266	33	activation	activation	NOUN
chd-130	266	34	of	of	ADP
chd-130	266	35	the	the	DET
chd-130	266	36	egfr	egfr	ADJ
chd-130	266	37	pathway	pathway	NOUN
chd-130	266	38	.	.	PUNCT
chd-130	267	1	with	with	ADP
chd-130	267	2	the	the	DET
chd-130	267	3	aid	aid	NOUN
chd-130	267	4	of	of	ADP
chd-130	267	5	genomic	genomic	ADJ
chd-130	267	6	amplification	amplification	NOUN
chd-130	267	7	,	,	PUNCT
chd-130	267	8	about	about	ADV
chd-130	267	9	10	10	NUM
chd-130	267	10	%	%	NOUN
chd-130	267	11	of	of	ADP
chd-130	267	12	gbcs	gbc	NOUN
chd-130	267	13	showed	show	VERB
chd-130	267	14	an	an	DET
chd-130	267	15	overexpression	overexpression	NOUN
chd-130	267	16	of	of	ADP
chd-130	267	17	her2	her2	PROPN
chd-130	267	18	gene	gene	NOUN
chd-130	267	19	.	.	PUNCT
chd-130	268	1	they	they	PRON
chd-130	268	2	went	go	VERB
chd-130	268	3	on	on	ADP
chd-130	268	4	to	to	PART
chd-130	268	5	conduct	conduct	VERB
chd-130	268	6	a	a	DET
chd-130	268	7	preclinical	preclinical	ADJ
chd-130	268	8	in	in	ADP
chd-130	268	9	-	-	PUNCT
chd-130	268	10	vitro	vitro	X
chd-130	268	11	study	study	NOUN
chd-130	268	12	using	use	VERB
chd-130	268	13	tgbc1tkb	tgbc1tkb	PROPN
chd-130	268	14	,	,	PUNCT
chd-130	268	15	a	a	DET
chd-130	268	16	gbc	gbc	NOUN
chd-130	268	17	cell	cell	NOUN
chd-130	268	18	line	line	NOUN
chd-130	268	19	(	(	PUNCT
chd-130	268	20	deleted	delete	VERB
chd-130	268	21	on	on	ADP
chd-130	268	22	pten	pten	NOUN
chd-130	268	23	and	and	CCONJ
chd-130	268	24	negative	negative	ADJ
chd-130	268	25	for	for	ADP
chd-130	268	26	her2	her2	NOUN
chd-130	268	27	expression	expression	NOUN
chd-130	268	28	)	)	PUNCT
chd-130	268	29	for	for	ADP
chd-130	268	30	testing	test	VERB
chd-130	268	31	the	the	DET
chd-130	268	32	efficacy	efficacy	NOUN
chd-130	268	33	of	of	ADP
chd-130	268	34	the	the	DET
chd-130	268	35	drugs	drug	NOUN
chd-130	268	36	either	either	CCONJ
chd-130	268	37	alone	alone	ADJ
chd-130	268	38	or	or	CCONJ
chd-130	268	39	in	in	ADP
chd-130	268	40	combination	combination	NOUN
chd-130	268	41	with	with	ADP
chd-130	268	42	gemcitabine	gemcitabine	NOUN
chd-130	268	43	,	,	PUNCT
chd-130	268	44	targeting	target	VERB
chd-130	268	45	the	the	DET
chd-130	268	46	aforementioned	aforementioned	ADJ
chd-130	268	47	molecules	molecule	NOUN
chd-130	268	48	.	.	PUNCT
chd-130	269	1	this	this	DET
chd-130	269	2	study	study	NOUN
chd-130	269	3	also	also	ADV
chd-130	269	4	demonstrated	demonstrate	VERB
chd-130	269	5	that	that	SCONJ
chd-130	269	6	the	the	DET
chd-130	269	7	her2	her2	PROPN
chd-130	269	8	and	and	CCONJ
chd-130	269	9	egfr	egfr	ADJ
chd-130	269	10	pathways	pathway	NOUN
chd-130	269	11	could	could	AUX
chd-130	269	12	pose	pose	VERB
chd-130	269	13	to	to	PART
chd-130	269	14	be	be	AUX
chd-130	269	15	potential	potential	ADJ
chd-130	269	16	therapeutic	therapeutic	ADJ
chd-130	269	17	targets	target	NOUN
chd-130	269	18	for	for	ADP
chd-130	269	19	biliary	biliary	ADJ
chd-130	269	20	tract	tract	NOUN
chd-130	269	21	cancers	cancer	NOUN
chd-130	269	22	(	(	PUNCT
chd-130	269	23	btcs	btcs	NOUN
chd-130	269	24	)	)	PUNCT
chd-130	269	25	.	.	PUNCT
chd-130	270	1	the	the	DET
chd-130	270	2	combination	combination	NOUN
chd-130	270	3	of	of	ADP
chd-130	270	4	gemcitabine	gemcitabine	NOUN
chd-130	270	5	with	with	ADP
chd-130	270	6	gefitinib	gefitinib	NOUN
chd-130	270	7	and	and	CCONJ
chd-130	270	8	lapatinib	lapatinib	NOUN
chd-130	270	9	(	(	PUNCT
chd-130	270	10	both	both	PRON
chd-130	270	11	of	of	ADP
chd-130	270	12	which	which	PRON
chd-130	270	13	are	be	AUX
chd-130	270	14	reversible	reversible	ADJ
chd-130	270	15	selective	selective	ADJ
chd-130	270	16	inhibitors	inhibitor	NOUN
chd-130	270	17	of	of	ADP
chd-130	270	18	the	the	DET
chd-130	270	19	tyrosine	tyrosine	NOUN
chd-130	270	20	kinase	kinase	PROPN
chd-130	270	21	domain	domain	NOUN
chd-130	270	22	of	of	ADP
chd-130	270	23	egfr	egfr	NOUN
chd-130	270	24	and	and	CCONJ
chd-130	270	25	drugs	drug	NOUN
chd-130	270	26	known	know	VERB
chd-130	270	27	to	to	PART
chd-130	270	28	target	target	VERB
chd-130	270	29	her2	her2	PROPN
chd-130	270	30	and	and	CCONJ
chd-130	270	31	egfr	egfr	ADJ
chd-130	270	32	pathways	pathway	NOUN
chd-130	270	33	)	)	PUNCT
chd-130	270	34	appeared	appear	VERB
chd-130	270	35	to	to	PART
chd-130	270	36	have	have	VERB
chd-130	270	37	encouraging	encourage	VERB
chd-130	270	38	results	result	NOUN
chd-130	270	39	and	and	CCONJ
chd-130	270	40	thus	thus	ADV
chd-130	270	41	warrants	warrant	NOUN
chd-130	270	42	for	for	ADP
chd-130	270	43	further	further	ADJ
chd-130	270	44	clinical	clinical	ADJ
chd-130	270	45	studies	study	NOUN
chd-130	270	46	for	for	ADP
chd-130	270	47	testing	test	VERB
chd-130	270	48	the	the	DET
chd-130	270	49	expression	expression	NOUN
chd-130	270	50	levels	level	NOUN
chd-130	270	51	and	and	CCONJ
chd-130	270	52	mutations	mutation	NOUN
chd-130	270	53	in	in	ADP
chd-130	270	54	these	these	DET
chd-130	270	55	signaling	signal	VERB
chd-130	270	56	molecules	molecule	NOUN
chd-130	270	57	in	in	ADP
chd-130	270	58	future	future	ADJ
chd-130	270	59	clinical	clinical	ADJ
chd-130	270	60	studies	study	NOUN
chd-130	270	61	(	(	PUNCT
chd-130	270	62	pignochino	pignochino	NOUN
chd-130	270	63	et	et	PROPN
chd-130	270	64	al	al	PROPN
chd-130	270	65	.	.	PROPN
chd-130	270	66	,	,	PUNCT
chd-130	270	67	2010	2010	NUM
chd-130	270	68	)	)	PUNCT
chd-130	270	69	.	.	PUNCT
chd-130	271	1	while	while	SCONJ
chd-130	271	2	developing	develop	VERB
chd-130	271	3	strategies	strategy	NOUN
chd-130	271	4	to	to	PART
chd-130	271	5	target	target	VERB
chd-130	271	6	gbc	gbc	NOUN
chd-130	271	7	molecularly	molecularly	ADV
chd-130	271	8	,	,	PUNCT
chd-130	271	9	it	it	PRON
chd-130	271	10	is	be	AUX
chd-130	271	11	important	important	ADJ
chd-130	271	12	to	to	PART
chd-130	271	13	understand	understand	VERB
chd-130	271	14	the	the	DET
chd-130	271	15	subtle	subtle	ADJ
chd-130	271	16	changes	change	NOUN
chd-130	271	17	at	at	ADP
chd-130	271	18	the	the	DET
chd-130	271	19	molecular	molecular	ADJ
chd-130	271	20	/	/	SYM
chd-130	271	21	genetic	genetic	ADJ
chd-130	271	22	level	level	NOUN
chd-130	271	23	between	between	ADP
chd-130	271	24	gbc	gbc	PROPN
chd-130	271	25	and	and	CCONJ
chd-130	271	26	other	other	ADJ
chd-130	271	27	related	related	ADJ
chd-130	271	28	cancers	cancer	NOUN
chd-130	271	29	.	.	PUNCT
chd-130	272	1	although	although	SCONJ
chd-130	272	2	they	they	PRON
chd-130	272	3	are	be	AUX
chd-130	272	4	histologically	histologically	ADV
chd-130	272	5	similar	similar	ADJ
chd-130	272	6	,	,	PUNCT
chd-130	272	7	they	they	PRON
chd-130	272	8	are	be	AUX
chd-130	272	9	anatomically	anatomically	ADV
chd-130	272	10	different	different	ADJ
chd-130	272	11	in	in	ADP
chd-130	272	12	terms	term	NOUN
chd-130	272	13	of	of	ADP
chd-130	272	14	the	the	DET
chd-130	272	15	origin	origin	NOUN
chd-130	272	16	of	of	ADP
chd-130	272	17	the	the	DET
chd-130	272	18	tumor	tumor	NOUN
chd-130	272	19	.	.	PUNCT
chd-130	273	1	for	for	ADP
chd-130	273	2	example	example	NOUN
chd-130	273	3	,	,	PUNCT
chd-130	273	4	cholangiocarcinomas	cholangiocarcinoma	NOUN
chd-130	273	5	arises	arise	VERB
chd-130	273	6	from	from	ADP
chd-130	273	7	within	within	ADP
chd-130	273	8	the	the	DET
chd-130	273	9	liver	liver	NOUN
chd-130	273	10	parenchyma	parenchyma	NOUN
chd-130	273	11	,	,	PUNCT
chd-130	273	12	peri	peri	NOUN
chd-130	273	13	-	-	PUNCT
chd-130	273	14	hilar	hilar	ADJ
chd-130	273	15	regions	region	NOUN
chd-130	273	16	,	,	PUNCT
chd-130	273	17	or	or	CCONJ
chd-130	273	18	the	the	DET
chd-130	273	19	distal	distal	ADJ
chd-130	273	20	biliary	biliary	NOUN
chd-130	273	21	tree	tree	NOUN
chd-130	273	22	,	,	PUNCT
chd-130	273	23	and	and	CCONJ
chd-130	273	24	these	these	DET
chd-130	273	25	tumors	tumor	NOUN
chd-130	273	26	are	be	AUX
chd-130	273	27	collectively	collectively	ADV
chd-130	273	28	known	know	VERB
chd-130	273	29	as	as	ADP
chd-130	273	30	btcs	btcs	NOUN
chd-130	273	31	.	.	PUNCT
chd-130	274	1	although	although	SCONJ
chd-130	274	2	these	these	DET
chd-130	274	3	tumors	tumor	NOUN
chd-130	274	4	share	share	VERB
chd-130	274	5	an	an	DET
chd-130	274	6	anatomic	anatomic	ADJ
chd-130	274	7	origin	origin	NOUN
chd-130	274	8	in	in	ADP
chd-130	274	9	the	the	DET
chd-130	274	10	biliary	biliary	ADJ
chd-130	274	11	system	system	NOUN
chd-130	274	12	,	,	PUNCT
chd-130	274	13	they	they	PRON
chd-130	274	14	have	have	VERB
chd-130	274	15	very	very	ADV
chd-130	274	16	different	different	ADJ
chd-130	274	17	disease	disease	NOUN
chd-130	274	18	patterns	pattern	NOUN
chd-130	274	19	,	,	PUNCT
chd-130	274	20	molecular	molecular	ADJ
chd-130	274	21	profiles	profile	NOUN
chd-130	274	22	and	and	CCONJ
chd-130	274	23	also	also	ADV
chd-130	274	24	respond	respond	VERB
chd-130	274	25	differently	differently	ADV
chd-130	274	26	to	to	ADP
chd-130	274	27	various	various	ADJ
chd-130	274	28	therapies	therapy	NOUN
chd-130	274	29	.	.	PUNCT
chd-130	275	1	historically	historically	ADV
chd-130	275	2	,	,	PUNCT
chd-130	275	3	gbc	gbc	PROPN
chd-130	275	4	has	have	VERB
chd-130	275	5	a	a	DET
chd-130	275	6	tendency	tendency	NOUN
chd-130	275	7	to	to	PART
chd-130	275	8	initially	initially	ADV
chd-130	275	9	be	be	AUX
chd-130	275	10	sensitive	sensitive	ADJ
chd-130	275	11	to	to	ADP
chd-130	275	12	chemotherapy	chemotherapy	NOUN
chd-130	275	13	but	but	CCONJ
chd-130	275	14	the	the	DET
chd-130	275	15	survival	survival	NOUN
chd-130	275	16	rate	rate	NOUN
chd-130	275	17	is	be	AUX
chd-130	275	18	much	much	ADV
chd-130	275	19	shorter	short	ADJ
chd-130	275	20	when	when	SCONJ
chd-130	275	21	compared	compare	VERB
chd-130	275	22	to	to	ADP
chd-130	275	23	cholangiocarcinoma	cholangiocarcinoma	NOUN
chd-130	275	24	(	(	PUNCT
chd-130	275	25	eckel	eckel	NOUN
chd-130	275	26	et	et	PROPN
chd-130	275	27	al	al	PROPN
chd-130	275	28	.	.	PROPN
chd-130	275	29	,	,	PUNCT
chd-130	275	30	2007	2007	NUM
chd-130	275	31	)	)	PUNCT
chd-130	275	32	.	.	PUNCT
chd-130	276	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	PROPN
chd-130	276	2	e17	e17	NOUN
chd-130	276	3	cancer	cancer	NOUN
chd-130	276	4	health	health	NOUN
chd-130	276	5	disparities	disparity	NOUN
chd-130	276	6	research	research	VERB
chd-130	276	7	traditionally	traditionally	ADV
chd-130	276	8	,	,	PUNCT
chd-130	276	9	treatment	treatment	NOUN
chd-130	276	10	of	of	ADP
chd-130	276	11	btcs	btcs	NOUN
chd-130	276	12	with	with	ADP
chd-130	276	13	cytotoxic	cytotoxic	ADJ
chd-130	276	14	chemotherapy	chemotherapy	NOUN
chd-130	276	15	have	have	AUX
chd-130	276	16	not	not	PART
chd-130	276	17	taken	take	VERB
chd-130	276	18	into	into	ADP
chd-130	276	19	account	account	NOUN
chd-130	276	20	the	the	DET
chd-130	276	21	anatomic	anatomic	ADJ
chd-130	276	22	origin	origin	NOUN
chd-130	276	23	of	of	ADP
chd-130	276	24	tumor	tumor	NOUN
chd-130	276	25	or	or	CCONJ
chd-130	276	26	its	its	PRON
chd-130	276	27	molecular	molecular	ADJ
chd-130	276	28	profile	profile	NOUN
chd-130	276	29	.	.	PUNCT
chd-130	277	1	however	however	ADV
chd-130	277	2	,	,	PUNCT
chd-130	277	3	in	in	ADP
chd-130	277	4	light	light	NOUN
chd-130	277	5	of	of	ADP
chd-130	277	6	emerging	emerge	VERB
chd-130	277	7	molecular	molecular	ADJ
chd-130	277	8	techniques	technique	NOUN
chd-130	277	9	,	,	PUNCT
chd-130	277	10	such	such	ADJ
chd-130	277	11	as	as	ADP
chd-130	277	12	cost	cost	NOUN
chd-130	277	13	effective	effective	ADJ
chd-130	277	14	sequencing	sequencing	NOUN
chd-130	277	15	platforms	platform	NOUN
chd-130	277	16	,	,	PUNCT
chd-130	277	17	it	it	PRON
chd-130	277	18	will	will	AUX
chd-130	277	19	be	be	AUX
chd-130	277	20	worthwhile	worthwhile	ADJ
chd-130	277	21	to	to	PART
chd-130	277	22	have	have	VERB
chd-130	277	23	a	a	DET
chd-130	277	24	detailed	detailed	ADJ
chd-130	277	25	molecular	molecular	ADJ
chd-130	277	26	genetic	genetic	ADJ
chd-130	277	27	profiling	profiling	NOUN
chd-130	277	28	of	of	ADP
chd-130	277	29	patients	patient	NOUN
chd-130	277	30	with	with	ADP
chd-130	277	31	gbc	gbc	PROPN
chd-130	277	32	before	before	ADP
chd-130	277	33	considering	consider	VERB
chd-130	277	34	a	a	DET
chd-130	277	35	regimen	regimen	NOUN
chd-130	277	36	of	of	ADP
chd-130	277	37	targeted	target	VERB
chd-130	277	38	therapy	therapy	NOUN
chd-130	277	39	for	for	ADP
chd-130	277	40	gbc	gbc	PROPN
chd-130	277	41	.	.	PUNCT
chd-130	278	1	increasingly	increasingly	ADV
chd-130	278	2	,	,	PUNCT
chd-130	278	3	molecular	molecular	ADJ
chd-130	278	4	tests	test	NOUN
chd-130	278	5	to	to	PART
chd-130	278	6	detect	detect	VERB
chd-130	278	7	changes	change	NOUN
chd-130	278	8	at	at	ADP
chd-130	278	9	genetic	genetic	ADJ
chd-130	278	10	level	level	NOUN
chd-130	278	11	are	be	AUX
chd-130	278	12	being	be	AUX
chd-130	278	13	applied	apply	VERB
chd-130	278	14	regularly	regularly	ADV
chd-130	278	15	(	(	PUNCT
chd-130	278	16	in	in	ADP
chd-130	278	17	developed	develop	VERB
chd-130	278	18	countries	country	NOUN
chd-130	278	19	where	where	SCONJ
chd-130	278	20	advance	advance	NOUN
chd-130	278	21	health	health	NOUN
chd-130	278	22	facilities	facility	NOUN
chd-130	278	23	are	be	AUX
chd-130	278	24	available	available	ADJ
chd-130	278	25	to	to	ADP
chd-130	278	26	common	common	ADJ
chd-130	278	27	people	people	NOUN
chd-130	278	28	)	)	PUNCT
chd-130	278	29	to	to	PART
chd-130	278	30	aid	aid	VERB
chd-130	278	31	in	in	ADP
chd-130	278	32	the	the	DET
chd-130	278	33	forming	forming	NOUN
chd-130	278	34	of	of	ADP
chd-130	278	35	therapeutic	therapeutic	ADJ
chd-130	278	36	decisions	decision	NOUN
chd-130	278	37	in	in	ADP
chd-130	278	38	cancer	cancer	NOUN
chd-130	278	39	treatment	treatment	NOUN
chd-130	278	40	.	.	PUNCT
chd-130	279	1	routine	routine	ADJ
chd-130	279	2	testing	testing	NOUN
chd-130	279	3	such	such	ADJ
chd-130	279	4	as	as	ADP
chd-130	279	5	genetic	genetic	ADJ
chd-130	279	6	amplification	amplification	NOUN
chd-130	279	7	of	of	ADP
chd-130	279	8	her2	her2	PROPN
chd-130	279	9	/	/	SYM
chd-130	279	10	neu	neu	PROPN
chd-130	279	11	,	,	PUNCT
chd-130	279	12	and/or	and/or	CCONJ
chd-130	279	13	genetic	genetic	ADJ
chd-130	279	14	mutations	mutation	NOUN
chd-130	279	15	involving	involve	VERB
chd-130	279	16	egfr	egfr	NOUN
chd-130	279	17	and	and	CCONJ
chd-130	279	18	kras	kra	NOUN
chd-130	279	19	are	be	AUX
chd-130	279	20	done	do	VERB
chd-130	279	21	in	in	ADP
chd-130	279	22	clinics	clinic	NOUN
chd-130	279	23	so	so	SCONJ
chd-130	279	24	as	as	SCONJ
chd-130	279	25	to	to	PART
chd-130	279	26	determine	determine	VERB
chd-130	279	27	treatment	treatment	NOUN
chd-130	279	28	benefit	benefit	NOUN
chd-130	279	29	with	with	ADP
chd-130	279	30	targeted	target	VERB
chd-130	279	31	specific	specific	ADJ
chd-130	279	32	anti	anti	ADJ
chd-130	279	33	-	-	ADJ
chd-130	279	34	cancer	cancer	ADJ
chd-130	279	35	therapies	therapy	NOUN
chd-130	279	36	(	(	PUNCT
chd-130	279	37	mcdermott	mcdermott	PROPN
chd-130	279	38	et	et	PROPN
chd-130	279	39	al	al	PROPN
chd-130	279	40	.	.	PROPN
chd-130	279	41	,	,	PUNCT
chd-130	279	42	2009	2009	NUM
chd-130	279	43	)	)	PUNCT
chd-130	279	44	.	.	PUNCT
chd-130	280	1	patients	patient	NOUN
chd-130	280	2	in	in	ADP
chd-130	280	3	which	which	PRON
chd-130	280	4	molecular	molecular	ADJ
chd-130	280	5	genetic	genetic	ADJ
chd-130	280	6	profiling	profiling	NOUN
chd-130	280	7	has	have	AUX
chd-130	280	8	been	be	AUX
chd-130	280	9	conducted	conduct	VERB
chd-130	280	10	that	that	PRON
chd-130	280	11	indicate	indicate	VERB
chd-130	280	12	a	a	DET
chd-130	280	13	potential	potential	ADJ
chd-130	280	14	benefit	benefit	NOUN
chd-130	280	15	with	with	ADP
chd-130	280	16	egfr	egfr	ADJ
chd-130	280	17	inhibitors	inhibitor	NOUN
chd-130	280	18	and	and	CCONJ
chd-130	280	19	other	other	ADJ
chd-130	280	20	molecularly	molecularly	ADV
chd-130	280	21	targeted	target	VERB
chd-130	280	22	drugs	drug	NOUN
chd-130	280	23	,	,	PUNCT
chd-130	280	24	braf	braf	NOUN
chd-130	280	25	inhibitors	inhibitor	NOUN
chd-130	280	26	are	be	AUX
chd-130	280	27	also	also	ADV
chd-130	280	28	being	be	AUX
chd-130	280	29	tested	test	VERB
chd-130	280	30	at	at	ADP
chd-130	280	31	the	the	DET
chd-130	280	32	earliest	early	ADJ
chd-130	280	33	phases	phase	NOUN
chd-130	280	34	of	of	ADP
chd-130	280	35	the	the	DET
chd-130	280	36	disease	disease	NOUN
chd-130	280	37	(	(	PUNCT
chd-130	280	38	brower	brower	PROPN
chd-130	280	39	t	t	PROPN
chd-130	280	40	,	,	PUNCT
chd-130	280	41	2010	2010	NUM
chd-130	280	42	)	)	PUNCT
chd-130	280	43	.	.	PUNCT
chd-130	281	1	discovering	discover	VERB
chd-130	281	2	patterns	pattern	NOUN
chd-130	281	3	of	of	ADP
chd-130	281	4	genetic	genetic	ADJ
chd-130	281	5	changes	change	NOUN
chd-130	281	6	within	within	ADP
chd-130	281	7	gbc	gbc	PROPN
chd-130	281	8	is	be	AUX
chd-130	281	9	very	very	ADV
chd-130	281	10	critical	critical	ADJ
chd-130	281	11	in	in	ADP
chd-130	281	12	order	order	NOUN
chd-130	281	13	to	to	PART
chd-130	281	14	not	not	PART
chd-130	281	15	only	only	ADV
chd-130	281	16	gain	gain	VERB
chd-130	281	17	insight	insight	NOUN
chd-130	281	18	into	into	ADP
chd-130	281	19	the	the	DET
chd-130	281	20	disease	disease	NOUN
chd-130	281	21	biology	biology	NOUN
chd-130	281	22	but	but	CCONJ
chd-130	281	23	also	also	ADV
chd-130	281	24	to	to	PART
chd-130	281	25	bring	bring	VERB
chd-130	281	26	out	out	ADP
chd-130	281	27	about	about	ADP
chd-130	281	28	improvised	improvise	VERB
chd-130	281	29	treatment	treatment	NOUN
chd-130	281	30	options	option	NOUN
chd-130	281	31	,	,	PUNCT
chd-130	281	32	especially	especially	ADV
chd-130	281	33	in	in	ADP
chd-130	281	34	light	light	NOUN
chd-130	281	35	of	of	ADP
chd-130	281	36	emerging	emerge	VERB
chd-130	281	37	and	and	CCONJ
chd-130	281	38	established	establish	VERB
chd-130	281	39	studies	study	NOUN
chd-130	281	40	showing	show	VERB
chd-130	281	41	that	that	SCONJ
chd-130	281	42	tumor	tumor	NOUN
chd-130	281	43	genetics	genetic	NOUN
chd-130	281	44	determine	determine	VERB
chd-130	281	45	drug	drug	NOUN
chd-130	281	46	sensitivity	sensitivity	NOUN
chd-130	281	47	.	.	PUNCT
chd-130	282	1	in	in	ADP
chd-130	282	2	another	another	DET
chd-130	282	3	study	study	NOUN
chd-130	282	4	carried	carry	VERB
chd-130	282	5	out	out	ADP
chd-130	282	6	at	at	ADP
chd-130	282	7	massachusetts	massachusetts	PROPN
chd-130	282	8	general	general	PROPN
chd-130	282	9	hospital	hospital	PROPN
chd-130	282	10	in	in	ADP
chd-130	282	11	the	the	DET
chd-130	282	12	us	us	PROPN
chd-130	282	13	,	,	PUNCT
chd-130	282	14	almost	almost	ADV
chd-130	282	15	13	13	NUM
chd-130	282	16	%	%	NOUN
chd-130	282	17	of	of	ADP
chd-130	282	18	patients	patient	NOUN
chd-130	282	19	with	with	ADP
chd-130	282	20	gbc	gbc	PROPN
chd-130	282	21	were	be	AUX
chd-130	282	22	identified	identify	VERB
chd-130	282	23	with	with	ADP
chd-130	282	24	activating	activate	VERB
chd-130	282	25	mutations	mutation	NOUN
chd-130	282	26	in	in	ADP
chd-130	282	27	pik3ca	pik3ca	PROPN
chd-130	282	28	(	(	PUNCT
chd-130	282	29	deshpande	deshpande	PROPN
chd-130	282	30	et	et	PROPN
chd-130	282	31	al	al	PROPN
chd-130	282	32	.	.	PROPN
chd-130	282	33	,	,	PUNCT
chd-130	282	34	2011	2011	NUM
chd-130	282	35	)	)	PUNCT
chd-130	282	36	.	.	PUNCT
chd-130	283	1	activating	activate	VERB
chd-130	283	2	mutations	mutation	NOUN
chd-130	283	3	in	in	ADP
chd-130	283	4	the	the	DET
chd-130	283	5	pik3ca	pik3ca	NOUN
chd-130	283	6	pathways	pathway	NOUN
chd-130	283	7	has	have	VERB
chd-130	283	8	dual	dual	ADJ
chd-130	283	9	advantages	advantage	NOUN
chd-130	283	10	in	in	ADP
chd-130	283	11	it	it	PRON
chd-130	283	12	being	be	AUX
chd-130	283	13	helpful	helpful	ADJ
chd-130	283	14	for	for	ADP
chd-130	283	15	cancer	cancer	NOUN
chd-130	283	16	diagnosis	diagnosis	NOUN
chd-130	283	17	as	as	ADV
chd-130	283	18	well	well	ADV
chd-130	283	19	as	as	ADP
chd-130	283	20	discovering	discover	VERB
chd-130	283	21	new	new	ADJ
chd-130	283	22	targets	target	NOUN
chd-130	283	23	for	for	ADP
chd-130	283	24	therapies	therapy	NOUN
chd-130	283	25	such	such	ADJ
chd-130	283	26	as	as	ADP
chd-130	283	27	pi3	pi3	NOUN
chd-130	283	28	kinase	kinase	ADJ
chd-130	283	29	inhibitors	inhibitor	NOUN
chd-130	283	30	.	.	PUNCT
chd-130	284	1	most	most	ADV
chd-130	284	2	recently	recently	ADV
chd-130	284	3	,	,	PUNCT
chd-130	284	4	in	in	ADP
chd-130	284	5	a	a	DET
chd-130	284	6	large	large	ADJ
chd-130	284	7	whole	whole	ADJ
chd-130	284	8	-	-	PUNCT
chd-130	284	9	exome	exome	NOUN
chd-130	284	10	and	and	CCONJ
chd-130	284	11	targeted	target	VERB
chd-130	284	12	gene	gene	NOUN
chd-130	284	13	sequencing	sequence	VERB
chd-130	284	14	based	base	VERB
chd-130	284	15	study	study	NOUN
chd-130	284	16	,	,	PUNCT
chd-130	284	17	a	a	DET
chd-130	284	18	chinese	chinese	ADJ
chd-130	284	19	chohort	chohort	NOUN
chd-130	284	20	of	of	ADP
chd-130	284	21	gbc	gbc	PROPN
chd-130	284	22	patients	patient	NOUN
chd-130	284	23	,	,	PUNCT
chd-130	284	24	several	several	ADJ
chd-130	284	25	recurrent	recurrent	ADJ
chd-130	284	26	mutations	mutation	NOUN
chd-130	284	27	in	in	ADP
chd-130	284	28	erbb	erbb	PROPN
chd-130	284	29	pathway	pathway	NOUN
chd-130	284	30	were	be	AUX
chd-130	284	31	identified	identify	VERB
chd-130	284	32	(	(	PUNCT
chd-130	284	33	li	li	PROPN
chd-130	284	34	et	et	PROPN
chd-130	284	35	al	al	PROPN
chd-130	284	36	.	.	PROPN
chd-130	284	37	,	,	PUNCT
chd-130	284	38	2014	2014	NUM
chd-130	284	39	)	)	PUNCT
chd-130	284	40	.	.	PUNCT
chd-130	285	1	in	in	ADP
chd-130	285	2	this	this	DET
chd-130	285	3	study	study	NOUN
chd-130	285	4	,	,	PUNCT
chd-130	285	5	it	it	PRON
chd-130	285	6	was	be	AUX
chd-130	285	7	observed	observe	VERB
chd-130	285	8	that	that	SCONJ
chd-130	285	9	genes	gene	NOUN
chd-130	285	10	like	like	ADP
chd-130	285	11	tp53	tp53	PROPN
chd-130	285	12	,	,	PUNCT
chd-130	285	13	k	k	PROPN
chd-130	285	14	-	-	PUNCT
chd-130	285	15	ras	ras	NOUN
chd-130	285	16	,	,	PUNCT
chd-130	285	17	and	and	CCONJ
chd-130	285	18	erbb3	erbb3	NOUN
chd-130	285	19	had	have	VERB
chd-130	285	20	a	a	DET
chd-130	285	21	significant	significant	ADJ
chd-130	285	22	frequency	frequency	NOUN
chd-130	285	23	of	of	ADP
chd-130	285	24	non	non	ADJ
chd-130	285	25	-	-	ADJ
chd-130	285	26	silent	silent	ADJ
chd-130	285	27	mutations	mutation	NOUN
chd-130	285	28	of	of	ADP
chd-130	285	29	47.1	47.1	NUM
chd-130	285	30	%	%	NOUN
chd-130	285	31	,	,	PUNCT
chd-130	285	32	7.8	7.8	NUM
chd-130	285	33	%	%	NOUN
chd-130	285	34	,	,	PUNCT
chd-130	285	35	and	and	CCONJ
chd-130	285	36	11.8	11.8	NUM
chd-130	285	37	%	%	NOUN
chd-130	285	38	respectively	respectively	ADV
chd-130	285	39	with	with	ADP
chd-130	285	40	a	a	DET
chd-130	285	41	false	false	ADJ
chd-130	285	42	discovery	discovery	NOUN
chd-130	285	43	rate	rate	NOUN
chd-130	285	44	(	(	PUNCT
chd-130	285	45	fdr	fdr	PROPN
chd-130	285	46	)	)	PUNCT
chd-130	285	47	of	of	ADP
chd-130	285	48	<	<	X
chd-130	285	49	0.0.5	0.0.5	X
chd-130	285	50	.	.	PUNCT
chd-130	286	1	furthermore	furthermore	ADV
chd-130	286	2	,	,	PUNCT
chd-130	286	3	it	it	PRON
chd-130	286	4	was	be	AUX
chd-130	286	5	also	also	ADV
chd-130	286	6	discovered	discover	VERB
chd-130	286	7	that	that	SCONJ
chd-130	286	8	the	the	DET
chd-130	286	9	erbb	erbb	NOUN
chd-130	286	10	signaling	signal	VERB
chd-130	286	11	pathway	pathway	NOUN
chd-130	286	12	including	include	VERB
chd-130	286	13	egfr	egfr	ADJ
chd-130	286	14	,	,	PUNCT
chd-130	286	15	erbb2	erbb2	PROPN
chd-130	286	16	,	,	PUNCT
chd-130	286	17	erbb3	erbb3	NOUN
chd-130	286	18	and	and	CCONJ
chd-130	286	19	erbb4	erbb4	VERB
chd-130	286	20	along	along	ADV
chd-130	286	21	with	with	ADP
chd-130	286	22	their	their	PRON
chd-130	286	23	downstream	downstream	ADJ
chd-130	286	24	genes	gene	NOUN
chd-130	286	25	,	,	PUNCT
chd-130	286	26	affected	affect	VERB
chd-130	286	27	36.8	36.8	NUM
chd-130	286	28	%	%	NOUN
chd-130	286	29	of	of	ADP
chd-130	286	30	gbc	gbc	NOUN
chd-130	286	31	samples	sample	NOUN
chd-130	286	32	,	,	PUNCT
chd-130	286	33	making	make	VERB
chd-130	286	34	it	it	PRON
chd-130	286	35	the	the	DET
chd-130	286	36	most	most	ADV
chd-130	286	37	extensively	extensively	ADV
chd-130	286	38	mutated	mutate	VERB
chd-130	286	39	pathway	pathway	NOUN
chd-130	286	40	.	.	PUNCT
chd-130	287	1	mutations	mutation	NOUN
chd-130	287	2	in	in	ADP
chd-130	287	3	the	the	DET
chd-130	287	4	erbb	erbb	PROPN
chd-130	287	5	pathway	pathway	NOUN
chd-130	287	6	genes	gene	NOUN
chd-130	287	7	were	be	AUX
chd-130	287	8	also	also	ADV
chd-130	287	9	found	find	VERB
chd-130	287	10	to	to	PART
chd-130	287	11	be	be	AUX
chd-130	287	12	associated	associate	VERB
chd-130	287	13	with	with	ADP
chd-130	287	14	a	a	DET
chd-130	287	15	dismal	dismal	ADJ
chd-130	287	16	prognosis	prognosis	NOUN
chd-130	287	17	in	in	ADP
chd-130	287	18	gbc	gbc	NOUN
chd-130	287	19	patients	patient	NOUN
chd-130	287	20	,	,	PUNCT
chd-130	287	21	thus	thus	ADV
chd-130	287	22	suggesting	suggest	VERB
chd-130	287	23	that	that	SCONJ
chd-130	287	24	targeted	target	VERB
chd-130	287	25	therapies	therapy	NOUN
chd-130	287	26	,	,	PUNCT
chd-130	287	27	that	that	PRON
chd-130	287	28	are	be	AUX
chd-130	287	29	presently	presently	ADV
chd-130	287	30	in	in	ADP
chd-130	287	31	development	development	NOUN
chd-130	287	32	or	or	CCONJ
chd-130	287	33	already	already	ADV
chd-130	287	34	in	in	ADP
chd-130	287	35	use	use	NOUN
chd-130	287	36	in	in	ADP
chd-130	287	37	clinics	clinic	NOUN
chd-130	287	38	,	,	PUNCT
chd-130	287	39	could	could	AUX
chd-130	287	40	be	be	AUX
chd-130	287	41	of	of	ADP
chd-130	287	42	major	major	ADJ
chd-130	287	43	benefit	benefit	NOUN
chd-130	287	44	(	(	PUNCT
chd-130	287	45	li	li	PROPN
chd-130	287	46	et	et	PROPN
chd-130	287	47	al	al	PROPN
chd-130	287	48	.	.	PROPN
chd-130	287	49	,	,	PUNCT
chd-130	287	50	2014	2014	NUM
chd-130	287	51	)	)	PUNCT
chd-130	287	52	.	.	PUNCT
chd-130	288	1	role	role	NOUN
chd-130	288	2	of	of	ADP
chd-130	288	3	erbb	erbb	PROPN
chd-130	288	4	pathway	pathway	NOUN
chd-130	288	5	in	in	ADP
chd-130	288	6	gbc	gbc	PROPN
chd-130	288	7	was	be	AUX
chd-130	288	8	further	far	ADV
chd-130	288	9	confirmed	confirm	VERB
chd-130	288	10	in	in	ADP
chd-130	288	11	few	few	ADJ
chd-130	288	12	other	other	ADJ
chd-130	288	13	independent	independent	ADJ
chd-130	288	14	studies	study	NOUN
chd-130	288	15	from	from	ADP
chd-130	288	16	different	different	ADJ
chd-130	288	17	cohorts	cohort	NOUN
chd-130	288	18	of	of	ADP
chd-130	288	19	patients	patient	NOUN
chd-130	288	20	.	.	PUNCT
chd-130	289	1	in	in	ADP
chd-130	289	2	one	one	NUM
chd-130	289	3	of	of	ADP
chd-130	289	4	such	such	ADJ
chd-130	289	5	study	study	NOUN
chd-130	289	6	,	,	PUNCT
chd-130	289	7	retrospectively	retrospectively	ADV
chd-130	289	8	conducted	conduct	VERB
chd-130	289	9	in	in	ADP
chd-130	289	10	the	the	DET
chd-130	289	11	patients	patient	NOUN
chd-130	289	12	with	with	ADP
chd-130	289	13	gbc	gbc	PROPN
chd-130	289	14	in	in	ADP
chd-130	289	15	the	the	DET
chd-130	289	16	united	united	PROPN
chd-130	289	17	states	states	PROPN
chd-130	289	18	,	,	PUNCT
chd-130	289	19	her2	her2	PROPN
chd-130	289	20	/	/	SYM
chd-130	289	21	neu	neu	PROPN
chd-130	289	22	blockade	blockade	NOUN
chd-130	289	23	was	be	AUX
chd-130	289	24	found	find	VERB
chd-130	289	25	to	to	PART
chd-130	289	26	be	be	AUX
chd-130	289	27	a	a	DET
chd-130	289	28	promising	promising	ADJ
chd-130	289	29	treatment	treatment	NOUN
chd-130	289	30	strategy	strategy	NOUN
chd-130	289	31	to	to	PART
chd-130	289	32	treat	treat	VERB
chd-130	289	33	gbc	gbc	PROPN
chd-130	289	34	patients	patient	NOUN
chd-130	289	35	who	who	PRON
chd-130	289	36	have	have	VERB
chd-130	289	37	gene	gene	NOUN
chd-130	289	38	amplification	amplification	NOUN
chd-130	289	39	(	(	PUNCT
chd-130	289	40	javle	javle	NOUN
chd-130	289	41	et	et	NOUN
chd-130	289	42	al	al	PROPN
chd-130	289	43	.	.	PROPN
chd-130	289	44	,	,	PUNCT
chd-130	289	45	2015	2015	NUM
chd-130	289	46	)	)	PUNCT
chd-130	289	47	.	.	PUNCT
chd-130	290	1	in	in	ADP
chd-130	290	2	another	another	DET
chd-130	290	3	significant	significant	ADJ
chd-130	290	4	study	study	NOUN
chd-130	290	5	conducted	conduct	VERB
chd-130	290	6	in	in	ADP
chd-130	290	7	japan	japan	PROPN
chd-130	290	8	,	,	PUNCT
chd-130	290	9	in	in	ADP
chd-130	290	10	a	a	DET
chd-130	290	11	large	large	ADJ
chd-130	290	12	cohort	cohort	NOUN
chd-130	290	13	of	of	ADP
chd-130	290	14	biliary	biliary	ADJ
chd-130	290	15	tract	tract	NOUN
chd-130	290	16	cancers	cancer	NOUN
chd-130	290	17	,	,	PUNCT
chd-130	290	18	egfr	egfr	ADJ
chd-130	290	19	family	family	NOUN
chd-130	290	20	genes	gene	NOUN
chd-130	290	21	such	such	ADJ
chd-130	290	22	as	as	ADP
chd-130	290	23	erbb2	erbb2	PROPN
chd-130	290	24	and	and	CCONJ
chd-130	290	25	erbb3	erbb3	NOUN
chd-130	290	26	were	be	AUX
chd-130	290	27	found	find	VERB
chd-130	290	28	to	to	PART
chd-130	290	29	be	be	AUX
chd-130	290	30	activated	activate	VERB
chd-130	290	31	while	while	SCONJ
chd-130	290	32	pten	pten	ADJ
chd-130	290	33	and	and	CCONJ
chd-130	290	34	tsc1	tsc1	PROPN
chd-130	290	35	genes	gene	NOUN
chd-130	290	36	were	be	AUX
chd-130	290	37	found	find	VERB
chd-130	290	38	to	to	PART
chd-130	290	39	be	be	AUX
chd-130	290	40	inactivated	inactivate	VERB
chd-130	290	41	,	,	PUNCT
chd-130	290	42	in	in	ADP
chd-130	290	43	gbc	gbc	PROPN
chd-130	290	44	.	.	PUNCT
chd-130	291	1	frequent	frequent	ADJ
chd-130	291	2	genetic	genetic	ADJ
chd-130	291	3	variations	variation	NOUN
chd-130	291	4	in	in	ADP
chd-130	291	5	the	the	DET
chd-130	291	6	tp53	tp53	PROPN
chd-130	291	7	and	and	CCONJ
chd-130	291	8	rb	rb	PROPN
chd-130	291	9	cell	cell	NOUN
chd-130	291	10	cycle	cycle	NOUN
chd-130	291	11	modules	module	NOUN
chd-130	291	12	were	be	AUX
chd-130	291	13	also	also	ADV
chd-130	291	14	reported	report	VERB
chd-130	291	15	in	in	ADP
chd-130	291	16	gbc	gbc	PROPN
chd-130	291	17	(	(	PUNCT
chd-130	291	18	nakamura	nakamura	NOUN
chd-130	291	19	et	et	PROPN
chd-130	291	20	al	al	PROPN
chd-130	291	21	.	.	PROPN
chd-130	291	22	,	,	PUNCT
chd-130	291	23	2015	2015	NUM
chd-130	291	24	)	)	PUNCT
chd-130	291	25	.	.	PUNCT
chd-130	292	1	an	an	DET
chd-130	292	2	interesting	interesting	ADJ
chd-130	292	3	study	study	NOUN
chd-130	292	4	from	from	ADP
chd-130	292	5	india	india	PROPN
chd-130	292	6	using	use	VERB
chd-130	292	7	integrated	integrate	VERB
chd-130	292	8	genomic	genomic	NOUN
chd-130	292	9	and	and	CCONJ
chd-130	292	10	proteomic	proteomic	ADJ
chd-130	292	11	analysis	analysis	NOUN
chd-130	292	12	provides	provide	VERB
chd-130	292	13	a	a	DET
chd-130	292	14	compelling	compelling	ADJ
chd-130	292	15	evidence	evidence	NOUN
chd-130	292	16	that	that	SCONJ
chd-130	292	17	erbb2	erbb2	PROPN
chd-130	292	18	is	be	AUX
chd-130	292	19	an	an	DET
chd-130	292	20	important	important	ADJ
chd-130	292	21	therapeutic	therapeutic	ADJ
chd-130	292	22	target	target	NOUN
chd-130	292	23	under	under	ADP
chd-130	292	24	neo	neo	NOUN
chd-130	292	25	-	-	PUNCT
chd-130	292	26	adjuvant	adjuvant	ADJ
chd-130	292	27	or	or	CCONJ
chd-130	292	28	adjuvant	adjuvant	ADJ
chd-130	292	29	settings	setting	NOUN
chd-130	292	30	for	for	ADP
chd-130	292	31	treatment	treatment	NOUN
chd-130	292	32	of	of	ADP
chd-130	292	33	patients	patient	NOUN
chd-130	292	34	with	with	ADP
chd-130	292	35	gbc	gbc	PROPN
chd-130	292	36	.	.	PUNCT
chd-130	293	1	in	in	ADP
chd-130	293	2	addition	addition	NOUN
chd-130	293	3	,	,	PUNCT
chd-130	293	4	this	this	DET
chd-130	293	5	study	study	NOUN
chd-130	293	6	also	also	ADV
chd-130	293	7	shows	show	VERB
chd-130	293	8	that	that	DET
chd-130	293	9	presence	presence	NOUN
chd-130	293	10	of	of	ADP
chd-130	293	11	k	k	PROPN
chd-130	293	12	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-130	293	13	e18	e18	PROPN
chd-130	293	14	cancer	cancer	NOUN
chd-130	293	15	health	health	NOUN
chd-130	293	16	disparities	disparity	NOUN
chd-130	293	17	research	research	NOUN
chd-130	293	18	ras	ra	NOUN
chd-130	293	19	mutations	mutation	NOUN
chd-130	293	20	may	may	AUX
chd-130	293	21	preclude	preclude	VERB
chd-130	293	22	patients	patient	NOUN
chd-130	293	23	with	with	ADP
chd-130	293	24	gbc	gbc	PROPN
chd-130	293	25	to	to	PART
chd-130	293	26	respond	respond	VERB
chd-130	293	27	to	to	ADP
chd-130	293	28	anti	anti	ADJ
chd-130	293	29	-	-	ADJ
chd-130	293	30	egfr	egfr	ADJ
chd-130	293	31	treatment	treatment	NOUN
chd-130	293	32	,	,	PUNCT
chd-130	293	33	similar	similar	ADJ
chd-130	293	34	as	as	ADP
chd-130	293	35	to	to	ADP
chd-130	293	36	how	how	SCONJ
chd-130	293	37	a	a	DET
chd-130	293	38	clinical	clinical	ADJ
chd-130	293	39	algorithm	algorithm	NOUN
chd-130	293	40	is	be	AUX
chd-130	293	41	often	often	ADV
chd-130	293	42	used	use	VERB
chd-130	293	43	to	to	PART
chd-130	293	44	opt	opt	VERB
chd-130	293	45	for	for	ADP
chd-130	293	46	antiegfr	antiegfr	NOUN
chd-130	293	47	treatment	treatment	NOUN
chd-130	293	48	in	in	ADP
chd-130	293	49	patients	patient	NOUN
chd-130	293	50	with	with	ADP
chd-130	293	51	colorectal	colorectal	ADJ
chd-130	293	52	cancer	cancer	NOUN
chd-130	293	53	(	(	PUNCT
chd-130	293	54	iyer	iyer	PROPN
chd-130	293	55	et	et	PROPN
chd-130	293	56	al	al	PROPN
chd-130	293	57	.	.	PROPN
chd-130	293	58	2018	2018	NUM
chd-130	293	59	)	)	PUNCT
chd-130	293	60	.	.	PUNCT
chd-130	294	1	most	most	ADV
chd-130	294	2	recently	recently	ADV
chd-130	294	3	,	,	PUNCT
chd-130	294	4	in	in	ADP
chd-130	294	5	a	a	DET
chd-130	294	6	collaborative	collaborative	ADJ
chd-130	294	7	study	study	NOUN
chd-130	294	8	between	between	ADP
chd-130	294	9	investigators	investigator	NOUN
chd-130	294	10	from	from	ADP
chd-130	294	11	india	india	PROPN
chd-130	294	12	and	and	CCONJ
chd-130	294	13	the	the	DET
chd-130	294	14	us	us	PROPN
chd-130	294	15	,	,	PUNCT
chd-130	294	16	pim1	pim1	PROPN
chd-130	294	17	kinase	kinase	PROPN
chd-130	294	18	has	have	AUX
chd-130	294	19	been	be	AUX
chd-130	294	20	demonstrated	demonstrate	VERB
chd-130	294	21	to	to	PART
chd-130	294	22	promote	promote	VERB
chd-130	294	23	cell	cell	NOUN
chd-130	294	24	proliferation	proliferation	NOUN
chd-130	294	25	of	of	ADP
chd-130	294	26	gallbladder	gallbladder	NOUN
chd-130	294	27	cancer	cancer	NOUN
chd-130	294	28	cells	cell	NOUN
chd-130	294	29	via	via	ADP
chd-130	294	30	inhibition	inhibition	NOUN
chd-130	294	31	of	of	ADP
chd-130	294	32	pras40	pras40	NOUN
chd-130	294	33	(	(	PUNCT
chd-130	294	34	subbannayya	subbannayya	PROPN
chd-130	294	35	et	et	PROPN
chd-130	294	36	al	al	PROPN
chd-130	294	37	.	.	PROPN
chd-130	294	38	,	,	PUNCT
chd-130	294	39	2019	2019	NUM
chd-130	294	40	)	)	PUNCT
chd-130	294	41	.	.	PUNCT
chd-130	295	1	it	it	PRON
chd-130	295	2	is	be	AUX
chd-130	295	3	important	important	ADJ
chd-130	295	4	to	to	PART
chd-130	295	5	note	note	VERB
chd-130	295	6	that	that	SCONJ
chd-130	295	7	several	several	ADJ
chd-130	295	8	small	small	ADJ
chd-130	295	9	molecule	molecule	NOUN
chd-130	295	10	inhibitors	inhibitor	NOUN
chd-130	295	11	of	of	ADP
chd-130	295	12	pim1	pim1	PROPN
chd-130	295	13	kinase	kinase	PROPN
chd-130	295	14	have	have	AUX
chd-130	295	15	been	be	AUX
chd-130	295	16	developed	develop	VERB
chd-130	295	17	,	,	PUNCT
chd-130	295	18	some	some	PRON
chd-130	295	19	of	of	ADP
chd-130	295	20	which	which	PRON
chd-130	295	21	are	be	AUX
chd-130	295	22	currently	currently	ADV
chd-130	295	23	being	be	AUX
chd-130	295	24	tested	test	VERB
chd-130	295	25	for	for	ADP
chd-130	295	26	their	their	PRON
chd-130	295	27	efficacy	efficacy	NOUN
chd-130	295	28	in	in	ADP
chd-130	295	29	clinical	clinical	ADJ
chd-130	295	30	trials	trial	NOUN
chd-130	295	31	for	for	ADP
chd-130	295	32	several	several	ADJ
chd-130	295	33	types	type	NOUN
chd-130	295	34	of	of	ADP
chd-130	295	35	cancers	cancer	NOUN
chd-130	295	36	.	.	PUNCT
chd-130	296	1	currently	currently	ADV
chd-130	296	2	,	,	PUNCT
chd-130	296	3	some	some	PRON
chd-130	296	4	of	of	ADP
chd-130	296	5	the	the	DET
chd-130	296	6	authors	author	NOUN
chd-130	296	7	of	of	ADP
chd-130	296	8	this	this	DET
chd-130	296	9	article	article	NOUN
chd-130	296	10	(	(	PUNCT
chd-130	296	11	cpg	cpg	PROPN
chd-130	296	12	,	,	PUNCT
chd-130	296	13	all	all	PRON
chd-130	296	14	and	and	CCONJ
chd-130	296	15	mks	mks	PROPN
chd-130	296	16	)	)	PUNCT
chd-130	296	17	are	be	AUX
chd-130	296	18	investigating	investigate	VERB
chd-130	296	19	the	the	DET
chd-130	296	20	role	role	NOUN
chd-130	296	21	of	of	ADP
chd-130	296	22	mycaurora	mycaurora	PROPN
chd-130	296	23	kinase	kinase	PROPN
chd-130	296	24	signaling	signal	VERB
chd-130	296	25	in	in	ADP
chd-130	296	26	the	the	DET
chd-130	296	27	gallbladder	gallbladder	NOUN
chd-130	296	28	cancer	cancer	NOUN
chd-130	296	29	and	and	CCONJ
chd-130	296	30	as	as	ADP
chd-130	296	31	to	to	ADP
chd-130	296	32	how	how	SCONJ
chd-130	296	33	this	this	DET
chd-130	296	34	signaling	signal	VERB
chd-130	296	35	axis	axis	NOUN
chd-130	296	36	can	can	AUX
chd-130	296	37	be	be	AUX
chd-130	296	38	therapeutically	therapeutically	ADV
chd-130	296	39	targeted	target	VERB
chd-130	296	40	(	(	PUNCT
chd-130	296	41	unpublished	unpublished	ADJ
chd-130	296	42	work	work	NOUN
chd-130	296	43	)	)	PUNCT
chd-130	296	44	.	.	PUNCT
chd-130	297	1	conclusion	conclusion	NOUN
chd-130	297	2	recent	recent	ADJ
chd-130	297	3	studies	study	NOUN
chd-130	297	4	employ	employ	VERB
chd-130	297	5	large	large	ADJ
chd-130	297	6	cohorts	cohort	NOUN
chd-130	297	7	of	of	ADP
chd-130	297	8	gbc	gbc	PROPN
chd-130	297	9	to	to	PART
chd-130	297	10	emphasize	emphasize	VERB
chd-130	297	11	the	the	DET
chd-130	297	12	differences	difference	NOUN
chd-130	297	13	between	between	ADP
chd-130	297	14	the	the	DET
chd-130	297	15	various	various	ADJ
chd-130	297	16	gbc	gbc	PROPN
chd-130	297	17	subtypes	subtype	NOUN
chd-130	297	18	at	at	ADP
chd-130	297	19	a	a	DET
chd-130	297	20	basic	basic	ADJ
chd-130	297	21	genetic	genetic	ADJ
chd-130	297	22	/	/	SYM
chd-130	297	23	molecular	molecular	ADJ
chd-130	297	24	level	level	NOUN
chd-130	297	25	.	.	PUNCT
chd-130	298	1	functional	functional	ADJ
chd-130	298	2	studies	study	NOUN
chd-130	298	3	and	and	CCONJ
chd-130	298	4	clinical	clinical	ADJ
chd-130	298	5	trials	trial	NOUN
chd-130	298	6	only	only	ADV
chd-130	298	7	including	include	VERB
chd-130	298	8	patients	patient	NOUN
chd-130	298	9	with	with	ADP
chd-130	298	10	specific	specific	ADJ
chd-130	298	11	subtypes	subtype	NOUN
chd-130	298	12	of	of	ADP
chd-130	298	13	gbc	gbc	PROPN
chd-130	298	14	,	,	PUNCT
chd-130	298	15	and	and	CCONJ
chd-130	298	16	stratifying	stratify	VERB
chd-130	298	17	them	they	PRON
chd-130	298	18	based	base	VERB
chd-130	298	19	on	on	ADP
chd-130	298	20	their	their	PRON
chd-130	298	21	genetic	genetic	ADJ
chd-130	298	22	drivers	driver	NOUN
chd-130	298	23	,	,	PUNCT
chd-130	298	24	were	be	AUX
chd-130	298	25	the	the	DET
chd-130	298	26	next	next	ADJ
chd-130	298	27	steps	step	NOUN
chd-130	298	28	to	to	ADP
chd-130	298	29	accomplishing	accomplish	VERB
chd-130	298	30	these	these	DET
chd-130	298	31	goals	goal	NOUN
chd-130	298	32	.	.	PUNCT
chd-130	299	1	for	for	ADP
chd-130	299	2	instance	instance	NOUN
chd-130	299	3	,	,	PUNCT
chd-130	299	4	use	use	NOUN
chd-130	299	5	of	of	ADP
chd-130	299	6	inhibitors	inhibitor	NOUN
chd-130	299	7	of	of	ADP
chd-130	299	8	the	the	DET
chd-130	299	9	egfr	egfr	NOUN
chd-130	299	10	were	be	AUX
chd-130	299	11	to	to	PART
chd-130	299	12	be	be	AUX
chd-130	299	13	examined	examine	VERB
chd-130	299	14	only	only	ADV
chd-130	299	15	in	in	ADP
chd-130	299	16	the	the	DET
chd-130	299	17	patients	patient	NOUN
chd-130	299	18	with	with	ADP
chd-130	299	19	gbc	gbc	PROPN
chd-130	299	20	carrying	carry	VERB
chd-130	299	21	mutations	mutation	NOUN
chd-130	299	22	/	/	SYM
chd-130	299	23	genetic	genetic	ADJ
chd-130	299	24	amplifications	amplification	NOUN
chd-130	299	25	of	of	ADP
chd-130	299	26	the	the	DET
chd-130	299	27	egfr	egfr	ADJ
chd-130	299	28	gene	gene	NOUN
chd-130	299	29	.	.	PUNCT
chd-130	300	1	constructing	construct	VERB
chd-130	300	2	a	a	DET
chd-130	300	3	precise	precise	ADJ
chd-130	300	4	approach	approach	NOUN
chd-130	300	5	to	to	ADP
chd-130	300	6	genomic	genomic	ADJ
chd-130	300	7	medicine	medicine	NOUN
chd-130	300	8	for	for	ADP
chd-130	300	9	the	the	DET
chd-130	300	10	treatment	treatment	NOUN
chd-130	300	11	of	of	ADP
chd-130	300	12	this	this	DET
chd-130	300	13	disease	disease	NOUN
chd-130	300	14	uses	use	VERB
chd-130	300	15	a	a	DET
chd-130	300	16	combination	combination	NOUN
chd-130	300	17	of	of	ADP
chd-130	300	18	biological	biological	ADJ
chd-130	300	19	studies	study	NOUN
chd-130	300	20	,	,	PUNCT
chd-130	300	21	drug	drug	NOUN
chd-130	300	22	research	research	NOUN
chd-130	300	23	and	and	CCONJ
chd-130	300	24	development	development	NOUN
chd-130	300	25	,	,	PUNCT
chd-130	300	26	technological	technological	ADJ
chd-130	300	27	advancements	advancement	NOUN
chd-130	300	28	in	in	ADP
chd-130	300	29	genomics	genomic	NOUN
chd-130	300	30	as	as	ADV
chd-130	300	31	well	well	ADV
chd-130	300	32	as	as	ADP
chd-130	300	33	research	research	NOUN
chd-130	300	34	that	that	PRON
chd-130	300	35	determines	determine	VERB
chd-130	300	36	health	health	NOUN
chd-130	300	37	outcomes	outcome	NOUN
chd-130	300	38	.	.	PUNCT
chd-130	301	1	based	base	VERB
chd-130	301	2	on	on	ADP
chd-130	301	3	the	the	DET
chd-130	301	4	genomic	genomic	ADJ
chd-130	301	5	information	information	NOUN
chd-130	301	6	as	as	SCONJ
chd-130	301	7	summarized	summarize	VERB
chd-130	301	8	in	in	ADP
chd-130	301	9	table	table	NOUN
chd-130	301	10	2	2	NUM
chd-130	301	11	,	,	PUNCT
chd-130	301	12	several	several	ADJ
chd-130	301	13	clinical	clinical	ADJ
chd-130	301	14	trials	trial	NOUN
chd-130	301	15	are	be	AUX
chd-130	301	16	currently	currently	ADV
chd-130	301	17	underway	underway	ADJ
chd-130	301	18	to	to	PART
chd-130	301	19	examine	examine	VERB
chd-130	301	20	the	the	DET
chd-130	301	21	efficacy	efficacy	NOUN
chd-130	301	22	of	of	ADP
chd-130	301	23	targeted	target	VERB
chd-130	301	24	therapies	therapy	NOUN
chd-130	301	25	in	in	ADP
chd-130	301	26	patients	patient	NOUN
chd-130	301	27	.	.	PUNCT
chd-130	302	1	this	this	PRON
chd-130	302	2	,	,	PUNCT
chd-130	302	3	in	in	ADP
chd-130	302	4	the	the	DET
chd-130	302	5	long	long	ADJ
chd-130	302	6	run	run	NOUN
chd-130	302	7	,	,	PUNCT
chd-130	302	8	is	be	AUX
chd-130	302	9	going	go	VERB
chd-130	302	10	to	to	PART
chd-130	302	11	help	help	VERB
chd-130	302	12	build	build	VERB
chd-130	302	13	a	a	DET
chd-130	302	14	staircase	staircase	NOUN
chd-130	302	15	to	to	ADP
chd-130	302	16	developing	develop	VERB
chd-130	302	17	a	a	DET
chd-130	302	18	targeted	target	VERB
chd-130	302	19	therapy	therapy	NOUN
chd-130	302	20	for	for	ADP
chd-130	302	21	gbc	gbc	PROPN
chd-130	302	22	.	.	PUNCT
chd-130	303	1	based	base	VERB
chd-130	303	2	on	on	ADP
chd-130	303	3	the	the	DET
chd-130	303	4	outcome	outcome	NOUN
chd-130	303	5	of	of	ADP
chd-130	303	6	these	these	DET
chd-130	303	7	studies	study	NOUN
chd-130	303	8	,	,	PUNCT
chd-130	303	9	we	we	PRON
chd-130	303	10	should	should	AUX
chd-130	303	11	be	be	AUX
chd-130	303	12	able	able	ADJ
chd-130	303	13	to	to	PART
chd-130	303	14	offer	offer	VERB
chd-130	303	15	effective	effective	ADJ
chd-130	303	16	therapies	therapy	NOUN
chd-130	303	17	based	base	VERB
chd-130	303	18	on	on	ADP
chd-130	303	19	their	their	PRON
chd-130	303	20	genomic	genomic	ADJ
chd-130	303	21	profiles	profile	NOUN
chd-130	303	22	to	to	ADP
chd-130	303	23	the	the	DET
chd-130	303	24	patients	patient	NOUN
chd-130	303	25	with	with	ADP
chd-130	303	26	deadly	deadly	ADJ
chd-130	303	27	gbc	gbc	NOUN
chd-130	303	28	in	in	ADP
chd-130	303	29	the	the	DET
chd-130	303	30	future	future	NOUN
chd-130	303	31	.	.	PUNCT
chd-130	304	1	table	table	NOUN
chd-130	304	2	2	2	NUM
chd-130	304	3	:	:	PUNCT
chd-130	304	4	ongoing	ongoing	ADJ
chd-130	304	5	clinical	clinical	ADJ
chd-130	304	6	trials	trial	NOUN
chd-130	304	7	using	use	VERB
chd-130	304	8	targeted	target	VERB
chd-130	304	9	therapies	therapy	NOUN
chd-130	304	10	in	in	ADP
chd-130	304	11	gallbladder	gallbladder	NOUN
chd-130	304	12	cancer	cancer	NOUN
chd-130	304	13	.	.	PUNCT
chd-130	305	1	drug(s	drug(s	NOUN
chd-130	305	2	)	)	PUNCT
chd-130	305	3	target	target	NOUN
chd-130	305	4	in	in	ADP
chd-130	305	5	combination	combination	NOUN
chd-130	305	6	with	with	ADP
chd-130	305	7	phase	phase	NOUN
chd-130	305	8	clinical	clinical	ADJ
chd-130	305	9	trials	trial	NOUN
chd-130	305	10	identifier	identifier	NOUN
chd-130	305	11	cetuximab	cetuximab	NOUN
chd-130	305	12	,	,	PUNCT
chd-130	305	13	gefitinib	gefitinib	NOUN
chd-130	305	14	trastuzumab	trastuzumab	NOUN
chd-130	305	15	,	,	PUNCT
chd-130	305	16	lapatinib	lapatinib	PROPN
chd-130	305	17	,	,	PUNCT
chd-130	305	18	everolimus	everolimus	ADJ
chd-130	305	19	sorafenib	sorafenib	NOUN
chd-130	305	20	crizotinib	crizotinib	VERB
chd-130	305	21	egfr	egfr	X
chd-130	305	22	,	,	PUNCT
chd-130	305	23	her2	her2	PROPN
chd-130	305	24	,	,	PUNCT
chd-130	305	25	her2	her2	PROPN
chd-130	305	26	,	,	PUNCT
chd-130	305	27	egfr	egfr	NOUN
chd-130	305	28	mtor	mtor	PROPN
chd-130	305	29	raf	raf	PROPN
chd-130	305	30	kinase	kinase	PROPN
chd-130	305	31	,	,	PUNCT
chd-130	305	32	vegfr-2	vegfr-2	NUM
chd-130	305	33	/	/	SYM
chd-130	305	34	pdgfr	pdgfr	ADJ
chd-130	305	35	-	-	PUNCT
chd-130	305	36	beta	beta	NOUN
chd-130	305	37	alk	alk	NOUN
chd-130	305	38	and	and	CCONJ
chd-130	305	39	ros1	ros1	PROPN
chd-130	305	40	gemcitabine	gemcitabine	NOUN
chd-130	305	41	,	,	PUNCT
chd-130	305	42	oxaliplatin	oxaliplatin	X
chd-130	305	43	(	(	PUNCT
chd-130	305	44	gem	gem	NOUN
chd-130	305	45	ox	ox	ADJ
chd-130	305	46	)	)	PUNCT
chd-130	305	47	ii	ii	PROPN
chd-130	305	48	nct02836847	nct02836847	NOUN
chd-130	305	49	sorafenib	sorafenib	PROPN
chd-130	305	50	raf	raf	PROPN
chd-130	305	51	kinase	kinase	PROPN
chd-130	305	52	,	,	PUNCT
chd-130	305	53	vegfr	vegfr	VERB
chd-130	305	54	2	2	NUM
chd-130	305	55	/	/	SYM
chd-130	305	56	pdgfr	pdgfr	ADJ
chd-130	305	57	-	-	PUNCT
chd-130	305	58	beta	beta	NOUN
chd-130	305	59	gemcitabine	gemcitabine	NOUN
chd-130	305	60	and	and	CCONJ
chd-130	305	61	cisplatin	cisplatin	PROPN
chd-130	305	62	p	p	PROPN
chd-130	305	63	ii	ii	PROPN
chd-130	305	64	nct00919061	nct00919061	PROPN
chd-130	305	65	guadecitabine	guadecitabine	PROPN
chd-130	305	66	durvalumab	durvalumab	PROPN
chd-130	305	67	dna	dna	PROPN
chd-130	305	68	methyltransferase	methyltransferase	NOUN
chd-130	305	69	programmed	program	VERB
chd-130	305	70	cell	cell	NOUN
chd-130	305	71	death-1	death-1	NUM
chd-130	305	72	ligand	ligand	NOUN
chd-130	305	73	1	1	NUM
chd-130	305	74	i	i	PRON
chd-130	305	75	nct03257761	nct03257761	VERB
chd-130	305	76	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	VERB
chd-130	305	77	e19	e19	ADJ
chd-130	305	78	cancer	cancer	NOUN
chd-130	305	79	health	health	NOUN
chd-130	305	80	disparities	disparity	NOUN
chd-130	305	81	research	research	NOUN
chd-130	305	82	sorafenib	sorafenib	NOUN
chd-130	305	83	raf	raf	PROPN
chd-130	305	84	kinase	kinase	PROPN
chd-130	305	85	,	,	PUNCT
chd-130	305	86	vegfr	vegfr	VERB
chd-130	305	87	2	2	NUM
chd-130	305	88	/	/	SYM
chd-130	305	89	pdgfr	pdgfr	ADJ
chd-130	305	90	-	-	PUNCT
chd-130	305	91	beta	beta	NOUN
chd-130	305	92	gemcitabine	gemcitabine	NOUN
chd-130	305	93	,	,	PUNCT
chd-130	305	94	oxaliplatin	oxaliplatin	X
chd-130	305	95	(	(	PUNCT
chd-130	305	96	gemox	gemox	PROPN
chd-130	305	97	)	)	PUNCT
chd-130	305	98	ii	ii	PROPN
chd-130	305	99	nct00955721	nct00955721	PROPN
chd-130	305	100	regorafenib	regorafenib	PROPN
chd-130	305	101	receptor	receptor	PROPN
chd-130	305	102	tyrosine	tyrosine	PROPN
chd-130	305	103	kinase	kinase	PROPN
chd-130	305	104	,	,	PUNCT
chd-130	305	105	vegfr2	vegfr2	PROPN
chd-130	305	106	ii	ii	PROPN
chd-130	305	107	nct02053376	nct02053376	NOUN
chd-130	305	108	pazopanib	pazopanib	PROPN
chd-130	305	109	receptor	receptor	NOUN
chd-130	305	110	tyrosine	tyrosine	NOUN
chd-130	305	111	kinases	kinase	NOUN
chd-130	305	112	including	include	VERB
chd-130	305	113	vegfr-1	vegfr-1	PROPN
chd-130	305	114	,	,	PUNCT
chd-130	305	115	vegfr	vegfr	NOUN
chd-130	305	116	2	2	NUM
chd-130	305	117	,	,	PUNCT
chd-130	305	118	vegfr-3	vegfr-3	NUM
chd-130	305	119	,	,	PUNCT
chd-130	305	120	pdgfr	pdgfr	ADJ
chd-130	305	121	-	-	PUNCT
chd-130	305	122	α	α	NOUN
chd-130	305	123	and	and	CCONJ
chd-130	305	124	–	–	PUNCT
chd-130	305	125	β	β	NOUN
chd-130	305	126	,	,	PUNCT
chd-130	305	127	fgfr	fgfr	ADJ
chd-130	305	128	-1	-1	PUNCT
chd-130	305	129	and	and	CCONJ
chd-130	305	130	-3	-3	ADJ
chd-130	305	131	gemcitabine	gemcitabine	PROPN
chd-130	305	132	ii	ii	PROPN
chd-130	305	133	nct01855724	nct01855724	PROPN
chd-130	305	134	ramucirumab	ramucirumab	PROPN
chd-130	305	135	vegfr2	vegfr2	PROPN
chd-130	305	136	ii	ii	PROPN
chd-130	305	137	nct02520141	nct02520141	PROPN
chd-130	305	138	lapatinib	lapatinib	PROPN
chd-130	305	139	her2	her2	PROPN
chd-130	305	140	,	,	PUNCT
chd-130	305	141	egfr	egfr	PROPN
chd-130	305	142	ii	ii	PROPN
chd-130	305	143	nct00107536	nct00107536	PROPN
chd-130	305	144	durvalumab	durvalumab	PROPN
chd-130	305	145	,	,	PUNCT
chd-130	305	146	tremelimumab	tremelimumab	NOUN
chd-130	305	147	programmed	program	VERB
chd-130	305	148	cell	cell	NOUN
chd-130	305	149	death-1	death-1	NUM
chd-130	305	150	ligand	ligand	ADJ
chd-130	305	151	1	1	NUM
chd-130	305	152	ctla-4	ctla-4	NOUN
chd-130	305	153	gemcitabine	gemcitabine	NOUN
chd-130	305	154	,	,	PUNCT
chd-130	305	155	cisplatin	cisplatin	PROPN
chd-130	305	156	ii	ii	PROPN
chd-130	305	157	nct03473574	nct03473574	ADJ
chd-130	305	158	pembrolizumab	pembrolizumab	NOUN
chd-130	305	159	programmed	program	VERB
chd-130	305	160	cell	cell	NOUN
chd-130	305	161	death	death	NOUN
chd-130	305	162	protein	protein	NOUN
chd-130	305	163	1	1	NUM
chd-130	305	164	gemcitabine	gemcitabine	NOUN
chd-130	305	165	,	,	PUNCT
chd-130	305	166	cisplatin	cisplatin	NOUN
chd-130	305	167	ii	ii	PROPN
chd-130	305	168	nct03260712	nct03260712	NOUN
chd-130	305	169	in	in	ADP
chd-130	305	170	patients	patient	NOUN
chd-130	305	171	with	with	ADP
chd-130	305	172	advanced	advanced	ADJ
chd-130	305	173	stages	stage	NOUN
chd-130	305	174	of	of	ADP
chd-130	305	175	unresectable	unresectable	ADJ
chd-130	305	176	gbc	gbc	NOUN
chd-130	305	177	,	,	PUNCT
chd-130	305	178	treatment	treatment	NOUN
chd-130	305	179	options	option	NOUN
chd-130	305	180	are	be	AUX
chd-130	305	181	limited	limit	VERB
chd-130	305	182	because	because	SCONJ
chd-130	305	183	of	of	ADP
chd-130	305	184	no	no	DET
chd-130	305	185	so	so	ADV
chd-130	305	186	well	well	ADV
chd-130	305	187	defined	define	VERB
chd-130	305	188	molecular	molecular	ADJ
chd-130	305	189	targets	target	NOUN
chd-130	305	190	.	.	PUNCT
chd-130	306	1	complete	complete	ADJ
chd-130	306	2	surgical	surgical	ADJ
chd-130	306	3	resection	resection	NOUN
chd-130	306	4	remains	remain	VERB
chd-130	306	5	the	the	DET
chd-130	306	6	only	only	ADJ
chd-130	306	7	curative	curative	ADJ
chd-130	306	8	modality	modality	NOUN
chd-130	306	9	to	to	PART
chd-130	306	10	treat	treat	VERB
chd-130	306	11	patients	patient	NOUN
chd-130	306	12	with	with	ADP
chd-130	306	13	gbc	gbc	PROPN
chd-130	306	14	,	,	PUNCT
chd-130	306	15	offering	offer	VERB
chd-130	306	16	benefit	benefit	NOUN
chd-130	306	17	only	only	ADV
chd-130	306	18	for	for	ADP
chd-130	306	19	patients	patient	NOUN
chd-130	306	20	with	with	ADP
chd-130	306	21	localized	localized	ADJ
chd-130	306	22	disease	disease	NOUN
chd-130	306	23	.	.	PUNCT
chd-130	307	1	as	as	ADP
chd-130	307	2	evident	evident	ADJ
chd-130	307	3	from	from	ADP
chd-130	307	4	the	the	DET
chd-130	307	5	past	past	ADJ
chd-130	307	6	studies	study	NOUN
chd-130	307	7	on	on	ADP
chd-130	307	8	gbc	gbc	PROPN
chd-130	307	9	,	,	PUNCT
chd-130	307	10	most	most	ADJ
chd-130	307	11	research	research	NOUN
chd-130	307	12	efforts	effort	NOUN
chd-130	307	13	have	have	AUX
chd-130	307	14	focused	focus	VERB
chd-130	307	15	on	on	ADP
chd-130	307	16	identifying	identify	VERB
chd-130	307	17	genetic	genetic	ADJ
chd-130	307	18	mutations	mutation	NOUN
chd-130	307	19	,	,	PUNCT
chd-130	307	20	which	which	PRON
chd-130	307	21	did	do	AUX
chd-130	307	22	not	not	PART
chd-130	307	23	provide	provide	VERB
chd-130	307	24	much	much	ADJ
chd-130	307	25	insight	insight	NOUN
chd-130	307	26	into	into	ADP
chd-130	307	27	signaling	signal	VERB
chd-130	307	28	molecules	molecule	NOUN
chd-130	307	29	that	that	PRON
chd-130	307	30	could	could	AUX
chd-130	307	31	be	be	AUX
chd-130	307	32	targeted	target	VERB
chd-130	307	33	therapeutically	therapeutically	ADV
chd-130	307	34	.	.	PUNCT
chd-130	308	1	gbc	gbc	NOUN
chd-130	308	2	still	still	ADV
chd-130	308	3	continues	continue	VERB
chd-130	308	4	to	to	PART
chd-130	308	5	have	have	VERB
chd-130	308	6	a	a	DET
chd-130	308	7	poor	poor	ADJ
chd-130	308	8	prognosis	prognosis	NOUN
chd-130	308	9	worldwide	worldwide	ADV
chd-130	308	10	.	.	PUNCT
chd-130	309	1	it	it	PRON
chd-130	309	2	is	be	AUX
chd-130	309	3	widely	widely	ADV
chd-130	309	4	accepted	accept	VERB
chd-130	309	5	that	that	SCONJ
chd-130	309	6	cancer	cancer	NOUN
chd-130	309	7	is	be	AUX
chd-130	309	8	primarily	primarily	ADV
chd-130	309	9	a	a	DET
chd-130	309	10	signaling	signal	VERB
chd-130	309	11	disease	disease	NOUN
chd-130	309	12	.	.	PUNCT
chd-130	310	1	therefore	therefore	ADV
chd-130	310	2	,	,	PUNCT
chd-130	310	3	one	one	NUM
chd-130	310	4	strategy	strategy	NOUN
chd-130	310	5	to	to	PART
chd-130	310	6	identify	identify	VERB
chd-130	310	7	functional	functional	ADJ
chd-130	310	8	therapeutic	therapeutic	ADJ
chd-130	310	9	targets	target	NOUN
chd-130	310	10	in	in	ADP
chd-130	310	11	gbc	gbc	PROPN
chd-130	310	12	is	be	AUX
chd-130	310	13	to	to	PART
chd-130	310	14	get	get	VERB
chd-130	310	15	deeper	deep	ADJ
chd-130	310	16	insights	insight	NOUN
chd-130	310	17	into	into	ADP
chd-130	310	18	major	major	ADJ
chd-130	310	19	signaling	signal	VERB
chd-130	310	20	mechanisms	mechanism	NOUN
chd-130	310	21	underlying	underlie	VERB
chd-130	310	22	initiation	initiation	NOUN
chd-130	310	23	and	and	CCONJ
chd-130	310	24	progression	progression	NOUN
chd-130	310	25	of	of	ADP
chd-130	310	26	gallbladder	gallbladder	NOUN
chd-130	310	27	cancer	cancer	NOUN
chd-130	310	28	,	,	PUNCT
chd-130	310	29	which	which	PRON
chd-130	310	30	will	will	AUX
chd-130	310	31	have	have	VERB
chd-130	310	32	potential	potential	NOUN
chd-130	310	33	to	to	PART
chd-130	310	34	be	be	AUX
chd-130	310	35	used	use	VERB
chd-130	310	36	in	in	ADP
chd-130	310	37	clinical	clinical	ADJ
chd-130	310	38	decision	decision	NOUN
chd-130	310	39	-	-	PUNCT
chd-130	310	40	making	making	NOUN
chd-130	310	41	as	as	ADV
chd-130	310	42	well	well	ADV
chd-130	310	43	as	as	ADV
chd-130	310	44	conducive	conducive	ADJ
chd-130	310	45	to	to	ADP
chd-130	310	46	the	the	DET
chd-130	310	47	design	design	NOUN
chd-130	310	48	of	of	ADP
chd-130	310	49	personalized	personalized	ADJ
chd-130	310	50	cancer	cancer	NOUN
chd-130	310	51	treatments	treatment	NOUN
chd-130	310	52	.	.	PUNCT
chd-130	311	1	given	give	VERB
chd-130	311	2	the	the	DET
chd-130	311	3	ethnic	ethnic	ADJ
chd-130	311	4	,	,	PUNCT
chd-130	311	5	geographic	geographic	ADJ
chd-130	311	6	,	,	PUNCT
chd-130	311	7	and	and	CCONJ
chd-130	311	8	gender	gender	NOUN
chd-130	311	9	disparities	disparity	NOUN
chd-130	311	10	associated	associate	VERB
chd-130	311	11	with	with	ADP
chd-130	311	12	gallbladder	gallbladder	NOUN
chd-130	311	13	cancer	cancer	NOUN
chd-130	311	14	,	,	PUNCT
chd-130	311	15	lack	lack	NOUN
chd-130	311	16	of	of	ADP
chd-130	311	17	funding	funding	NOUN
chd-130	311	18	and	and	CCONJ
chd-130	311	19	resources	resource	NOUN
chd-130	311	20	to	to	PART
chd-130	311	21	initiate	initiate	VERB
chd-130	311	22	prospective	prospective	ADJ
chd-130	311	23	studies	study	NOUN
chd-130	311	24	using	use	VERB
chd-130	311	25	cutting	cut	VERB
chd-130	311	26	edge	edge	NOUN
chd-130	311	27	omics	omic	NOUN
chd-130	311	28	studies	study	NOUN
chd-130	311	29	to	to	ADP
chd-130	311	30	decipher	decipher	NOUN
chd-130	311	31	signaling	signal	VERB
chd-130	311	32	events	event	NOUN
chd-130	311	33	underlying	underlie	VERB
chd-130	311	34	gallbladder	gallbladder	NOUN
chd-130	311	35	cancer	cancer	NOUN
chd-130	311	36	is	be	AUX
chd-130	311	37	a	a	DET
chd-130	311	38	major	major	ADJ
chd-130	311	39	impediment	impediment	NOUN
chd-130	311	40	.	.	PUNCT
chd-130	312	1	in	in	ADP
chd-130	312	2	recent	recent	ADJ
chd-130	312	3	years	year	NOUN
chd-130	312	4	,	,	PUNCT
chd-130	312	5	with	with	ADP
chd-130	312	6	identification	identification	NOUN
chd-130	312	7	of	of	ADP
chd-130	312	8	few	few	ADJ
chd-130	312	9	molecular	molecular	ADJ
chd-130	312	10	targets	target	NOUN
chd-130	312	11	in	in	ADP
chd-130	312	12	gbc	gbc	PROPN
chd-130	312	13	such	such	ADJ
chd-130	312	14	as	as	ADP
chd-130	312	15	erbb2	erbb2	PROPN
chd-130	312	16	,	,	PUNCT
chd-130	312	17	erbb3	erbb3	PROPN
chd-130	312	18	,	,	PUNCT
chd-130	312	19	and	and	CCONJ
chd-130	312	20	myc	myc	PROPN
chd-130	312	21	amplifications	amplification	NOUN
chd-130	312	22	,	,	PUNCT
chd-130	312	23	it	it	PRON
chd-130	312	24	is	be	AUX
chd-130	312	25	becoming	become	VERB
chd-130	312	26	apparent	apparent	ADJ
chd-130	312	27	that	that	SCONJ
chd-130	312	28	development	development	NOUN
chd-130	312	29	of	of	ADP
chd-130	312	30	effective	effective	ADJ
chd-130	312	31	therapies	therapy	NOUN
chd-130	312	32	will	will	AUX
chd-130	312	33	be	be	AUX
chd-130	312	34	benefitted	benefit	VERB
chd-130	312	35	by	by	ADP
chd-130	312	36	focusing	focus	VERB
chd-130	312	37	on	on	ADP
chd-130	312	38	personalized	personalized	ADJ
chd-130	312	39	therapy	therapy	NOUN
chd-130	312	40	such	such	ADJ
chd-130	312	41	as	as	ADP
chd-130	312	42	by	by	ADP
chd-130	312	43	identification	identification	NOUN
chd-130	312	44	and	and	CCONJ
chd-130	312	45	targeting	targeting	NOUN
chd-130	312	46	of	of	ADP
chd-130	312	47	genetic	genetic	ADJ
chd-130	312	48	mutations	mutation	NOUN
chd-130	312	49	specific	specific	ADJ
chd-130	312	50	to	to	ADP
chd-130	312	51	an	an	DET
chd-130	312	52	individual	individual	ADJ
chd-130	312	53	patient	patient	NOUN
chd-130	312	54	.	.	PUNCT
chd-130	313	1	investigation	investigation	NOUN
chd-130	313	2	of	of	ADP
chd-130	313	3	epidermal	epidermal	ADJ
chd-130	313	4	growth	growth	NOUN
chd-130	313	5	factor	factor	NOUN
chd-130	313	6	receptors	receptor	NOUN
chd-130	313	7	(	(	PUNCT
chd-130	313	8	egfr	egfr	X
chd-130	313	9	)	)	PUNCT
chd-130	313	10	such	such	ADJ
chd-130	313	11	as	as	ADP
chd-130	313	12	cetuximab	cetuximab	NOUN
chd-130	313	13	and	and	CCONJ
chd-130	313	14	erlotinib	erlotinib	NOUN
chd-130	313	15	in	in	ADP
chd-130	313	16	a	a	DET
chd-130	313	17	clinical	clinical	ADJ
chd-130	313	18	trial	trial	NOUN
chd-130	313	19	for	for	ADP
chd-130	313	20	gbc	gbc	NOUN
chd-130	313	21	patients	patient	NOUN
chd-130	313	22	’	'	PUNCT
chd-130	313	23	cohorts	cohort	NOUN
chd-130	313	24	will	will	AUX
chd-130	313	25	in	in	ADP
chd-130	313	26	turn	turn	NOUN
chd-130	313	27	help	help	VERB
chd-130	313	28	decide	decide	VERB
chd-130	313	29	whether	whether	SCONJ
chd-130	313	30	or	or	CCONJ
chd-130	313	31	not	not	PART
chd-130	313	32	such	such	ADJ
chd-130	313	33	targeted	target	VERB
chd-130	313	34	therapeutics	therapeutic	NOUN
chd-130	313	35	can	can	AUX
chd-130	313	36	be	be	AUX
chd-130	313	37	recommended	recommend	VERB
chd-130	313	38	as	as	ADP
chd-130	313	39	standard	standard	NOUN
chd-130	313	40	-	-	PUNCT
chd-130	313	41	of	of	ADP
chd-130	313	42	-	-	PUNCT
chd-130	313	43	care	care	NOUN
chd-130	313	44	.	.	PUNCT
chd-130	314	1	acknowledgements	acknowledgement	NOUN
chd-130	314	2	authors	author	NOUN
chd-130	314	3	acknowledge	acknowledge	VERB
chd-130	314	4	support	support	NOUN
chd-130	314	5	by	by	ADP
chd-130	314	6	sylvester	sylvester	PROPN
chd-130	314	7	comprehensive	comprehensive	ADJ
chd-130	314	8	cancer	cancer	NOUN
chd-130	314	9	center	center	NOUN
chd-130	314	10	startup	startup	NOUN
chd-130	314	11	funds	fund	NOUN
chd-130	314	12	(	(	PUNCT
chd-130	314	13	to	to	ADP
chd-130	314	14	mks	mks	PROPN
chd-130	314	15	)	)	PUNCT
chd-130	314	16	as	as	ADV
chd-130	314	17	well	well	ADV
chd-130	314	18	as	as	ADP
chd-130	314	19	departmental	departmental	ADJ
chd-130	314	20	support	support	NOUN
chd-130	314	21	by	by	ADP
chd-130	314	22	nih	nih	PROPN
chd-130	314	23	grants	grants	PROPN
chd-130	314	24	r01	r01	PROPN
chd-130	314	25	ca124723	ca124723	PROPN
chd-130	314	26	and	and	CCONJ
chd-130	314	27	r01	r01	PROPN
chd-130	314	28	ca170946	ca170946	PROPN
chd-130	314	29	.	.	PUNCT
chd-130	315	1	special	special	ADJ
chd-130	315	2	thanks	thank	NOUN
chd-130	315	3	to	to	ADP
chd-130	315	4	anthony	anthony	PROPN
chd-130	315	5	ferrantella	ferrantella	PROPN
chd-130	315	6	,	,	PUNCT
chd-130	315	7	a	a	DET
chd-130	315	8	gastrointestinal	gastrointestinal	ADJ
chd-130	315	9	surgeon	surgeon	NOUN
chd-130	315	10	at	at	ADP
chd-130	315	11	university	university	PROPN
chd-130	315	12	of	of	ADP
chd-130	315	13	miami	miami	PROPN
chd-130	315	14	miller	miller	PROPN
chd-130	315	15	school	school	PROPN
chd-130	315	16	of	of	ADP
chd-130	315	17	medicine	medicine	NOUN
chd-130	315	18	,	,	PUNCT
chd-130	315	19	for	for	ADP
chd-130	315	20	reading	read	VERB
chd-130	315	21	the	the	DET
chd-130	315	22	manuscript	manuscript	NOUN
chd-130	315	23	and	and	CCONJ
chd-130	315	24	correcting	correct	VERB
chd-130	315	25	it	it	PRON
chd-130	315	26	where	where	SCONJ
chd-130	315	27	ever	ever	ADV
chd-130	315	28	needed	need	VERB
chd-130	315	29	.	.	PUNCT
chd-130	316	1	conflict	conflict	NOUN
chd-130	316	2	of	of	ADP
chd-130	316	3	interest	interest	NOUN
chd-130	316	4	the	the	DET
chd-130	316	5	authors	author	NOUN
chd-130	316	6	declare	declare	VERB
chd-130	316	7	no	no	DET
chd-130	316	8	conflict	conflict	NOUN
chd-130	316	9	of	of	ADP
chd-130	316	10	interest	interest	NOUN
chd-130	316	11	.	.	PUNCT
chd-130	317	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-130	317	2	e20	e20	NOUN
chd-130	317	3	cancer	cancer	NOUN
chd-130	317	4	health	health	NOUN
chd-130	317	5	disparities	disparity	NOUN
chd-130	317	6	research	research	NOUN
chd-130	317	7	authors	author	NOUN
chd-130	317	8	’	’	PART
chd-130	317	9	contributions	contribution	NOUN
chd-130	317	10	this	this	PRON
chd-130	317	11	invited	invite	VERB
chd-130	317	12	review	review	NOUN
chd-130	317	13	article	article	NOUN
chd-130	317	14	was	be	AUX
chd-130	317	15	conceptualized	conceptualize	VERB
chd-130	317	16	and	and	CCONJ
chd-130	317	17	designed	design	VERB
chd-130	317	18	by	by	ADP
chd-130	317	19	bm	bm	PROPN
chd-130	317	20	and	and	CCONJ
chd-130	317	21	mks	mks	PROPN
chd-130	317	22	.	.	PROPN
chd-130	318	1	review	review	NOUN
chd-130	318	2	of	of	ADP
chd-130	318	3	literature	literature	NOUN
chd-130	318	4	and	and	CCONJ
chd-130	318	5	other	other	ADJ
chd-130	318	6	data	datum	NOUN
chd-130	318	7	was	be	AUX
chd-130	318	8	collected	collect	VERB
chd-130	318	9	by	by	ADP
chd-130	318	10	cpg	cpg	NOUN
chd-130	318	11	,	,	PUNCT
chd-130	318	12	all	all	PRON
chd-130	318	13	,	,	PUNCT
chd-130	318	14	and	and	CCONJ
chd-130	318	15	mks	mks	PROPN
chd-130	318	16	.	.	PUNCT
chd-130	319	1	article	article	NOUN
chd-130	319	2	was	be	AUX
chd-130	319	3	written	write	VERB
chd-130	319	4	,	,	PUNCT
chd-130	319	5	reviewed	review	VERB
chd-130	319	6	,	,	PUNCT
chd-130	319	7	and	and	CCONJ
chd-130	319	8	edited	edit	VERB
chd-130	319	9	by	by	ADP
chd-130	319	10	mrk	mrk	PROPN
chd-130	319	11	and	and	CCONJ
chd-130	319	12	mks	mks	PROPN
chd-130	319	13	.	.	PROPN
chd-130	320	1	references	reference	NOUN
chd-130	320	2	agrawal	agrawal	PROPN
chd-130	320	3	,	,	PUNCT
chd-130	320	4	m.	m.	NOUN
chd-130	320	5	(	(	PUNCT
chd-130	320	6	2015	2015	NUM
chd-130	320	7	)	)	PUNCT
chd-130	320	8	.	.	PUNCT
chd-130	321	1	natural	natural	ADJ
chd-130	321	2	polyphenols	polyphenol	NOUN
chd-130	321	3	based	base	VERB
chd-130	321	4	new	new	ADJ
chd-130	321	5	therapeutic	therapeutic	ADJ
chd-130	321	6	avenues	avenue	NOUN
chd-130	321	7	for	for	ADP
chd-130	321	8	advanced	advanced	ADJ
chd-130	321	9	biomedical	biomedical	ADJ
chd-130	321	10	applications	application	NOUN
chd-130	321	11	.	.	PUNCT
chd-130	322	1	drug	drug	NOUN
chd-130	322	2	metab	metab	PROPN
chd-130	322	3	rev	rev	PROPN
chd-130	322	4	.	.	PROPN
chd-130	322	5	47	47	NUM
chd-130	322	6	,	,	PUNCT
chd-130	322	7	420	420	NUM
chd-130	322	8	-	-	SYM
chd-130	322	9	30	30	NUM
chd-130	322	10	.	.	PUNCT
chd-130	323	1	ajiki	ajiki	PROPN
chd-130	323	2	,	,	PUNCT
chd-130	323	3	t.	t.	NOUN
chd-130	323	4	,	,	PUNCT
chd-130	323	5	onoyama	onoyama	NOUN
chd-130	323	6	,	,	PUNCT
chd-130	323	7	h.	h.	PROPN
chd-130	323	8	,	,	PUNCT
chd-130	323	9	yamamoto	yamamoto	PROPN
chd-130	323	10	,	,	PUNCT
chd-130	323	11	m.	m.	NOUN
chd-130	323	12	,	,	PUNCT
chd-130	323	13	asaka	asaka	PROPN
chd-130	323	14	,	,	PUNCT
chd-130	323	15	k.	k.	PROPN
chd-130	323	16	,	,	PUNCT
chd-130	323	17	fujimori	fujimori	PROPN
chd-130	323	18	,	,	PUNCT
chd-130	323	19	t.	t.	PROPN
chd-130	323	20	,	,	PUNCT
chd-130	323	21	maeda	maeda	PROPN
chd-130	323	22	,	,	PUNCT
chd-130	323	23	s.	s.	PROPN
chd-130	323	24	,	,	PUNCT
chd-130	323	25	saitoh	saitoh	PROPN
chd-130	323	26	,	,	PUNCT
chd-130	323	27	y.	y.	PROPN
chd-130	323	28	(	(	PUNCT
chd-130	323	29	1996	1996	NUM
chd-130	323	30	)	)	PUNCT
chd-130	323	31	.	.	PUNCT
chd-130	324	1	p53	p53	NOUN
chd-130	324	2	protein	protein	NOUN
chd-130	324	3	expression	expression	NOUN
chd-130	324	4	and	and	CCONJ
chd-130	324	5	prognosis	prognosis	NOUN
chd-130	324	6	in	in	ADP
chd-130	324	7	gallbladder	gallbladder	NOUN
chd-130	324	8	carcinoma	carcinoma	NOUN
chd-130	324	9	and	and	CCONJ
chd-130	324	10	premalignant	premalignant	ADJ
chd-130	324	11	lesions	lesion	NOUN
chd-130	324	12	.	.	PUNCT
chd-130	325	1	hepatogastroenterology	hepatogastroenterology	NOUN
chd-130	325	2	.	.	PUNCT
chd-130	326	1	43	43	NUM
chd-130	326	2	,	,	PUNCT
chd-130	326	3	521	521	NUM
chd-130	326	4	-	-	SYM
chd-130	326	5	6	6	NUM
chd-130	326	6	.	.	PUNCT
chd-130	327	1	alvarez	alvarez	PROPN
chd-130	327	2	,	,	PUNCT
chd-130	327	3	h.	h.	PROPN
chd-130	327	4	,	,	PUNCT
chd-130	327	5	corvalan	corvalan	PROPN
chd-130	327	6	,	,	PUNCT
chd-130	327	7	a.	a.	PROPN
chd-130	327	8	,	,	PUNCT
chd-130	327	9	roa	roa	PROPN
chd-130	327	10	,	,	PUNCT
chd-130	327	11	j.c	j.c	PROPN
chd-130	327	12	.	.	PROPN
chd-130	327	13	,	,	PUNCT
chd-130	327	14	argani	argani	PROPN
chd-130	327	15	,	,	PUNCT
chd-130	327	16	p.	p.	PROPN
chd-130	327	17	,	,	PUNCT
chd-130	327	18	murillo	murillo	PROPN
chd-130	327	19	,	,	PUNCT
chd-130	327	20	f.	f.	PROPN
chd-130	327	21	,	,	PUNCT
chd-130	327	22	edwards	edwards	PROPN
chd-130	327	23	,	,	PUNCT
chd-130	327	24	j.	j.	PROPN
chd-130	327	25	,	,	PUNCT
chd-130	327	26	beaty	beaty	PROPN
chd-130	327	27	,	,	PUNCT
chd-130	327	28	r.	r.	PROPN
chd-130	327	29	,	,	PUNCT
chd-130	327	30	feldmann	feldmann	PROPN
chd-130	327	31	,	,	PUNCT
chd-130	327	32	g.	g.	PROPN
chd-130	327	33	,	,	PUNCT
chd-130	327	34	hong	hong	PROPN
chd-130	327	35	,	,	PUNCT
chd-130	327	36	s.m	s.m	PROPN
chd-130	327	37	.	.	PROPN
chd-130	327	38	,	,	PUNCT
chd-130	327	39	mullendore	mullendore	PROPN
chd-130	327	40	,	,	PUNCT
chd-130	327	41	m.	m.	NOUN
chd-130	327	42	,	,	PUNCT
chd-130	327	43	et	et	PROPN
chd-130	327	44	al	al	PROPN
chd-130	327	45	.	.	PUNCT
chd-130	327	46	(	(	PUNCT
chd-130	327	47	2008	2008	NUM
chd-130	327	48	)	)	PUNCT
chd-130	327	49	.	.	PUNCT
chd-130	328	1	serial	serial	ADJ
chd-130	328	2	analysis	analysis	NOUN
chd-130	328	3	of	of	ADP
chd-130	328	4	gene	gene	NOUN
chd-130	328	5	expression	expression	NOUN
chd-130	328	6	identifies	identify	VERB
chd-130	328	7	connective	connective	ADJ
chd-130	328	8	tissue	tissue	NOUN
chd-130	328	9	growth	growth	NOUN
chd-130	328	10	factor	factor	NOUN
chd-130	328	11	expression	expression	NOUN
chd-130	328	12	as	as	ADP
chd-130	328	13	a	a	DET
chd-130	328	14	prognostic	prognostic	ADJ
chd-130	328	15	biomarker	biomarker	NOUN
chd-130	328	16	in	in	ADP
chd-130	328	17	gallbladder	gallbladder	NOUN
chd-130	328	18	cancer	cancer	NOUN
chd-130	328	19	.	.	PUNCT
chd-130	329	1	clin	clin	PROPN
chd-130	329	2	cancer	cancer	NOUN
chd-130	329	3	res	re	NOUN
chd-130	329	4	.	.	PUNCT
chd-130	330	1	14	14	NUM
chd-130	330	2	,	,	PUNCT
chd-130	330	3	2631	2631	NUM
chd-130	330	4	-	-	SYM
chd-130	330	5	8	8	NUM
chd-130	330	6	.	.	PUNCT
chd-130	330	7	andia	andia	PROPN
chd-130	330	8	,	,	PUNCT
chd-130	330	9	m.e	m.e	PROPN
chd-130	330	10	.	.	PROPN
chd-130	330	11	,	,	PUNCT
chd-130	330	12	hsing	hsing	PROPN
chd-130	330	13	,	,	PUNCT
chd-130	330	14	a.w	a.w	PROPN
chd-130	330	15	.	.	PROPN
chd-130	330	16	,	,	PUNCT
chd-130	330	17	andreotti	andreotti	PROPN
chd-130	330	18	,	,	PUNCT
chd-130	330	19	g.	g.	PROPN
chd-130	330	20	,	,	PUNCT
chd-130	330	21	ferreccio	ferreccio	NOUN
chd-130	330	22	,	,	PUNCT
chd-130	330	23	c.	c.	PROPN
chd-130	330	24	,	,	PUNCT
chd-130	330	25	(	(	PUNCT
chd-130	330	26	2008	2008	NUM
chd-130	330	27	)	)	PUNCT
chd-130	330	28	.	.	PUNCT
chd-130	331	1	geographic	geographic	ADJ
chd-130	331	2	variation	variation	NOUN
chd-130	331	3	ofgallbladder	ofgallbladder	NOUN
chd-130	331	4	cancer	cancer	NOUN
chd-130	331	5	mortality	mortality	NOUN
chd-130	331	6	and	and	CCONJ
chd-130	331	7	risk	risk	NOUN
chd-130	331	8	factors	factor	NOUN
chd-130	331	9	in	in	ADP
chd-130	331	10	chile	chile	PROPN
chd-130	331	11	:	:	PUNCT
chd-130	331	12	a	a	DET
chd-130	331	13	population	population	NOUN
chd-130	331	14	-	-	PUNCT
chd-130	331	15	based	base	VERB
chd-130	331	16	ecologic	ecologic	ADJ
chd-130	331	17	study	study	NOUN
chd-130	331	18	.	.	PUNCT
chd-130	332	1	int	int	PROPN
chd-130	332	2	j	j	PROPN
chd-130	332	3	cancer.sep	cancer.sep	NOUN
chd-130	332	4	.	.	NOUN
chd-130	332	5	123	123	NUM
chd-130	332	6	,	,	PUNCT
chd-130	332	7	1411	1411	NUM
chd-130	332	8	-	-	SYM
chd-130	332	9	6	6	NUM
chd-130	332	10	.	.	PUNCT
chd-130	333	1	bloomston	bloomston	NOUN
chd-130	333	2	,	,	PUNCT
chd-130	333	3	m.	m.	NOUN
chd-130	333	4	,	,	PUNCT
chd-130	333	5	kneile	kneile	NOUN
chd-130	333	6	,	,	PUNCT
chd-130	333	7	j.	j.	PROPN
chd-130	333	8	,	,	PUNCT
chd-130	333	9	butterfield	butterfield	PROPN
chd-130	333	10	,	,	PUNCT
chd-130	333	11	m.	m.	NOUN
chd-130	333	12	,	,	PUNCT
chd-130	333	13	dillhoff	dillhoff	NOUN
chd-130	333	14	,	,	PUNCT
chd-130	333	15	m.	m.	NOUN
chd-130	333	16	,	,	PUNCT
chd-130	333	17	muscarella	muscarella	NOUN
chd-130	333	18	,	,	PUNCT
chd-130	333	19	p.	p.	PROPN
chd-130	333	20	,	,	PUNCT
chd-130	333	21	ellison	ellison	PROPN
chd-130	333	22	,	,	PUNCT
chd-130	333	23	e.c	e.c	PROPN
chd-130	333	24	.	.	PROPN
chd-130	333	25	,	,	PUNCT
chd-130	333	26	melvin	melvin	PROPN
chd-130	333	27	,	,	PUNCT
chd-130	333	28	w.s	w.s	PROPN
chd-130	333	29	.	.	PROPN
chd-130	333	30	,	,	PUNCT
chd-130	333	31	croce	croce	PROPN
chd-130	333	32	,	,	PUNCT
chd-130	333	33	c.m	c.m	PROPN
chd-130	333	34	.	.	PROPN
chd-130	333	35	,	,	PUNCT
chd-130	333	36	pichiorri	pichiorri	PROPN
chd-130	333	37	,	,	PUNCT
chd-130	333	38	f.	f.	PROPN
chd-130	333	39	,	,	PUNCT
chd-130	333	40	huebner	huebner	PROPN
chd-130	333	41	,	,	PUNCT
chd-130	333	42	k.	k.	PROPN
chd-130	333	43	,	,	PUNCT
chd-130	333	44	frankel	frankel	PROPN
chd-130	333	45	,	,	PUNCT
chd-130	333	46	w.l	w.l	PROPN
chd-130	333	47	.	.	PROPN
chd-130	333	48	(	(	PUNCT
chd-130	333	49	2009	2009	NUM
chd-130	333	50	)	)	PUNCT
chd-130	333	51	.	.	PUNCT
chd-130	334	1	coordinate	coordinate	VERB
chd-130	334	2	loss	loss	NOUN
chd-130	334	3	of	of	ADP
chd-130	334	4	fragile	fragile	ADJ
chd-130	334	5	gene	gene	NOUN
chd-130	334	6	expression	expression	NOUN
chd-130	334	7	in	in	ADP
chd-130	334	8	pancreatobiliary	pancreatobiliary	ADJ
chd-130	334	9	cancers	cancer	NOUN
chd-130	334	10	:	:	PUNCT
chd-130	335	1	correlations	correlation	NOUN
chd-130	335	2	among	among	ADP
chd-130	335	3	markers	marker	NOUN
chd-130	335	4	and	and	CCONJ
chd-130	335	5	clinical	clinical	ADJ
chd-130	335	6	features	feature	NOUN
chd-130	335	7	.	.	PUNCT
chd-130	336	1	ann	ann	PROPN
chd-130	336	2	surg	surg	PROPN
chd-130	336	3	oncol	oncol	PROPN
chd-130	336	4	.	.	PUNCT
chd-130	337	1	16	16	NUM
chd-130	337	2	,	,	PUNCT
chd-130	337	3	2331	2331	NUM
chd-130	337	4	-	-	SYM
chd-130	337	5	8	8	NUM
chd-130	337	6	.	.	PUNCT
chd-130	337	7	brower	brower	NOUN
chd-130	337	8	,	,	PUNCT
chd-130	337	9	v.	v.	PROPN
chd-130	337	10	(	(	PUNCT
chd-130	337	11	2010	2010	NUM
chd-130	337	12	)	)	PUNCT
chd-130	337	13	.	.	PUNCT
chd-130	338	1	braf	braf	NOUN
chd-130	338	2	inhibitors	inhibitor	NOUN
chd-130	338	3	:	:	PUNCT
chd-130	338	4	research	research	NOUN
chd-130	338	5	accelerates	accelerate	VERB
chd-130	338	6	in	in	ADP
chd-130	338	7	wake	wake	NOUN
chd-130	338	8	of	of	ADP
chd-130	338	9	positive	positive	ADJ
chd-130	338	10	findings	finding	NOUN
chd-130	338	11	.	.	PUNCT
chd-130	339	1	j	j	PROPN
chd-130	339	2	natl	natl	PROPN
chd-130	339	3	cancer	cancer	PROPN
chd-130	339	4	inst	inst	PROPN
chd-130	339	5	.	.	PROPN
chd-130	340	1	102	102	NUM
chd-130	340	2	,	,	PUNCT
chd-130	340	3	214	214	NUM
chd-130	340	4	-	-	SYM
chd-130	340	5	5	5	NUM
chd-130	340	6	.	.	PUNCT
chd-130	340	7	chang	chang	PROPN
chd-130	340	8	,	,	PUNCT
chd-130	340	9	h.j	h.j	PROPN
chd-130	340	10	.	.	PROPN
chd-130	340	11	,	,	PUNCT
chd-130	340	12	kim	kim	PROPN
chd-130	340	13	,	,	PUNCT
chd-130	340	14	s.w	s.w	PROPN
chd-130	340	15	.	.	PROPN
chd-130	340	16	,	,	PUNCT
chd-130	340	17	kim	kim	PROPN
chd-130	340	18	,	,	PUNCT
chd-130	340	19	y.t	y.t	PROPN
chd-130	340	20	.	.	PROPN
chd-130	340	21	,	,	PUNCT
chd-130	340	22	kim	kim	PROPN
chd-130	340	23	,	,	PUNCT
chd-130	340	24	w.h	w.h	PROPN
chd-130	340	25	.	.	PROPN
chd-130	340	26	(	(	PUNCT
chd-130	340	27	1999	1999	NUM
chd-130	340	28	)	)	PUNCT
chd-130	340	29	.	.	PUNCT
chd-130	341	1	loss	loss	NOUN
chd-130	341	2	of	of	ADP
chd-130	341	3	heterozygosity	heterozygosity	NOUN
chd-130	341	4	in	in	ADP
chd-130	341	5	dysplasia	dysplasia	NOUN
chd-130	341	6	and	and	CCONJ
chd-130	341	7	carcinoma	carcinoma	NOUN
chd-130	341	8	of	of	ADP
chd-130	341	9	the	the	DET
chd-130	341	10	gallbladder	gallbladder	NOUN
chd-130	341	11	.	.	PUNCT
chd-130	342	1	mod	mod	PROPN
chd-130	342	2	pathol	pathol	PROPN
chd-130	342	3	.	.	PUNCT
chd-130	343	1	12	12	NUM
chd-130	343	2	,	,	PUNCT
chd-130	343	3	763	763	NUM
chd-130	343	4	-	-	SYM
chd-130	343	5	9	9	NUM
chd-130	343	6	.	.	PUNCT
chd-130	344	1	chhabra	chhabra	PROPN
chd-130	344	2	d	d	PROPN
chd-130	344	3	,	,	PUNCT
chd-130	344	4	oda	oda	PROPN
chd-130	344	5	k	k	PROPN
chd-130	344	6	,	,	PUNCT
chd-130	344	7	jagannath	jagannath	PROPN
chd-130	344	8	p	p	PROPN
chd-130	344	9	,	,	PUNCT
chd-130	344	10	utsunomiya	utsunomiya	PROPN
chd-130	344	11	h	h	NOUN
chd-130	344	12	,	,	PUNCT
chd-130	344	13	takekoshi	takekoshi	PROPN
chd-130	344	14	s	s	PROPN
chd-130	344	15	,	,	PUNCT
chd-130	344	16	nimura	nimura	ADV
chd-130	344	17	y.	y.	PROPN
chd-130	344	18	(	(	PUNCT
chd-130	344	19	2012	2012	NUM
chd-130	344	20	)	)	PUNCT
chd-130	344	21	.	.	PUNCT
chd-130	345	1	chronic	chronic	ADJ
chd-130	345	2	heavy	heavy	ADJ
chd-130	345	3	metal	metal	NOUN
chd-130	345	4	exposure	exposure	NOUN
chd-130	345	5	and	and	CCONJ
chd-130	345	6	gallbladder	gallbladder	NOUN
chd-130	345	7	cancer	cancer	NOUN
chd-130	345	8	risk	risk	NOUN
chd-130	345	9	in	in	ADP
chd-130	345	10	india	india	PROPN
chd-130	345	11	,	,	PUNCT
chd-130	345	12	a	a	DET
chd-130	345	13	comparative	comparative	ADJ
chd-130	345	14	study	study	NOUN
chd-130	345	15	with	with	ADP
chd-130	345	16	japan	japan	PROPN
chd-130	345	17	.	.	PUNCT
chd-130	346	1	asian	asian	PROPN
chd-130	346	2	pac	pac	PROPN
chd-130	346	3	j	j	PROPN
chd-130	346	4	cancer	cancer	PROPN
chd-130	346	5	prev	prev	PROPN
chd-130	346	6	.	.	PROPN
chd-130	346	7	13	13	NUM
chd-130	346	8	,	,	PUNCT
chd-130	346	9	187	187	NUM
chd-130	346	10	-	-	SYM
chd-130	346	11	90	90	NUM
chd-130	346	12	.	.	PUNCT
chd-130	347	1	deshpande	deshpande	PROPN
chd-130	347	2	,	,	PUNCT
chd-130	347	3	v.	v.	ADV
chd-130	347	4	,	,	PUNCT
chd-130	347	5	nduaguba	nduaguba	PROPN
chd-130	347	6	,	,	PUNCT
chd-130	347	7	a	a	DET
chd-130	347	8	,	,	PUNCT
chd-130	347	9	zimmerman	zimmerman	PROPN
chd-130	347	10	,	,	PUNCT
chd-130	347	11	s.m	s.m	PROPN
chd-130	347	12	.	.	PROPN
chd-130	347	13	,	,	PUNCT
chd-130	347	14	kehoe	kehoe	PROPN
chd-130	347	15	,	,	PUNCT
chd-130	347	16	s.m	s.m	PROPN
chd-130	347	17	.	.	PROPN
chd-130	347	18	,	,	PUNCT
chd-130	347	19	macconaill	macconaill	PROPN
chd-130	347	20	,	,	PUNCT
chd-130	347	21	l.e	l.e	PROPN
chd-130	347	22	.	.	PROPN
chd-130	347	23	,	,	PUNCT
chd-130	347	24	lauwers	lauwers	PROPN
chd-130	347	25	,	,	PUNCT
chd-130	347	26	g.y	g.y	PROPN
chd-130	347	27	.	.	PROPN
chd-130	347	28	,	,	PUNCT
chd-130	347	29	ferrone	ferrone	NOUN
chd-130	347	30	,	,	PUNCT
chd-130	347	31	c.	c.	NOUN
chd-130	347	32	,	,	PUNCT
chd-130	347	33	bardeesy	bardeesy	ADJ
chd-130	347	34	,	,	PUNCT
chd-130	347	35	n.	n.	NOUN
chd-130	347	36	,	,	PUNCT
chd-130	347	37	zhu	zhu	PROPN
chd-130	347	38	,	,	PUNCT
chd-130	347	39	a.x	a.x	PROPN
chd-130	347	40	.	.	PROPN
chd-130	347	41	,	,	PUNCT
chd-130	347	42	hezel	hezel	PROPN
chd-130	347	43	,	,	PUNCT
chd-130	347	44	a.f	a.f	PROPN
chd-130	347	45	.	.	PROPN
chd-130	347	46	(	(	PUNCT
chd-130	347	47	2011	2011	NUM
chd-130	347	48	)	)	PUNCT
chd-130	347	49	.	.	PUNCT
chd-130	348	1	mutational	mutational	ADJ
chd-130	348	2	profiling	profiling	NOUN
chd-130	348	3	reveals	reveal	VERB
chd-130	348	4	pik3ca	pik3ca	VERB
chd-130	348	5	mutations	mutation	NOUN
chd-130	348	6	in	in	ADP
chd-130	348	7	gallbladder	gallbladder	NOUN
chd-130	348	8	carcinoma	carcinoma	NOUN
chd-130	348	9	.	.	PUNCT
chd-130	349	1	bmc	bmc	ADJ
chd-130	349	2	cancer	cancer	NOUN
chd-130	349	3	.	.	PUNCT
chd-130	350	1	11	11	NUM
chd-130	350	2	,	,	PUNCT
chd-130	350	3	60	60	NUM
chd-130	350	4	.	.	PUNCT
chd-130	351	1	eckel	eckel	PROPN
chd-130	351	2	,	,	PUNCT
chd-130	351	3	f.	f.	PROPN
chd-130	351	4	,	,	PUNCT
chd-130	351	5	schmid	schmid	PROPN
chd-130	351	6	,	,	PUNCT
chd-130	351	7	r.m	r.m	PROPN
chd-130	351	8	.	.	PROPN
chd-130	351	9	,	,	PUNCT
chd-130	351	10	(	(	PUNCT
chd-130	351	11	2007	2007	NUM
chd-130	351	12	)	)	PUNCT
chd-130	351	13	.	.	PUNCT
chd-130	352	1	chemotherapy	chemotherapy	NOUN
chd-130	352	2	in	in	ADP
chd-130	352	3	advanced	advanced	ADJ
chd-130	352	4	biliary	biliary	ADJ
chd-130	352	5	tract	tract	NOUN
chd-130	352	6	carcinoma	carcinoma	NOUN
chd-130	352	7	:	:	PUNCT
chd-130	352	8	a	a	DET
chd-130	352	9	pooled	pool	VERB
chd-130	352	10	analysis	analysis	NOUN
chd-130	352	11	of	of	ADP
chd-130	352	12	clinical	clinical	ADJ
chd-130	352	13	trials	trial	NOUN
chd-130	352	14	.	.	PUNCT
chd-130	353	1	br	br	PROPN
chd-130	353	2	j	j	PROPN
chd-130	353	3	cancer	cancer	NOUN
chd-130	353	4	.	.	PUNCT
chd-130	354	1	96	96	NUM
chd-130	354	2	,	,	PUNCT
chd-130	354	3	896	896	NUM
chd-130	354	4	-	-	SYM
chd-130	354	5	902	902	NUM
chd-130	354	6	.	.	PUNCT
chd-130	355	1	fujii	fujii	PROPN
chd-130	355	2	,	,	PUNCT
chd-130	355	3	k.	k.	PROPN
chd-130	355	4	,	,	PUNCT
chd-130	355	5	yokozaki	yokozaki	PROPN
chd-130	355	6	,	,	PUNCT
chd-130	355	7	h.	h.	PROPN
chd-130	355	8	,	,	PUNCT
chd-130	355	9	yasui	yasui	PROPN
chd-130	355	10	,	,	PUNCT
chd-130	355	11	w.	w.	PROPN
chd-130	355	12	,	,	PUNCT
chd-130	355	13	kuniyasu	kuniyasu	PROPN
chd-130	355	14	,	,	PUNCT
chd-130	355	15	h.	h.	PROPN
chd-130	355	16	,	,	PUNCT
chd-130	355	17	hirata	hirata	NOUN
chd-130	355	18	,	,	PUNCT
chd-130	355	19	m.	m.	NOUN
chd-130	355	20	,	,	PUNCT
chd-130	355	21	kajiyama	kajiyama	PROPN
chd-130	355	22	,	,	PUNCT
chd-130	355	23	g.	g.	PROPN
chd-130	355	24	,	,	PUNCT
chd-130	355	25	tahara	tahara	PROPN
chd-130	355	26	,	,	PUNCT
chd-130	355	27	e.	e.	PROPN
chd-130	355	28	(	(	PUNCT
chd-130	355	29	1996	1996	NUM
chd-130	355	30	)	)	PUNCT
chd-130	355	31	.	.	PUNCT
chd-130	356	1	high	high	ADJ
chd-130	356	2	frequency	frequency	NOUN
chd-130	356	3	of	of	ADP
chd-130	356	4	p53	p53	NOUN
chd-130	356	5	gene	gene	NOUN
chd-130	356	6	mutation	mutation	NOUN
chd-130	356	7	in	in	ADP
chd-130	356	8	adenocarcinomas	adenocarcinoma	NOUN
chd-130	356	9	of	of	ADP
chd-130	356	10	the	the	DET
chd-130	356	11	gallbladder	gallbladder	NOUN
chd-130	356	12	.	.	PUNCT
chd-130	357	1	cancer	cancer	NOUN
chd-130	357	2	epidemiol	epidemiol	PROPN
chd-130	357	3	biomarkers	biomarker	NOUN
chd-130	357	4	prev	prev	X
chd-130	357	5	.	.	PUNCT
chd-130	358	1	5	5	NUM
chd-130	358	2	,	,	PUNCT
chd-130	358	3	461	461	NUM
chd-130	358	4	-	-	SYM
chd-130	358	5	6	6	NUM
chd-130	358	6	.	.	PUNCT
chd-130	359	1	hanada	hanada	PROPN
chd-130	359	2	,	,	PUNCT
chd-130	359	3	k.	k.	PROPN
chd-130	359	4	,	,	PUNCT
chd-130	359	5	itoh	itoh	PROPN
chd-130	359	6	,	,	PUNCT
chd-130	359	7	m.	m.	NOUN
chd-130	359	8	,	,	PUNCT
chd-130	359	9	fujii	fujii	PROPN
chd-130	359	10	,	,	PUNCT
chd-130	359	11	k.	k.	PROPN
chd-130	359	12	,	,	PUNCT
chd-130	359	13	tsuchida	tsuchida	PROPN
chd-130	359	14	,	,	PUNCT
chd-130	359	15	a.	a.	NOUN
chd-130	359	16	,	,	PUNCT
chd-130	359	17	hirata	hirata	NOUN
chd-130	359	18	,	,	PUNCT
chd-130	359	19	m.	m.	NOUN
chd-130	359	20	,	,	PUNCT
chd-130	359	21	iwao	iwao	PROPN
chd-130	359	22	,	,	PUNCT
chd-130	359	23	t.	t.	NOUN
chd-130	359	24	,	,	PUNCT
chd-130	359	25	eguchi	eguchi	NOUN
chd-130	359	26	,	,	PUNCT
chd-130	359	27	n.	n.	NOUN
chd-130	359	28	,	,	PUNCT
chd-130	359	29	sasaki	sasaki	PROPN
chd-130	359	30	,	,	PUNCT
chd-130	359	31	t.	t.	PROPN
chd-130	359	32	,	,	PUNCT
chd-130	359	33	matsubara	matsubara	PROPN
chd-130	359	34	,	,	PUNCT
chd-130	359	35	k.	k.	PROPN
chd-130	359	36	,	,	PUNCT
chd-130	359	37	kajiyama	kajiyama	PROPN
chd-130	359	38	,	,	PUNCT
chd-130	359	39	g.	g.	PROPN
chd-130	359	40	,	,	PUNCT
chd-130	359	41	(	(	PUNCT
chd-130	359	42	1997	1997	NUM
chd-130	359	43	)	)	PUNCT
chd-130	359	44	.	.	PUNCT
chd-130	360	1	tp53	tp53	PROPN
chd-130	360	2	mutations	mutation	NOUN
chd-130	360	3	in	in	ADP
chd-130	360	4	stage	stage	NOUN
chd-130	360	5	i	i	PRON
chd-130	360	6	gallbladder	gallbladder	VERB
chd-130	360	7	carcinoma	carcinoma	NOUN
chd-130	360	8	with	with	ADP
chd-130	360	9	special	special	ADJ
chd-130	360	10	attention	attention	NOUN
chd-130	360	11	to	to	ADP
chd-130	360	12	growth	growth	NOUN
chd-130	360	13	patterns	pattern	NOUN
chd-130	360	14	.	.	PUNCT
chd-130	361	1	eur	eur	PROPN
chd-130	361	2	j	j	PROPN
chd-130	361	3	cancer	cancer	NOUN
chd-130	361	4	.	.	PUNCT
chd-130	362	1	33	33	NUM
chd-130	362	2	,	,	PUNCT
chd-130	362	3	1136	1136	NUM
chd-130	362	4	-	-	SYM
chd-130	362	5	40	40	NUM
chd-130	362	6	.	.	PUNCT
chd-130	363	1	hanada	hanada	PROPN
chd-130	363	2	,	,	PUNCT
chd-130	363	3	k.	k.	PROPN
chd-130	363	4	,	,	PUNCT
chd-130	363	5	itoh	itoh	PROPN
chd-130	363	6	,	,	PUNCT
chd-130	363	7	m.	m.	NOUN
chd-130	363	8	,	,	PUNCT
chd-130	363	9	fujii	fujii	PROPN
chd-130	363	10	,	,	PUNCT
chd-130	363	11	k.	k.	PROPN
chd-130	363	12	,	,	PUNCT
chd-130	363	13	tsuchida	tsuchida	PROPN
chd-130	363	14	,	,	PUNCT
chd-130	363	15	a.	a.	NOUN
chd-130	363	16	,	,	PUNCT
chd-130	363	17	ooishi	ooishi	PROPN
chd-130	363	18	,	,	PUNCT
chd-130	363	19	h.	h.	PROPN
chd-130	363	20	,	,	PUNCT
chd-130	363	21	kajiyama	kajiyama	PROPN
chd-130	363	22	,	,	PUNCT
chd-130	363	23	g.	g.	PROPN
chd-130	363	24	(	(	PUNCT
chd-130	363	25	1996	1996	NUM
chd-130	363	26	)	)	PUNCT
chd-130	363	27	.	.	PUNCT
chd-130	364	1	k	k	X
chd-130	364	2	-	-	PUNCT
chd-130	364	3	ras	ras	ADJ
chd-130	364	4	and	and	CCONJ
chd-130	364	5	p53	p53	NOUN
chd-130	364	6	mutations	mutation	NOUN
chd-130	364	7	in	in	ADP
chd-130	364	8	stage	stage	NOUN
chd-130	364	9	i	i	PRON
chd-130	364	10	gallbladder	gallbladder	VERB
chd-130	364	11	carcinoma	carcinoma	NOUN
chd-130	364	12	with	with	ADP
chd-130	364	13	an	an	DET
chd-130	364	14	anomalous	anomalous	ADJ
chd-130	364	15	junction	junction	NOUN
chd-130	364	16	of	of	ADP
chd-130	364	17	the	the	DET
chd-130	364	18	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	364	19	duct	duct	NOUN
chd-130	364	20	.	.	PUNCT
chd-130	365	1	cancer	cancer	NOUN
chd-130	365	2	.	.	PUNCT
chd-130	366	1	77	77	NUM
chd-130	366	2	,	,	PUNCT
chd-130	366	3	452	452	NUM
chd-130	366	4	-	-	SYM
chd-130	366	5	8	8	NUM
chd-130	366	6	hecht	hecht	PROPN
chd-130	366	7	,	,	PUNCT
chd-130	366	8	f.	f.	PROPN
chd-130	366	9	,	,	PUNCT
chd-130	366	10	kuban	kuban	PROPN
chd-130	366	11	,	,	PUNCT
chd-130	366	12	d.j	d.j	PROPN
chd-130	366	13	.	.	PROPN
chd-130	366	14	,	,	PUNCT
chd-130	366	15	berger	berger	PROPN
chd-130	366	16	,	,	PUNCT
chd-130	366	17	c.	c.	PROPN
chd-130	366	18	,	,	PUNCT
chd-130	366	19	hecht	hecht	PROPN
chd-130	366	20	,	,	PUNCT
chd-130	366	21	b.k	b.k	PROPN
chd-130	366	22	.	.	PROPN
chd-130	366	23	,	,	PUNCT
chd-130	366	24	sandberg	sandberg	PROPN
chd-130	366	25	,	,	PUNCT
chd-130	366	26	a.a	a.a	PROPN
chd-130	366	27	.	.	PROPN
chd-130	366	28	(	(	PUNCT
chd-130	366	29	1983	1983	NUM
chd-130	366	30	)	)	PUNCT
chd-130	366	31	.	.	PUNCT
chd-130	367	1	adenocarcinoma	adenocarcinoma	NOUN
chd-130	367	2	of	of	ADP
chd-130	367	3	the	the	DET
chd-130	367	4	gallbladder	gallbladder	NOUN
chd-130	367	5	:	:	PUNCT
chd-130	367	6	chromosome	chromosome	NOUN
chd-130	367	7	abnormalities	abnormality	NOUN
chd-130	367	8	in	in	ADP
chd-130	367	9	a	a	DET
chd-130	367	10	genetic	genetic	ADJ
chd-130	367	11	form	form	NOUN
chd-130	367	12	of	of	ADP
chd-130	367	13	cancer	cancer	NOUN
chd-130	367	14	.	.	PUNCT
chd-130	368	1	cancer	cancer	NOUN
chd-130	368	2	genet	genet	NOUN
chd-130	368	3	cytogenet	cytogenet	NOUN
chd-130	368	4	.	.	PUNCT
chd-130	369	1	8	8	NUM
chd-130	369	2	,	,	PUNCT
chd-130	369	3	185	185	NUM
chd-130	369	4	-	-	SYM
chd-130	369	5	90	90	NUM
chd-130	369	6	.	.	PUNCT
chd-130	369	7	henley	henley	PROPN
chd-130	369	8	,	,	PUNCT
chd-130	369	9	s.j	s.j	PROPN
chd-130	369	10	.	.	PROPN
chd-130	369	11	,	,	PUNCT
chd-130	369	12	weir	weir	PROPN
chd-130	369	13	,	,	PUNCT
chd-130	369	14	h.k	h.k	PROPN
chd-130	369	15	.	.	PROPN
chd-130	369	16	,	,	PUNCT
chd-130	369	17	jim	jim	PROPN
chd-130	369	18	,	,	PUNCT
chd-130	369	19	m.a	m.a	PROPN
chd-130	369	20	.	.	PROPN
chd-130	369	21	,	,	PUNCT
chd-130	369	22	watson	watson	PROPN
chd-130	369	23	,	,	PUNCT
chd-130	369	24	m.	m.	NOUN
chd-130	369	25	,	,	PUNCT
chd-130	369	26	richardson	richardson	PROPN
chd-130	369	27	,	,	PUNCT
chd-130	369	28	l.c	l.c	PROPN
chd-130	369	29	.	.	PROPN
chd-130	369	30	,	,	PUNCT
chd-130	369	31	(	(	PUNCT
chd-130	369	32	2015	2015	NUM
chd-130	369	33	)	)	PUNCT
chd-130	369	34	.	.	PUNCT
chd-130	370	1	gallbladder	gallbladder	NOUN
chd-130	370	2	cancer	cancer	NOUN
chd-130	370	3	incidence	incidence	NOUN
chd-130	370	4	and	and	CCONJ
chd-130	370	5	mortality	mortality	NOUN
chd-130	370	6	,	,	PUNCT
chd-130	370	7	united	united	PROPN
chd-130	370	8	states	states	PROPN
chd-130	370	9	1999	1999	NUM
chd-130	370	10	-	-	SYM
chd-130	370	11	2011	2011	NUM
chd-130	370	12	.	.	PUNCT
chd-130	371	1	cancer	cancer	NOUN
chd-130	371	2	epidemiol	epidemiol	PROPN
chd-130	371	3	biomarkers	biomarker	NOUN
chd-130	371	4	prev	prev	X
chd-130	371	5	.	.	PUNCT
chd-130	372	1	24	24	NUM
chd-130	372	2	,	,	PUNCT
chd-130	372	3	1319	1319	NUM
chd-130	372	4	-	-	SYM
chd-130	372	5	26	26	NUM
chd-130	372	6	.	.	PUNCT
chd-130	373	1	hidaka	hidaka	PROPN
chd-130	373	2	,	,	PUNCT
chd-130	373	3	e.	e.	PROPN
chd-130	373	4	,	,	PUNCT
chd-130	373	5	yanagisawa	yanagisawa	PROPN
chd-130	373	6	,	,	PUNCT
chd-130	373	7	a.	a.	NOUN
chd-130	373	8	,	,	PUNCT
chd-130	373	9	sakai	sakai	PROPN
chd-130	373	10	,	,	PUNCT
chd-130	373	11	y.	y.	PROPN
chd-130	373	12	,	,	PUNCT
chd-130	373	13	seki	seki	PROPN
chd-130	373	14	,	,	PUNCT
chd-130	373	15	m.	m.	NOUN
chd-130	373	16	,	,	PUNCT
chd-130	373	17	kitagawa	kitagawa	PROPN
chd-130	373	18	,	,	PUNCT
chd-130	373	19	t.	t.	PROPN
chd-130	373	20	,	,	PUNCT
chd-130	373	21	setoguchi	setoguchi	NOUN
chd-130	373	22	,	,	PUNCT
chd-130	373	23	t.	t.	PROPN
chd-130	373	24	,	,	PUNCT
chd-130	373	25	kato	kato	PROPN
chd-130	373	26	,	,	PUNCT
chd-130	373	27	y.	y.	PROPN
chd-130	373	28	(	(	PUNCT
chd-130	373	29	1999	1999	NUM
chd-130	373	30	)	)	PUNCT
chd-130	373	31	.	.	PUNCT
chd-130	374	1	losses	loss	NOUN
chd-130	374	2	of	of	ADP
chd-130	374	3	heterozygosity	heterozygosity	NOUN
chd-130	374	4	on	on	ADP
chd-130	374	5	chromosomes	chromosome	NOUN
chd-130	374	6	17p	17p	NOUN
chd-130	374	7	and	and	CCONJ
chd-130	374	8	9p/18q	9p/18q	PRON
chd-130	374	9	may	may	AUX
chd-130	374	10	play	play	VERB
chd-130	374	11	important	important	ADJ
chd-130	374	12	roles	role	NOUN
chd-130	374	13	in	in	ADP
chd-130	374	14	early	early	ADJ
chd-130	374	15	and	and	CCONJ
chd-130	374	16	advanced	advanced	ADJ
chd-130	374	17	phases	phase	NOUN
chd-130	374	18	of	of	ADP
chd-130	374	19	gallbladder	gallbladder	NOUN
chd-130	374	20	carcinogenesis	carcinogenesis	NOUN
chd-130	374	21	.	.	PUNCT
chd-130	375	1	j	j	PROPN
chd-130	375	2	cancer	cancer	NOUN
chd-130	375	3	res	re	VERB
chd-130	375	4	clin	clin	PROPN
chd-130	375	5	oncol	oncol	PROPN
chd-130	375	6	.	.	PUNCT
chd-130	376	1	125	125	NUM
chd-130	376	2	,	,	PUNCT
chd-130	376	3	439	439	NUM
chd-130	376	4	-	-	SYM
chd-130	376	5	43	43	NUM
chd-130	376	6	.	.	PUNCT
chd-130	377	1	hou	hou	PROPN
chd-130	377	2	,	,	PUNCT
chd-130	377	3	l.	l.	PROPN
chd-130	377	4	,	,	PUNCT
chd-130	377	5	xu	xu	PROPN
chd-130	377	6	,	,	PUNCT
chd-130	377	7	j.	j.	PROPN
chd-130	377	8	,	,	PUNCT
chd-130	377	9	gao	gao	PROPN
chd-130	377	10	,	,	PUNCT
chd-130	377	11	y.t	y.t	PROPN
chd-130	377	12	.	.	PROPN
chd-130	377	13	,	,	PUNCT
chd-130	377	14	rashid	rashid	PROPN
chd-130	377	15	,	,	PUNCT
chd-130	377	16	a.	a.	PROPN
chd-130	377	17	,	,	PUNCT
chd-130	377	18	zheng	zheng	PROPN
chd-130	377	19	,	,	PUNCT
chd-130	377	20	s.l	s.l	PROPN
chd-130	377	21	.	.	PROPN
chd-130	377	22	,	,	PUNCT
chd-130	377	23	sakoda	sakoda	PROPN
chd-130	377	24	,	,	PUNCT
chd-130	377	25	l.c	l.c	PROPN
chd-130	377	26	.	.	PROPN
chd-130	377	27	,	,	PUNCT
chd-130	377	28	shen	shen	PROPN
chd-130	377	29	,	,	PUNCT
chd-130	377	30	m.c	m.c	PROPN
chd-130	377	31	.	.	PROPN
chd-130	377	32	,	,	PUNCT
chd-130	377	33	wang	wang	PROPN
chd-130	377	34	,	,	PUNCT
chd-130	377	35	b.s	b.s	PROPN
chd-130	377	36	.	.	PROPN
chd-130	377	37	,	,	PUNCT
chd-130	377	38	deng	deng	PROPN
chd-130	377	39	,	,	PUNCT
chd-130	377	40	j.	j.	PROPN
chd-130	377	41	,	,	PUNCT
chd-130	377	42	han	han	PROPN
chd-130	377	43	,	,	PUNCT
chd-130	377	44	t.q	t.q	PROPN
chd-130	377	45	.	.	PROPN
chd-130	377	46	,	,	PUNCT
chd-130	377	47	zhang	zhang	PROPN
chd-130	377	48	,	,	PUNCT
chd-130	377	49	b.h	b.h	PROPN
chd-130	377	50	.	.	PROPN
chd-130	377	51	,	,	PUNCT
chd-130	377	52	meyers	meyers	PROPN
chd-130	377	53	,	,	PUNCT
chd-130	377	54	d.a	d.a	PROPN
chd-130	377	55	.	.	PROPN
chd-130	377	56	,	,	PUNCT
chd-130	377	57	fraumeni	fraumeni	PROPN
chd-130	377	58	,	,	PUNCT
chd-130	377	59	j.f	j.f	PROPN
chd-130	377	60	.	.	PROPN
chd-130	377	61	jr	jr	PROPN
chd-130	377	62	,	,	PUNCT
chd-130	377	63	hsing	hsing	PROPN
chd-130	377	64	,	,	PUNCT
chd-130	377	65	a.w	a.w	PROPN
chd-130	377	66	.	.	PROPN
chd-130	377	67	(	(	PUNCT
chd-130	377	68	2006	2006	NUM
chd-130	377	69	)	)	PUNCT
chd-130	377	70	.	.	PUNCT
chd-130	378	1	cyp17	cyp17	PROPN
chd-130	378	2	mspa1	mspa1	NOUN
chd-130	378	3	polymorphism	polymorphism	NOUN
chd-130	378	4	and	and	CCONJ
chd-130	378	5	risk	risk	NOUN
chd-130	378	6	of	of	ADP
chd-130	378	7	biliary	biliary	ADJ
chd-130	378	8	tract	tract	NOUN
chd-130	378	9	cancers	cancer	NOUN
chd-130	378	10	and	and	CCONJ
chd-130	378	11	gallstones	gallstone	NOUN
chd-130	378	12	:	:	PUNCT
chd-130	378	13	a	a	DET
chd-130	378	14	population	population	NOUN
chd-130	378	15	-	-	PUNCT
chd-130	378	16	based	base	VERB
chd-130	378	17	study	study	NOUN
chd-130	378	18	in	in	ADP
chd-130	378	19	shanghai	shanghai	PROPN
chd-130	378	20	,	,	PUNCT
chd-130	378	21	china	china	PROPN
chd-130	378	22	.	.	PUNCT
chd-130	379	1	int	int	PROPN
chd-130	379	2	j	j	PROPN
chd-130	379	3	cancer	cancer	NOUN
chd-130	379	4	.	.	PUNCT
chd-130	380	1	118	118	NUM
chd-130	380	2	,	,	PUNCT
chd-130	380	3	2847	2847	NUM
chd-130	380	4	-	-	SYM
chd-130	380	5	53	53	NUM
chd-130	380	6	.	.	PUNCT
chd-130	381	1	house	house	PROPN
chd-130	381	2	,	,	PUNCT
chd-130	381	3	m.g	m.g	PROPN
chd-130	381	4	.	.	PROPN
chd-130	381	5	,	,	PUNCT
chd-130	381	6	wistuba	wistuba	PROPN
chd-130	381	7	,	,	PUNCT
chd-130	381	8	i.i	i.i	PROPN
chd-130	381	9	.	.	PROPN
chd-130	381	10	,	,	PUNCT
chd-130	381	11	argani	argani	PROPN
chd-130	381	12	,	,	PUNCT
chd-130	381	13	p.	p.	PROPN
chd-130	381	14	,	,	PUNCT
chd-130	381	15	guo	guo	PROPN
chd-130	381	16	,	,	PUNCT
chd-130	381	17	m.	m.	NOUN
chd-130	381	18	,	,	PUNCT
chd-130	381	19	schulick	schulick	NOUN
chd-130	381	20	,	,	PUNCT
chd-130	381	21	r.d	r.d	PROPN
chd-130	381	22	.	.	PROPN
chd-130	381	23	,	,	PUNCT
chd-130	381	24	hruban	hruban	PROPN
chd-130	381	25	,	,	PUNCT
chd-130	381	26	r.h	r.h	PROPN
chd-130	381	27	.	.	PROPN
chd-130	381	28	,	,	PUNCT
chd-130	381	29	herman	herman	PROPN
chd-130	381	30	,	,	PUNCT
chd-130	381	31	j.g	j.g	PROPN
chd-130	381	32	.	.	PROPN
chd-130	381	33	,	,	PUNCT
chd-130	381	34	maitra	maitra	PROPN
chd-130	381	35	,	,	PUNCT
chd-130	381	36	a.	a.	NOUN
chd-130	381	37	(	(	PUNCT
chd-130	381	38	2003	2003	NUM
chd-130	381	39	)	)	PUNCT
chd-130	381	40	.	.	PUNCT
chd-130	382	1	progression	progression	NOUN
chd-130	382	2	of	of	ADP
chd-130	382	3	gene	gene	NOUN
chd-130	382	4	hypermethylation	hypermethylation	NOUN
chd-130	382	5	in	in	ADP
chd-130	382	6	gallstone	gallstone	NOUN
chd-130	382	7	disease	disease	NOUN
chd-130	382	8	leading	lead	VERB
chd-130	382	9	to	to	ADP
chd-130	382	10	gallbladder	gallbladder	NOUN
chd-130	382	11	cancer	cancer	NOUN
chd-130	382	12	.	.	PUNCT
chd-130	383	1	ann	ann	PROPN
chd-130	383	2	surg	surg	PROPN
chd-130	383	3	oncol	oncol	PROPN
chd-130	383	4	.	.	PUNCT
chd-130	384	1	10	10	NUM
chd-130	384	2	,	,	PUNCT
chd-130	384	3	882	882	NUM
chd-130	384	4	-	-	SYM
chd-130	384	5	9	9	NUM
chd-130	384	6	.	.	PUNCT
chd-130	384	7	iwase	iwase	NOUN
chd-130	384	8	,	,	PUNCT
chd-130	384	9	t.	t.	PROPN
chd-130	384	10	,	,	PUNCT
chd-130	384	11	nakazawa	nakazawa	PROPN
chd-130	384	12	,	,	PUNCT
chd-130	384	13	s.	s.	PROPN
chd-130	384	14	,	,	PUNCT
chd-130	384	15	yamao	yamao	PROPN
chd-130	384	16	,	,	PUNCT
chd-130	384	17	k.	k.	PROPN
chd-130	384	18	,	,	PUNCT
chd-130	384	19	yoshino	yoshino	PROPN
chd-130	384	20	,	,	PUNCT
chd-130	384	21	j.	j.	PROPN
chd-130	384	22	,	,	PUNCT
chd-130	384	23	inui	inui	PROPN
chd-130	384	24	,	,	PUNCT
chd-130	384	25	k.	k.	PROPN
chd-130	384	26	,	,	PUNCT
chd-130	384	27	yamachika	yamachika	PROPN
chd-130	384	28	,	,	PUNCT
chd-130	384	29	h.	h.	PROPN
chd-130	384	30	,	,	PUNCT
chd-130	384	31	kanemaki	kanemaki	PROPN
chd-130	384	32	,	,	PUNCT
chd-130	384	33	n.	n.	NOUN
chd-130	384	34	,	,	PUNCT
chd-130	384	35	fujimoto	fujimoto	PROPN
chd-130	384	36	,	,	PUNCT
chd-130	384	37	m.	m.	NOUN
chd-130	384	38	,	,	PUNCT
chd-130	384	39	okushima	okushima	PROPN
chd-130	384	40	,	,	PUNCT
chd-130	384	41	k.	k.	PROPN
chd-130	384	42	,	,	PUNCT
chd-130	384	43	miyoshi	miyoshi	PROPN
chd-130	384	44	,	,	PUNCT
chd-130	384	45	h.	h.	PROPN
chd-130	384	46	(	(	PUNCT
chd-130	384	47	1997	1997	NUM
chd-130	384	48	)	)	PUNCT
chd-130	384	49	.	.	PUNCT
chd-130	385	1	ras	ras	NOUN
chd-130	385	2	gene	gene	NOUN
chd-130	385	3	point	point	NOUN
chd-130	385	4	mutations	mutation	NOUN
chd-130	385	5	in	in	ADP
chd-130	385	6	gallbladder	gallbladder	NOUN
chd-130	385	7	lesions	lesion	NOUN
chd-130	385	8	associated	associate	VERB
chd-130	385	9	with	with	ADP
chd-130	385	10	anomalous	anomalous	ADJ
chd-130	385	11	connection	connection	NOUN
chd-130	385	12	of	of	ADP
chd-130	385	13	pancreatobiliary	pancreatobiliary	ADJ
chd-130	385	14	ducts	duct	NOUN
chd-130	385	15	.	.	PUNCT
chd-130	386	1	hepatogastroenterology	hepatogastroenterology	NOUN
chd-130	386	2	.	.	PUNCT
chd-130	387	1	44	44	NUM
chd-130	387	2	,	,	PUNCT
chd-130	387	3	1457	1457	NUM
chd-130	387	4	-	-	SYM
chd-130	387	5	62	62	NUM
chd-130	387	6	.	.	PUNCT
chd-130	388	1	iyer	iyer	PROPN
chd-130	388	2	,	,	PUNCT
chd-130	388	3	p.	p.	NOUN
chd-130	388	4	,	,	PUNCT
chd-130	388	5	shrikhande	shrikhande	ADJ
chd-130	388	6	,	,	PUNCT
chd-130	388	7	s.v	s.v	PROPN
chd-130	388	8	.	.	PROPN
chd-130	388	9	,	,	PUNCT
chd-130	388	10	ranjan	ranjan	PROPN
chd-130	388	11	,	,	PUNCT
chd-130	388	12	m.	m.	NOUN
chd-130	388	13	,	,	PUNCT
chd-130	388	14	joshi	joshi	PROPN
chd-130	388	15	,	,	PUNCT
chd-130	388	16	a.	a.	PROPN
chd-130	388	17	,	,	PUNCT
chd-130	388	18	gardi	gardi	PROPN
chd-130	388	19	,	,	PUNCT
chd-130	388	20	n.	n.	NOUN
chd-130	388	21	,	,	PUNCT
chd-130	388	22	prasad	prasad	PROPN
chd-130	388	23	,	,	PUNCT
chd-130	388	24	r.	r.	PROPN
chd-130	388	25	,	,	PUNCT
chd-130	388	26	dharavath	dharavath	PROPN
chd-130	388	27	,	,	PUNCT
chd-130	388	28	b.	b.	PROPN
chd-130	388	29	,	,	PUNCT
chd-130	388	30	thorat	thorat	NOUN
chd-130	388	31	,	,	PUNCT
chd-130	388	32	r.	r.	PROPN
chd-130	388	33	,	,	PUNCT
chd-130	388	34	salunkhe	salunkhe	PROPN
chd-130	388	35	,	,	PUNCT
chd-130	388	36	s.	s.	PROPN
chd-130	388	37	,	,	PUNCT
chd-130	388	38	sahoo	sahoo	PROPN
chd-130	388	39	,	,	PUNCT
chd-130	388	40	b.	b.	PROPN
chd-130	388	41	,	,	PUNCT
chd-130	388	42	et	et	PROPN
chd-130	388	43	al	al	PROPN
chd-130	388	44	.	.	PUNCT
chd-130	388	45	(	(	PUNCT
chd-130	388	46	2018	2018	NUM
chd-130	388	47	)	)	PUNCT
chd-130	388	48	.	.	PUNCT
chd-130	389	1	erbb2	erbb2	PROPN
chd-130	389	2	and	and	CCONJ
chd-130	389	3	kras	kras	PROPN
chd-130	389	4	alterations	alteration	NOUN
chd-130	389	5	mediate	mediate	VERB
chd-130	389	6	response	response	NOUN
chd-130	389	7	to	to	PART
chd-130	389	8	egfr	egfr	VERB
chd-130	389	9	inhibitors	inhibitor	NOUN
chd-130	389	10	in	in	ADP
chd-130	389	11	early	early	ADJ
chd-130	389	12	stage	stage	NOUN
chd-130	389	13	gallbladder	gallbladder	NOUN
chd-130	389	14	cancer	cancer	NOUN
chd-130	389	15	.	.	PUNCT
chd-130	390	1	int	int	NOUN
chd-130	390	2	j	j	PROPN
chd-130	390	3	cancer	cancer	NOUN
chd-130	390	4	.	.	PUNCT
chd-130	391	1	oct	oct	PROPN
chd-130	391	2	10	10	NUM
chd-130	391	3	.	.	PUNCT
chd-130	392	1	javle	javle	NOUN
chd-130	392	2	,	,	PUNCT
chd-130	392	3	m.	m.	NOUN
chd-130	392	4	,	,	PUNCT
chd-130	392	5	churi	churi	PROPN
chd-130	392	6	,	,	PUNCT
chd-130	392	7	c.	c.	PROPN
chd-130	392	8	,	,	PUNCT
chd-130	392	9	kang	kang	PROPN
chd-130	392	10	,	,	PUNCT
chd-130	392	11	h.c	h.c	PROPN
chd-130	392	12	.	.	PROPN
chd-130	392	13	,	,	PUNCT
chd-130	392	14	shroff	shroff	PROPN
chd-130	392	15	,	,	PUNCT
chd-130	392	16	r.	r.	PROPN
chd-130	392	17	,	,	PUNCT
chd-130	392	18	janku	janku	PROPN
chd-130	392	19	,	,	PUNCT
chd-130	392	20	f.	f.	PROPN
chd-130	392	21	,	,	PUNCT
chd-130	392	22	surapaneni	surapaneni	NOUN
chd-130	392	23	,	,	PUNCT
chd-130	392	24	r.	r.	PROPN
chd-130	392	25	,	,	PUNCT
chd-130	392	26	zuo	zuo	PROPN
chd-130	392	27	,	,	PUNCT
chd-130	392	28	m.	m.	NOUN
chd-130	392	29	,	,	PUNCT
chd-130	392	30	barrera	barrera	NOUN
chd-130	392	31	,	,	PUNCT
chd-130	392	32	c.	c.	PROPN
chd-130	392	33	,	,	PUNCT
chd-130	392	34	alshamsi	alshamsi	NOUN
chd-130	392	35	,	,	PUNCT
chd-130	392	36	h.	h.	PROPN
chd-130	392	37	,	,	PUNCT
chd-130	392	38	krishnan	krishnan	PROPN
chd-130	392	39	,	,	PUNCT
chd-130	392	40	s.	s.	PROPN
chd-130	392	41	,	,	PUNCT
chd-130	392	42	et	et	PROPN
chd-130	392	43	al	al	PROPN
chd-130	392	44	.	.	PUNCT
chd-130	392	45	(	(	PUNCT
chd-130	392	46	2015	2015	NUM
chd-130	392	47	)	)	PUNCT
chd-130	392	48	.	.	PUNCT
chd-130	393	1	her2	her2	PROPN
chd-130	393	2	/	/	SYM
chd-130	393	3	neu	neu	NOUN
chd-130	393	4	-	-	PUNCT
chd-130	393	5	directed	direct	VERB
chd-130	393	6	therapy	therapy	NOUN
chd-130	393	7	for	for	ADP
chd-130	393	8	biliary	biliary	ADJ
chd-130	393	9	tract	tract	NOUN
chd-130	393	10	cancer	cancer	NOUN
chd-130	393	11	.	.	PUNCT
chd-130	394	1	j	j	PROPN
chd-130	394	2	hematol	hematol	PROPN
chd-130	394	3	oncol	oncol	ADJ
chd-130	394	4	.	.	PUNCT
chd-130	394	5	8	8	NUM
chd-130	394	6	,	,	PUNCT
chd-130	394	7	58	58	NUM
chd-130	394	8	.	.	PUNCT
chd-130	395	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-130	395	2	e21	e21	ADJ
chd-130	395	3	cancer	cancer	NOUN
chd-130	395	4	health	health	NOUN
chd-130	395	5	disparities	disparity	NOUN
chd-130	395	6	research	research	PROPN
chd-130	395	7	jiao	jiao	PROPN
chd-130	395	8	,	,	PUNCT
chd-130	395	9	x.	x.	PROPN
chd-130	395	10	,	,	PUNCT
chd-130	395	11	huang	huang	PROPN
chd-130	395	12	,	,	PUNCT
chd-130	395	13	j.	j.	PROPN
chd-130	395	14	,	,	PUNCT
chd-130	395	15	wu	wu	PROPN
chd-130	395	16	,	,	PUNCT
chd-130	395	17	s.	s.	PROPN
chd-130	395	18	,	,	PUNCT
chd-130	395	19	lv	lv	PROPN
chd-130	395	20	,	,	PUNCT
chd-130	395	21	m.	m.	NOUN
chd-130	395	22	,	,	PUNCT
chd-130	395	23	hu	hu	PROPN
chd-130	395	24	,	,	PUNCT
chd-130	395	25	y.	y.	PROPN
chd-130	395	26	,	,	PUNCT
chd-130	395	27	jianfu	jianfu	PROPN
chd-130	395	28	,	,	PUNCT
chd-130	395	29	su	su	PROPN
chd-130	395	30	,	,	PUNCT
chd-130	395	31	x.	x.	PROPN
chd-130	395	32	,	,	PUNCT
chd-130	395	33	luo	luo	PROPN
chd-130	395	34	,	,	PUNCT
chd-130	395	35	c.	c.	PROPN
chd-130	395	36	,	,	PUNCT
chd-130	395	37	ce	ce	PROPN
chd-130	395	38	,	,	PUNCT
chd-130	395	39	b.	b.	PROPN
chd-130	395	40	(	(	PUNCT
chd-130	395	41	2007	2007	NUM
chd-130	395	42	)	)	PUNCT
chd-130	395	43	.	.	PUNCT
chd-130	396	1	hogg1	hogg1	NOUN
chd-130	396	2	ser326cys	ser326cy	VERB
chd-130	396	3	polymorphism	polymorphism	NOUN
chd-130	396	4	and	and	CCONJ
chd-130	396	5	susceptibility	susceptibility	NOUN
chd-130	396	6	to	to	ADP
chd-130	396	7	gallbladder	gallbladder	NOUN
chd-130	396	8	cancer	cancer	NOUN
chd-130	396	9	in	in	ADP
chd-130	396	10	a	a	DET
chd-130	396	11	chinese	chinese	ADJ
chd-130	396	12	population	population	NOUN
chd-130	396	13	.	.	PUNCT
chd-130	397	1	int	int	PROPN
chd-130	397	2	j	j	PROPN
chd-130	397	3	cancer	cancer	NOUN
chd-130	397	4	.	.	PUNCT
chd-130	398	1	121	121	NUM
chd-130	398	2	,	,	PUNCT
chd-130	398	3	501	501	NUM
chd-130	398	4	-	-	SYM
chd-130	398	5	5	5	NUM
chd-130	398	6	.	.	PUNCT
chd-130	398	7	jonas	jonas	PROPN
chd-130	398	8	,	,	PUNCT
chd-130	398	9	s.	s.	PROPN
chd-130	398	10	,	,	PUNCT
chd-130	398	11	springmeier	springmeier	PROPN
chd-130	398	12	,	,	PUNCT
chd-130	398	13	g.	g.	PROPN
chd-130	398	14	,	,	PUNCT
chd-130	398	15	tauber	tauber	PROPN
chd-130	398	16	,	,	PUNCT
chd-130	398	17	r.	r.	PROPN
chd-130	398	18	,	,	PUNCT
chd-130	398	19	wiedenmann	wiedenmann	PROPN
chd-130	398	20	,	,	PUNCT
chd-130	398	21	b.	b.	PROPN
chd-130	398	22	,	,	PUNCT
chd-130	398	23	gessner	gessner	PROPN
chd-130	398	24	,	,	PUNCT
chd-130	398	25	r.	r.	PROPN
chd-130	398	26	,	,	PUNCT
chd-130	398	27	kling	kling	PROPN
chd-130	398	28	,	,	PUNCT
chd-130	398	29	n.	n.	PROPN
chd-130	398	30	,	,	PUNCT
chd-130	398	31	lobeck	lobeck	PROPN
chd-130	398	32	,	,	PUNCT
chd-130	398	33	h.	h.	PROPN
chd-130	398	34	,	,	PUNCT
chd-130	398	35	fieger	fieger	PROPN
chd-130	398	36	,	,	PUNCT
chd-130	398	37	c.	c.	PROPN
chd-130	398	38	,	,	PUNCT
chd-130	398	39	bechstein	bechstein	PROPN
chd-130	398	40	,	,	PUNCT
chd-130	398	41	w.o	w.o	PROPN
chd-130	398	42	.	.	PROPN
chd-130	398	43	,	,	PUNCT
chd-130	398	44	neuhaus	neuhaus	PROPN
chd-130	398	45	,	,	PUNCT
chd-130	398	46	p.	p.	NOUN
chd-130	398	47	(	(	PUNCT
chd-130	398	48	1997	1997	NUM
chd-130	398	49	)	)	PUNCT
chd-130	398	50	.	.	PUNCT
chd-130	399	1	p53	p53	NOUN
chd-130	399	2	hot	hot	ADJ
chd-130	399	3	-	-	PUNCT
chd-130	399	4	spot	spot	NOUN
chd-130	399	5	mutational	mutational	ADJ
chd-130	399	6	analysis	analysis	NOUN
chd-130	399	7	in	in	ADP
chd-130	399	8	advanced	advanced	ADJ
chd-130	399	9	western	western	ADJ
chd-130	399	10	gallbladder	gallbladder	NOUN
chd-130	399	11	carcinoma	carcinoma	NOUN
chd-130	399	12	.	.	PUNCT
chd-130	400	1	world	world	PROPN
chd-130	400	2	j	j	PROPN
chd-130	400	3	surg	surg	PROPN
chd-130	400	4	.	.	PUNCT
chd-130	401	1	21	21	NUM
chd-130	401	2	,	,	PUNCT
chd-130	401	3	768	768	NUM
chd-130	401	4	-	-	SYM
chd-130	401	5	72	72	NUM
chd-130	401	6	.	.	PUNCT
chd-130	402	1	khan	khan	PROPN
chd-130	402	2	zs	zs	PROPN
chd-130	402	3	,	,	PUNCT
chd-130	402	4	livingston	livingston	PROPN
chd-130	402	5	eh	eh	INTJ
chd-130	402	6	,	,	PUNCT
chd-130	402	7	huerta	huerta	PROPN
chd-130	402	8	s.	s.	PROPN
chd-130	402	9	reassessing	reassess	VERB
chd-130	402	10	the	the	DET
chd-130	402	11	need	need	NOUN
chd-130	402	12	for	for	ADP
chd-130	402	13	prophylactic	prophylactic	ADJ
chd-130	402	14	surgery	surgery	NOUN
chd-130	402	15	in	in	ADP
chd-130	402	16	patients	patient	NOUN
chd-130	402	17	with	with	ADP
chd-130	402	18	porcelain	porcelain	NOUN
chd-130	402	19	gallbladder	gallbladder	NOUN
chd-130	402	20	:	:	PUNCT
chd-130	402	21	case	case	NOUN
chd-130	402	22	series	series	NOUN
chd-130	402	23	and	and	CCONJ
chd-130	402	24	systematic	systematic	ADJ
chd-130	402	25	review	review	NOUN
chd-130	402	26	of	of	ADP
chd-130	402	27	the	the	DET
chd-130	402	28	literature	literature	NOUN
chd-130	402	29	.	.	PUNCT
chd-130	403	1	arch	arch	ADJ
chd-130	403	2	surg	surg	NOUN
chd-130	403	3	.	.	PUNCT
chd-130	404	1	2011	2011	NUM
chd-130	404	2	oct;146(10):1143	oct;146(10):1143	PROPN
chd-130	404	3	-	-	PUNCT
chd-130	404	4	7	7	NUM
chd-130	404	5	.	.	PUNCT
chd-130	405	1	kim	kim	PROPN
chd-130	405	2	,	,	PUNCT
chd-130	405	3	y.t	y.t	PROPN
chd-130	405	4	.	.	PROPN
chd-130	405	5	,	,	PUNCT
chd-130	405	6	kim	kim	PROPN
chd-130	405	7	,	,	PUNCT
chd-130	405	8	j.	j.	PROPN
chd-130	405	9	,	,	PUNCT
chd-130	405	10	jang	jang	PROPN
chd-130	405	11	,	,	PUNCT
chd-130	405	12	y.h	y.h	PROPN
chd-130	405	13	.	.	PROPN
chd-130	405	14	,	,	PUNCT
chd-130	405	15	lee	lee	PROPN
chd-130	405	16	,	,	PUNCT
chd-130	405	17	w.j	w.j	PROPN
chd-130	405	18	.	.	PROPN
chd-130	405	19	,	,	PUNCT
chd-130	405	20	ryu	ryu	PROPN
chd-130	405	21	,	,	PUNCT
chd-130	405	22	j.k	j.k	PROPN
chd-130	405	23	.	.	PROPN
chd-130	405	24	,	,	PUNCT
chd-130	405	25	park	park	PROPN
chd-130	405	26	,	,	PUNCT
chd-130	405	27	y.k	y.k	PROPN
chd-130	405	28	.	.	PROPN
chd-130	405	29	,	,	PUNCT
chd-130	405	30	kim	kim	PROPN
chd-130	405	31	,	,	PUNCT
chd-130	405	32	s.w	s.w	PROPN
chd-130	405	33	.	.	PROPN
chd-130	405	34	,	,	PUNCT
chd-130	405	35	kim	kim	PROPN
chd-130	405	36	,	,	PUNCT
chd-130	405	37	w.h	w.h	PROPN
chd-130	405	38	.	.	PROPN
chd-130	405	39	,	,	PUNCT
chd-130	405	40	yoon	yoon	PROPN
chd-130	405	41	,	,	PUNCT
chd-130	405	42	y.b	y.b	PROPN
chd-130	405	43	.	.	PROPN
chd-130	405	44	,	,	PUNCT
chd-130	405	45	kim	kim	PROPN
chd-130	405	46	,	,	PUNCT
chd-130	405	47	c.y	c.y	PROPN
chd-130	405	48	.	.	PROPN
chd-130	405	49	(	(	PUNCT
chd-130	405	50	2001	2001	NUM
chd-130	405	51	)	)	PUNCT
chd-130	405	52	.	.	PUNCT
chd-130	406	1	genetic	genetic	ADJ
chd-130	406	2	alterations	alteration	NOUN
chd-130	406	3	in	in	ADP
chd-130	406	4	gallbladder	gallbladder	NOUN
chd-130	406	5	adenoma	adenoma	ADJ
chd-130	406	6	,	,	PUNCT
chd-130	406	7	dysplasia	dysplasia	NOUN
chd-130	406	8	and	and	CCONJ
chd-130	406	9	carcinoma	carcinoma	NOUN
chd-130	406	10	.	.	PUNCT
chd-130	407	1	cancer	cancer	NOUN
chd-130	407	2	lett	lett	PROPN
chd-130	407	3	.	.	PROPN
chd-130	408	1	169	169	NUM
chd-130	408	2	,	,	PUNCT
chd-130	408	3	59	59	NUM
chd-130	408	4	-	-	SYM
chd-130	408	5	68	68	NUM
chd-130	408	6	.	.	PUNCT
chd-130	409	1	kimura	kimura	NOUN
chd-130	409	2	,	,	PUNCT
chd-130	409	3	a.	a.	PROPN
chd-130	409	4	,	,	PUNCT
chd-130	409	5	tsuchiya	tsuchiya	PROPN
chd-130	409	6	,	,	PUNCT
chd-130	409	7	y.	y.	PROPN
chd-130	409	8	,	,	PUNCT
chd-130	409	9	lang	lang	PROPN
chd-130	409	10	,	,	PUNCT
chd-130	409	11	i.	i.	PROPN
chd-130	409	12	,	,	PUNCT
chd-130	409	13	zoltan	zoltan	PROPN
chd-130	409	14	,	,	PUNCT
chd-130	409	15	s.	s.	PROPN
chd-130	409	16	,	,	PUNCT
chd-130	409	17	nakadaira	nakadaira	PROPN
chd-130	409	18	,	,	PUNCT
chd-130	409	19	h.	h.	PROPN
chd-130	409	20	,	,	PUNCT
chd-130	409	21	ajioka	ajioka	NOUN
chd-130	409	22	,	,	PUNCT
chd-130	409	23	y.	y.	PROPN
chd-130	409	24	,	,	PUNCT
chd-130	409	25	kiyohara	kiyohara	PROPN
chd-130	409	26	,	,	PUNCT
chd-130	409	27	c.	c.	PROPN
chd-130	409	28	,	,	PUNCT
chd-130	409	29	oyama	oyama	PROPN
chd-130	409	30	,	,	PUNCT
chd-130	409	31	m.	m.	NOUN
chd-130	409	32	,	,	PUNCT
chd-130	409	33	nakamura	nakamura	PROPN
chd-130	409	34	,	,	PUNCT
chd-130	409	35	k.	k.	PROPN
chd-130	409	36	(	(	PUNCT
chd-130	409	37	2008	2008	NUM
chd-130	409	38	)	)	PUNCT
chd-130	409	39	.	.	PUNCT
chd-130	410	1	effect	effect	NOUN
chd-130	410	2	of	of	ADP
chd-130	410	3	genetic	genetic	ADJ
chd-130	410	4	predisposition	predisposition	NOUN
chd-130	410	5	on	on	ADP
chd-130	410	6	the	the	DET
chd-130	410	7	risk	risk	NOUN
chd-130	410	8	of	of	ADP
chd-130	410	9	gallbladder	gallbladder	NOUN
chd-130	410	10	cancer	cancer	NOUN
chd-130	410	11	in	in	ADP
chd-130	410	12	hungary	hungary	PROPN
chd-130	410	13	.	.	PUNCT
chd-130	411	1	asian	asian	PROPN
chd-130	411	2	pac	pac	PROPN
chd-130	411	3	j	j	PROPN
chd-130	411	4	cancer	cancer	NOUN
chd-130	411	5	prev	prev	X
chd-130	411	6	.	.	PUNCT
chd-130	411	7	9	9	NUM
chd-130	411	8	,	,	PUNCT
chd-130	411	9	391	391	NUM
chd-130	411	10	-	-	SYM
chd-130	411	11	6	6	NUM
chd-130	411	12	.	.	PUNCT
chd-130	412	1	lazcano	lazcano	ADJ
chd-130	412	2	-	-	PUNCT
chd-130	412	3	ponce	ponce	NOUN
chd-130	412	4	,	,	PUNCT
chd-130	412	5	e.c	e.c	PROPN
chd-130	412	6	.	.	PROPN
chd-130	412	7	,	,	PUNCT
chd-130	412	8	miquel	miquel	PROPN
chd-130	412	9	,	,	PUNCT
chd-130	412	10	j.f	j.f	PROPN
chd-130	412	11	.	.	PROPN
chd-130	412	12	,	,	PUNCT
chd-130	412	13	muñoz	muñoz	PROPN
chd-130	412	14	,	,	PUNCT
chd-130	412	15	n.	n.	PROPN
chd-130	412	16	,	,	PUNCT
chd-130	412	17	herrero	herrero	PROPN
chd-130	412	18	,	,	PUNCT
chd-130	412	19	r.	r.	PROPN
chd-130	412	20	,	,	PUNCT
chd-130	412	21	ferrecio	ferrecio	PROPN
chd-130	412	22	,	,	PUNCT
chd-130	412	23	c.	c.	NOUN
chd-130	412	24	,	,	PUNCT
chd-130	412	25	wistuba	wistuba	PROPN
chd-130	412	26	,	,	PUNCT
chd-130	412	27	i.i	i.i	PROPN
chd-130	412	28	.	.	PROPN
chd-130	412	29	,	,	PUNCT
chd-130	412	30	alonso	alonso	PROPN
chd-130	412	31	de	de	X
chd-130	412	32	ruiz	ruiz	PROPN
chd-130	412	33	,	,	PUNCT
chd-130	412	34	p.	p.	PROPN
chd-130	412	35	,	,	PUNCT
chd-130	412	36	aristi	aristi	PROPN
chd-130	412	37	urista	urista	PROPN
chd-130	412	38	,	,	PUNCT
chd-130	412	39	g.	g.	PROPN
chd-130	412	40	,	,	PUNCT
chd-130	412	41	nervi	nervi	PROPN
chd-130	412	42	,	,	PUNCT
chd-130	412	43	f.	f.	PROPN
chd-130	412	44	(	(	PUNCT
chd-130	412	45	2001	2001	NUM
chd-130	412	46	)	)	PUNCT
chd-130	412	47	.	.	PUNCT
chd-130	413	1	epidemiology	epidemiology	NOUN
chd-130	413	2	and	and	CCONJ
chd-130	413	3	molecular	molecular	ADJ
chd-130	413	4	pathology	pathology	NOUN
chd-130	413	5	of	of	ADP
chd-130	413	6	gallbladder	gallbladder	NOUN
chd-130	413	7	cancer	cancer	NOUN
chd-130	413	8	.	.	PUNCT
chd-130	414	1	ca	can	AUX
chd-130	414	2	cancer	cancer	PROPN
chd-130	414	3	j	j	PROPN
chd-130	414	4	clin	clin	PROPN
chd-130	414	5	.	.	PUNCT
chd-130	415	1	51	51	NUM
chd-130	415	2	,	,	PUNCT
chd-130	415	3	349	349	NUM
chd-130	415	4	-	-	SYM
chd-130	415	5	64	64	NUM
chd-130	415	6	.	.	PUNCT
chd-130	416	1	leone	leone	PROPN
chd-130	416	2	,	,	PUNCT
chd-130	416	3	f.	f.	PROPN
chd-130	416	4	,	,	PUNCT
chd-130	416	5	cavalloni	cavalloni	NOUN
chd-130	416	6	,	,	PUNCT
chd-130	416	7	g.	g.	PROPN
chd-130	416	8	,	,	PUNCT
chd-130	416	9	pignochino	pignochino	NOUN
chd-130	416	10	,	,	PUNCT
chd-130	416	11	y.	y.	PROPN
chd-130	416	12	,	,	PUNCT
chd-130	416	13	sarotto	sarotto	PROPN
chd-130	416	14	,	,	PUNCT
chd-130	416	15	i.	i.	PROPN
chd-130	416	16	,	,	PUNCT
chd-130	416	17	ferraris	ferraris	PROPN
chd-130	416	18	,	,	PUNCT
chd-130	416	19	r.	r.	PROPN
chd-130	416	20	,	,	PUNCT
chd-130	416	21	piacibello	piacibello	ADV
chd-130	416	22	,	,	PUNCT
chd-130	416	23	w.	w.	PROPN
chd-130	416	24	,	,	PUNCT
chd-130	416	25	venesio	venesio	VERB
chd-130	416	26	,	,	PUNCT
chd-130	416	27	t.	t.	PROPN
chd-130	416	28	,	,	PUNCT
chd-130	416	29	capussotti	capussotti	PROPN
chd-130	416	30	,	,	PUNCT
chd-130	416	31	l.	l.	PROPN
chd-130	416	32	,	,	PUNCT
chd-130	416	33	risio	risio	ADJ
chd-130	416	34	,	,	PUNCT
chd-130	416	35	m.	m.	NOUN
chd-130	416	36	,	,	PUNCT
chd-130	416	37	aglietta	aglietta	ADJ
chd-130	416	38	,	,	PUNCT
chd-130	416	39	m.	m.	NOUN
chd-130	416	40	(	(	PUNCT
chd-130	416	41	2006	2006	NUM
chd-130	416	42	)	)	PUNCT
chd-130	416	43	.	.	PUNCT
chd-130	417	1	somatic	somatic	ADJ
chd-130	417	2	mutations	mutation	NOUN
chd-130	417	3	of	of	ADP
chd-130	417	4	epidermal	epidermal	ADJ
chd-130	417	5	growth	growth	NOUN
chd-130	417	6	factor	factor	NOUN
chd-130	417	7	receptor	receptor	NOUN
chd-130	417	8	in	in	ADP
chd-130	417	9	bile	bile	NOUN
chd-130	417	10	duct	duct	NOUN
chd-130	417	11	and	and	CCONJ
chd-130	417	12	gallbladder	gallbladder	NOUN
chd-130	417	13	carcinoma	carcinoma	NOUN
chd-130	417	14	.	.	PUNCT
chd-130	418	1	clin	clin	PROPN
chd-130	418	2	cancer	cancer	NOUN
chd-130	418	3	res	re	NOUN
chd-130	418	4	.	.	PROPN
chd-130	419	1	12	12	NUM
chd-130	419	2	,	,	PUNCT
chd-130	419	3	1680	1680	NUM
chd-130	419	4	-	-	SYM
chd-130	419	5	5	5	NUM
chd-130	419	6	.	.	PUNCT
chd-130	420	1	li	li	PROPN
chd-130	420	2	,	,	PUNCT
chd-130	420	3	m.	m.	NOUN
chd-130	420	4	,	,	PUNCT
chd-130	420	5	zhang	zhang	PROPN
chd-130	420	6	,	,	PUNCT
chd-130	420	7	z.	z.	PROPN
chd-130	420	8	,	,	PUNCT
chd-130	420	9	li	li	PROPN
chd-130	420	10	,	,	PUNCT
chd-130	420	11	x.	x.	NOUN
chd-130	420	12	,	,	PUNCT
chd-130	420	13	ye	ye	PROPN
chd-130	420	14	,	,	PUNCT
chd-130	420	15	j.	j.	PROPN
chd-130	420	16	,	,	PUNCT
chd-130	420	17	wu	wu	PROPN
chd-130	420	18	,	,	PUNCT
chd-130	420	19	x.	x.	PROPN
chd-130	420	20	,	,	PUNCT
chd-130	420	21	tan	tan	PROPN
chd-130	420	22	,	,	PUNCT
chd-130	420	23	z.	z.	PROPN
chd-130	420	24	,	,	PUNCT
chd-130	420	25	liu	liu	PROPN
chd-130	420	26	,	,	PUNCT
chd-130	420	27	c.	c.	PROPN
chd-130	420	28	,	,	PUNCT
chd-130	420	29	shen	shen	PROPN
chd-130	420	30	,	,	PUNCT
chd-130	420	31	b.	b.	PROPN
chd-130	420	32	,	,	PUNCT
chd-130	420	33	wang	wang	PROPN
chd-130	420	34	,	,	PUNCT
chd-130	420	35	x.a	x.a	PROPN
chd-130	420	36	.	.	PROPN
chd-130	420	37	,	,	PUNCT
chd-130	420	38	wu	wu	PROPN
chd-130	420	39	,	,	PUNCT
chd-130	420	40	w.	w.	PROPN
chd-130	420	41	(	(	PUNCT
chd-130	420	42	2014	2014	NUM
chd-130	420	43	)	)	PUNCT
chd-130	420	44	.	.	PUNCT
chd-130	421	1	whole	whole	ADJ
chd-130	421	2	-	-	PUNCT
chd-130	421	3	exome	exome	NOUN
chd-130	421	4	and	and	CCONJ
chd-130	421	5	targeted	target	VERB
chd-130	421	6	gene	gene	NOUN
chd-130	421	7	sequencing	sequencing	NOUN
chd-130	421	8	of	of	ADP
chd-130	421	9	gallbladder	gallbladder	NOUN
chd-130	421	10	carcinoma	carcinoma	NOUN
chd-130	421	11	identifies	identify	VERB
chd-130	421	12	recurrent	recurrent	ADJ
chd-130	421	13	mutations	mutation	NOUN
chd-130	421	14	in	in	ADP
chd-130	421	15	the	the	DET
chd-130	421	16	erbb	erbb	NOUN
chd-130	421	17	pathway	pathway	NOUN
chd-130	421	18	.	.	PUNCT
chd-130	422	1	nat	nat	PROPN
chd-130	422	2	genet	genet	PROPN
chd-130	422	3	.	.	PUNCT
chd-130	423	1	46	46	NUM
chd-130	423	2	,	,	PUNCT
chd-130	423	3	872	872	NUM
chd-130	423	4	-	-	SYM
chd-130	423	5	6	6	NUM
chd-130	423	6	.	.	PUNCT
chd-130	423	7	lubner	lubner	NOUN
chd-130	423	8	,	,	PUNCT
chd-130	423	9	s.j	s.j	PROPN
chd-130	423	10	.	.	PROPN
chd-130	423	11	,	,	PUNCT
chd-130	423	12	mahoney	mahoney	PROPN
chd-130	423	13	,	,	PUNCT
chd-130	423	14	m.r	m.r	PROPN
chd-130	423	15	.	.	PROPN
chd-130	423	16	,	,	PUNCT
chd-130	423	17	kolesar	kolesar	PROPN
chd-130	423	18	,	,	PUNCT
chd-130	423	19	j.l	j.l	PROPN
chd-130	423	20	.	.	PROPN
chd-130	423	21	,	,	PUNCT
chd-130	423	22	loconte	loconte	PROPN
chd-130	423	23	,	,	PUNCT
chd-130	423	24	n.k	n.k	PROPN
chd-130	423	25	.	.	PROPN
chd-130	423	26	,	,	PUNCT
chd-130	423	27	kim	kim	PROPN
chd-130	423	28	,	,	PUNCT
chd-130	423	29	g.p	g.p	PROPN
chd-130	423	30	.	.	PROPN
chd-130	423	31	,	,	PUNCT
chd-130	423	32	pitot	pitot	NOUN
chd-130	423	33	,	,	PUNCT
chd-130	423	34	h.c	h.c	PROPN
chd-130	423	35	.	.	PROPN
chd-130	423	36	,	,	PUNCT
chd-130	423	37	philip	philip	PROPN
chd-130	423	38	,	,	PUNCT
chd-130	423	39	p.a	p.a	PROPN
chd-130	423	40	.	.	PROPN
chd-130	423	41	,	,	PUNCT
chd-130	423	42	picus	picus	PROPN
chd-130	423	43	,	,	PUNCT
chd-130	423	44	j.	j.	PROPN
chd-130	423	45	,	,	PUNCT
chd-130	423	46	yong	yong	PROPN
chd-130	423	47	,	,	PUNCT
chd-130	423	48	w.p	w.p	PROPN
chd-130	423	49	.	.	PROPN
chd-130	423	50	,	,	PUNCT
chd-130	423	51	horvath	horvath	PROPN
chd-130	423	52	,	,	PUNCT
chd-130	423	53	l.	l.	PROPN
chd-130	423	54	et	et	PROPN
chd-130	423	55	al	al	PROPN
chd-130	423	56	.	.	PROPN
chd-130	423	57	(	(	PUNCT
chd-130	423	58	2010	2010	NUM
chd-130	423	59	)	)	PUNCT
chd-130	423	60	.	.	PUNCT
chd-130	424	1	report	report	NOUN
chd-130	424	2	of	of	ADP
chd-130	424	3	a	a	DET
chd-130	424	4	multicenter	multicenter	ADJ
chd-130	424	5	phase	phase	NOUN
chd-130	424	6	ii	ii	NOUN
chd-130	424	7	trial	trial	NOUN
chd-130	424	8	testing	test	VERB
chd-130	424	9	a	a	DET
chd-130	424	10	combination	combination	NOUN
chd-130	424	11	of	of	ADP
chd-130	424	12	biweekly	biweekly	ADJ
chd-130	424	13	bevacizumab	bevacizumab	NOUN
chd-130	424	14	and	and	CCONJ
chd-130	424	15	daily	daily	ADJ
chd-130	424	16	erlotinib	erlotinib	NOUN
chd-130	424	17	in	in	ADP
chd-130	424	18	patients	patient	NOUN
chd-130	424	19	with	with	ADP
chd-130	424	20	unresectable	unresectable	ADJ
chd-130	424	21	biliary	biliary	ADJ
chd-130	424	22	cancer	cancer	NOUN
chd-130	424	23	:	:	PUNCT
chd-130	424	24	a	a	DET
chd-130	424	25	phase	phase	NOUN
chd-130	424	26	ii	ii	PROPN
chd-130	424	27	consortium	consortium	NOUN
chd-130	424	28	study	study	NOUN
chd-130	424	29	.	.	PUNCT
chd-130	425	1	j	j	PROPN
chd-130	425	2	clin	clin	PROPN
chd-130	425	3	oncol	oncol	PROPN
chd-130	425	4	.	.	PUNCT
chd-130	426	1	28	28	NUM
chd-130	426	2	,	,	PUNCT
chd-130	426	3	3491	3491	NUM
chd-130	426	4	-	-	SYM
chd-130	426	5	7	7	NUM
chd-130	426	6	.	.	PUNCT
chd-130	426	7	matsubara	matsubara	NOUN
chd-130	426	8	,	,	PUNCT
chd-130	426	9	t.	t.	PROPN
chd-130	426	10	,	,	PUNCT
chd-130	426	11	sakurai	sakurai	PROPN
chd-130	426	12	,	,	PUNCT
chd-130	426	13	y.	y.	NOUN
chd-130	426	14	,	,	PUNCT
chd-130	426	15	sasayama	sasayama	NOUN
chd-130	426	16	,	,	PUNCT
chd-130	426	17	y.	y.	PROPN
chd-130	426	18	,	,	PUNCT
chd-130	426	19	hori	hori	PROPN
chd-130	426	20	,	,	PUNCT
chd-130	426	21	h.	h.	PROPN
chd-130	426	22	,	,	PUNCT
chd-130	426	23	ochiai	ochiai	PROPN
chd-130	426	24	,	,	PUNCT
chd-130	426	25	m.	m.	NOUN
chd-130	426	26	,	,	PUNCT
chd-130	426	27	funabiki	funabiki	NOUN
chd-130	426	28	,	,	PUNCT
chd-130	426	29	t.	t.	PROPN
chd-130	426	30	,	,	PUNCT
chd-130	426	31	matsumoto	matsumoto	PROPN
chd-130	426	32	,	,	PUNCT
chd-130	426	33	k.	k.	PROPN
chd-130	426	34	,	,	PUNCT
chd-130	426	35	hirono	hirono	PROPN
chd-130	426	36	,	,	PUNCT
chd-130	426	37	i.	i.	PROPN
chd-130	426	38	(	(	PUNCT
chd-130	426	39	1996	1996	NUM
chd-130	426	40	)	)	PUNCT
chd-130	426	41	.	.	PUNCT
chd-130	427	1	k	k	X
chd-130	427	2	-	-	PUNCT
chd-130	427	3	ras	ra	VERB
chd-130	427	4	point	point	NOUN
chd-130	427	5	mutations	mutation	NOUN
chd-130	427	6	in	in	ADP
chd-130	427	7	cancerous	cancerous	ADJ
chd-130	427	8	and	and	CCONJ
chd-130	427	9	noncancerous	noncancerous	ADJ
chd-130	427	10	biliary	biliary	ADJ
chd-130	427	11	epithelium	epithelium	NOUN
chd-130	427	12	in	in	ADP
chd-130	427	13	patients	patient	NOUN
chd-130	427	14	with	with	ADP
chd-130	427	15	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	427	16	maljunction	maljunction	NOUN
chd-130	427	17	.	.	PUNCT
chd-130	428	1	cancer	cancer	NOUN
chd-130	428	2	.	.	PUNCT
chd-130	429	1	77	77	NUM
chd-130	429	2	,	,	PUNCT
chd-130	429	3	1752	1752	NUM
chd-130	429	4	-	-	SYM
chd-130	429	5	7	7	NUM
chd-130	429	6	.	.	PUNCT
chd-130	429	7	mcdermott	mcdermott	PROPN
chd-130	429	8	,	,	PUNCT
chd-130	429	9	u.	u.	PROPN
chd-130	429	10	,	,	PUNCT
chd-130	429	11	settleman	settleman	ADJ
chd-130	429	12	,	,	PUNCT
chd-130	429	13	j.	j.	PROPN
chd-130	429	14	(	(	PUNCT
chd-130	429	15	2009	2009	NUM
chd-130	429	16	)	)	PUNCT
chd-130	429	17	.	.	PUNCT
chd-130	430	1	personalized	personalize	VERB
chd-130	430	2	cancer	cancer	NOUN
chd-130	430	3	therapy	therapy	NOUN
chd-130	430	4	with	with	ADP
chd-130	430	5	selective	selective	ADJ
chd-130	430	6	kinase	kinase	PROPN
chd-130	430	7	inhibitors	inhibitor	NOUN
chd-130	430	8	:	:	PUNCT
chd-130	430	9	an	an	DET
chd-130	430	10	emerging	emerge	VERB
chd-130	430	11	paradigm	paradigm	NOUN
chd-130	430	12	in	in	ADP
chd-130	430	13	medical	medical	ADJ
chd-130	430	14	oncology	oncology	NOUN
chd-130	430	15	.	.	PUNCT
chd-130	431	1	j	j	PROPN
chd-130	431	2	clin	clin	PROPN
chd-130	431	3	oncol	oncol	PROPN
chd-130	431	4	.	.	PUNCT
chd-130	432	1	27	27	NUM
chd-130	432	2	,	,	PUNCT
chd-130	432	3	5650	5650	NUM
chd-130	432	4	-	-	SYM
chd-130	432	5	9	9	NUM
chd-130	432	6	.	.	X
chd-130	432	7	mody	mody	NOUN
chd-130	432	8	,	,	PUNCT
chd-130	432	9	k.	k.	PROPN
chd-130	432	10	,	,	PUNCT
chd-130	432	11	strauss	strauss	PROPN
chd-130	432	12	,	,	PUNCT
chd-130	432	13	e.	e.	PROPN
chd-130	432	14	,	,	PUNCT
chd-130	432	15	lincer	lincer	PROPN
chd-130	432	16	,	,	PUNCT
chd-130	432	17	r.	r.	PROPN
chd-130	432	18	,	,	PUNCT
chd-130	432	19	frank	frank	PROPN
chd-130	432	20	,	,	PUNCT
chd-130	432	21	r.c	r.c	PROPN
chd-130	432	22	.	.	PROPN
chd-130	432	23	(	(	PUNCT
chd-130	432	24	2010	2010	NUM
chd-130	432	25	)	)	PUNCT
chd-130	432	26	.	.	PUNCT
chd-130	433	1	complete	complete	ADJ
chd-130	433	2	response	response	NOUN
chd-130	433	3	in	in	ADP
chd-130	433	4	gallbladder	gallbladder	NOUN
chd-130	433	5	cancer	cancer	NOUN
chd-130	433	6	to	to	ADP
chd-130	433	7	erlotinib	erlotinib	NOUN
chd-130	433	8	plus	plus	CCONJ
chd-130	433	9	gemcitabine	gemcitabine	NOUN
chd-130	433	10	does	do	AUX
chd-130	433	11	not	not	PART
chd-130	433	12	require	require	VERB
chd-130	433	13	mutation	mutation	NOUN
chd-130	433	14	of	of	ADP
chd-130	433	15	the	the	DET
chd-130	433	16	epidermal	epidermal	ADJ
chd-130	433	17	growth	growth	NOUN
chd-130	433	18	factor	factor	NOUN
chd-130	433	19	receptor	receptor	NOUN
chd-130	433	20	gene	gene	NOUN
chd-130	433	21	:	:	PUNCT
chd-130	433	22	a	a	DET
chd-130	433	23	case	case	NOUN
chd-130	433	24	report	report	NOUN
chd-130	433	25	.	.	PUNCT
chd-130	434	1	bmc	bmc	ADJ
chd-130	434	2	cancer	cancer	NOUN
chd-130	434	3	.	.	PUNCT
chd-130	435	1	10	10	NUM
chd-130	435	2	,	,	PUNCT
chd-130	435	3	570	570	NUM
chd-130	435	4	.	.	PUNCT
chd-130	436	1	nagahashi	nagahashi	PROPN
chd-130	436	2	,	,	PUNCT
chd-130	436	3	m.	m.	NOUN
chd-130	436	4	,	,	PUNCT
chd-130	436	5	ajioka	ajioka	NOUN
chd-130	436	6	,	,	PUNCT
chd-130	436	7	y.	y.	PROPN
chd-130	436	8	,	,	PUNCT
chd-130	436	9	lang	lang	PROPN
chd-130	436	10	,	,	PUNCT
chd-130	436	11	i.	i.	PROPN
chd-130	436	12	,	,	PUNCT
chd-130	436	13	szentirmay	szentirmay	PROPN
chd-130	436	14	,	,	PUNCT
chd-130	436	15	z.	z.	PROPN
chd-130	436	16	,	,	PUNCT
chd-130	436	17	kasler	kasler	PROPN
chd-130	436	18	,	,	PUNCT
chd-130	436	19	m.	m.	NOUN
chd-130	436	20	,	,	PUNCT
chd-130	436	21	nakadaira	nakadaira	PROPN
chd-130	436	22	,	,	PUNCT
chd-130	436	23	h.	h.	PROPN
chd-130	436	24	,	,	PUNCT
chd-130	436	25	yokoyama	yokoyama	PROPN
chd-130	436	26	,	,	PUNCT
chd-130	436	27	n.	n.	PROPN
chd-130	436	28	,	,	PUNCT
chd-130	436	29	watanabe	watanabe	PROPN
chd-130	436	30	.	.	PUNCT
chd-130	437	1	g.	g.	PROPN
chd-130	437	2	,	,	PUNCT
chd-130	437	3	nishikura	nishikura	PROPN
chd-130	437	4	,	,	PUNCT
chd-130	437	5	k.	k.	PROPN
chd-130	437	6	,	,	PUNCT
chd-130	437	7	wakai	wakai	PROPN
chd-130	437	8	,	,	PUNCT
chd-130	437	9	t.	t.	PROPN
chd-130	437	10	,	,	PUNCT
chd-130	437	11	shirai	shirai	VERB
chd-130	437	12	,	,	PUNCT
chd-130	437	13	y.	y.	PROPN
chd-130	437	14	,	,	PUNCT
chd-130	437	15	hatakeyama	hatakeyama	PROPN
chd-130	437	16	,	,	PUNCT
chd-130	437	17	k.	k.	PROPN
chd-130	437	18	,	,	PUNCT
chd-130	437	19	yamamoto	yamamoto	PROPN
chd-130	437	20	,	,	PUNCT
chd-130	437	21	m.	m.	NOUN
chd-130	437	22	(	(	PUNCT
chd-130	437	23	2008	2008	NUM
chd-130	437	24	)	)	PUNCT
chd-130	437	25	.	.	PUNCT
chd-130	438	1	genetic	genetic	ADJ
chd-130	438	2	changes	change	NOUN
chd-130	438	3	of	of	ADP
chd-130	438	4	p53	p53	NOUN
chd-130	438	5	,	,	PUNCT
chd-130	438	6	k	k	PROPN
chd-130	438	7	-	-	PUNCT
chd-130	438	8	ras	ras	NOUN
chd-130	438	9	,	,	PUNCT
chd-130	438	10	and	and	CCONJ
chd-130	438	11	microsatellite	microsatellite	ADJ
chd-130	438	12	instability	instability	NOUN
chd-130	438	13	in	in	ADP
chd-130	438	14	gallbladder	gallbladder	NOUN
chd-130	438	15	carcinoma	carcinoma	NOUN
chd-130	438	16	in	in	ADP
chd-130	438	17	high	high	ADJ
chd-130	438	18	-	-	PUNCT
chd-130	438	19	incidence	incidence	NOUN
chd-130	438	20	areas	area	NOUN
chd-130	438	21	of	of	ADP
chd-130	438	22	japan	japan	PROPN
chd-130	438	23	and	and	CCONJ
chd-130	438	24	hungary	hungary	PROPN
chd-130	438	25	.	.	PUNCT
chd-130	439	1	world	world	PROPN
chd-130	439	2	j	j	PROPN
chd-130	439	3	gastroenterol	gastroenterol	PROPN
chd-130	439	4	.	.	PUNCT
chd-130	440	1	14	14	NUM
chd-130	440	2	,	,	PUNCT
chd-130	440	3	70	70	NUM
chd-130	440	4	-	-	SYM
chd-130	440	5	5	5	NUM
chd-130	440	6	.	.	PUNCT
chd-130	440	7	nakamura	nakamura	PROPN
chd-130	440	8	,	,	PUNCT
chd-130	440	9	h.	h.	PROPN
chd-130	440	10	,	,	PUNCT
chd-130	440	11	arai	arai	PROPN
chd-130	440	12	,	,	PUNCT
chd-130	440	13	y.	y.	PROPN
chd-130	440	14	,	,	PUNCT
chd-130	440	15	totoki	totoki	NOUN
chd-130	440	16	,	,	PUNCT
chd-130	440	17	y.	y.	NOUN
chd-130	440	18	,	,	PUNCT
chd-130	440	19	shirota	shirota	NOUN
chd-130	440	20	,	,	PUNCT
chd-130	440	21	t.	t.	PROPN
chd-130	440	22	,	,	PUNCT
chd-130	440	23	elzawahry	elzawahry	PROPN
chd-130	440	24	,	,	PUNCT
chd-130	440	25	a.	a.	PROPN
chd-130	440	26	,	,	PUNCT
chd-130	440	27	kato	kato	PROPN
chd-130	440	28	,	,	PUNCT
chd-130	440	29	m.	m.	NOUN
chd-130	440	30	,	,	PUNCT
chd-130	440	31	hama	hama	NOUN
chd-130	440	32	,	,	PUNCT
chd-130	440	33	n.	n.	NOUN
chd-130	440	34	,	,	PUNCT
chd-130	440	35	hosoda	hosoda	PROPN
chd-130	440	36	,	,	PUNCT
chd-130	440	37	f.	f.	PROPN
chd-130	440	38	,	,	PUNCT
chd-130	440	39	urushidate	urushidate	VERB
chd-130	440	40	,	,	PUNCT
chd-130	440	41	t.	t.	PROPN
chd-130	440	42	,	,	PUNCT
chd-130	440	43	ohashi	ohashi	PROPN
chd-130	440	44	,	,	PUNCT
chd-130	440	45	s.	s.	PROPN
chd-130	440	46	et	et	PROPN
chd-130	440	47	al	al	PROPN
chd-130	440	48	.	.	PROPN
chd-130	440	49	(	(	PUNCT
chd-130	440	50	2015	2015	NUM
chd-130	440	51	)	)	PUNCT
chd-130	440	52	.	.	PUNCT
chd-130	441	1	genomic	genomic	ADJ
chd-130	441	2	spectra	spectra	NOUN
chd-130	441	3	of	of	ADP
chd-130	441	4	biliary	biliary	ADJ
chd-130	441	5	tract	tract	NOUN
chd-130	441	6	cancer	cancer	NOUN
chd-130	441	7	.	.	PUNCT
chd-130	442	1	nat	nat	PROPN
chd-130	442	2	genet	genet	PROPN
chd-130	442	3	.	.	PUNCT
chd-130	443	1	47	47	NUM
chd-130	443	2	,	,	PUNCT
chd-130	443	3	1003	1003	NUM
chd-130	443	4	-	-	SYM
chd-130	443	5	10	10	NUM
chd-130	443	6	.	.	PUNCT
chd-130	443	7	nakayama	nakayama	PROPN
chd-130	443	8	,	,	PUNCT
chd-130	443	9	k.	k.	PROPN
chd-130	443	10	,	,	PUNCT
chd-130	443	11	konno	konno	NOUN
chd-130	443	12	,	,	PUNCT
chd-130	443	13	m.	m.	NOUN
chd-130	443	14	,	,	PUNCT
chd-130	443	15	kanzaki	kanzaki	PROPN
chd-130	443	16	,	,	PUNCT
chd-130	443	17	a.	a.	NOUN
chd-130	443	18	,	,	PUNCT
chd-130	443	19	morikawa	morikawa	NOUN
chd-130	443	20	,	,	PUNCT
chd-130	443	21	t.	t.	PROPN
chd-130	443	22	,	,	PUNCT
chd-130	443	23	miyashita	miyashita	PROPN
chd-130	443	24	,	,	PUNCT
chd-130	443	25	h.	h.	PROPN
chd-130	443	26	,	,	PUNCT
chd-130	443	27	fujioka	fujioka	NOUN
chd-130	443	28	,	,	PUNCT
chd-130	443	29	t.	t.	PROPN
chd-130	443	30	,	,	PUNCT
chd-130	443	31	uchida	uchida	PROPN
chd-130	443	32	,	,	PUNCT
chd-130	443	33	t.	t.	PROPN
chd-130	443	34	,	,	PUNCT
chd-130	443	35	miyazaki	miyazaki	PROPN
chd-130	443	36	,	,	PUNCT
chd-130	443	37	k.	k.	PROPN
chd-130	443	38	,	,	PUNCT
chd-130	443	39	takao	takao	PROPN
chd-130	443	40	,	,	PUNCT
chd-130	443	41	s.	s.	PROPN
chd-130	443	42	,	,	PUNCT
chd-130	443	43	aikou	aikou	PROPN
chd-130	443	44	,	,	PUNCT
chd-130	443	45	t.	t.	PROPN
chd-130	443	46	et	et	PROPN
chd-130	443	47	al	al	PROPN
chd-130	443	48	.	.	PROPN
chd-130	443	49	(	(	PUNCT
chd-130	443	50	2001	2001	NUM
chd-130	443	51	)	)	PUNCT
chd-130	443	52	.	.	PUNCT
chd-130	444	1	allelotype	allelotype	NOUN
chd-130	444	2	analysis	analysis	NOUN
chd-130	444	3	of	of	ADP
chd-130	444	4	gallbladder	gallbladder	NOUN
chd-130	444	5	carcinoma	carcinoma	NOUN
chd-130	444	6	associated	associate	VERB
chd-130	444	7	with	with	ADP
chd-130	444	8	anomalous	anomalous	ADJ
chd-130	444	9	junction	junction	NOUN
chd-130	444	10	of	of	ADP
chd-130	444	11	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	444	12	duct	duct	NOUN
chd-130	444	13	.	.	PUNCT
chd-130	445	1	cancer	cancer	NOUN
chd-130	445	2	lett	lett	PROPN
chd-130	445	3	.	.	PUNCT
chd-130	446	1	166	166	NUM
chd-130	446	2	,	,	PUNCT
chd-130	446	3	135	135	NUM
chd-130	446	4	-	-	SYM
chd-130	446	5	41	41	NUM
chd-130	446	6	.	.	PUNCT
chd-130	447	1	nakazawa	nakazawa	PROPN
chd-130	447	2	,	,	PUNCT
chd-130	447	3	k.	k.	PROPN
chd-130	447	4	,	,	PUNCT
chd-130	447	5	dobashi	dobashi	PROPN
chd-130	447	6	,	,	PUNCT
chd-130	447	7	y.	y.	PROPN
chd-130	447	8	,	,	PUNCT
chd-130	447	9	suzuki	suzuki	PROPN
chd-130	447	10	,	,	PUNCT
chd-130	447	11	s.	s.	PROPN
chd-130	447	12	,	,	PUNCT
chd-130	447	13	fujii	fujii	PROPN
chd-130	447	14	,	,	PUNCT
chd-130	447	15	h.	h.	PROPN
chd-130	447	16	,	,	PUNCT
chd-130	447	17	takeda	takeda	PROPN
chd-130	447	18	,	,	PUNCT
chd-130	447	19	y.	y.	PROPN
chd-130	447	20	,	,	PUNCT
chd-130	447	21	ooi	ooi	PROPN
chd-130	447	22	,	,	PUNCT
chd-130	447	23	a.	a.	NOUN
chd-130	447	24	(	(	PUNCT
chd-130	447	25	2005	2005	NUM
chd-130	447	26	)	)	PUNCT
chd-130	447	27	.	.	PUNCT
chd-130	448	1	amplification	amplification	NOUN
chd-130	448	2	and	and	CCONJ
chd-130	448	3	overexpression	overexpression	NOUN
chd-130	448	4	of	of	ADP
chd-130	448	5	c	c	NOUN
chd-130	448	6	-	-	PUNCT
chd-130	448	7	erbb-2	erbb-2	NOUN
chd-130	448	8	,	,	PUNCT
chd-130	448	9	epidermal	epidermal	ADJ
chd-130	448	10	growth	growth	NOUN
chd-130	448	11	factor	factor	NOUN
chd-130	448	12	receptor	receptor	NOUN
chd-130	448	13	,	,	PUNCT
chd-130	448	14	and	and	CCONJ
chd-130	448	15	c	c	AUX
chd-130	448	16	-	-	PUNCT
chd-130	448	17	met	meet	VERB
chd-130	448	18	in	in	ADP
chd-130	448	19	biliary	biliary	ADJ
chd-130	448	20	tract	tract	NOUN
chd-130	448	21	cancers	cancer	NOUN
chd-130	448	22	.	.	PUNCT
chd-130	449	1	j	j	PROPN
chd-130	449	2	pathol	pathol	NOUN
chd-130	449	3	.	.	PUNCT
chd-130	450	1	206	206	NUM
chd-130	450	2	,	,	PUNCT
chd-130	450	3	356	356	NUM
chd-130	450	4	-	-	SYM
chd-130	450	5	65	65	NUM
chd-130	450	6	.	.	PUNCT
chd-130	450	7	nath	nath	PROPN
chd-130	450	8	g	g	PROPN
chd-130	450	9	,	,	PUNCT
chd-130	450	10	singh	singh	PROPN
chd-130	450	11	h	h	NOUN
chd-130	450	12	,	,	PUNCT
chd-130	450	13	shukla	shukla	PROPN
chd-130	450	14	vk	vk	PROPN
chd-130	450	15	.	.	PUNCT
chd-130	450	16	(	(	PUNCT
chd-130	450	17	1997	1997	NUM
chd-130	450	18	)	)	PUNCT
chd-130	450	19	.	.	PUNCT
chd-130	451	1	chronic	chronic	ADJ
chd-130	451	2	typhoid	typhoid	NOUN
chd-130	451	3	carriage	carriage	NOUN
chd-130	451	4	and	and	CCONJ
chd-130	451	5	carcinoma	carcinoma	NOUN
chd-130	451	6	of	of	ADP
chd-130	451	7	the	the	DET
chd-130	451	8	gallbladder	gallbladder	NOUN
chd-130	451	9	.	.	PUNCT
chd-130	452	1	eur	eur	PROPN
chd-130	452	2	j	j	PROPN
chd-130	452	3	cancer	cancer	NOUN
chd-130	452	4	prev	prev	PROPN
chd-130	452	5	.	.	PUNCT
chd-130	453	1	6:557	6:557	X
chd-130	453	2	-	-	PUNCT
chd-130	453	3	9	9	NUM
chd-130	453	4	.	.	PUNCT
chd-130	454	1	obara	obara	PROPN
chd-130	454	2	,	,	PUNCT
chd-130	454	3	t.	t.	PROPN
chd-130	454	4	,	,	PUNCT
chd-130	454	5	tanno	tanno	PROPN
chd-130	454	6	,	,	PUNCT
chd-130	454	7	s.	s.	PROPN
chd-130	454	8	,	,	PUNCT
chd-130	454	9	fujii	fujii	PROPN
chd-130	454	10	,	,	PUNCT
chd-130	454	11	t.	t.	PROPN
chd-130	454	12	,	,	PUNCT
chd-130	454	13	izawa	izawa	PROPN
chd-130	454	14	,	,	PUNCT
chd-130	454	15	t.	t.	PROPN
chd-130	454	16	,	,	PUNCT
chd-130	454	17	mizukami	mizukami	NOUN
chd-130	454	18	,	,	PUNCT
chd-130	454	19	y.	y.	PROPN
chd-130	454	20	,	,	PUNCT
chd-130	454	21	yanagawa	yanagawa	NOUN
chd-130	454	22	,	,	PUNCT
chd-130	454	23	n.	n.	NOUN
chd-130	454	24	,	,	PUNCT
chd-130	454	25	ura	ura	NOUN
chd-130	454	26	,	,	PUNCT
chd-130	454	27	h.	h.	PROPN
chd-130	454	28	,	,	PUNCT
chd-130	454	29	kohgo	kohgo	PROPN
chd-130	454	30	,	,	PUNCT
chd-130	454	31	y.	y.	PROPN
chd-130	454	32	(	(	PUNCT
chd-130	454	33	1999	1999	NUM
chd-130	454	34	)	)	PUNCT
chd-130	454	35	.	.	PUNCT
chd-130	455	1	epithelial	epithelial	ADJ
chd-130	455	2	cell	cell	NOUN
chd-130	455	3	proliferation	proliferation	NOUN
chd-130	455	4	and	and	CCONJ
chd-130	455	5	gene	gene	NOUN
chd-130	455	6	mutation	mutation	NOUN
chd-130	455	7	in	in	ADP
chd-130	455	8	the	the	DET
chd-130	455	9	mucosa	mucosa	NOUN
chd-130	455	10	of	of	ADP
chd-130	455	11	gallbladder	gallbladder	NOUN
chd-130	455	12	with	with	ADP
chd-130	455	13	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	455	14	malunion	malunion	NOUN
chd-130	455	15	and	and	CCONJ
chd-130	455	16	cancer	cancer	NOUN
chd-130	455	17	.	.	PUNCT
chd-130	456	1	j	j	PROPN
chd-130	456	2	hepatobiliary	hepatobiliary	PROPN
chd-130	456	3	pancreat	pancreat	PROPN
chd-130	456	4	surg	surg	PROPN
chd-130	456	5	.	.	PUNCT
chd-130	457	1	6	6	NUM
chd-130	457	2	,	,	PUNCT
chd-130	457	3	229	229	NUM
chd-130	457	4	-	-	SYM
chd-130	457	5	36	36	NUM
chd-130	457	6	.	.	PUNCT
chd-130	458	1	ooi	ooi	PROPN
chd-130	458	2	,	,	PUNCT
chd-130	458	3	a.	a.	PROPN
chd-130	458	4	,	,	PUNCT
chd-130	458	5	suzuki	suzuki	PROPN
chd-130	458	6	,	,	PUNCT
chd-130	458	7	s.	s.	PROPN
chd-130	458	8	,	,	PUNCT
chd-130	458	9	nakazawa	nakazawa	PROPN
chd-130	458	10	,	,	PUNCT
chd-130	458	11	k.	k.	PROPN
chd-130	458	12	,	,	PUNCT
chd-130	458	13	itakura	itakura	PROPN
chd-130	458	14	,	,	PUNCT
chd-130	458	15	j.	j.	PROPN
chd-130	458	16	,	,	PUNCT
chd-130	458	17	imoto	imoto	PROPN
chd-130	458	18	,	,	PUNCT
chd-130	458	19	i.	i.	PROPN
chd-130	458	20	,	,	PUNCT
chd-130	458	21	nakamura	nakamura	PROPN
chd-130	458	22	,	,	PUNCT
chd-130	458	23	h.	h.	PROPN
chd-130	458	24	,	,	PUNCT
chd-130	458	25	dobashi	dobashi	PROPN
chd-130	458	26	,	,	PUNCT
chd-130	458	27	y.	y.	PROPN
chd-130	458	28	(	(	PUNCT
chd-130	458	29	2009	2009	NUM
chd-130	458	30	)	)	PUNCT
chd-130	458	31	.	.	PUNCT
chd-130	459	1	gene	gene	NOUN
chd-130	459	2	amplification	amplification	NOUN
chd-130	459	3	of	of	ADP
chd-130	459	4	myc	myc	PROPN
chd-130	459	5	and	and	CCONJ
chd-130	459	6	its	its	PRON
chd-130	459	7	coamplification	coamplification	NOUN
chd-130	459	8	with	with	ADP
chd-130	459	9	erbb2	erbb2	PROPN
chd-130	459	10	and	and	CCONJ
chd-130	459	11	egfr	egfr	VERB
chd-130	459	12	in	in	ADP
chd-130	459	13	gallbladder	gallbladder	NOUN
chd-130	459	14	adenocarcinoma	adenocarcinoma	NOUN
chd-130	459	15	.	.	PUNCT
chd-130	460	1	anticancer	anticancer	NOUN
chd-130	460	2	res	re	NOUN
chd-130	460	3	.	.	PROPN
chd-130	460	4	29	29	NUM
chd-130	460	5	,	,	PUNCT
chd-130	460	6	19	19	NUM
chd-130	460	7	-	-	SYM
chd-130	460	8	26	26	NUM
chd-130	460	9	.	.	PUNCT
chd-130	461	1	pandey	pandey	PROPN
chd-130	461	2	,	,	PUNCT
chd-130	461	3	s.n	s.n	PROPN
chd-130	461	4	.	.	PROPN
chd-130	461	5	,	,	PUNCT
chd-130	461	6	jain	jain	PROPN
chd-130	461	7	,	,	PUNCT
chd-130	461	8	m.	m.	NOUN
chd-130	461	9	,	,	PUNCT
chd-130	461	10	nigam	nigam	PROPN
chd-130	461	11	,	,	PUNCT
chd-130	461	12	p.	p.	PROPN
chd-130	461	13	,	,	PUNCT
chd-130	461	14	choudhuri	choudhuri	PROPN
chd-130	461	15	,	,	PUNCT
chd-130	461	16	g.	g.	PROPN
chd-130	461	17	,	,	PUNCT
chd-130	461	18	mittal	mittal	PROPN
chd-130	461	19	,	,	PUNCT
chd-130	461	20	b.	b.	PROPN
chd-130	461	21	(	(	PUNCT
chd-130	461	22	2006	2006	NUM
chd-130	461	23	)	)	PUNCT
chd-130	461	24	.	.	PUNCT
chd-130	462	1	genetic	genetic	ADJ
chd-130	462	2	polymorphisms	polymorphism	NOUN
chd-130	462	3	in	in	ADP
chd-130	462	4	gstm1	gstm1	PROPN
chd-130	462	5	,	,	PUNCT
chd-130	462	6	gstt1	gstt1	NOUN
chd-130	462	7	,	,	PUNCT
chd-130	462	8	gstp1	gstp1	NOUN
chd-130	462	9	,	,	PUNCT
chd-130	462	10	gstm3	gstm3	NOUN
chd-130	462	11	and	and	CCONJ
chd-130	462	12	the	the	DET
chd-130	462	13	susceptibility	susceptibility	NOUN
chd-130	462	14	to	to	ADP
chd-130	462	15	gallbladder	gallbladder	NOUN
chd-130	462	16	cancer	cancer	NOUN
chd-130	462	17	in	in	ADP
chd-130	462	18	north	north	PROPN
chd-130	462	19	india	india	PROPN
chd-130	462	20	.	.	PUNCT
chd-130	463	1	biomarkers	biomarker	NOUN
chd-130	463	2	.	.	PUNCT
chd-130	464	1	11	11	NUM
chd-130	464	2	,	,	PUNCT
chd-130	464	3	250	250	NUM
chd-130	464	4	-	-	SYM
chd-130	464	5	61	61	NUM
chd-130	464	6	.	.	PUNCT
chd-130	465	1	pandey	pandey	PROPN
chd-130	465	2	,	,	PUNCT
chd-130	465	3	s.n	s.n	PROPN
chd-130	465	4	.	.	PROPN
chd-130	465	5	,	,	PUNCT
chd-130	465	6	modi	modi	PROPN
chd-130	465	7	,	,	PUNCT
chd-130	465	8	d.r	d.r	PROPN
chd-130	465	9	.	.	PROPN
chd-130	465	10	,	,	PUNCT
chd-130	465	11	choudhuri	choudhuri	PROPN
chd-130	465	12	,	,	PUNCT
chd-130	465	13	g.	g.	PROPN
chd-130	465	14	,	,	PUNCT
chd-130	465	15	mittal	mittal	PROPN
chd-130	465	16	,	,	PUNCT
chd-130	465	17	b.	b.	PROPN
chd-130	465	18	(	(	PUNCT
chd-130	465	19	2007	2007	NUM
chd-130	465	20	)	)	PUNCT
chd-130	465	21	.	.	PUNCT
chd-130	466	1	slow	slow	ADJ
chd-130	466	2	acetylator	acetylator	PROPN
chd-130	466	3	genotype	genotype	NOUN
chd-130	466	4	of	of	ADP
chd-130	466	5	n	n	CCONJ
chd-130	466	6	-	-	PUNCT
chd-130	466	7	acetyl	acetyl	NOUN
chd-130	466	8	transferase2	transferase2	NOUN
chd-130	466	9	(	(	PUNCT
chd-130	466	10	nat2	nat2	PROPN
chd-130	466	11	)	)	PUNCT
chd-130	466	12	is	be	AUX
chd-130	466	13	associated	associate	VERB
chd-130	466	14	with	with	ADP
chd-130	466	15	increased	increase	VERB
chd-130	466	16	susceptibility	susceptibility	NOUN
chd-130	466	17	to	to	ADP
chd-130	466	18	gallbladder	gallbladder	NOUN
chd-130	466	19	cancer	cancer	NOUN
chd-130	466	20	:	:	PUNCT
chd-130	466	21	the	the	DET
chd-130	466	22	cancer	cancer	NOUN
chd-130	466	23	risk	risk	NOUN
chd-130	466	24	not	not	PART
chd-130	466	25	modulated	modulate	VERB
chd-130	466	26	by	by	ADP
chd-130	466	27	gallstone	gallstone	NOUN
chd-130	466	28	disease	disease	NOUN
chd-130	466	29	.	.	PUNCT
chd-130	467	1	cancer	cancer	NOUN
chd-130	467	2	biol	biol	PROPN
chd-130	467	3	ther	ther	ADV
chd-130	467	4	.	.	PUNCT
chd-130	468	1	6	6	NUM
chd-130	468	2	,	,	PUNCT
chd-130	468	3	91	91	NUM
chd-130	468	4	-	-	SYM
chd-130	468	5	6	6	NUM
chd-130	468	6	.	.	PUNCT
chd-130	468	7	pignochino	pignochino	NOUN
chd-130	468	8	,	,	PUNCT
chd-130	468	9	y.	y.	PROPN
chd-130	468	10	,	,	PUNCT
chd-130	468	11	sarotto	sarotto	PROPN
chd-130	468	12	,	,	PUNCT
chd-130	468	13	i.	i.	NOUN
chd-130	468	14	,	,	PUNCT
chd-130	468	15	peraldo	peraldo	NOUN
chd-130	468	16	-	-	PUNCT
chd-130	468	17	neia	neia	PROPN
chd-130	468	18	,	,	PUNCT
chd-130	468	19	c.	c.	NOUN
chd-130	468	20	,	,	PUNCT
chd-130	468	21	penachioni	penachioni	NOUN
chd-130	468	22	,	,	PUNCT
chd-130	468	23	j.y	j.y	PROPN
chd-130	468	24	.	.	PROPN
chd-130	468	25	,	,	PUNCT
chd-130	468	26	cavalloni	cavalloni	PROPN
chd-130	468	27	,	,	PUNCT
chd-130	468	28	g.	g.	PROPN
chd-130	468	29	,	,	PUNCT
chd-130	468	30	migliardi	migliardi	PROPN
chd-130	468	31	,	,	PUNCT
chd-130	468	32	g.	g.	PROPN
chd-130	468	33	,	,	PUNCT
chd-130	468	34	casorzo	casorzo	PROPN
chd-130	468	35	,	,	PUNCT
chd-130	468	36	l.	l.	PROPN
chd-130	468	37	,	,	PUNCT
chd-130	468	38	chiorino	chiorino	PROPN
chd-130	468	39	,	,	PUNCT
chd-130	468	40	g.	g.	PROPN
chd-130	468	41	,	,	PUNCT
chd-130	468	42	risio	risio	ADJ
chd-130	468	43	,	,	PUNCT
chd-130	468	44	m.	m.	NOUN
chd-130	468	45	,	,	PUNCT
chd-130	468	46	bardelli	bardelli	NOUN
chd-130	468	47	,	,	PUNCT
chd-130	468	48	a.	a.	NOUN
chd-130	468	49	,	,	PUNCT
chd-130	468	50	aglietta	aglietta	ADJ
chd-130	468	51	,	,	PUNCT
chd-130	468	52	m.	m.	NOUN
chd-130	468	53	,	,	PUNCT
chd-130	468	54	leone	leone	PROPN
chd-130	468	55	,	,	PUNCT
chd-130	468	56	f.	f.	PROPN
chd-130	468	57	(	(	PUNCT
chd-130	468	58	2010	2010	NUM
chd-130	468	59	)	)	PUNCT
chd-130	468	60	.	.	PUNCT
chd-130	469	1	targeting	target	VERB
chd-130	469	2	egfr	egfr	NOUN
chd-130	469	3	/	/	SYM
chd-130	469	4	her2	her2	PROPN
chd-130	469	5	pathways	pathway	NOUN
chd-130	469	6	enhances	enhance	VERB
chd-130	469	7	the	the	DET
chd-130	469	8	antiproliferative	antiproliferative	ADJ
chd-130	469	9	effect	effect	NOUN
chd-130	469	10	of	of	ADP
chd-130	469	11	gemcitabine	gemcitabine	NOUN
chd-130	469	12	in	in	ADP
chd-130	469	13	biliary	biliary	ADJ
chd-130	469	14	tract	tract	NOUN
chd-130	469	15	and	and	CCONJ
chd-130	469	16	gallbladder	gallbladder	NOUN
chd-130	469	17	carcinomas	carcinoma	NOUN
chd-130	469	18	.	.	PUNCT
chd-130	470	1	bmc	bmc	ADJ
chd-130	470	2	cancer	cancer	NOUN
chd-130	470	3	.	.	PUNCT
chd-130	471	1	10	10	NUM
chd-130	471	2	,	,	PUNCT
chd-130	471	3	631	631	NUM
chd-130	471	4	.	.	PUNCT
chd-130	471	5	priya	priya	PROPN
chd-130	471	6	,	,	PUNCT
chd-130	471	7	t.p	t.p	PROPN
chd-130	471	8	.	.	PROPN
chd-130	471	9	,	,	PUNCT
chd-130	471	10	kapoor	kapoor	PROPN
chd-130	471	11	,	,	PUNCT
chd-130	471	12	v.k	v.k	PROPN
chd-130	471	13	.	.	PROPN
chd-130	471	14	,	,	PUNCT
chd-130	471	15	krishnani	krishnani	PROPN
chd-130	471	16	,	,	PUNCT
chd-130	471	17	n.	n.	NOUN
chd-130	471	18	,	,	PUNCT
chd-130	471	19	agrawal	agrawal	PROPN
chd-130	471	20	,	,	PUNCT
chd-130	471	21	v.	v.	PROPN
chd-130	471	22	,	,	PUNCT
chd-130	471	23	agarwal	agarwal	PROPN
chd-130	471	24	,	,	PUNCT
chd-130	471	25	s.	s.	PROPN
chd-130	471	26	(	(	PUNCT
chd-130	471	27	2009	2009	NUM
chd-130	471	28	)	)	PUNCT
chd-130	471	29	.	.	PUNCT
chd-130	472	1	fragile	fragile	ADJ
chd-130	472	2	histidine	histidine	NOUN
chd-130	472	3	triad	triad	PROPN
chd-130	472	4	(	(	PUNCT
chd-130	472	5	fhit	fhit	NOUN
chd-130	472	6	)	)	PUNCT
chd-130	472	7	gene	gene	NOUN
chd-130	472	8	and	and	CCONJ
chd-130	472	9	its	its	PRON
chd-130	472	10	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	NUM
chd-130	472	11	e22	e22	PROPN
chd-130	472	12	cancer	cancer	NOUN
chd-130	472	13	health	health	NOUN
chd-130	472	14	disparities	disparity	NOUN
chd-130	472	15	research	research	NOUN
chd-130	472	16	association	association	NOUN
chd-130	472	17	with	with	ADP
chd-130	472	18	p53	p53	NOUN
chd-130	472	19	protein	protein	NOUN
chd-130	472	20	expression	expression	NOUN
chd-130	472	21	in	in	ADP
chd-130	472	22	the	the	DET
chd-130	472	23	progression	progression	NOUN
chd-130	472	24	of	of	ADP
chd-130	472	25	gall	gall	NOUN
chd-130	472	26	bladder	bladder	NOUN
chd-130	472	27	cancer	cancer	NOUN
chd-130	472	28	.	.	PUNCT
chd-130	473	1	cancer	cancer	NOUN
chd-130	473	2	invest	invest	PROPN
chd-130	473	3	.	.	PUNCT
chd-130	474	1	27	27	NUM
chd-130	474	2	,	,	PUNCT
chd-130	474	3	764	764	NUM
chd-130	474	4	-	-	SYM
chd-130	474	5	73	73	NUM
chd-130	474	6	.	.	PUNCT
chd-130	475	1	priya	priya	PROPN
chd-130	475	2	,	,	PUNCT
chd-130	475	3	t.p	t.p	PROPN
chd-130	475	4	.	.	PROPN
chd-130	475	5	,	,	PUNCT
chd-130	475	6	kapoor	kapoor	PROPN
chd-130	475	7	,	,	PUNCT
chd-130	475	8	v.k	v.k	PROPN
chd-130	475	9	.	.	PROPN
chd-130	475	10	,	,	PUNCT
chd-130	475	11	krishnani	krishnani	PROPN
chd-130	475	12	,	,	PUNCT
chd-130	475	13	n.	n.	NOUN
chd-130	475	14	,	,	PUNCT
chd-130	475	15	agrawal	agrawal	PROPN
chd-130	475	16	,	,	PUNCT
chd-130	475	17	v.	v.	PROPN
chd-130	475	18	,	,	PUNCT
chd-130	475	19	agrawal	agrawal	PROPN
chd-130	475	20	,	,	PUNCT
chd-130	475	21	s.	s.	PROPN
chd-130	475	22	(	(	PUNCT
chd-130	475	23	2010	2010	NUM
chd-130	475	24	)	)	PUNCT
chd-130	475	25	.	.	PUNCT
chd-130	476	1	role	role	NOUN
chd-130	476	2	of	of	ADP
chd-130	476	3	e	e	NOUN
chd-130	476	4	-	-	NOUN
chd-130	476	5	cadherin	cadherin	NOUN
chd-130	476	6	gene	gene	NOUN
chd-130	476	7	in	in	ADP
chd-130	476	8	gall	gall	NOUN
chd-130	476	9	bladder	bladder	NOUN
chd-130	476	10	cancer	cancer	NOUN
chd-130	476	11	and	and	CCONJ
chd-130	476	12	its	its	PRON
chd-130	476	13	precursor	precursor	NOUN
chd-130	476	14	lesions	lesion	NOUN
chd-130	476	15	.	.	PUNCT
chd-130	477	1	virchows	virchow	NOUN
chd-130	477	2	arch	arch	VERB
chd-130	477	3	.	.	PUNCT
chd-130	478	1	456	456	NUM
chd-130	478	2	,	,	PUNCT
chd-130	478	3	507	507	NUM
chd-130	478	4	-	-	SYM
chd-130	478	5	14	14	NUM
chd-130	478	6	.	.	PUNCT
chd-130	479	1	puhalla	puhalla	NOUN
chd-130	479	2	,	,	PUNCT
chd-130	479	3	h.	h.	PROPN
chd-130	479	4	,	,	PUNCT
chd-130	479	5	wrba	wrba	NOUN
chd-130	479	6	,	,	PUNCT
chd-130	479	7	f.	f.	PROPN
chd-130	479	8	,	,	PUNCT
chd-130	479	9	kandioler	kandioler	PROPN
chd-130	479	10	,	,	PUNCT
chd-130	479	11	d.	d.	PROPN
chd-130	479	12	,	,	PUNCT
chd-130	479	13	lehnert	lehnert	PROPN
chd-130	479	14	,	,	PUNCT
chd-130	479	15	m.	m.	NOUN
chd-130	479	16	,	,	PUNCT
chd-130	479	17	huynh	huynh	PROPN
chd-130	479	18	,	,	PUNCT
chd-130	479	19	a.	a.	NOUN
chd-130	479	20	,	,	PUNCT
chd-130	479	21	gruenberger	gruenberger	NOUN
chd-130	479	22	,	,	PUNCT
chd-130	479	23	t.	t.	NOUN
chd-130	479	24	,	,	PUNCT
chd-130	479	25	tamandl	tamandl	NOUN
chd-130	479	26	,	,	PUNCT
chd-130	479	27	d.	d.	PROPN
chd-130	479	28	,	,	PUNCT
chd-130	479	29	filipits	filipit	NOUN
chd-130	479	30	,	,	PUNCT
chd-130	479	31	m.	m.	NOUN
chd-130	479	32	(	(	PUNCT
chd-130	479	33	2007	2007	NUM
chd-130	479	34	)	)	PUNCT
chd-130	479	35	.	.	PUNCT
chd-130	480	1	expression	expression	NOUN
chd-130	480	2	of	of	ADP
chd-130	480	3	p21(wafl	p21(wafl	NOUN
chd-130	480	4	/	/	SYM
chd-130	480	5	cip1	cip1	NOUN
chd-130	480	6	)	)	PUNCT
chd-130	480	7	,	,	PUNCT
chd-130	480	8	p57(kip2	p57(kip2	NOUN
chd-130	480	9	)	)	PUNCT
chd-130	480	10	and	and	CCONJ
chd-130	480	11	her2	her2	PROPN
chd-130	480	12	/	/	SYM
chd-130	480	13	neu	neu	PROPN
chd-130	480	14	in	in	ADP
chd-130	480	15	patients	patient	NOUN
chd-130	480	16	with	with	ADP
chd-130	480	17	gallbladder	gallbladder	NOUN
chd-130	480	18	cancer	cancer	NOUN
chd-130	480	19	.	.	PUNCT
chd-130	481	1	anticancer	anticancer	NOUN
chd-130	481	2	res	re	NOUN
chd-130	481	3	.	.	PROPN
chd-130	482	1	27	27	NUM
chd-130	482	2	,	,	PUNCT
chd-130	482	3	1679	1679	NUM
chd-130	482	4	-	-	SYM
chd-130	482	5	84	84	NUM
chd-130	482	6	.	.	PUNCT
chd-130	483	1	rai	rai	PROPN
chd-130	483	2	,	,	PUNCT
chd-130	483	3	r.	r.	PROPN
chd-130	483	4	,	,	PUNCT
chd-130	483	5	sharma	sharma	PROPN
chd-130	483	6	,	,	PUNCT
chd-130	483	7	k.l	k.l	PROPN
chd-130	483	8	.	.	PROPN
chd-130	483	9	,	,	PUNCT
chd-130	483	10	misra	misra	PROPN
chd-130	483	11	,	,	PUNCT
chd-130	483	12	s.	s.	PROPN
chd-130	483	13	,	,	PUNCT
chd-130	483	14	kumar	kumar	PROPN
chd-130	483	15	,	,	PUNCT
chd-130	483	16	a.	a.	PROPN
chd-130	483	17	,	,	PUNCT
chd-130	483	18	mittal	mittal	PROPN
chd-130	483	19	,	,	PUNCT
chd-130	483	20	b.	b.	PROPN
chd-130	483	21	(	(	PUNCT
chd-130	483	22	2013b	2013b	NUM
chd-130	483	23	)	)	PUNCT
chd-130	483	24	.	.	PUNCT
chd-130	484	1	psca	psca	NOUN
chd-130	484	2	gene	gene	NOUN
chd-130	484	3	variants	variant	NOUN
chd-130	484	4	(	(	PUNCT
chd-130	484	5	rs2294008	rs2294008	NOUN
chd-130	484	6	and	and	CCONJ
chd-130	484	7	rs2978974	rs2978974	PROPN
chd-130	484	8	)	)	PUNCT
chd-130	484	9	confer	confer	NOUN
chd-130	484	10	increased	increase	VERB
chd-130	484	11	susceptibility	susceptibility	NOUN
chd-130	484	12	of	of	ADP
chd-130	484	13	gallbladder	gallbladder	NOUN
chd-130	484	14	carcinoma	carcinoma	NOUN
chd-130	484	15	in	in	ADP
chd-130	484	16	females	female	NOUN
chd-130	484	17	.	.	PUNCT
chd-130	485	1	gene	gene	NOUN
chd-130	485	2	.	.	PUNCT
chd-130	486	1	530	530	NUM
chd-130	486	2	,	,	PUNCT
chd-130	486	3	172	172	NUM
chd-130	486	4	-	-	SYM
chd-130	486	5	7	7	NUM
chd-130	486	6	.	.	PUNCT
chd-130	486	7	rai	rai	PROPN
chd-130	486	8	,	,	PUNCT
chd-130	486	9	r.	r.	PROPN
chd-130	486	10	,	,	PUNCT
chd-130	486	11	sharma	sharma	PROPN
chd-130	486	12	,	,	PUNCT
chd-130	486	13	k.l	k.l	PROPN
chd-130	486	14	.	.	PROPN
chd-130	486	15	,	,	PUNCT
chd-130	486	16	tiwari	tiwari	PROPN
chd-130	486	17	,	,	PUNCT
chd-130	486	18	s.	s.	PROPN
chd-130	486	19	,	,	PUNCT
chd-130	486	20	misra	misra	PROPN
chd-130	486	21	,	,	PUNCT
chd-130	486	22	s.	s.	PROPN
chd-130	486	23	,	,	PUNCT
chd-130	486	24	kumar	kumar	PROPN
chd-130	486	25	,	,	PUNCT
chd-130	486	26	a.	a.	PROPN
chd-130	486	27	,	,	PUNCT
chd-130	486	28	mittal	mittal	PROPN
chd-130	486	29	,	,	PUNCT
chd-130	486	30	b.	b.	PROPN
chd-130	486	31	(	(	PUNCT
chd-130	486	32	2013a	2013a	NUM
chd-130	486	33	)	)	PUNCT
chd-130	486	34	.	.	PUNCT
chd-130	487	1	dcc	dcc	PROPN
chd-130	487	2	(	(	PUNCT
chd-130	487	3	deleted	delete	VERB
chd-130	487	4	in	in	ADP
chd-130	487	5	colorectal	colorectal	ADJ
chd-130	487	6	carcinoma	carcinoma	NOUN
chd-130	487	7	)	)	PUNCT
chd-130	487	8	gene	gene	NOUN
chd-130	487	9	variants	variant	NOUN
chd-130	487	10	confer	confer	NOUN
chd-130	487	11	increased	increase	VERB
chd-130	487	12	susceptibility	susceptibility	NOUN
chd-130	487	13	to	to	ADP
chd-130	487	14	gallbladder	gallbladder	NOUN
chd-130	487	15	cancer	cancer	NOUN
chd-130	487	16	.	.	PUNCT
chd-130	488	1	gene	gene	NOUN
chd-130	488	2	.	.	PUNCT
chd-130	489	1	518	518	NUM
chd-130	489	2	,	,	PUNCT
chd-130	489	3	303	303	NUM
chd-130	489	4	-	-	SYM
chd-130	489	5	9	9	NUM
chd-130	489	6	.	.	PUNCT
chd-130	490	1	riener	riener	PROPN
chd-130	490	2	,	,	PUNCT
chd-130	490	3	m.o	m.o	PROPN
chd-130	490	4	.	.	PROPN
chd-130	490	5	,	,	PUNCT
chd-130	490	6	bawohl	bawohl	NOUN
chd-130	490	7	,	,	PUNCT
chd-130	490	8	m.	m.	NOUN
chd-130	490	9	,	,	PUNCT
chd-130	490	10	clavien	clavien	NOUN
chd-130	490	11	,	,	PUNCT
chd-130	490	12	p.a	p.a	PROPN
chd-130	490	13	.	.	PROPN
chd-130	490	14	,	,	PUNCT
chd-130	490	15	jochum	jochum	NOUN
chd-130	490	16	,	,	PUNCT
chd-130	490	17	w.	w.	NOUN
chd-130	490	18	(	(	PUNCT
chd-130	490	19	2008	2008	NUM
chd-130	490	20	)	)	PUNCT
chd-130	490	21	.	.	PUNCT
chd-130	491	1	rare	rare	ADJ
chd-130	491	2	pik3ca	pik3ca	NOUN
chd-130	491	3	hotspot	hotspot	NOUN
chd-130	491	4	mutations	mutation	NOUN
chd-130	491	5	in	in	ADP
chd-130	491	6	carcinomas	carcinoma	NOUN
chd-130	491	7	of	of	ADP
chd-130	491	8	the	the	DET
chd-130	491	9	biliary	biliary	ADJ
chd-130	491	10	tract	tract	NOUN
chd-130	491	11	.	.	PUNCT
chd-130	492	1	genes	gene	NOUN
chd-130	492	2	chromosomes	chromosome	NOUN
chd-130	492	3	cancer	cancer	NOUN
chd-130	492	4	.	.	PUNCT
chd-130	493	1	47	47	NUM
chd-130	493	2	,	,	PUNCT
chd-130	493	3	363	363	NUM
chd-130	493	4	-	-	SYM
chd-130	493	5	7	7	NUM
chd-130	493	6	.	.	PUNCT
chd-130	493	7	riquelme	riquelme	PROPN
chd-130	493	8	,	,	PUNCT
chd-130	493	9	e.	e.	PROPN
chd-130	493	10	,	,	PUNCT
chd-130	493	11	tang	tang	PROPN
chd-130	493	12	,	,	PUNCT
chd-130	493	13	m.	m.	NOUN
chd-130	493	14	,	,	PUNCT
chd-130	493	15	baez	baez	PROPN
chd-130	493	16	,	,	PUNCT
chd-130	493	17	s.	s.	PROPN
chd-130	493	18	,	,	PUNCT
chd-130	493	19	diaz	diaz	PROPN
chd-130	493	20	,	,	PUNCT
chd-130	493	21	a.	a.	PROPN
chd-130	493	22	,	,	PUNCT
chd-130	493	23	pruyas	pruyas	NOUN
chd-130	493	24	,	,	PUNCT
chd-130	493	25	m.	m.	NOUN
chd-130	493	26	,	,	PUNCT
chd-130	493	27	wistuba	wistuba	PROPN
chd-130	493	28	,	,	PUNCT
chd-130	493	29	i.i	i.i	PROPN
chd-130	493	30	.	.	PROPN
chd-130	493	31	,	,	PUNCT
chd-130	493	32	corvalan	corvalan	PROPN
chd-130	493	33	,	,	PUNCT
chd-130	493	34	a.	a.	NOUN
chd-130	493	35	(	(	PUNCT
chd-130	493	36	2007	2007	NUM
chd-130	493	37	)	)	PUNCT
chd-130	493	38	.	.	PUNCT
chd-130	494	1	frequent	frequent	ADJ
chd-130	494	2	epigenetic	epigenetic	ADJ
chd-130	494	3	inactivation	inactivation	NOUN
chd-130	494	4	of	of	ADP
chd-130	494	5	chromosome	chromosome	NOUN
chd-130	494	6	3p	3p	NUM
chd-130	494	7	candidate	candidate	NOUN
chd-130	494	8	tumor	tumor	NOUN
chd-130	494	9	suppressor	suppressor	NOUN
chd-130	494	10	genes	gene	NOUN
chd-130	494	11	in	in	ADP
chd-130	494	12	gallbladder	gallbladder	NOUN
chd-130	494	13	carcinoma	carcinoma	NOUN
chd-130	494	14	.	.	PUNCT
chd-130	495	1	cancer	cancer	NOUN
chd-130	495	2	lett	lett	PROPN
chd-130	495	3	.	.	PROPN
chd-130	496	1	250	250	NUM
chd-130	496	2	,	,	PUNCT
chd-130	496	3	100	100	NUM
chd-130	496	4	-	-	SYM
chd-130	496	5	6	6	NUM
chd-130	496	6	.	.	PUNCT
chd-130	496	7	roa	roa	PROPN
chd-130	496	8	,	,	PUNCT
chd-130	496	9	i.	i.	PROPN
chd-130	496	10	,	,	PUNCT
chd-130	496	11	araya	araya	PROPN
chd-130	496	12	,	,	PUNCT
chd-130	496	13	j.c	j.c	PROPN
chd-130	496	14	.	.	PROPN
chd-130	496	15	,	,	PUNCT
chd-130	496	16	shiraishi	shiraishi	PROPN
chd-130	496	17	,	,	PUNCT
chd-130	496	18	t.	t.	PROPN
chd-130	496	19	,	,	PUNCT
chd-130	496	20	yatani	yatani	PROPN
chd-130	496	21	,	,	PUNCT
chd-130	496	22	r.	r.	PROPN
chd-130	496	23	,	,	PUNCT
chd-130	496	24	wistuba	wistuba	PROPN
chd-130	496	25	,	,	PUNCT
chd-130	496	26	i.	i.	NOUN
chd-130	496	27	,	,	PUNCT
chd-130	496	28	villaseca	villaseca	NOUN
chd-130	496	29	,	,	PUNCT
chd-130	496	30	m.	m.	NOUN
chd-130	496	31	,	,	PUNCT
chd-130	496	32	de	de	X
chd-130	496	33	aretxabala	aretxabala	NOUN
chd-130	496	34	,	,	PUNCT
chd-130	496	35	x.	x.	NOUN
chd-130	496	36	(	(	PUNCT
chd-130	496	37	1993	1993	NUM
chd-130	496	38	)	)	PUNCT
chd-130	496	39	.	.	PUNCT
chd-130	497	1	dna	dna	PROPN
chd-130	497	2	content	content	NOUN
chd-130	497	3	in	in	ADP
chd-130	497	4	gallbladder	gallbladder	NOUN
chd-130	497	5	carcinoma	carcinoma	NOUN
chd-130	497	6	:	:	PUNCT
chd-130	497	7	a	a	DET
chd-130	497	8	flow	flow	NOUN
chd-130	497	9	cytometric	cytometric	ADJ
chd-130	497	10	study	study	NOUN
chd-130	497	11	of	of	ADP
chd-130	497	12	96	96	NUM
chd-130	497	13	cases	case	NOUN
chd-130	497	14	.	.	PUNCT
chd-130	498	1	histopathology	histopathology	NOUN
chd-130	498	2	.	.	PUNCT
chd-130	499	1	23	23	NUM
chd-130	499	2	,	,	PUNCT
chd-130	499	3	459	459	NUM
chd-130	499	4	-	-	SYM
chd-130	499	5	64	64	NUM
chd-130	499	6	.	.	PUNCT
chd-130	500	1	roa	roa	PROPN
chd-130	500	2	,	,	PUNCT
chd-130	500	3	j.c	j.c	PROPN
chd-130	500	4	.	.	PROPN
chd-130	500	5	,	,	PUNCT
chd-130	500	6	anabalón	anabalón	PROPN
chd-130	500	7	,	,	PUNCT
chd-130	500	8	l.	l.	PROPN
chd-130	500	9	,	,	PUNCT
chd-130	500	10	roa	roa	PROPN
chd-130	500	11	,	,	PUNCT
chd-130	500	12	i.	i.	PROPN
chd-130	500	13	,	,	PUNCT
chd-130	500	14	melo	melo	PROPN
chd-130	500	15	,	,	PUNCT
chd-130	500	16	a.	a.	PROPN
chd-130	500	17	,	,	PUNCT
chd-130	500	18	araya	araya	PROPN
chd-130	500	19	,	,	PUNCT
chd-130	500	20	j.c	j.c	PROPN
chd-130	500	21	.	.	PROPN
chd-130	500	22	,	,	PUNCT
chd-130	500	23	tapia	tapia	PROPN
chd-130	500	24	,	,	PUNCT
chd-130	500	25	o.	o.	PROPN
chd-130	500	26	,	,	PUNCT
chd-130	500	27	de	de	X
chd-130	500	28	aretxabala	aretxabala	NOUN
chd-130	500	29	,	,	PUNCT
chd-130	500	30	x.	x.	PROPN
chd-130	500	31	,	,	PUNCT
chd-130	500	32	muñoz	muñoz	PROPN
chd-130	500	33	,	,	PUNCT
chd-130	500	34	s.	s.	PROPN
chd-130	500	35	,	,	PUNCT
chd-130	500	36	schneider	schneider	PROPN
chd-130	500	37	,	,	PUNCT
chd-130	500	38	b.	b.	PROPN
chd-130	500	39	(	(	PUNCT
chd-130	500	40	2006	2006	NUM
chd-130	500	41	)	)	PUNCT
chd-130	500	42	.	.	PUNCT
chd-130	501	1	promoter	promoter	NOUN
chd-130	501	2	methylation	methylation	NOUN
chd-130	501	3	profile	profile	NOUN
chd-130	501	4	in	in	ADP
chd-130	501	5	gallbladder	gallbladder	NOUN
chd-130	501	6	cancer	cancer	NOUN
chd-130	501	7	.	.	PUNCT
chd-130	502	1	j	j	PROPN
chd-130	502	2	gastroenterol	gastroenterol	PROPN
chd-130	502	3	.	.	PUNCT
chd-130	503	1	41	41	NUM
chd-130	503	2	,	,	PUNCT
chd-130	503	3	269	269	NUM
chd-130	503	4	-	-	SYM
chd-130	503	5	75	75	NUM
chd-130	503	6	.	.	PUNCT
chd-130	504	1	roa	roa	PROPN
chd-130	504	2	,	,	PUNCT
chd-130	504	3	j.c	j.c	PROPN
chd-130	504	4	.	.	PROPN
chd-130	504	5	,	,	PUNCT
chd-130	504	6	roa	roa	PROPN
chd-130	504	7	,	,	PUNCT
chd-130	504	8	i.	i.	PROPN
chd-130	504	9	,	,	PUNCT
chd-130	504	10	correa	correa	PROPN
chd-130	504	11	,	,	PUNCT
chd-130	504	12	p.	p.	PROPN
chd-130	504	13	,	,	PUNCT
chd-130	504	14	vo	vo	PROPN
chd-130	504	15	,	,	PUNCT
chd-130	504	16	q.	q.	PROPN
chd-130	504	17	,	,	PUNCT
chd-130	504	18	araya	araya	PROPN
chd-130	504	19	,	,	PUNCT
chd-130	504	20	j.c	j.c	PROPN
chd-130	504	21	,	,	PUNCT
chd-130	504	22	villaseca	villaseca	NOUN
chd-130	504	23	,	,	PUNCT
chd-130	504	24	m.	m.	NOUN
chd-130	504	25	,	,	PUNCT
chd-130	504	26	guzmán	guzmán	NOUN
chd-130	504	27	,	,	PUNCT
chd-130	504	28	p.	p.	PROPN
chd-130	504	29	,	,	PUNCT
chd-130	504	30	schneider	schneider	PROPN
chd-130	504	31	,	,	PUNCT
chd-130	504	32	b.g	b.g	PROPN
chd-130	504	33	.	.	PROPN
chd-130	504	34	(	(	PUNCT
chd-130	504	35	2005	2005	NUM
chd-130	504	36	)	)	PUNCT
chd-130	504	37	.	.	PUNCT
chd-130	505	1	microsatellite	microsatellite	ADJ
chd-130	505	2	instability	instability	NOUN
chd-130	505	3	in	in	ADP
chd-130	505	4	preneoplastic	preneoplastic	ADJ
chd-130	505	5	and	and	CCONJ
chd-130	505	6	neoplastic	neoplastic	ADJ
chd-130	505	7	lesions	lesion	NOUN
chd-130	505	8	of	of	ADP
chd-130	505	9	the	the	DET
chd-130	505	10	gallbladder	gallbladder	NOUN
chd-130	505	11	.	.	PUNCT
chd-130	506	1	j	j	PROPN
chd-130	506	2	gastroenterol	gastroenterol	PROPN
chd-130	506	3	.	.	PUNCT
chd-130	507	1	40	40	NUM
chd-130	507	2	,	,	PUNCT
chd-130	507	3	79	79	NUM
chd-130	507	4	-	-	SYM
chd-130	507	5	86	86	NUM
chd-130	507	6	.	.	PUNCT
chd-130	508	1	saetta	saetta	PROPN
chd-130	508	2	,	,	PUNCT
chd-130	508	3	a.	a.	NOUN
chd-130	508	4	,	,	PUNCT
chd-130	508	5	lazaris	lazaris	PROPN
chd-130	508	6	,	,	PUNCT
chd-130	508	7	a.c	a.c	PROPN
chd-130	508	8	.	.	PROPN
chd-130	508	9	,	,	PUNCT
chd-130	508	10	davaris	davaris	PROPN
chd-130	508	11	,	,	PUNCT
chd-130	508	12	p.s	p.s	PROPN
chd-130	508	13	.	.	PUNCT
chd-130	508	14	(	(	PUNCT
chd-130	508	15	1996	1996	NUM
chd-130	508	16	)	)	PUNCT
chd-130	508	17	.	.	PUNCT
chd-130	509	1	detection	detection	NOUN
chd-130	509	2	of	of	ADP
chd-130	509	3	ras	ras	PROPN
chd-130	509	4	oncogene	oncogene	NOUN
chd-130	509	5	point	point	NOUN
chd-130	509	6	mutations	mutation	NOUN
chd-130	509	7	and	and	CCONJ
chd-130	509	8	simultaneous	simultaneous	ADJ
chd-130	509	9	proliferative	proliferative	ADJ
chd-130	509	10	fraction	fraction	NOUN
chd-130	509	11	estimation	estimation	NOUN
chd-130	509	12	in	in	ADP
chd-130	509	13	gallbladder	gallbladder	NOUN
chd-130	509	14	cancer	cancer	NOUN
chd-130	509	15	.	.	PUNCT
chd-130	510	1	pathol	pathol	VERB
chd-130	510	2	res	re	NOUN
chd-130	510	3	pract	pract	NOUN
chd-130	510	4	.	.	PUNCT
chd-130	511	1	192	192	NUM
chd-130	511	2	,	,	PUNCT
chd-130	511	3	532	532	NUM
chd-130	511	4	-	-	SYM
chd-130	511	5	40	40	NUM
chd-130	511	6	.	.	PUNCT
chd-130	512	1	saetta	saetta	PROPN
chd-130	512	2	,	,	PUNCT
chd-130	512	3	a.	a.	NOUN
chd-130	512	4	,	,	PUNCT
chd-130	512	5	lazaris	lazaris	PROPN
chd-130	512	6	,	,	PUNCT
chd-130	512	7	a.c	a.c	PROPN
chd-130	512	8	.	.	PROPN
chd-130	512	9	,	,	PUNCT
chd-130	512	10	michalopoulos	michalopoulos	PROPN
chd-130	512	11	,	,	PUNCT
chd-130	512	12	n.v	n.v	PROPN
chd-130	512	13	.	.	PROPN
chd-130	512	14	,	,	PUNCT
chd-130	512	15	davaris	davaris	PROPN
chd-130	512	16	,	,	PUNCT
chd-130	512	17	p.s	p.s	PROPN
chd-130	512	18	.	.	PROPN
chd-130	512	19	(	(	PUNCT
chd-130	512	20	2001	2001	NUM
chd-130	512	21	)	)	PUNCT
chd-130	512	22	.	.	PUNCT
chd-130	513	1	genetic	genetic	ADJ
chd-130	513	2	alterations	alteration	NOUN
chd-130	513	3	involved	involve	VERB
chd-130	513	4	in	in	ADP
chd-130	513	5	the	the	DET
chd-130	513	6	development	development	NOUN
chd-130	513	7	of	of	ADP
chd-130	513	8	gallbladder	gallbladder	NOUN
chd-130	513	9	carcinomas	carcinoma	NOUN
chd-130	513	10	from	from	ADP
chd-130	513	11	greek	greek	ADJ
chd-130	513	12	patients	patient	NOUN
chd-130	513	13	.	.	PUNCT
chd-130	514	1	hepatogastroenterology	hepatogastroenterology	NOUN
chd-130	514	2	.	.	PUNCT
chd-130	515	1	48	48	NUM
chd-130	515	2	,	,	PUNCT
chd-130	515	3	1284	1284	NUM
chd-130	515	4	-	-	SYM
chd-130	515	5	8	8	NUM
chd-130	515	6	.	.	PUNCT
chd-130	516	1	saetta	saetta	PROPN
chd-130	516	2	,	,	PUNCT
chd-130	516	3	a.a	a.a	PROPN
chd-130	516	4	.	.	PROPN
chd-130	516	5	,	,	PUNCT
chd-130	516	6	gigelou	gigelou	PROPN
chd-130	516	7	,	,	PUNCT
chd-130	516	8	f.	f.	PROPN
chd-130	516	9	,	,	PUNCT
chd-130	516	10	papanastasiou	papanastasiou	NOUN
chd-130	516	11	,	,	PUNCT
chd-130	516	12	p.i	p.i	PROPN
chd-130	516	13	.	.	PROPN
chd-130	516	14	,	,	PUNCT
chd-130	516	15	koilakou	koilakou	PROPN
chd-130	516	16	.	.	PUNCT
chd-130	517	1	]	]	X
chd-130	517	2	,	,	PUNCT
chd-130	517	3	s.v	s.v	PROPN
chd-130	517	4	.	.	PROPN
chd-130	517	5	,	,	PUNCT
chd-130	517	6	kalekou	kalekou	PROPN
chd-130	517	7	-	-	PUNCT
chd-130	517	8	greca	greca	PROPN
chd-130	517	9	,	,	PUNCT
chd-130	517	10	h.	h.	PROPN
chd-130	517	11	,	,	PUNCT
chd-130	517	12	miliaras	miliara	NOUN
chd-130	517	13	,	,	PUNCT
chd-130	517	14	d.	d.	PROPN
chd-130	517	15	,	,	PUNCT
chd-130	517	16	michalopoulos	michalopoulos	PROPN
chd-130	517	17	,	,	PUNCT
chd-130	517	18	n.v	n.v	PROPN
chd-130	517	19	.	.	PROPN
chd-130	517	20	,	,	PUNCT
chd-130	517	21	patsouris	patsouris	PROPN
chd-130	517	22	,	,	PUNCT
chd-130	517	23	e.	e.	PROPN
chd-130	517	24	(	(	PUNCT
chd-130	517	25	2006	2006	NUM
chd-130	517	26	)	)	PUNCT
chd-130	517	27	.	.	PUNCT
chd-130	518	1	high	high	ADJ
chd-130	518	2	-	-	PUNCT
chd-130	518	3	level	level	NOUN
chd-130	518	4	microsatellite	microsatellite	NOUN
chd-130	518	5	instability	instability	NOUN
chd-130	518	6	is	be	AUX
chd-130	518	7	not	not	PART
chd-130	518	8	involved	involve	VERB
chd-130	518	9	in	in	ADP
chd-130	518	10	gallbladder	gallbladder	NOUN
chd-130	518	11	carcinogenesis	carcinogenesis	NOUN
chd-130	518	12	.	.	PUNCT
chd-130	519	1	exp	exp	NOUN
chd-130	519	2	mol	mol	ADP
chd-130	519	3	pathol	pathol	NOUN
chd-130	519	4	.	.	PUNCT
chd-130	520	1	80	80	NUM
chd-130	520	2	,	,	PUNCT
chd-130	520	3	67	67	NUM
chd-130	520	4	-	-	SYM
chd-130	520	5	71	71	NUM
chd-130	520	6	.	.	PUNCT
chd-130	521	1	saetta	saetta	PROPN
chd-130	521	2	,	,	PUNCT
chd-130	521	3	a.a	a.a	PROPN
chd-130	521	4	.	.	PROPN
chd-130	521	5	,	,	PUNCT
chd-130	521	6	papanastasiou	papanastasiou	NOUN
chd-130	521	7	,	,	PUNCT
chd-130	521	8	p.	p.	NOUN
chd-130	521	9	,	,	PUNCT
chd-130	521	10	michalopoulos	michalopoulo	NOUN
chd-130	521	11	,	,	PUNCT
chd-130	521	12	n.v	n.v	PROPN
chd-130	521	13	.	.	PROPN
chd-130	521	14	,	,	PUNCT
chd-130	521	15	gigelou	gigelou	PROPN
chd-130	521	16	,	,	PUNCT
chd-130	521	17	f.	f.	PROPN
chd-130	521	18	,	,	PUNCT
chd-130	521	19	korkolopoulou	korkolopoulou	PROPN
chd-130	521	20	,	,	PUNCT
chd-130	521	21	p.	p.	PROPN
chd-130	521	22	,	,	PUNCT
chd-130	521	23	bei	bei	PROPN
chd-130	521	24	,	,	PUNCT
chd-130	521	25	t.	t.	PROPN
chd-130	521	26	,	,	PUNCT
chd-130	521	27	patsouris	patsouris	PROPN
chd-130	521	28	,	,	PUNCT
chd-130	521	29	e.	e.	PROPN
chd-130	521	30	(	(	PUNCT
chd-130	521	31	2004	2004	NUM
chd-130	521	32	)	)	PUNCT
chd-130	521	33	.	.	PUNCT
chd-130	522	1	mutational	mutational	ADJ
chd-130	522	2	analysis	analysis	NOUN
chd-130	522	3	of	of	ADP
chd-130	522	4	braf	braf	NOUN
chd-130	522	5	in	in	ADP
chd-130	522	6	gallbladder	gallbladder	NOUN
chd-130	522	7	carcinomas	carcinoma	NOUN
chd-130	522	8	in	in	ADP
chd-130	522	9	association	association	NOUN
chd-130	522	10	with	with	ADP
chd-130	522	11	k	k	X
chd-130	522	12	-	-	PUNCT
chd-130	522	13	ras	ras	ADJ
chd-130	522	14	and	and	CCONJ
chd-130	522	15	p53	p53	NOUN
chd-130	522	16	mutations	mutation	NOUN
chd-130	522	17	and	and	CCONJ
chd-130	522	18	microsatellite	microsatellite	ADJ
chd-130	522	19	instability	instability	NOUN
chd-130	522	20	.	.	PUNCT
chd-130	523	1	virchows	virchow	NOUN
chd-130	523	2	arch	arch	VERB
chd-130	523	3	.	.	PUNCT
chd-130	524	1	445	445	NUM
chd-130	524	2	,	,	PUNCT
chd-130	524	3	179	179	NUM
chd-130	524	4	-	-	SYM
chd-130	524	5	82	82	NUM
chd-130	524	6	.	.	PUNCT
chd-130	525	1	scanu	scanu	PROPN
chd-130	525	2	t	t	PROPN
chd-130	525	3	,	,	PUNCT
chd-130	525	4	spaapen	spaapen	PROPN
chd-130	525	5	rm	rm	PROPN
chd-130	525	6	,	,	PUNCT
chd-130	525	7	bakker	bakker	PROPN
chd-130	525	8	jm	jm	PROPN
chd-130	525	9	,	,	PUNCT
chd-130	525	10	pratap	pratap	PROPN
chd-130	525	11	cb	cb	PROPN
chd-130	525	12	,	,	PUNCT
chd-130	525	13	wu	wu	PROPN
chd-130	525	14	le	le	PROPN
chd-130	525	15	,	,	PUNCT
chd-130	525	16	hofland	hofland	PROPN
chd-130	526	1	i	i	PROPN
chd-130	526	2	,	,	PUNCT
chd-130	526	3	broeks	broeks	PROPN
chd-130	526	4	a	a	PRON
chd-130	526	5	,	,	PUNCT
chd-130	526	6	shukla	shukla	NOUN
chd-130	526	7	vk	vk	PROPN
chd-130	526	8	,	,	PUNCT
chd-130	526	9	kumar	kumar	PROPN
chd-130	526	10	m	m	PROPN
chd-130	526	11	,	,	PUNCT
chd-130	526	12	janssen	janssen	PROPN
chd-130	526	13	h	h	PROPN
chd-130	526	14	,	,	PUNCT
chd-130	526	15	song	song	PROPN
chd-130	526	16	jy	jy	PROPN
chd-130	526	17	,	,	PUNCT
chd-130	526	18	neefjes	neefjes	PROPN
chd-130	526	19	-	-	PUNCT
chd-130	526	20	borst	borst	PROPN
chd-130	526	21	ea	ea	NOUN
chd-130	526	22	,	,	PUNCT
chd-130	526	23	te	te	PROPN
chd-130	526	24	riele	riele	PROPN
chd-130	526	25	h	h	PROPN
chd-130	526	26	,	,	PUNCT
chd-130	526	27	holden	holden	PROPN
chd-130	526	28	dw	dw	PROPN
chd-130	526	29	,	,	PUNCT
chd-130	526	30	nath	nath	PROPN
chd-130	526	31	g	g	PROPN
chd-130	526	32	,	,	PUNCT
chd-130	526	33	neefjes	neefjes	PROPN
chd-130	526	34	j.	j.	PROPN
chd-130	526	35	salmonella	salmonella	PROPN
chd-130	526	36	manipulation	manipulation	NOUN
chd-130	526	37	of	of	ADP
chd-130	526	38	host	host	NOUN
chd-130	526	39	signaling	signal	VERB
chd-130	526	40	pathways	pathway	NOUN
chd-130	526	41	provokes	provoke	VERB
chd-130	526	42	cellular	cellular	ADJ
chd-130	526	43	transformation	transformation	NOUN
chd-130	526	44	associated	associate	VERB
chd-130	526	45	with	with	ADP
chd-130	526	46	gallbladder	gallbladder	NOUN
chd-130	526	47	carcinoma	carcinoma	NOUN
chd-130	526	48	.	.	PUNCT
chd-130	527	1	cell	cell	NOUN
chd-130	527	2	host	host	NOUN
chd-130	527	3	microbe	microbe	NOUN
chd-130	527	4	.	.	PUNCT
chd-130	528	1	2015	2015	NUM
chd-130	528	2	jun	jun	PROPN
chd-130	528	3	10;17(6):763	10;17(6):763	NUM
chd-130	528	4	-	-	SYM
chd-130	528	5	74	74	NUM
chd-130	528	6	.	.	PUNCT
chd-130	529	1	sessa	sessa	PROPN
chd-130	529	2	,	,	PUNCT
chd-130	529	3	f.	f.	PROPN
chd-130	529	4	,	,	PUNCT
chd-130	529	5	furlan	furlan	PROPN
chd-130	529	6	,	,	PUNCT
chd-130	529	7	d.	d.	PROPN
chd-130	529	8	,	,	PUNCT
chd-130	529	9	genasetti	genasetti	PROPN
chd-130	529	10	,	,	PUNCT
chd-130	529	11	a.	a.	PROPN
chd-130	529	12	,	,	PUNCT
chd-130	529	13	billo	billo	PROPN
chd-130	529	14	,	,	PUNCT
chd-130	529	15	p.	p.	PROPN
chd-130	529	16	,	,	PUNCT
chd-130	529	17	feltri	feltri	ADJ
chd-130	529	18	,	,	PUNCT
chd-130	529	19	m.	m.	NOUN
chd-130	529	20	,	,	PUNCT
chd-130	529	21	capella	capella	NOUN
chd-130	529	22	,	,	PUNCT
chd-130	529	23	c.	c.	PROPN
chd-130	529	24	(	(	PUNCT
chd-130	529	25	2003	2003	NUM
chd-130	529	26	)	)	PUNCT
chd-130	529	27	.	.	PUNCT
chd-130	530	1	microsatellite	microsatellite	ADJ
chd-130	530	2	instability	instability	NOUN
chd-130	530	3	and	and	CCONJ
chd-130	530	4	p53	p53	NOUN
chd-130	530	5	expression	expression	NOUN
chd-130	530	6	in	in	ADP
chd-130	530	7	gallbladder	gallbladder	NOUN
chd-130	530	8	carcinomas	carcinoma	NOUN
chd-130	530	9	.	.	PUNCT
chd-130	531	1	diagn	diagn	NOUN
chd-130	531	2	mol	mol	ADP
chd-130	531	3	pathol	pathol	NOUN
chd-130	531	4	.	.	PUNCT
chd-130	532	1	12	12	NUM
chd-130	532	2	,	,	PUNCT
chd-130	532	3	96	96	NUM
chd-130	532	4	-	-	SYM
chd-130	532	5	102	102	NUM
chd-130	532	6	.	.	PUNCT
chd-130	533	1	sharma	sharma	PROPN
chd-130	533	2	v	v	PROPN
chd-130	533	3	,	,	PUNCT
chd-130	533	4	chauhan	chauhan	PROPN
chd-130	533	5	vs	vs	ADP
chd-130	533	6	,	,	PUNCT
chd-130	533	7	nath	nath	NOUN
chd-130	533	8	g	g	PROPN
chd-130	533	9	,	,	PUNCT
chd-130	533	10	kumar	kumar	PROPN
chd-130	533	11	a	a	PROPN
chd-130	533	12	,	,	PUNCT
chd-130	533	13	shukla	shukla	NOUN
chd-130	533	14	vk	vk	PROPN
chd-130	533	15	.	.	PUNCT
chd-130	534	1	role	role	NOUN
chd-130	534	2	of	of	ADP
chd-130	534	3	bile	bile	NOUN
chd-130	534	4	bacteria	bacteria	NOUN
chd-130	534	5	in	in	ADP
chd-130	534	6	gallbladder	gallbladder	NOUN
chd-130	534	7	carcinoma	carcinoma	NOUN
chd-130	534	8	.	.	PUNCT
chd-130	535	1	hepatogastroenterology	hepatogastroenterology	NOUN
chd-130	535	2	.	.	PUNCT
chd-130	536	1	2007	2007	NUM
chd-130	536	2	sep;54(78):1622	sep;54(78):1622	NOUN
chd-130	536	3	-	-	PUNCT
chd-130	536	4	5	5	PROPN
chd-130	536	5	.	.	PUNCT
chd-130	536	6	sharma	sharma	PROPN
chd-130	536	7	,	,	PUNCT
chd-130	536	8	k.l	k.l	PROPN
chd-130	536	9	.	.	PROPN
chd-130	536	10	,	,	PUNCT
chd-130	536	11	umar	umar	PROPN
chd-130	536	12	,	,	PUNCT
chd-130	536	13	m.	m.	NOUN
chd-130	536	14	,	,	PUNCT
chd-130	536	15	pandey	pandey	PROPN
chd-130	536	16	,	,	PUNCT
chd-130	536	17	m.	m.	NOUN
chd-130	536	18	,	,	PUNCT
chd-130	536	19	misra	misra	PROPN
chd-130	536	20	,	,	PUNCT
chd-130	536	21	s.	s.	PROPN
chd-130	536	22	,	,	PUNCT
chd-130	536	23	kumar	kumar	PROPN
chd-130	536	24	,	,	PUNCT
chd-130	536	25	a.	a.	PROPN
chd-130	536	26	,	,	PUNCT
chd-130	536	27	kumar	kumar	PROPN
chd-130	536	28	,	,	PUNCT
chd-130	536	29	v.	v.	PROPN
chd-130	536	30	,	,	PUNCT
chd-130	536	31	mittal	mittal	PROPN
chd-130	536	32	,	,	PUNCT
chd-130	536	33	b.	b.	PROPN
chd-130	536	34	(	(	PUNCT
chd-130	536	35	2013	2013	NUM
chd-130	536	36	)	)	PUNCT
chd-130	536	37	.	.	PUNCT
chd-130	537	1	association	association	NOUN
chd-130	537	2	of	of	ADP
chd-130	537	3	potentially	potentially	ADV
chd-130	537	4	functional	functional	ADJ
chd-130	537	5	genetic	genetic	ADJ
chd-130	537	6	variants	variant	NOUN
chd-130	537	7	of	of	ADP
chd-130	537	8	plce1	plce1	NOUN
chd-130	537	9	with	with	ADP
chd-130	537	10	gallbladder	gallbladder	NOUN
chd-130	537	11	cancer	cancer	NOUN
chd-130	537	12	susceptibility	susceptibility	NOUN
chd-130	537	13	in	in	ADP
chd-130	537	14	north	north	PROPN
chd-130	537	15	indian	indian	ADJ
chd-130	537	16	population	population	NOUN
chd-130	537	17	.	.	PUNCT
chd-130	538	1	j	j	PROPN
chd-130	538	2	gastrointest	gastroint	ADJ
chd-130	538	3	cancer	cancer	NOUN
chd-130	538	4	.	.	PUNCT
chd-130	539	1	44	44	NUM
chd-130	539	2	,	,	PUNCT
chd-130	539	3	436	436	NUM
chd-130	539	4	-	-	SYM
chd-130	539	5	43	43	NUM
chd-130	539	6	.	.	PUNCT
chd-130	540	1	shukla	shukla	PROPN
chd-130	540	2	vk	vk	PROPN
chd-130	540	3	,	,	PUNCT
chd-130	540	4	prakash	prakash	PROPN
chd-130	540	5	a	a	PROPN
chd-130	540	6	,	,	PUNCT
chd-130	540	7	tripathi	tripathi	PROPN
chd-130	540	8	bd	bd	PROPN
chd-130	540	9	,	,	PUNCT
chd-130	540	10	reddy	reddy	PROPN
chd-130	540	11	dc	dc	PROPN
chd-130	540	12	,	,	PUNCT
chd-130	540	13	singh	singh	PROPN
chd-130	540	14	s.	s.	PROPN
chd-130	540	15	(	(	PUNCT
chd-130	540	16	1998	1998	NUM
chd-130	540	17	)	)	PUNCT
chd-130	540	18	.	.	PUNCT
chd-130	541	1	biliary	biliary	ADJ
chd-130	541	2	heavy	heavy	ADJ
chd-130	541	3	metal	metal	NOUN
chd-130	541	4	concentrations	concentration	NOUN
chd-130	541	5	in	in	ADP
chd-130	541	6	carcinoma	carcinoma	NOUN
chd-130	541	7	of	of	ADP
chd-130	541	8	the	the	DET
chd-130	541	9	gall	gall	NOUN
chd-130	541	10	bladder	bladder	NOUN
chd-130	541	11	:	:	PUNCT
chd-130	541	12	case	case	NOUN
chd-130	541	13	-	-	PUNCT
chd-130	541	14	control	control	NOUN
chd-130	541	15	study	study	NOUN
chd-130	541	16	.	.	PUNCT
chd-130	542	1	bmj	bmj	PROPN
chd-130	542	2	.	.	PUNCT
chd-130	543	1	317:1288	317:1288	NUM
chd-130	543	2	-	-	SYM
chd-130	543	3	9	9	NUM
chd-130	543	4	.	.	PUNCT
chd-130	544	1	singh	singh	PROPN
chd-130	544	2	,	,	PUNCT
chd-130	544	3	m.k	m.k	PROPN
chd-130	544	4	.	.	PROPN
chd-130	544	5	,	,	PUNCT
chd-130	544	6	chetri	chetri	PROPN
chd-130	544	7	,	,	PUNCT
chd-130	544	8	k.	k.	PROPN
chd-130	544	9	,	,	PUNCT
chd-130	544	10	pandey	pandey	PROPN
chd-130	544	11	,	,	PUNCT
chd-130	544	12	u.b	u.b	PROPN
chd-130	544	13	.	.	PROPN
chd-130	544	14	,	,	PUNCT
chd-130	544	15	kapoor	kapoor	PROPN
chd-130	544	16	,	,	PUNCT
chd-130	544	17	v.k	v.k	PROPN
chd-130	544	18	.	.	PROPN
chd-130	544	19	,	,	PUNCT
chd-130	544	20	mittal	mittal	PROPN
chd-130	544	21	,	,	PUNCT
chd-130	544	22	b.	b.	PROPN
chd-130	544	23	,	,	PUNCT
chd-130	544	24	choudhuri	choudhuri	PROPN
chd-130	544	25	,	,	PUNCT
chd-130	544	26	g.	g.	PROPN
chd-130	544	27	(	(	PUNCT
chd-130	544	28	2004b	2004b	NUM
chd-130	544	29	)	)	PUNCT
chd-130	544	30	.	.	PUNCT
chd-130	545	1	mutational	mutational	ADJ
chd-130	545	2	spectrum	spectrum	NOUN
chd-130	545	3	of	of	ADP
chd-130	545	4	k	k	PROPN
chd-130	545	5	-	-	PUNCT
chd-130	545	6	ras	ras	ADJ
chd-130	545	7	oncogene	oncogene	NOUN
chd-130	545	8	among	among	ADP
chd-130	545	9	indian	indian	ADJ
chd-130	545	10	patients	patient	NOUN
chd-130	545	11	with	with	ADP
chd-130	545	12	gallbladder	gallbladder	NOUN
chd-130	545	13	cancer	cancer	NOUN
chd-130	545	14	.	.	PUNCT
chd-130	546	1	j	j	PROPN
chd-130	546	2	gastroenterol	gastroenterol	PROPN
chd-130	546	3	hepatol.19	hepatol.19	PROPN
chd-130	546	4	,	,	PUNCT
chd-130	546	5	916	916	NUM
chd-130	546	6	-	-	SYM
chd-130	546	7	21	21	NUM
chd-130	546	8	.	.	PUNCT
chd-130	547	1	singh	singh	PROPN
chd-130	547	2	,	,	PUNCT
chd-130	547	3	m.k	m.k	PROPN
chd-130	547	4	.	.	PROPN
chd-130	547	5	,	,	PUNCT
chd-130	547	6	pandey	pandey	PROPN
chd-130	547	7	,	,	PUNCT
chd-130	547	8	u.b	u.b	PROPN
chd-130	547	9	.	.	PROPN
chd-130	547	10	,	,	PUNCT
chd-130	547	11	ghoshal	ghoshal	NOUN
chd-130	547	12	,	,	PUNCT
chd-130	547	13	u.c	u.c	PROPN
chd-130	547	14	.	.	PROPN
chd-130	547	15	,	,	PUNCT
chd-130	547	16	srivenu	srivenu	NOUN
chd-130	547	17	,	,	PUNCT
chd-130	547	18	i.	i.	PROPN
chd-130	547	19	,	,	PUNCT
chd-130	547	20	kapoor	kapoor	PROPN
chd-130	547	21	,	,	PUNCT
chd-130	547	22	v.k	v.k	PROPN
chd-130	547	23	.	.	PROPN
chd-130	547	24	,	,	PUNCT
chd-130	547	25	choudhuri	choudhuri	PROPN
chd-130	547	26	,	,	PUNCT
chd-130	547	27	g.	g.	PROPN
chd-130	547	28	,	,	PUNCT
chd-130	547	29	mittal	mittal	PROPN
chd-130	547	30	,	,	PUNCT
chd-130	547	31	b.	b.	PROPN
chd-130	547	32	(	(	PUNCT
chd-130	547	33	2004a	2004a	NUM
chd-130	547	34	)	)	PUNCT
chd-130	547	35	.	.	PUNCT
chd-130	548	1	apolipoprotein	apolipoprotein	VERB
chd-130	548	2	b100	b100	PROPN
chd-130	548	3	xbai	xbai	PROPN
chd-130	548	4	gene	gene	NOUN
chd-130	548	5	polymorphism	polymorphism	NOUN
chd-130	548	6	in	in	ADP
chd-130	548	7	gallbladder	gallbladder	NOUN
chd-130	548	8	cancer	cancer	NOUN
chd-130	548	9	.	.	PUNCT
chd-130	549	1	hum	hum	PROPN
chd-130	549	2	genet	genet	PROPN
chd-130	549	3	.	.	PUNCT
chd-130	550	1	114	114	NUM
chd-130	550	2	,	,	PUNCT
chd-130	550	3	280	280	NUM
chd-130	550	4	-	-	SYM
chd-130	550	5	3	3	NUM
chd-130	550	6	.	.	PUNCT
chd-130	551	1	srivastava	srivastava	PROPN
chd-130	551	2	,	,	PUNCT
chd-130	551	3	a.	a.	PROPN
chd-130	551	4	,	,	PUNCT
chd-130	551	5	pandey	pandey	PROPN
chd-130	551	6	,	,	PUNCT
chd-130	551	7	s.n	s.n	PROPN
chd-130	551	8	.	.	PROPN
chd-130	551	9	,	,	PUNCT
chd-130	551	10	choudhuri	choudhuri	PROPN
chd-130	551	11	,	,	PUNCT
chd-130	551	12	g.	g.	PROPN
chd-130	551	13	,	,	PUNCT
chd-130	551	14	mittal	mittal	PROPN
chd-130	551	15	,	,	PUNCT
chd-130	551	16	b.	b.	PROPN
chd-130	551	17	(	(	PUNCT
chd-130	551	18	2008a	2008a	NUM
chd-130	551	19	)	)	PUNCT
chd-130	551	20	.	.	PUNCT
chd-130	552	1	role	role	NOUN
chd-130	552	2	of	of	ADP
chd-130	552	3	genetic	genetic	ADJ
chd-130	552	4	variant	variant	ADJ
chd-130	552	5	a-204c	a-204c	NOUN
chd-130	552	6	of	of	ADP
chd-130	552	7	cholesterol	cholesterol	NOUN
chd-130	552	8	7alphahydroxylase	7alphahydroxylase	NUM
chd-130	552	9	(	(	PUNCT
chd-130	552	10	cyp7a1	cyp7a1	NOUN
chd-130	552	11	)	)	PUNCT
chd-130	552	12	in	in	ADP
chd-130	552	13	susceptibility	susceptibility	NOUN
chd-130	552	14	to	to	ADP
chd-130	552	15	gallbladder	gallbladder	NOUN
chd-130	552	16	cancer	cancer	NOUN
chd-130	552	17	.	.	PUNCT
chd-130	553	1	mol	mol	ADP
chd-130	553	2	genet	genet	PROPN
chd-130	553	3	metab	metab	PROPN
chd-130	553	4	.	.	PUNCT
chd-130	554	1	94	94	NUM
chd-130	554	2	,	,	PUNCT
chd-130	554	3	83	83	NUM
chd-130	554	4	-	-	SYM
chd-130	554	5	9	9	NUM
chd-130	554	6	.	.	PUNCT
chd-130	555	1	srivastava	srivastava	PROPN
chd-130	555	2	,	,	PUNCT
chd-130	555	3	a.	a.	PROPN
chd-130	555	4	,	,	PUNCT
chd-130	555	5	pandey	pandey	PROPN
chd-130	555	6	,	,	PUNCT
chd-130	555	7	s.n	s.n	PROPN
chd-130	555	8	.	.	PROPN
chd-130	555	9	,	,	PUNCT
chd-130	555	10	dixit	dixit	PROPN
chd-130	555	11	,	,	PUNCT
chd-130	555	12	m.	m.	NOUN
chd-130	555	13	,	,	PUNCT
chd-130	555	14	choudhuri	choudhuri	PROPN
chd-130	555	15	,	,	PUNCT
chd-130	555	16	g.	g.	PROPN
chd-130	555	17	,	,	PUNCT
chd-130	555	18	mittal	mittal	PROPN
chd-130	555	19	,	,	PUNCT
chd-130	555	20	b.	b.	PROPN
chd-130	555	21	(	(	PUNCT
chd-130	555	22	2008b	2008b	NUM
chd-130	555	23	)	)	PUNCT
chd-130	555	24	.	.	PUNCT
chd-130	556	1	cholecystokinin	cholecystokinin	ADJ
chd-130	556	2	receptor	receptor	NOUN
chd-130	556	3	a	a	DET
chd-130	556	4	gene	gene	NOUN
chd-130	556	5	polymorphism	polymorphism	NOUN
chd-130	556	6	in	in	ADP
chd-130	556	7	gallstone	gallstone	NOUN
chd-130	556	8	disease	disease	NOUN
chd-130	556	9	and	and	CCONJ
chd-130	556	10	gallbladder	gallbladder	NOUN
chd-130	556	11	cancer	cancer	NOUN
chd-130	556	12	.	.	PUNCT
chd-130	557	1	j	j	PROPN
chd-130	557	2	gastroenterol	gastroenterol	NOUN
chd-130	557	3	hepatol	hepatol	ADJ
chd-130	557	4	.	.	PUNCT
chd-130	558	1	23	23	NUM
chd-130	558	2	,	,	PUNCT
chd-130	558	3	970	970	NUM
chd-130	558	4	-	-	SYM
chd-130	558	5	5	5	NUM
chd-130	558	6	.	.	PUNCT
chd-130	559	1	srivastava	srivastava	PROPN
chd-130	559	2	,	,	PUNCT
chd-130	559	3	a.	a.	PROPN
chd-130	559	4	,	,	PUNCT
chd-130	559	5	tulsyan	tulsyan	PROPN
chd-130	559	6	,	,	PUNCT
chd-130	559	7	s.	s.	PROPN
chd-130	559	8	,	,	PUNCT
chd-130	559	9	pandey	pandey	PROPN
chd-130	559	10	,	,	PUNCT
chd-130	559	11	s.n	s.n	PROPN
chd-130	559	12	.	.	PROPN
chd-130	559	13	,	,	PUNCT
chd-130	559	14	choudhuri	choudhuri	PROPN
chd-130	559	15	,	,	PUNCT
chd-130	559	16	g.	g.	PROPN
chd-130	559	17	,	,	PUNCT
chd-130	559	18	mittal	mittal	PROPN
chd-130	559	19	,	,	PUNCT
chd-130	559	20	b.	b.	PROPN
chd-130	559	21	(	(	PUNCT
chd-130	559	22	2009	2009	NUM
chd-130	559	23	)	)	PUNCT
chd-130	559	24	.	.	PUNCT
chd-130	560	1	single	single	ADJ
chd-130	560	2	nucleotide	nucleotide	ADJ
chd-130	560	3	polymorphism	polymorphism	NOUN
chd-130	560	4	in	in	ADP
chd-130	560	5	the	the	DET
chd-130	560	6	abcg8	abcg8	NOUN
chd-130	560	7	transporter	transporter	NOUN
chd-130	560	8	gene	gene	NOUN
chd-130	560	9	is	be	AUX
chd-130	560	10	associated	associate	VERB
chd-130	560	11	with	with	ADP
chd-130	560	12	gallbladder	gallbladder	NOUN
chd-130	560	13	cancer	cancer	NOUN
chd-130	560	14	susceptibility	susceptibility	NOUN
chd-130	560	15	.	.	PUNCT
chd-130	561	1	liver	liver	NOUN
chd-130	561	2	int	int	PROPN
chd-130	561	3	.	.	PUNCT
chd-130	562	1	29	29	NUM
chd-130	562	2	,	,	PUNCT
chd-130	562	3	831	831	NUM
chd-130	562	4	-	-	SYM
chd-130	562	5	7	7	NUM
chd-130	562	6	.	.	PUNCT
chd-130	563	1	srivastava	srivastava	PROPN
chd-130	563	2	,	,	PUNCT
chd-130	563	3	k.	k.	PROPN
chd-130	563	4	,	,	PUNCT
chd-130	563	5	srivastava	srivastava	PROPN
chd-130	563	6	,	,	PUNCT
chd-130	563	7	a.	a.	PROPN
chd-130	563	8	,	,	PUNCT
chd-130	563	9	kumar	kumar	PROPN
chd-130	563	10	,	,	PUNCT
chd-130	563	11	a.	a.	PROPN
chd-130	563	12	,	,	PUNCT
chd-130	563	13	mittal	mittal	PROPN
chd-130	563	14	,	,	PUNCT
chd-130	563	15	b.	b.	PROPN
chd-130	563	16	(	(	PUNCT
chd-130	563	17	2010	2010	NUM
chd-130	563	18	)	)	PUNCT
chd-130	563	19	.	.	PUNCT
chd-130	564	1	significant	significant	ADJ
chd-130	564	2	association	association	NOUN
chd-130	564	3	between	between	ADP
chd-130	564	4	toll	toll	NOUN
chd-130	564	5	-	-	PUNCT
chd-130	564	6	like	like	ADJ
chd-130	564	7	receptor	receptor	NOUN
chd-130	564	8	gene	gene	NOUN
chd-130	564	9	polymorphisms	polymorphism	NOUN
chd-130	564	10	and	and	CCONJ
chd-130	564	11	gallbladder	gallbladder	NOUN
chd-130	564	12	cancer	cancer	NOUN
chd-130	564	13	.	.	PUNCT
chd-130	565	1	liver	liver	NOUN
chd-130	565	2	int	int	PROPN
chd-130	565	3	.	.	PUNCT
chd-130	566	1	30	30	NUM
chd-130	566	2	,	,	PUNCT
chd-130	566	3	1067	1067	NUM
chd-130	566	4	-	-	SYM
chd-130	566	5	72	72	NUM
chd-130	566	6	.	.	PUNCT
chd-130	567	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-130	567	2	e23	e23	NOUN
chd-130	567	3	cancer	cancer	NOUN
chd-130	567	4	health	health	NOUN
chd-130	567	5	disparities	disparity	NOUN
chd-130	567	6	research	research	PROPN
chd-130	567	7	srivastava	srivastava	PROPN
chd-130	567	8	,	,	PUNCT
chd-130	567	9	k.	k.	PROPN
chd-130	567	10	,	,	PUNCT
chd-130	567	11	srivastava	srivastava	PROPN
chd-130	567	12	,	,	PUNCT
chd-130	567	13	a.	a.	PROPN
chd-130	567	14	,	,	PUNCT
chd-130	567	15	mittal	mittal	PROPN
chd-130	567	16	,	,	PUNCT
chd-130	567	17	b.	b.	PROPN
chd-130	567	18	(	(	PUNCT
chd-130	567	19	2010	2010	NUM
chd-130	567	20	)	)	PUNCT
chd-130	567	21	.	.	PUNCT
chd-130	568	1	caspase-8	caspase-8	NOUN
chd-130	568	2	polymorphisms	polymorphism	NOUN
chd-130	568	3	and	and	CCONJ
chd-130	568	4	risk	risk	NOUN
chd-130	568	5	of	of	ADP
chd-130	568	6	gallbladder	gallbladder	NOUN
chd-130	568	7	cancer	cancer	NOUN
chd-130	568	8	in	in	ADP
chd-130	568	9	a	a	DET
chd-130	568	10	northern	northern	ADJ
chd-130	568	11	indian	indian	ADJ
chd-130	568	12	population	population	NOUN
chd-130	568	13	.	.	PUNCT
chd-130	569	1	mol	mol	ADP
chd-130	569	2	carcinog	carcinog	PROPN
chd-130	569	3	.	.	PUNCT
chd-130	570	1	49	49	NUM
chd-130	570	2	,	,	PUNCT
chd-130	570	3	684	684	NUM
chd-130	570	4	-	-	SYM
chd-130	570	5	92	92	NUM
chd-130	570	6	.	.	PUNCT
chd-130	571	1	stephen	stephen	PROPN
chd-130	571	2	ae	ae	PROPN
chd-130	571	3	,	,	PUNCT
chd-130	571	4	berger	berger	PROPN
chd-130	571	5	dl	dl	PROPN
chd-130	571	6	.	.	PROPN
chd-130	571	7	carcinoma	carcinoma	PROPN
chd-130	571	8	in	in	ADP
chd-130	571	9	the	the	DET
chd-130	571	10	porcelain	porcelain	NOUN
chd-130	571	11	gallbladder	gallbladder	NOUN
chd-130	571	12	:	:	PUNCT
chd-130	571	13	a	a	DET
chd-130	571	14	relationship	relationship	NOUN
chd-130	571	15	revisited	revisit	VERB
chd-130	571	16	.	.	PUNCT
chd-130	572	1	surgery	surgery	NOUN
chd-130	572	2	.	.	PUNCT
chd-130	573	1	2001	2001	NUM
chd-130	573	2	jun;129(6):699	jun;129(6):699	NOUN
chd-130	573	3	-	-	PUNCT
chd-130	573	4	703	703	NUM
chd-130	573	5	.	.	PUNCT
chd-130	574	1	subbannayya	subbannayya	ADJ
chd-130	574	2	,	,	PUNCT
chd-130	574	3	t.	t.	NOUN
chd-130	574	4	,	,	PUNCT
chd-130	574	5	leal	leal	NOUN
chd-130	574	6	-	-	PUNCT
chd-130	574	7	rojas	rojas	NOUN
chd-130	574	8	,	,	PUNCT
chd-130	574	9	p.	p.	PROPN
chd-130	574	10	,	,	PUNCT
chd-130	574	11	zhavoronkov	zhavoronkov	PROPN
chd-130	574	12	,	,	PUNCT
chd-130	574	13	a.	a.	NOUN
chd-130	574	14	,	,	PUNCT
chd-130	574	15	ozerov	ozerov	ADJ
chd-130	574	16	,	,	PUNCT
chd-130	574	17	i.v	i.v	PROPN
chd-130	574	18	.	.	PROPN
chd-130	574	19	,	,	PUNCT
chd-130	574	20	korzinkin	korzinkin	PROPN
chd-130	574	21	,	,	PUNCT
chd-130	574	22	m.	m.	NOUN
chd-130	574	23	,	,	PUNCT
chd-130	574	24	babu	babu	PROPN
chd-130	574	25	,	,	PUNCT
chd-130	574	26	n.	n.	PROPN
chd-130	574	27	,	,	PUNCT
chd-130	574	28	radhakrishnan	radhakrishnan	PROPN
chd-130	574	29	,	,	PUNCT
chd-130	574	30	a.	a.	PROPN
chd-130	574	31	,	,	PUNCT
chd-130	574	32	chavan	chavan	PROPN
chd-130	574	33	,	,	PUNCT
chd-130	574	34	s.	s.	PROPN
chd-130	574	35	,	,	PUNCT
chd-130	574	36	raja	raja	PROPN
chd-130	574	37	,	,	PUNCT
chd-130	574	38	r.	r.	PROPN
chd-130	574	39	,	,	PUNCT
chd-130	574	40	pinto	pinto	NOUN
chd-130	574	41	,	,	PUNCT
chd-130	574	42	s.m	s.m	PROPN
chd-130	574	43	.	.	PROPN
chd-130	574	44	,	,	PUNCT
chd-130	574	45	et	et	PROPN
chd-130	574	46	al	al	PROPN
chd-130	574	47	.	.	PROPN
chd-130	575	1	(	(	PUNCT
chd-130	575	2	2019	2019	NUM
chd-130	575	3	)	)	PUNCT
chd-130	575	4	pim1	pim1	PROPN
chd-130	575	5	kinase	kinase	PROPN
chd-130	575	6	promotes	promote	VERB
chd-130	575	7	gallbladder	gallbladder	NOUN
chd-130	575	8	cancer	cancer	NOUN
chd-130	575	9	cell	cell	NOUN
chd-130	575	10	proliferation	proliferation	NOUN
chd-130	575	11	via	via	ADP
chd-130	575	12	inhibition	inhibition	NOUN
chd-130	575	13	of	of	ADP
chd-130	575	14	proline	proline	NOUN
chd-130	575	15	-	-	PUNCT
chd-130	575	16	rich	rich	ADJ
chd-130	575	17	akt	akt	NOUN
chd-130	575	18	substrate	substrate	NOUN
chd-130	575	19	of	of	ADP
chd-130	575	20	40	40	NUM
chd-130	575	21	kda	kda	NOUN
chd-130	575	22	(	(	PUNCT
chd-130	575	23	pras40	pras40	NOUN
chd-130	575	24	)	)	PUNCT
chd-130	575	25	.	.	PUNCT
chd-130	576	1	j	j	PROPN
chd-130	576	2	cell	cell	PROPN
chd-130	576	3	commun	commun	PROPN
chd-130	576	4	signal	signal	PROPN
chd-130	576	5	.	.	PUNCT
chd-130	577	1	jan	jan	PROPN
chd-130	577	2	21	21	NUM
chd-130	577	3	.	.	PUNCT
chd-130	578	1	tadokoro	tadokoro	NUM
chd-130	578	2	,	,	PUNCT
chd-130	578	3	h.	h.	PROPN
chd-130	578	4	,	,	PUNCT
chd-130	578	5	shigihara	shigihara	PROPN
chd-130	578	6	,	,	PUNCT
chd-130	578	7	t.	t.	PROPN
chd-130	578	8	,	,	PUNCT
chd-130	578	9	ikeda	ikeda	PROPN
chd-130	578	10	,	,	PUNCT
chd-130	578	11	t.	t.	PROPN
chd-130	578	12	,	,	PUNCT
chd-130	578	13	takase	takase	NOUN
chd-130	578	14	,	,	PUNCT
chd-130	578	15	m.	m.	NOUN
chd-130	578	16	,	,	PUNCT
chd-130	578	17	suyama	suyama	NOUN
chd-130	578	18	,	,	PUNCT
chd-130	578	19	m.	m.	NOUN
chd-130	578	20	(	(	PUNCT
chd-130	578	21	2007	2007	NUM
chd-130	578	22	)	)	PUNCT
chd-130	578	23	.	.	PUNCT
chd-130	579	1	two	two	NUM
chd-130	579	2	distinct	distinct	ADJ
chd-130	579	3	pathways	pathway	NOUN
chd-130	579	4	of	of	ADP
chd-130	579	5	p16	p16	NOUN
chd-130	579	6	gene	gene	NOUN
chd-130	579	7	inactivation	inactivation	NOUN
chd-130	579	8	in	in	ADP
chd-130	579	9	gallbladder	gallbladder	NOUN
chd-130	579	10	cancer	cancer	NOUN
chd-130	579	11	.	.	PUNCT
chd-130	580	1	world	world	PROPN
chd-130	580	2	j	j	PROPN
chd-130	580	3	gastroenterol	gastroenterol	PROPN
chd-130	580	4	.	.	PUNCT
chd-130	581	1	13	13	NUM
chd-130	581	2	,	,	PUNCT
chd-130	581	3	6396	6396	NUM
chd-130	581	4	-	-	SYM
chd-130	581	5	403	403	NUM
chd-130	581	6	.	.	PUNCT
chd-130	582	1	takada	takada	NOUN
chd-130	582	2	,	,	PUNCT
chd-130	582	3	m.	m.	NOUN
chd-130	582	4	,	,	PUNCT
chd-130	582	5	horita	horita	PROPN
chd-130	582	6	,	,	PUNCT
chd-130	582	7	y.	y.	PROPN
chd-130	582	8	,	,	PUNCT
chd-130	582	9	okuda	okuda	PROPN
chd-130	582	10	,	,	PUNCT
chd-130	582	11	s.	s.	PROPN
chd-130	582	12	,	,	PUNCT
chd-130	582	13	okumoto	okumoto	NOUN
chd-130	582	14	,	,	PUNCT
chd-130	582	15	s.	s.	PROPN
chd-130	582	16	,	,	PUNCT
chd-130	582	17	samizo	samizo	VERB
chd-130	582	18	,	,	PUNCT
chd-130	582	19	m.	m.	NOUN
chd-130	582	20	,	,	PUNCT
chd-130	582	21	wada	wada	PROPN
chd-130	582	22	,	,	PUNCT
chd-130	582	23	t.	t.	PROPN
chd-130	582	24	,	,	PUNCT
chd-130	582	25	kuroda	kuroda	PROPN
chd-130	582	26	,	,	PUNCT
chd-130	582	27	y.	y.	PROPN
chd-130	582	28	,	,	PUNCT
chd-130	582	29	maeda	maeda	PROPN
chd-130	582	30	,	,	PUNCT
chd-130	582	31	s.	s.	PROPN
chd-130	582	32	(	(	PUNCT
chd-130	582	33	2002	2002	NUM
chd-130	582	34	)	)	PUNCT
chd-130	582	35	.	.	PUNCT
chd-130	583	1	genetic	genetic	ADJ
chd-130	583	2	analysis	analysis	NOUN
chd-130	583	3	of	of	ADP
chd-130	583	4	xanthogranulomatous	xanthogranulomatous	ADJ
chd-130	583	5	cholecystitis	cholecystitis	NOUN
chd-130	583	6	:	:	PUNCT
chd-130	583	7	precancerous	precancerous	ADJ
chd-130	583	8	lesion	lesion	NOUN
chd-130	583	9	of	of	ADP
chd-130	583	10	gallbladder	gallbladder	NOUN
chd-130	583	11	cancer	cancer	NOUN
chd-130	583	12	?	?	PUNCT
chd-130	584	1	hepatogastroenterology	hepatogastroenterology	NOUN
chd-130	584	2	.	.	PUNCT
chd-130	585	1	49	49	NUM
chd-130	585	2	,	,	PUNCT
chd-130	585	3	935	935	NUM
chd-130	585	4	-	-	SYM
chd-130	585	5	7	7	NUM
chd-130	585	6	.	.	PUNCT
chd-130	585	7	takagi	takagi	PROPN
chd-130	585	8	,	,	PUNCT
chd-130	585	9	s.	s.	PROPN
chd-130	585	10	,	,	PUNCT
chd-130	585	11	naito	naito	PROPN
chd-130	585	12	,	,	PUNCT
chd-130	585	13	e.	e.	PROPN
chd-130	585	14	,	,	PUNCT
chd-130	585	15	yamanouchi	yamanouchi	PROPN
chd-130	585	16	,	,	PUNCT
chd-130	585	17	h.	h.	PROPN
chd-130	585	18	,	,	PUNCT
chd-130	585	19	ohtsuka	ohtsuka	PROPN
chd-130	585	20	,	,	PUNCT
chd-130	585	21	h.	h.	PROPN
chd-130	585	22	,	,	PUNCT
chd-130	585	23	kominami	kominami	PROPN
chd-130	585	24	,	,	PUNCT
chd-130	585	25	r.	r.	PROPN
chd-130	585	26	,	,	PUNCT
chd-130	585	27	yamamoto	yamamoto	NOUN
chd-130	585	28	,	,	PUNCT
chd-130	585	29	m.	m.	NOUN
chd-130	585	30	(	(	PUNCT
chd-130	585	31	1994	1994	NUM
chd-130	585	32	)	)	PUNCT
chd-130	585	33	.	.	PUNCT
chd-130	586	1	mutation	mutation	NOUN
chd-130	586	2	of	of	ADP
chd-130	586	3	the	the	DET
chd-130	586	4	p53	p53	NOUN
chd-130	586	5	gene	gene	NOUN
chd-130	586	6	in	in	ADP
chd-130	586	7	gallbladder	gallbladder	NOUN
chd-130	586	8	cancer	cancer	NOUN
chd-130	586	9	.	.	PUNCT
chd-130	587	1	tohoku	tohoku	PROPN
chd-130	587	2	j	j	PROPN
chd-130	587	3	exp	exp	NOUN
chd-130	587	4	med	med	PROPN
chd-130	587	5	.	.	PUNCT
chd-130	588	1	172	172	NUM
chd-130	588	2	,	,	PUNCT
chd-130	588	3	283	283	NUM
chd-130	588	4	-	-	SYM
chd-130	588	5	9	9	NUM
chd-130	588	6	.	.	PUNCT
chd-130	589	1	takahashi	takahashi	PROPN
chd-130	589	2	,	,	PUNCT
chd-130	589	3	t.	t.	PROPN
chd-130	589	4	,	,	PUNCT
chd-130	589	5	shivapurkar	shivapurkar	NOUN
chd-130	589	6	,	,	PUNCT
chd-130	589	7	n.	n.	NOUN
chd-130	589	8	,	,	PUNCT
chd-130	589	9	riquelme	riquelme	PROPN
chd-130	589	10	,	,	PUNCT
chd-130	589	11	e.	e.	PROPN
chd-130	589	12	,	,	PUNCT
chd-130	589	13	shigematsu	shigematsu	PROPN
chd-130	589	14	,	,	PUNCT
chd-130	589	15	h.	h.	PROPN
chd-130	589	16	,	,	PUNCT
chd-130	589	17	reddy	reddy	PROPN
chd-130	589	18	,	,	PUNCT
chd-130	589	19	j.	j.	PROPN
chd-130	589	20	,	,	PUNCT
chd-130	589	21	suzuki	suzuki	PROPN
chd-130	589	22	,	,	PUNCT
chd-130	589	23	m.	m.	NOUN
chd-130	589	24	,	,	PUNCT
chd-130	589	25	miyajima	miyajima	PROPN
chd-130	589	26	,	,	PUNCT
chd-130	589	27	k.	k.	PROPN
chd-130	589	28	,	,	PUNCT
chd-130	589	29	zhou	zhou	PROPN
chd-130	589	30	,	,	PUNCT
chd-130	589	31	x.	x.	PROPN
chd-130	589	32	,	,	PUNCT
chd-130	589	33	bekele	bekele	PROPN
chd-130	589	34	,	,	PUNCT
chd-130	589	35	b.n	b.n	PROPN
chd-130	589	36	.	.	PROPN
chd-130	589	37	,	,	PUNCT
chd-130	589	38	gazdar	gazdar	PROPN
chd-130	589	39	,	,	PUNCT
chd-130	589	40	a.f	a.f	PROPN
chd-130	589	41	.	.	PROPN
chd-130	589	42	,	,	PUNCT
chd-130	589	43	wistuba	wistuba	PROPN
chd-130	589	44	,	,	PUNCT
chd-130	589	45	i.i	i.i	PROPN
chd-130	589	46	.	.	PROPN
chd-130	589	47	(	(	PUNCT
chd-130	589	48	2004	2004	NUM
chd-130	589	49	)	)	PUNCT
chd-130	589	50	.	.	PUNCT
chd-130	590	1	aberrant	aberrant	ADJ
chd-130	590	2	promoter	promoter	NOUN
chd-130	590	3	hypermethylation	hypermethylation	NOUN
chd-130	590	4	of	of	ADP
chd-130	590	5	multiple	multiple	ADJ
chd-130	590	6	genes	gene	NOUN
chd-130	590	7	in	in	ADP
chd-130	590	8	gallbladder	gallbladder	NOUN
chd-130	590	9	carcinoma	carcinoma	NOUN
chd-130	590	10	and	and	CCONJ
chd-130	590	11	chronic	chronic	ADJ
chd-130	590	12	cholecystitis	cholecystitis	PROPN
chd-130	590	13	.	.	PUNCT
chd-130	591	1	clin	clin	PROPN
chd-130	591	2	cancer	cancer	PROPN
chd-130	591	3	res.10	res.10	PROPN
chd-130	591	4	,	,	PUNCT
chd-130	591	5	6126	6126	NUM
chd-130	591	6	-	-	SYM
chd-130	591	7	33	33	NUM
chd-130	591	8	.	.	PUNCT
chd-130	591	9	tang	tang	PROPN
chd-130	591	10	,	,	PUNCT
chd-130	591	11	m.	m.	NOUN
chd-130	591	12	,	,	PUNCT
chd-130	591	13	baez	baez	PROPN
chd-130	591	14	,	,	PUNCT
chd-130	591	15	s.	s.	PROPN
chd-130	591	16	,	,	PUNCT
chd-130	591	17	pruyas	pruyas	NOUN
chd-130	591	18	,	,	PUNCT
chd-130	591	19	m.	m.	NOUN
chd-130	591	20	,	,	PUNCT
chd-130	591	21	diaz	diaz	PROPN
chd-130	591	22	,	,	PUNCT
chd-130	591	23	a.	a.	PROPN
chd-130	591	24	,	,	PUNCT
chd-130	591	25	calvo	calvo	PROPN
chd-130	591	26	,	,	PUNCT
chd-130	591	27	a.	a.	NOUN
chd-130	591	28	,	,	PUNCT
chd-130	591	29	riquelme	riquelme	PROPN
chd-130	591	30	,	,	PUNCT
chd-130	591	31	e.	e.	PROPN
chd-130	591	32	,	,	PUNCT
chd-130	591	33	wistuba	wistuba	PROPN
chd-130	591	34	,	,	PUNCT
chd-130	591	35	i.i	i.i	PROPN
chd-130	591	36	.	.	PROPN
chd-130	591	37	(	(	PUNCT
chd-130	591	38	2004	2004	NUM
chd-130	591	39	)	)	PUNCT
chd-130	591	40	.	.	PUNCT
chd-130	592	1	mitochondrial	mitochondrial	ADJ
chd-130	592	2	dna	dna	NOUN
chd-130	592	3	mutation	mutation	NOUN
chd-130	592	4	at	at	ADP
chd-130	592	5	the	the	DET
chd-130	592	6	d310	d310	PROPN
chd-130	592	7	(	(	PUNCT
chd-130	592	8	displacement	displacement	NOUN
chd-130	592	9	loop	loop	NOUN
chd-130	592	10	)	)	PUNCT
chd-130	592	11	mononucleotide	mononucleotide	NOUN
chd-130	592	12	sequence	sequence	NOUN
chd-130	592	13	in	in	ADP
chd-130	592	14	the	the	DET
chd-130	592	15	pathogenesis	pathogenesis	NOUN
chd-130	592	16	of	of	ADP
chd-130	592	17	gallbladder	gallbladder	NOUN
chd-130	592	18	carcinoma	carcinoma	NOUN
chd-130	592	19	.	.	PUNCT
chd-130	593	1	clin	clin	PROPN
chd-130	593	2	cancer	cancer	NOUN
chd-130	593	3	res	re	NOUN
chd-130	593	4	.	.	PROPN
chd-130	594	1	10	10	NUM
chd-130	594	2	,	,	PUNCT
chd-130	594	3	1041	1041	NUM
chd-130	594	4	-	-	SYM
chd-130	594	5	6	6	NUM
chd-130	594	6	.	.	PUNCT
chd-130	594	7	tanno	tanno	PROPN
chd-130	594	8	,	,	PUNCT
chd-130	594	9	s.	s.	PROPN
chd-130	594	10	,	,	PUNCT
chd-130	594	11	obara	obara	PROPN
chd-130	594	12	,	,	PUNCT
chd-130	594	13	t.	t.	PROPN
chd-130	594	14	,	,	PUNCT
chd-130	594	15	fujii	fujii	PROPN
chd-130	594	16	,	,	PUNCT
chd-130	594	17	t.	t.	PROPN
chd-130	594	18	,	,	PUNCT
chd-130	594	19	mizukami	mizukami	NOUN
chd-130	594	20	,	,	PUNCT
chd-130	594	21	y.	y.	PROPN
chd-130	594	22	,	,	PUNCT
chd-130	594	23	shudo	shudo	PROPN
chd-130	594	24	,	,	PUNCT
chd-130	594	25	r.	r.	PROPN
chd-130	594	26	,	,	PUNCT
chd-130	594	27	nishino	nishino	PROPN
chd-130	594	28	,	,	PUNCT
chd-130	594	29	n.	n.	NOUN
chd-130	594	30	,	,	PUNCT
chd-130	594	31	ura	ura	PROPN
chd-130	594	32	,	,	PUNCT
chd-130	594	33	h.	h.	PROPN
chd-130	594	34	,	,	PUNCT
chd-130	594	35	klein	klein	PROPN
chd-130	594	36	-	-	PUNCT
chd-130	594	37	szanto	szanto	PROPN
chd-130	594	38	,	,	PUNCT
chd-130	594	39	a.j	a.j	PROPN
chd-130	594	40	.	.	PROPN
chd-130	594	41	,	,	PUNCT
chd-130	594	42	kohgo	kohgo	PROPN
chd-130	594	43	,	,	PUNCT
chd-130	595	1	y.	y.	PROPN
chd-130	595	2	(	(	PUNCT
chd-130	595	3	1998	1998	NUM
chd-130	595	4	)	)	PUNCT
chd-130	595	5	.	.	PUNCT
chd-130	596	1	proliferative	proliferative	ADJ
chd-130	596	2	potential	potential	NOUN
chd-130	596	3	and	and	CCONJ
chd-130	596	4	k	k	NOUN
chd-130	596	5	-	-	PUNCT
chd-130	596	6	ras	ras	ADJ
chd-130	596	7	mutation	mutation	NOUN
chd-130	596	8	in	in	ADP
chd-130	596	9	epithelial	epithelial	ADJ
chd-130	596	10	hyperplasia	hyperplasia	NOUN
chd-130	596	11	of	of	ADP
chd-130	596	12	the	the	DET
chd-130	596	13	gallbladder	gallbladder	NOUN
chd-130	596	14	in	in	ADP
chd-130	596	15	patients	patient	NOUN
chd-130	596	16	with	with	ADP
chd-130	596	17	anomalous	anomalous	ADJ
chd-130	596	18	pancreaticobiliary	pancreaticobiliary	ADJ
chd-130	596	19	ductal	ductal	ADJ
chd-130	596	20	union	union	NOUN
chd-130	596	21	.	.	PUNCT
chd-130	597	1	cancer	cancer	NOUN
chd-130	597	2	.	.	PUNCT
chd-130	598	1	83	83	NUM
chd-130	598	2	,	,	PUNCT
chd-130	598	3	267	267	NUM
chd-130	598	4	-	-	SYM
chd-130	598	5	75	75	NUM
chd-130	598	6	.	.	PUNCT
chd-130	599	1	tian	tian	ADJ
chd-130	599	2	,	,	PUNCT
chd-130	599	3	y.	y.	PROPN
chd-130	599	4	,	,	PUNCT
chd-130	599	5	ding	ding	NOUN
chd-130	599	6	,	,	PUNCT
chd-130	599	7	r.y	r.y	PROPN
chd-130	599	8	.	.	PROPN
chd-130	599	9	,	,	PUNCT
chd-130	599	10	zhi	zhi	PROPN
chd-130	599	11	,	,	PUNCT
chd-130	599	12	y.h	y.h	PROPN
chd-130	599	13	.	.	PROPN
chd-130	599	14	,	,	PUNCT
chd-130	599	15	guo	guo	PROPN
chd-130	599	16	,	,	PUNCT
chd-130	599	17	r.x	r.x	PROPN
chd-130	599	18	.	.	PROPN
chd-130	599	19	,	,	PUNCT
chd-130	599	20	wu	wu	PROPN
chd-130	599	21	,	,	PUNCT
chd-130	599	22	s.d	s.d	PROPN
chd-130	599	23	.	.	PROPN
chd-130	599	24	(	(	PUNCT
chd-130	599	25	2006	2006	NUM
chd-130	599	26	)	)	PUNCT
chd-130	599	27	.	.	PUNCT
chd-130	600	1	analysis	analysis	NOUN
chd-130	600	2	of	of	ADP
chd-130	600	3	p53	p53	NOUN
chd-130	600	4	and	and	CCONJ
chd-130	600	5	vascular	vascular	ADJ
chd-130	600	6	endothelial	endothelial	ADJ
chd-130	600	7	growth	growth	NOUN
chd-130	600	8	factor	factor	NOUN
chd-130	600	9	expression	expression	NOUN
chd-130	600	10	in	in	ADP
chd-130	600	11	human	human	ADJ
chd-130	600	12	gallbladder	gallbladder	NOUN
chd-130	600	13	carcinoma	carcinoma	NOUN
chd-130	600	14	for	for	ADP
chd-130	600	15	the	the	DET
chd-130	600	16	determination	determination	NOUN
chd-130	600	17	of	of	ADP
chd-130	600	18	tumor	tumor	NOUN
chd-130	600	19	vascularity	vascularity	NOUN
chd-130	600	20	.	.	PUNCT
chd-130	601	1	world	world	PROPN
chd-130	601	2	j	j	PROPN
chd-130	601	3	gastroenterol	gastroenterol	PROPN
chd-130	601	4	.	.	PUNCT
chd-130	602	1	12	12	NUM
chd-130	602	2	,	,	PUNCT
chd-130	602	3	415	415	NUM
chd-130	602	4	-	-	SYM
chd-130	602	5	9	9	NUM
chd-130	602	6	.	.	PUNCT
chd-130	602	7	tomono	tomono	PROPN
chd-130	602	8	,	,	PUNCT
chd-130	602	9	h.	h.	PROPN
chd-130	602	10	,	,	PUNCT
chd-130	602	11	nimura	nimura	ADV
chd-130	602	12	,	,	PUNCT
chd-130	602	13	y.	y.	PROPN
chd-130	602	14	,	,	PUNCT
chd-130	602	15	aono	aono	PROPN
chd-130	602	16	,	,	PUNCT
chd-130	602	17	k.	k.	PROPN
chd-130	602	18	,	,	PUNCT
chd-130	602	19	nakashima	nakashima	PROPN
chd-130	602	20	,	,	PUNCT
chd-130	602	21	i.	i.	PROPN
chd-130	602	22	,	,	PUNCT
chd-130	602	23	iwamoto	iwamoto	ADJ
chd-130	602	24	,	,	PUNCT
chd-130	602	25	t.	t.	PROPN
chd-130	602	26	,	,	PUNCT
chd-130	602	27	nakashima	nakashima	PROPN
chd-130	602	28	,	,	PUNCT
chd-130	602	29	n.	n.	PROPN
chd-130	602	30	(	(	PUNCT
chd-130	602	31	1996	1996	NUM
chd-130	602	32	)	)	PUNCT
chd-130	602	33	.	.	PUNCT
chd-130	603	1	point	point	NOUN
chd-130	603	2	mutations	mutation	NOUN
chd-130	603	3	of	of	ADP
chd-130	603	4	the	the	DET
chd-130	603	5	c	c	PROPN
chd-130	603	6	-	-	PUNCT
chd-130	603	7	ki	ki	PROPN
chd-130	603	8	-	-	PUNCT
chd-130	603	9	ras	ras	NOUN
chd-130	603	10	gene	gene	NOUN
chd-130	603	11	in	in	ADP
chd-130	603	12	carcinoma	carcinoma	NOUN
chd-130	603	13	and	and	CCONJ
chd-130	603	14	atypical	atypical	ADJ
chd-130	603	15	epithelium	epithelium	NOUN
chd-130	603	16	associated	associate	VERB
chd-130	603	17	with	with	ADP
chd-130	603	18	congenital	congenital	ADJ
chd-130	603	19	biliary	biliary	ADJ
chd-130	603	20	dilation	dilation	NOUN
chd-130	603	21	.	.	PUNCT
chd-130	604	1	am	be	AUX
chd-130	604	2	j	j	PROPN
chd-130	604	3	gastroenterol	gastroenterol	NOUN
chd-130	604	4	.	.	PUNCT
chd-130	605	1	91	91	NUM
chd-130	605	2	,	,	PUNCT
chd-130	605	3	1211	1211	NUM
chd-130	605	4	-	-	SYM
chd-130	605	5	4	4	NUM
chd-130	605	6	.	.	PUNCT
chd-130	605	7	trajber	trajber	NOUN
chd-130	605	8	,	,	PUNCT
chd-130	605	9	h.j	h.j	PROPN
chd-130	605	10	.	.	PROPN
chd-130	605	11	,	,	PUNCT
chd-130	605	12	szego	szego	PROPN
chd-130	605	13	,	,	PUNCT
chd-130	605	14	t.	t.	PROPN
chd-130	605	15	,	,	PUNCT
chd-130	605	16	de	de	PROPN
chd-130	605	17	camargo	camargo	PROPN
chd-130	605	18	,	,	PUNCT
chd-130	605	19	h.s	h.s	PROPN
chd-130	605	20	.	.	PROPN
chd-130	605	21	jr	jr	PROPN
chd-130	605	22	.	.	PROPN
chd-130	605	23	,	,	PUNCT
chd-130	605	24	mester	mester	NOUN
chd-130	605	25	,	,	PUNCT
chd-130	605	26	m.	m.	NOUN
chd-130	605	27	,	,	PUNCT
chd-130	605	28	marujo	marujo	PROPN
chd-130	605	29	,	,	PUNCT
chd-130	605	30	w.c	w.c	PROPN
chd-130	605	31	.	.	PROPN
chd-130	605	32	,	,	PUNCT
chd-130	605	33	roll	roll	NOUN
chd-130	605	34	,	,	PUNCT
chd-130	605	35	s.	s.	PROPN
chd-130	605	36	(	(	PUNCT
chd-130	605	37	1982	1982	NUM
chd-130	605	38	)	)	PUNCT
chd-130	605	39	.	.	PUNCT
chd-130	606	1	adenocarcinoma	adenocarcinoma	NOUN
chd-130	606	2	of	of	ADP
chd-130	606	3	the	the	DET
chd-130	606	4	gallbladder	gallbladder	NOUN
chd-130	606	5	in	in	ADP
chd-130	606	6	two	two	NUM
chd-130	606	7	siblings	sibling	NOUN
chd-130	606	8	.	.	PUNCT
chd-130	607	1	cancer	cancer	NOUN
chd-130	607	2	.	.	PUNCT
chd-130	608	1	50	50	NUM
chd-130	608	2	,	,	PUNCT
chd-130	608	3	1200	1200	NUM
chd-130	608	4	-	-	SYM
chd-130	608	5	3	3	NUM
chd-130	608	6	.	.	X
chd-130	608	7	tsuchiya	tsuchiya	PROPN
chd-130	608	8	,	,	PUNCT
chd-130	608	9	y.	y.	PROPN
chd-130	608	10	,	,	PUNCT
chd-130	608	11	kiyohara	kiyohara	PROPN
chd-130	608	12	,	,	PUNCT
chd-130	608	13	c.	c.	NOUN
chd-130	608	14	,	,	PUNCT
chd-130	608	15	sato	sato	PROPN
chd-130	608	16	,	,	PUNCT
chd-130	608	17	t.	t.	PROPN
chd-130	608	18	,	,	PUNCT
chd-130	608	19	nakamura	nakamura	PROPN
chd-130	608	20	,	,	PUNCT
chd-130	608	21	k.	k.	PROPN
chd-130	608	22	,	,	PUNCT
chd-130	608	23	kimura	kimura	PROPN
chd-130	608	24	,	,	PUNCT
chd-130	608	25	a.	a.	NOUN
chd-130	608	26	,	,	PUNCT
chd-130	608	27	yamamoto	yamamoto	NOUN
chd-130	608	28	,	,	PUNCT
chd-130	608	29	m.	m.	NOUN
chd-130	608	30	(	(	PUNCT
chd-130	608	31	2007	2007	NUM
chd-130	608	32	)	)	PUNCT
chd-130	608	33	.	.	PUNCT
chd-130	609	1	polymorphisms	polymorphism	NOUN
chd-130	609	2	of	of	ADP
chd-130	609	3	cytochrome	cytochrome	NOUN
chd-130	609	4	p450	p450	PROPN
chd-130	609	5	1a1	1a1	NUM
chd-130	609	6	,	,	PUNCT
chd-130	609	7	glutathione	glutathione	NOUN
chd-130	609	8	s	s	NOUN
chd-130	609	9	-	-	PUNCT
chd-130	609	10	transferase	transferase	NOUN
chd-130	609	11	class	class	NOUN
chd-130	609	12	mu	mu	NOUN
chd-130	609	13	,	,	PUNCT
chd-130	609	14	and	and	CCONJ
chd-130	609	15	tumour	tumour	NOUN
chd-130	609	16	protein	protein	NOUN
chd-130	609	17	p53	p53	NOUN
chd-130	609	18	genes	gene	NOUN
chd-130	609	19	and	and	CCONJ
chd-130	609	20	the	the	DET
chd-130	609	21	risk	risk	NOUN
chd-130	609	22	of	of	ADP
chd-130	609	23	developing	develop	VERB
chd-130	609	24	gallbladder	gallbladder	NOUN
chd-130	609	25	cancer	cancer	NOUN
chd-130	609	26	in	in	ADP
chd-130	609	27	japanese	japanese	PROPN
chd-130	609	28	.	.	PUNCT
chd-130	610	1	clin	clin	PROPN
chd-130	610	2	biochem	biochem	PROPN
chd-130	610	3	.	.	PUNCT
chd-130	611	1	40	40	NUM
chd-130	611	2	,	,	PUNCT
chd-130	611	3	881	881	NUM
chd-130	611	4	-	-	SYM
chd-130	611	5	6	6	NUM
chd-130	611	6	.	.	PUNCT
chd-130	611	7	tsuchiya	tsuchiya	PROPN
chd-130	611	8	,	,	PUNCT
chd-130	611	9	y.	y.	PROPN
chd-130	611	10	,	,	PUNCT
chd-130	611	11	sato	sato	PROPN
chd-130	611	12	,	,	PUNCT
chd-130	611	13	t.	t.	PROPN
chd-130	611	14	,	,	PUNCT
chd-130	611	15	kiyohara	kiyohara	PROPN
chd-130	611	16	,	,	PUNCT
chd-130	611	17	c.	c.	PROPN
chd-130	611	18	,	,	PUNCT
chd-130	611	19	yoshida	yoshida	PROPN
chd-130	611	20	,	,	PUNCT
chd-130	611	21	k.	k.	PROPN
chd-130	611	22	,	,	PUNCT
chd-130	611	23	ogoshi	ogoshi	PROPN
chd-130	611	24	,	,	PUNCT
chd-130	611	25	k.	k.	PROPN
chd-130	611	26	,	,	PUNCT
chd-130	611	27	nakamura	nakamura	PROPN
chd-130	611	28	,	,	PUNCT
chd-130	611	29	k.	k.	PROPN
chd-130	611	30	,	,	PUNCT
chd-130	611	31	yamamoto	yamamoto	PROPN
chd-130	611	32	,	,	PUNCT
chd-130	611	33	m.	m.	NOUN
chd-130	611	34	(	(	PUNCT
chd-130	611	35	2002	2002	NUM
chd-130	611	36	)	)	PUNCT
chd-130	611	37	.	.	PUNCT
chd-130	612	1	genetic	genetic	ADJ
chd-130	612	2	polymorphisms	polymorphism	NOUN
chd-130	612	3	of	of	ADP
chd-130	612	4	cytochrome	cytochrome	NOUN
chd-130	612	5	p450	p450	PROPN
chd-130	612	6	1a1	1a1	NUM
chd-130	612	7	and	and	CCONJ
chd-130	612	8	risk	risk	NOUN
chd-130	612	9	of	of	ADP
chd-130	612	10	gallbladder	gallbladder	NOUN
chd-130	612	11	cancer	cancer	NOUN
chd-130	612	12	.	.	PUNCT
chd-130	613	1	j	j	PROPN
chd-130	613	2	exp	exp	PROPN
chd-130	613	3	clin	clin	PROPN
chd-130	613	4	cancer	cancer	NOUN
chd-130	613	5	res	re	NOUN
chd-130	613	6	.	.	PUNCT
chd-130	614	1	21	21	NUM
chd-130	614	2	,	,	PUNCT
chd-130	614	3	119	119	NUM
chd-130	614	4	-	-	SYM
chd-130	614	5	24	24	NUM
chd-130	614	6	.	.	PUNCT
chd-130	614	7	vishnoi	vishnoi	NOUN
chd-130	614	8	,	,	PUNCT
chd-130	614	9	m.	m.	NOUN
chd-130	614	10	,	,	PUNCT
chd-130	614	11	pandey	pandey	PROPN
chd-130	614	12	,	,	PUNCT
chd-130	614	13	s.n	s.n	PROPN
chd-130	614	14	.	.	PROPN
chd-130	614	15	,	,	PUNCT
chd-130	614	16	choudhuri	choudhuri	PROPN
chd-130	614	17	,	,	PUNCT
chd-130	614	18	g.	g.	PROPN
chd-130	614	19	,	,	PUNCT
chd-130	614	20	mittal	mittal	PROPN
chd-130	614	21	,	,	PUNCT
chd-130	614	22	b.	b.	PROPN
chd-130	614	23	(	(	PUNCT
chd-130	614	24	2008	2008	NUM
chd-130	614	25	)	)	PUNCT
chd-130	614	26	.	.	PUNCT
chd-130	615	1	il-1	il-1	PROPN
chd-130	615	2	gene	gene	NOUN
chd-130	615	3	polymorphisms	polymorphism	NOUN
chd-130	615	4	and	and	CCONJ
chd-130	615	5	genetic	genetic	ADJ
chd-130	615	6	susceptibility	susceptibility	NOUN
chd-130	615	7	of	of	ADP
chd-130	615	8	gallbladder	gallbladder	NOUN
chd-130	615	9	cancer	cancer	NOUN
chd-130	615	10	in	in	ADP
chd-130	615	11	a	a	DET
chd-130	615	12	north	north	NOUN
chd-130	615	13	indian	indian	ADJ
chd-130	615	14	population	population	NOUN
chd-130	615	15	.	.	PUNCT
chd-130	616	1	cancer	cancer	NOUN
chd-130	616	2	genet	genet	NOUN
chd-130	616	3	cytogenet	cytogenet	NOUN
chd-130	616	4	.	.	PUNCT
chd-130	617	1	186	186	NUM
chd-130	617	2	,	,	PUNCT
chd-130	617	3	63	63	NUM
chd-130	617	4	-	-	SYM
chd-130	617	5	8	8	NUM
chd-130	617	6	.	.	PUNCT
chd-130	617	7	vishnoi	vishnoi	NOUN
chd-130	617	8	,	,	PUNCT
chd-130	617	9	m.	m.	NOUN
chd-130	617	10	,	,	PUNCT
chd-130	617	11	pandey	pandey	PROPN
chd-130	617	12	,	,	PUNCT
chd-130	617	13	s.n	s.n	PROPN
chd-130	617	14	.	.	PROPN
chd-130	617	15	,	,	PUNCT
chd-130	617	16	choudhury	choudhury	PROPN
chd-130	617	17	,	,	PUNCT
chd-130	617	18	g.	g.	PROPN
chd-130	617	19	,	,	PUNCT
chd-130	617	20	kumar	kumar	PROPN
chd-130	617	21	,	,	PUNCT
chd-130	617	22	a.	a.	PROPN
chd-130	617	23	,	,	PUNCT
chd-130	617	24	modi	modi	PROPN
chd-130	617	25	,	,	PUNCT
chd-130	617	26	d.r	d.r	PROPN
chd-130	617	27	.	.	PROPN
chd-130	617	28	,	,	PUNCT
chd-130	617	29	mittal	mittal	PROPN
chd-130	617	30	,	,	PUNCT
chd-130	617	31	b.	b.	PROPN
chd-130	617	32	(	(	PUNCT
chd-130	617	33	2007	2007	NUM
chd-130	617	34	)	)	PUNCT
chd-130	617	35	.	.	PUNCT
chd-130	618	1	do	do	VERB
chd-130	618	2	tnfa	tnfa	PRON
chd-130	619	1	-308g	-308g	VERB
chd-130	619	2	/	/	SYM
chd-130	619	3	a	a	NOUN
chd-130	619	4	and	and	CCONJ
chd-130	619	5	il6	il6	VERB
chd-130	619	6	-174	-174	PROPN
chd-130	619	7	g	g	NOUN
chd-130	619	8	/	/	SYM
chd-130	619	9	c	c	NOUN
chd-130	619	10	gene	gene	NOUN
chd-130	619	11	polymorphisms	polymorphism	NOUN
chd-130	619	12	modulate	modulate	VERB
chd-130	619	13	risk	risk	NOUN
chd-130	619	14	of	of	ADP
chd-130	619	15	gallbladder	gallbladder	NOUN
chd-130	619	16	cancer	cancer	NOUN
chd-130	619	17	in	in	ADP
chd-130	619	18	the	the	DET
chd-130	619	19	north	north	NOUN
chd-130	619	20	indian	indian	ADJ
chd-130	619	21	population	population	NOUN
chd-130	619	22	?	?	PUNCT
chd-130	620	1	asian	asian	PROPN
chd-130	620	2	pac	pac	PROPN
chd-130	620	3	j	j	PROPN
chd-130	620	4	cancer	cancer	NOUN
chd-130	620	5	prev	prev	X
chd-130	620	6	.	.	PROPN
chd-130	620	7	8	8	NUM
chd-130	620	8	,	,	PUNCT
chd-130	620	9	567	567	NUM
chd-130	620	10	-	-	SYM
chd-130	620	11	72	72	NUM
chd-130	620	12	.	.	PUNCT
chd-130	621	1	wang	wang	PROPN
chd-130	621	2	,	,	PUNCT
chd-130	621	3	j.w	j.w	PROPN
chd-130	621	4	.	.	PROPN
chd-130	621	5	,	,	PUNCT
chd-130	621	6	peng	peng	PROPN
chd-130	621	7	,	,	PUNCT
chd-130	621	8	s.y	s.y	PROPN
chd-130	621	9	.	.	PROPN
chd-130	621	10	,	,	PUNCT
chd-130	621	11	li	li	PROPN
chd-130	621	12	,	,	PUNCT
chd-130	621	13	j.t	j.t	PROPN
chd-130	621	14	.	.	PROPN
chd-130	621	15	,	,	PUNCT
chd-130	621	16	wang	wang	PROPN
chd-130	621	17	,	,	PUNCT
chd-130	621	18	y.	y.	PROPN
chd-130	621	19	,	,	PUNCT
chd-130	621	20	zhang	zhang	PROPN
chd-130	621	21	,	,	PUNCT
chd-130	621	22	z.p	z.p	PROPN
chd-130	621	23	.	.	PROPN
chd-130	621	24	,	,	PUNCT
chd-130	621	25	cheng	cheng	PROPN
chd-130	621	26	,	,	PUNCT
chd-130	621	27	y.	y.	PROPN
chd-130	621	28	,	,	PUNCT
chd-130	621	29	cheng	cheng	PROPN
chd-130	621	30	,	,	PUNCT
chd-130	621	31	d.q	d.q	PROPN
chd-130	621	32	.	.	PROPN
chd-130	621	33	,	,	PUNCT
chd-130	621	34	weng	weng	PROPN
chd-130	621	35	.	.	PUNCT
chd-130	622	1	w.h	w.h	PROPN
chd-130	622	2	.	.	PROPN
chd-130	622	3	,	,	PUNCT
chd-130	622	4	wu	wu	PROPN
chd-130	622	5	,	,	PUNCT
chd-130	622	6	x.s	x.s	PROPN
chd-130	622	7	.	.	PROPN
chd-130	622	8	,	,	PUNCT
chd-130	622	9	fei	fei	PROPN
chd-130	622	10	,	,	PUNCT
chd-130	622	11	x.z	x.z	PROPN
chd-130	622	12	.	.	PROPN
chd-130	622	13	,	,	PUNCT
chd-130	622	14	et	et	PROPN
chd-130	622	15	al	al	PROPN
chd-130	622	16	.	.	PUNCT
chd-130	623	1	(	(	PUNCT
chd-130	623	2	2009	2009	NUM
chd-130	623	3	)	)	PUNCT
chd-130	623	4	.	.	PUNCT
chd-130	624	1	identification	identification	NOUN
chd-130	624	2	of	of	ADP
chd-130	624	3	metastasis	metastasis	NOUN
chd-130	624	4	-	-	PUNCT
chd-130	624	5	associated	associate	VERB
chd-130	624	6	proteins	protein	NOUN
chd-130	624	7	involved	involve	VERB
chd-130	624	8	in	in	ADP
chd-130	624	9	gallbladder	gallbladder	NOUN
chd-130	624	10	carcinoma	carcinoma	NOUN
chd-130	624	11	metastasis	metastasis	NOUN
chd-130	624	12	by	by	ADP
chd-130	624	13	proteomic	proteomic	ADJ
chd-130	624	14	analysis	analysis	NOUN
chd-130	624	15	and	and	CCONJ
chd-130	624	16	functional	functional	ADJ
chd-130	624	17	exploration	exploration	NOUN
chd-130	624	18	of	of	ADP
chd-130	624	19	chloride	chloride	NOUN
chd-130	624	20	intracellular	intracellular	ADJ
chd-130	624	21	channel	channel	NOUN
chd-130	624	22	1	1	NUM
chd-130	624	23	.	.	PUNCT
chd-130	624	24	cancer	cancer	PROPN
chd-130	624	25	lett	lett	PROPN
chd-130	624	26	.	.	PUNCT
chd-130	625	1	281	281	NUM
chd-130	625	2	,	,	PUNCT
chd-130	625	3	71	71	NUM
chd-130	625	4	-	-	SYM
chd-130	625	5	81	81	NUM
chd-130	625	6	.	.	PUNCT
chd-130	626	1	washiro	washiro	PROPN
chd-130	626	2	,	,	PUNCT
chd-130	626	3	m.	m.	NOUN
chd-130	626	4	,	,	PUNCT
chd-130	626	5	ohtsuka	ohtsuka	NOUN
chd-130	626	6	,	,	PUNCT
chd-130	626	7	m.	m.	NOUN
chd-130	626	8	,	,	PUNCT
chd-130	626	9	kimura	kimura	NOUN
chd-130	626	10	,	,	PUNCT
chd-130	626	11	f.	f.	PROPN
chd-130	626	12	,	,	PUNCT
chd-130	626	13	shimizu	shimizu	PROPN
chd-130	626	14	,	,	PUNCT
chd-130	626	15	h.	h.	PROPN
chd-130	626	16	,	,	PUNCT
chd-130	626	17	yoshidome	yoshidome	PROPN
chd-130	626	18	,	,	PUNCT
chd-130	626	19	h.	h.	PROPN
chd-130	626	20	,	,	PUNCT
chd-130	626	21	sugimoto	sugimoto	PROPN
chd-130	626	22	,	,	PUNCT
chd-130	626	23	t.	t.	PROPN
chd-130	626	24	,	,	PUNCT
chd-130	626	25	seki	seki	PROPN
chd-130	626	26	,	,	PUNCT
chd-130	626	27	n.	n.	PROPN
chd-130	626	28	,	,	PUNCT
chd-130	626	29	miyazaki	miyazaki	PROPN
chd-130	626	30	,	,	PUNCT
chd-130	626	31	m.	m.	NOUN
chd-130	626	32	(	(	PUNCT
chd-130	626	33	2008	2008	NUM
chd-130	626	34	)	)	PUNCT
chd-130	626	35	.	.	PUNCT
chd-130	627	1	upregulation	upregulation	NOUN
chd-130	627	2	of	of	ADP
chd-130	627	3	topoisomerase	topoisomerase	ADJ
chd-130	627	4	iialpha	iialpha	ADJ
chd-130	627	5	expression	expression	NOUN
chd-130	627	6	in	in	ADP
chd-130	627	7	advanced	advanced	ADJ
chd-130	627	8	gallbladder	gallbladder	NOUN
chd-130	627	9	carcinoma	carcinoma	NOUN
chd-130	627	10	:	:	PUNCT
chd-130	627	11	a	a	DET
chd-130	627	12	potential	potential	ADJ
chd-130	627	13	chemotherapeutic	chemotherapeutic	ADJ
chd-130	627	14	target	target	NOUN
chd-130	627	15	.	.	PUNCT
chd-130	628	1	j	j	PROPN
chd-130	628	2	cancer	cancer	NOUN
chd-130	628	3	res	re	VERB
chd-130	628	4	clin	clin	PROPN
chd-130	628	5	oncol	oncol	PROPN
chd-130	628	6	.	.	PUNCT
chd-130	629	1	134	134	NUM
chd-130	629	2	,	,	PUNCT
chd-130	629	3	793	793	NUM
chd-130	629	4	-	-	SYM
chd-130	629	5	801	801	NUM
chd-130	629	6	.	.	PUNCT
chd-130	630	1	watanabe	watanabe	PROPN
chd-130	630	2	,	,	PUNCT
chd-130	630	3	m.	m.	NOUN
chd-130	630	4	,	,	PUNCT
chd-130	630	5	asaka	asaka	PROPN
chd-130	630	6	,	,	PUNCT
chd-130	630	7	m.	m.	NOUN
chd-130	630	8	,	,	PUNCT
chd-130	630	9	tanaka	tanaka	PROPN
chd-130	630	10	,	,	PUNCT
chd-130	630	11	j.	j.	PROPN
chd-130	630	12	,	,	PUNCT
chd-130	630	13	kurosawa	kurosawa	PROPN
chd-130	630	14	,	,	PUNCT
chd-130	630	15	m.	m.	NOUN
chd-130	630	16	,	,	PUNCT
chd-130	630	17	kasai	kasai	PROPN
chd-130	630	18	,	,	PUNCT
chd-130	630	19	m.	m.	NOUN
chd-130	630	20	,	,	PUNCT
chd-130	630	21	miyazaki	miyazaki	PROPN
chd-130	630	22	,	,	PUNCT
chd-130	630	23	t.	t.	PROPN
chd-130	630	24	(	(	PUNCT
chd-130	630	25	1994	1994	NUM
chd-130	630	26	)	)	PUNCT
chd-130	630	27	.	.	PUNCT
chd-130	631	1	point	point	NOUN
chd-130	631	2	mutation	mutation	NOUN
chd-130	631	3	of	of	ADP
chd-130	631	4	k	k	PROPN
chd-130	631	5	-	-	PUNCT
chd-130	631	6	ras	ra	VERB
chd-130	631	7	gene	gene	NOUN
chd-130	631	8	codon	codon	NOUN
chd-130	631	9	12	12	NUM
chd-130	631	10	in	in	ADP
chd-130	631	11	biliary	biliary	ADJ
chd-130	631	12	tract	tract	NOUN
chd-130	631	13	tumors	tumor	NOUN
chd-130	631	14	.	.	PUNCT
chd-130	632	1	gastroenterology	gastroenterology	NOUN
chd-130	632	2	.	.	PUNCT
chd-130	633	1	107	107	NUM
chd-130	633	2	,	,	PUNCT
chd-130	633	3	1147	1147	NUM
chd-130	633	4	-	-	SYM
chd-130	633	5	53	53	NUM
chd-130	633	6	.	.	PUNCT
chd-130	634	1	weiss	weiss	PROPN
chd-130	634	2	,	,	PUNCT
chd-130	634	3	k.m	k.m	PROPN
chd-130	634	4	.	.	PROPN
chd-130	634	5	,	,	PUNCT
chd-130	634	6	ferrell	ferrell	PROPN
chd-130	634	7	,	,	PUNCT
chd-130	634	8	r.e	r.e	PROPN
chd-130	634	9	.	.	PROPN
chd-130	634	10	,	,	PUNCT
chd-130	634	11	hanis	hanis	PROPN
chd-130	634	12	,	,	PUNCT
chd-130	634	13	c.l	c.l	PROPN
chd-130	634	14	.	.	PROPN
chd-130	634	15	,	,	PUNCT
chd-130	634	16	styne	styne	PROPN
chd-130	634	17	,	,	PUNCT
chd-130	634	18	p.n	p.n	PROPN
chd-130	634	19	.	.	PROPN
chd-130	634	20	(	(	PUNCT
chd-130	634	21	1984	1984	NUM
chd-130	634	22	)	)	PUNCT
chd-130	634	23	.	.	PUNCT
chd-130	635	1	genetics	genetic	NOUN
chd-130	635	2	and	and	CCONJ
chd-130	635	3	epidemiology	epidemiology	NOUN
chd-130	635	4	of	of	ADP
chd-130	635	5	gallbladder	gallbladder	NOUN
chd-130	635	6	disease	disease	NOUN
chd-130	635	7	in	in	ADP
chd-130	635	8	new	new	ADJ
chd-130	635	9	world	world	NOUN
chd-130	635	10	native	native	ADJ
chd-130	635	11	peoples	people	NOUN
chd-130	635	12	.	.	PUNCT
chd-130	636	1	am	be	AUX
chd-130	636	2	j	j	PROPN
chd-130	636	3	hum	hum	PROPN
chd-130	636	4	genet	genet	PROPN
chd-130	636	5	.	.	PUNCT
chd-130	637	1	36	36	NUM
chd-130	637	2	,	,	PUNCT
chd-130	637	3	1259	1259	NUM
chd-130	637	4	-	-	SYM
chd-130	637	5	78	78	NUM
chd-130	637	6	.	.	PUNCT
chd-130	638	1	wistuba	wistuba	PROPN
chd-130	638	2	,	,	PUNCT
chd-130	638	3	i.i	i.i	PROPN
chd-130	638	4	.	.	PROPN
chd-130	638	5	,	,	PUNCT
chd-130	638	6	albores	albores	PROPN
chd-130	638	7	-	-	PUNCT
chd-130	638	8	saavedra	saavedra	PROPN
chd-130	638	9	,	,	PUNCT
chd-130	638	10	j.	j.	PROPN
chd-130	638	11	(	(	PUNCT
chd-130	638	12	1999	1999	NUM
chd-130	638	13	)	)	PUNCT
chd-130	638	14	.	.	PUNCT
chd-130	639	1	genetic	genetic	ADJ
chd-130	639	2	abnormalities	abnormality	NOUN
chd-130	639	3	involved	involve	VERB
chd-130	639	4	in	in	ADP
chd-130	639	5	the	the	DET
chd-130	639	6	pathogenesis	pathogenesis	NOUN
chd-130	639	7	of	of	ADP
chd-130	639	8	gallbladder	gallbladder	NOUN
chd-130	639	9	carcinoma	carcinoma	NOUN
chd-130	639	10	.	.	PUNCT
chd-130	640	1	j	j	PROPN
chd-130	640	2	hepatobiliary	hepatobiliary	PROPN
chd-130	640	3	pancreat	pancreat	PROPN
chd-130	640	4	surg	surg	PROPN
chd-130	640	5	.	.	PUNCT
chd-130	641	1	6	6	NUM
chd-130	641	2	,	,	PUNCT
chd-130	641	3	237	237	NUM
chd-130	641	4	-	-	SYM
chd-130	641	5	44	44	NUM
chd-130	641	6	.	.	PUNCT
chd-130	641	7	wistuba	wistuba	PROPN
chd-130	641	8	,	,	PUNCT
chd-130	641	9	i.i	i.i	PROPN
chd-130	641	10	.	.	PROPN
chd-130	641	11	,	,	PUNCT
chd-130	641	12	ashfaq	ashfaq	PROPN
chd-130	641	13	,	,	PUNCT
chd-130	641	14	r.	r.	PROPN
chd-130	641	15	,	,	PUNCT
chd-130	641	16	maitra	maitra	PROPN
chd-130	641	17	,	,	PUNCT
chd-130	641	18	a.	a.	PROPN
chd-130	641	19	,	,	PUNCT
chd-130	641	20	alvarez	alvarez	PROPN
chd-130	641	21	,	,	PUNCT
chd-130	641	22	h.	h.	PROPN
chd-130	641	23	,	,	PUNCT
chd-130	641	24	riquelme	riquelme	PROPN
chd-130	641	25	,	,	PUNCT
chd-130	641	26	e.	e.	PROPN
chd-130	641	27	,	,	PUNCT
chd-130	641	28	gazdar	gazdar	PROPN
chd-130	641	29	,	,	PUNCT
chd-130	641	30	a.f	a.f	PROPN
chd-130	641	31	.	.	PROPN
chd-130	641	32	(	(	PUNCT
chd-130	641	33	2002	2002	NUM
chd-130	641	34	)	)	PUNCT
chd-130	641	35	.	.	PUNCT
chd-130	642	1	fragile	fragile	ADJ
chd-130	642	2	histidine	histidine	ADJ
chd-130	642	3	triad	triad	ADJ
chd-130	642	4	gene	gene	NOUN
chd-130	642	5	abnormalities	abnormality	NOUN
chd-130	642	6	in	in	ADP
chd-130	642	7	the	the	DET
chd-130	642	8	pathogenesis	pathogenesis	NOUN
chd-130	642	9	of	of	ADP
chd-130	642	10	gallbladder	gallbladder	NOUN
chd-130	642	11	carcinoma	carcinoma	NOUN
chd-130	642	12	.	.	PUNCT
chd-130	643	1	am	be	AUX
chd-130	643	2	j	j	PROPN
chd-130	643	3	pathol	pathol	NOUN
chd-130	643	4	.	.	PUNCT
chd-130	644	1	160	160	NUM
chd-130	644	2	,	,	PUNCT
chd-130	644	3	2073	2073	NUM
chd-130	644	4	-	-	SYM
chd-130	644	5	9	9	NUM
chd-130	644	6	.	.	PUNCT
chd-130	644	7	wistuba	wistuba	PROPN
chd-130	644	8	,	,	PUNCT
chd-130	644	9	i.i	i.i	PROPN
chd-130	644	10	.	.	PROPN
chd-130	644	11	,	,	PUNCT
chd-130	644	12	miquel	miquel	PROPN
chd-130	644	13	,	,	PUNCT
chd-130	644	14	j.f	j.f	PROPN
chd-130	644	15	.	.	PROPN
chd-130	644	16	,	,	PUNCT
chd-130	644	17	gazdar	gazdar	PROPN
chd-130	644	18	,	,	PUNCT
chd-130	644	19	a.f	a.f	PROPN
chd-130	644	20	.	.	PROPN
chd-130	644	21	,	,	PUNCT
chd-130	644	22	albores	albores	PROPN
chd-130	644	23	-	-	PUNCT
chd-130	644	24	saavedra	saavedra	PROPN
chd-130	644	25	,	,	PUNCT
chd-130	644	26	j.	j.	PROPN
chd-130	644	27	(	(	PUNCT
chd-130	644	28	1999	1999	NUM
chd-130	644	29	)	)	PUNCT
chd-130	644	30	.	.	PUNCT
chd-130	645	1	gallbladder	gallbladder	NOUN
chd-130	645	2	adenomas	adenoma	NOUN
chd-130	645	3	have	have	VERB
chd-130	645	4	molecular	molecular	ADJ
chd-130	645	5	abnormalities	abnormality	NOUN
chd-130	645	6	different	different	ADJ
chd-130	645	7	from	from	ADP
chd-130	645	8	those	those	PRON
chd-130	645	9	present	present	ADJ
chd-130	645	10	in	in	ADP
chd-130	645	11	gallbladder	gallbladder	NOUN
chd-130	645	12	carcinomas	carcinoma	NOUN
chd-130	645	13	.	.	PUNCT
chd-130	646	1	hum	hum	PROPN
chd-130	646	2	pathol	pathol	PROPN
chd-130	646	3	.	.	PUNCT
chd-130	647	1	30	30	NUM
chd-130	647	2	,	,	PUNCT
chd-130	647	3	21	21	NUM
chd-130	647	4	-	-	SYM
chd-130	647	5	5	5	NUM
chd-130	647	6	.	.	PUNCT
chd-130	647	7	wistuba	wistuba	PROPN
chd-130	647	8	,	,	PUNCT
chd-130	647	9	i.i	i.i	PROPN
chd-130	647	10	.	.	PROPN
chd-130	647	11	,	,	PUNCT
chd-130	647	12	tang	tang	PROPN
chd-130	647	13	,	,	PUNCT
chd-130	647	14	m.	m.	NOUN
chd-130	647	15	,	,	PUNCT
chd-130	647	16	maitra	maitra	PROPN
chd-130	647	17	,	,	PUNCT
chd-130	647	18	a.	a.	PROPN
chd-130	647	19	,	,	PUNCT
chd-130	647	20	alvarez	alvarez	PROPN
chd-130	647	21	,	,	PUNCT
chd-130	647	22	h.	h.	PROPN
chd-130	647	23	,	,	PUNCT
chd-130	647	24	troncoso	troncoso	NOUN
chd-130	647	25	,	,	PUNCT
chd-130	647	26	p.	p.	NOUN
chd-130	647	27	,	,	PUNCT
chd-130	647	28	pimentel	pimentel	PROPN
chd-130	647	29	,	,	PUNCT
chd-130	647	30	f.	f.	PROPN
chd-130	647	31	,	,	PUNCT
chd-130	647	32	gazdar	gazdar	PROPN
chd-130	647	33	,	,	PUNCT
chd-130	647	34	a.f	a.f	PROPN
chd-130	647	35	.	.	PROPN
chd-130	647	36	(	(	PUNCT
chd-130	647	37	2001	2001	NUM
chd-130	647	38	)	)	PUNCT
chd-130	647	39	.	.	PUNCT
chd-130	648	1	genome	genome	NOUN
chd-130	648	2	-	-	PUNCT
chd-130	648	3	wide	wide	ADJ
chd-130	648	4	allelotyping	allelotype	VERB
chd-130	648	5	analysis	analysis	NOUN
chd-130	648	6	reveals	reveal	VERB
chd-130	648	7	multiple	multiple	ADJ
chd-130	648	8	sites	site	NOUN
chd-130	648	9	of	of	ADP
chd-130	648	10	allelic	allelic	ADJ
chd-130	648	11	loss	loss	NOUN
chd-130	648	12	in	in	ADP
chd-130	648	13	gallbladder	gallbladder	NOUN
chd-130	648	14	carcinoma	carcinoma	NOUN
chd-130	648	15	.	.	PUNCT
chd-130	649	1	cancer	cancer	NOUN
chd-130	649	2	res	re	NOUN
chd-130	649	3	.	.	PROPN
chd-130	649	4	61	61	NUM
chd-130	649	5	,	,	PUNCT
chd-130	649	6	3795	3795	NUM
chd-130	649	7	-	-	SYM
chd-130	649	8	800	800	NUM
chd-130	649	9	.	.	PUNCT
chd-130	650	1	www.companyofscientists.com/index.php/chd	www.companyofscientists.com/index.php/chd	AUX
chd-130	650	2	e24	e24	PROPN
chd-130	650	3	cancer	cancer	NOUN
chd-130	650	4	health	health	NOUN
chd-130	650	5	disparities	disparity	NOUN
chd-130	650	6	research	research	PROPN
chd-130	650	7	yadav	yadav	PROPN
chd-130	650	8	,	,	PUNCT
chd-130	650	9	s.	s.	PROPN
chd-130	650	10	,	,	PUNCT
chd-130	650	11	chandra	chandra	PROPN
chd-130	650	12	,	,	PUNCT
chd-130	650	13	a.	a.	PROPN
chd-130	650	14	,	,	PUNCT
chd-130	650	15	kumar	kumar	PROPN
chd-130	650	16	,	,	PUNCT
chd-130	650	17	a.	a.	PROPN
chd-130	650	18	,	,	PUNCT
chd-130	650	19	mittal	mittal	PROPN
chd-130	650	20	,	,	PUNCT
chd-130	650	21	b.	b.	PROPN
chd-130	650	22	(	(	PUNCT
chd-130	650	23	2018	2018	NUM
chd-130	650	24	)	)	PUNCT
chd-130	650	25	.	.	PUNCT
chd-130	651	1	association	association	NOUN
chd-130	651	2	of	of	ADP
chd-130	651	3	tert	tert	NOUN
chd-130	651	4	-	-	PUNCT
chd-130	651	5	clptm1l	clptm1l	ADJ
chd-130	651	6	and	and	CCONJ
chd-130	651	7	8q24	8q24	NOUN
chd-130	651	8	common	common	ADJ
chd-130	651	9	genetic	genetic	ADJ
chd-130	651	10	variants	variant	NOUN
chd-130	651	11	with	with	ADP
chd-130	651	12	gallbladder	gallbladder	NOUN
chd-130	651	13	cancer	cancer	NOUN
chd-130	651	14	susceptibility	susceptibility	NOUN
chd-130	651	15	and	and	CCONJ
chd-130	651	16	prognosis	prognosis	NOUN
chd-130	651	17	in	in	ADP
chd-130	651	18	north	north	PROPN
chd-130	651	19	indian	indian	ADJ
chd-130	651	20	population	population	NOUN
chd-130	651	21	.	.	PUNCT
chd-130	652	1	biochem	biochem	PROPN
chd-130	652	2	genet	genet	PROPN
chd-130	652	3	.	.	PUNCT
chd-130	653	1	56	56	NUM
chd-130	653	2	,	,	PUNCT
chd-130	653	3	267	267	NUM
chd-130	653	4	-	-	SYM
chd-130	653	5	282	282	NUM
chd-130	653	6	.	.	PUNCT
chd-130	654	1	yadav	yadav	PROPN
chd-130	654	2	,	,	PUNCT
chd-130	654	3	s.	s.	PROPN
chd-130	654	4	,	,	PUNCT
chd-130	654	5	de	de	PROPN
chd-130	654	6	sarkar	sarkar	PROPN
chd-130	654	7	,	,	PUNCT
chd-130	654	8	n.	n.	PROPN
chd-130	654	9	,	,	PUNCT
chd-130	654	10	kumari	kumari	PROPN
chd-130	654	11	,	,	PUNCT
chd-130	654	12	n.	n.	NOUN
chd-130	654	13	,	,	PUNCT
chd-130	654	14	krishnani	krishnani	PROPN
chd-130	654	15	,	,	PUNCT
chd-130	654	16	n.	n.	PROPN
chd-130	654	17	,	,	PUNCT
chd-130	654	18	kumar	kumar	PROPN
chd-130	654	19	,	,	PUNCT
chd-130	654	20	a.	a.	PROPN
chd-130	654	21	,	,	PUNCT
chd-130	654	22	mittal	mittal	PROPN
chd-130	654	23	,	,	PUNCT
chd-130	654	24	b.	b.	PROPN
chd-130	654	25	(	(	PUNCT
chd-130	654	26	2017	2017	NUM
chd-130	654	27	)	)	PUNCT
chd-130	654	28	.	.	PUNCT
chd-130	655	1	targeted	target	VERB
chd-130	655	2	gene	gene	NOUN
chd-130	655	3	sequencing	sequencing	NOUN
chd-130	655	4	of	of	ADP
chd-130	655	5	gallbladder	gallbladder	NOUN
chd-130	655	6	carcinoma	carcinoma	NOUN
chd-130	655	7	identifies	identify	VERB
chd-130	655	8	high	high	ADJ
chd-130	655	9	-	-	PUNCT
chd-130	655	10	impact	impact	NOUN
chd-130	655	11	somatic	somatic	ADJ
chd-130	655	12	and	and	CCONJ
chd-130	655	13	rare	rare	ADJ
chd-130	655	14	germline	germline	NOUN
chd-130	655	15	mutations	mutation	NOUN
chd-130	655	16	.	.	PUNCT
chd-130	656	1	cancer	cancer	NOUN
chd-130	656	2	genomics	genomics	NOUN
chd-130	656	3	proteomics	proteomic	NOUN
chd-130	656	4	.	.	PUNCT
chd-130	657	1	14	14	NUM
chd-130	657	2	,	,	PUNCT
chd-130	657	3	495	495	NUM
chd-130	657	4	-	-	SYM
chd-130	657	5	506	506	NUM
chd-130	657	6	.	.	PUNCT
chd-130	658	1	yamaguchi	yamaguchi	PROPN
chd-130	658	2	,	,	PUNCT
chd-130	658	3	j.	j.	PROPN
chd-130	658	4	,	,	PUNCT
chd-130	658	5	sasaki	sasaki	PROPN
chd-130	658	6	,	,	PUNCT
chd-130	658	7	m.	m.	NOUN
chd-130	658	8	,	,	PUNCT
chd-130	658	9	sato	sato	PROPN
chd-130	658	10	,	,	PUNCT
chd-130	658	11	y.	y.	PROPN
chd-130	658	12	,	,	PUNCT
chd-130	658	13	itatsu	itatsu	ADJ
chd-130	658	14	,	,	PUNCT
chd-130	658	15	k.	k.	PROPN
chd-130	658	16	,	,	PUNCT
chd-130	658	17	harada	harada	PROPN
chd-130	658	18	,	,	PUNCT
chd-130	658	19	k.	k.	PROPN
chd-130	658	20	,	,	PUNCT
chd-130	658	21	zen	zen	PROPN
chd-130	658	22	,	,	PUNCT
chd-130	658	23	y.	y.	PROPN
chd-130	658	24	,	,	PUNCT
chd-130	658	25	ikeda	ikeda	PROPN
chd-130	658	26	,	,	PUNCT
chd-130	658	27	h.	h.	PROPN
chd-130	658	28	,	,	PUNCT
chd-130	658	29	nimura	nimura	ADV
chd-130	658	30	,	,	PUNCT
chd-130	658	31	y.	y.	PROPN
chd-130	658	32	,	,	PUNCT
chd-130	658	33	nagino	nagino	PROPN
chd-130	658	34	,	,	PUNCT
chd-130	658	35	m.	m.	NOUN
chd-130	658	36	,	,	PUNCT
chd-130	658	37	nakanuma	nakanuma	ADV
chd-130	658	38	,	,	PUNCT
chd-130	658	39	y.	y.	PROPN
chd-130	658	40	(	(	PUNCT
chd-130	658	41	2010	2010	NUM
chd-130	658	42	)	)	PUNCT
chd-130	658	43	.	.	PUNCT
chd-130	659	1	histone	histone	NOUN
chd-130	659	2	deacetylase	deacetylase	VERB
chd-130	659	3	inhibitor	inhibitor	NOUN
chd-130	659	4	(	(	PUNCT
chd-130	659	5	saha	saha	PROPN
chd-130	659	6	)	)	PUNCT
chd-130	659	7	and	and	CCONJ
chd-130	659	8	repression	repression	NOUN
chd-130	659	9	of	of	ADP
chd-130	659	10	ezh2	ezh2	NOUN
chd-130	659	11	synergistically	synergistically	ADV
chd-130	659	12	inhibit	inhibit	VERB
chd-130	659	13	proliferation	proliferation	NOUN
chd-130	659	14	of	of	ADP
chd-130	659	15	gallbladder	gallbladder	NOUN
chd-130	659	16	carcinoma	carcinoma	NOUN
chd-130	659	17	.	.	PUNCT
chd-130	660	1	cancer	cancer	PROPN
chd-130	660	2	sci	sci	PROPN
chd-130	660	3	.	.	PROPN
chd-130	661	1	101	101	NUM
chd-130	661	2	,	,	PUNCT
chd-130	661	3	355	355	NUM
chd-130	661	4	-	-	SYM
chd-130	661	5	62	62	NUM
chd-130	661	6	.	.	PUNCT
chd-130	662	1	yamato	yamato	PROPN
chd-130	662	2	,	,	PUNCT
chd-130	662	3	t.	t.	PROPN
chd-130	662	4	,	,	PUNCT
chd-130	662	5	sasaki	sasaki	PROPN
chd-130	662	6	,	,	PUNCT
chd-130	662	7	m.	m.	NOUN
chd-130	662	8	,	,	PUNCT
chd-130	662	9	watanabe	watanabe	PROPN
chd-130	662	10	,	,	PUNCT
chd-130	662	11	y.	y.	PROPN
chd-130	662	12	,	,	PUNCT
chd-130	662	13	nakanuma	nakanuma	ADV
chd-130	662	14	,	,	PUNCT
chd-130	662	15	y.	y.	PROPN
chd-130	662	16	(	(	PUNCT
chd-130	662	17	1999	1999	NUM
chd-130	662	18	)	)	PUNCT
chd-130	662	19	.	.	PUNCT
chd-130	663	1	expression	expression	NOUN
chd-130	663	2	of	of	ADP
chd-130	663	3	muc1	muc1	PROPN
chd-130	663	4	and	and	CCONJ
chd-130	663	5	muc2	muc2	PROPN
chd-130	663	6	mucin	mucin	NOUN
chd-130	663	7	core	core	NOUN
chd-130	663	8	proteins	protein	NOUN
chd-130	663	9	and	and	CCONJ
chd-130	663	10	their	their	PRON
chd-130	663	11	messenger	messenger	NOUN
chd-130	663	12	rna	rna	NOUN
chd-130	663	13	in	in	ADP
chd-130	663	14	gall	gall	NOUN
chd-130	663	15	bladder	bladder	NOUN
chd-130	663	16	carcinoma	carcinoma	NOUN
chd-130	663	17	:	:	PUNCT
chd-130	663	18	an	an	DET
chd-130	663	19	immunohistochemical	immunohistochemical	ADJ
chd-130	663	20	and	and	CCONJ
chd-130	663	21	in	in	ADP
chd-130	663	22	situ	situ	ADJ
chd-130	663	23	hybridization	hybridization	NOUN
chd-130	663	24	study	study	NOUN
chd-130	663	25	.	.	PUNCT
chd-130	664	1	j	j	PROPN
chd-130	664	2	pathol	pathol	NOUN
chd-130	664	3	.	.	PUNCT
chd-130	665	1	188	188	NUM
chd-130	665	2	,	,	PUNCT
chd-130	665	3	30	30	NUM
chd-130	665	4	-	-	SYM
chd-130	665	5	7	7	NUM
chd-130	665	6	.	.	PUNCT
chd-130	665	7	yanagisawa	yanagisawa	PROPN
chd-130	665	8	,	,	PUNCT
chd-130	665	9	n.	n.	NOUN
chd-130	665	10	,	,	PUNCT
chd-130	665	11	mikami	mikami	PROPN
chd-130	665	12	,	,	PUNCT
chd-130	665	13	t.	t.	PROPN
chd-130	665	14	,	,	PUNCT
chd-130	665	15	saegusa	saegusa	NOUN
chd-130	665	16	,	,	PUNCT
chd-130	665	17	m.	m.	NOUN
chd-130	665	18	,	,	PUNCT
chd-130	665	19	okayasu	okayasu	NOUN
chd-130	665	20	,	,	PUNCT
chd-130	665	21	i.	i.	NOUN
chd-130	665	22	(	(	PUNCT
chd-130	665	23	2001	2001	NUM
chd-130	665	24	)	)	PUNCT
chd-130	665	25	.	.	PUNCT
chd-130	666	1	more	more	ADV
chd-130	666	2	frequent	frequent	ADJ
chd-130	666	3	beta	beta	NOUN
chd-130	666	4	-	-	PUNCT
chd-130	666	5	catenin	catenin	NOUN
chd-130	666	6	exon	exon	NOUN
chd-130	666	7	3	3	NUM
chd-130	666	8	mutations	mutation	NOUN
chd-130	666	9	in	in	ADP
chd-130	666	10	gallbladder	gallbladder	NOUN
chd-130	666	11	adenomas	adenoma	NOUN
chd-130	666	12	than	than	ADP
chd-130	666	13	in	in	ADP
chd-130	666	14	carcinomas	carcinoma	NOUN
chd-130	666	15	indicate	indicate	VERB
chd-130	666	16	different	different	ADJ
chd-130	666	17	lineages	lineage	NOUN
chd-130	666	18	.	.	PUNCT
chd-130	667	1	cancer	cancer	NOUN
chd-130	667	2	res	re	NOUN
chd-130	667	3	.	.	PROPN
chd-130	668	1	61	61	NUM
chd-130	668	2	,	,	PUNCT
chd-130	668	3	19	19	NUM
chd-130	668	4	-	-	SYM
chd-130	668	5	22	22	NUM
chd-130	668	6	.	.	PUNCT
chd-130	669	1	yokoyama	yokoyama	PROPN
chd-130	669	2	,	,	PUNCT
chd-130	669	3	n.	n.	NOUN
chd-130	669	4	,	,	PUNCT
chd-130	669	5	hitomi	hitomi	PROPN
chd-130	669	6	,	,	PUNCT
chd-130	669	7	j.	j.	PROPN
chd-130	669	8	,	,	PUNCT
chd-130	669	9	watanabe	watanabe	PROPN
chd-130	669	10	,	,	PUNCT
chd-130	669	11	h.	h.	PROPN
chd-130	669	12	,	,	PUNCT
chd-130	669	13	ajioka	ajioka	NOUN
chd-130	669	14	,	,	PUNCT
chd-130	669	15	y.	y.	PROPN
chd-130	669	16	,	,	PUNCT
chd-130	669	17	pruyas	pruyas	NOUN
chd-130	669	18	,	,	PUNCT
chd-130	669	19	m.	m.	NOUN
chd-130	669	20	,	,	PUNCT
chd-130	669	21	serra	serra	PROPN
chd-130	669	22	,	,	PUNCT
chd-130	669	23	i.	i.	PROPN
chd-130	669	24	,	,	PUNCT
chd-130	669	25	shirai	shirai	VERB
chd-130	669	26	,	,	PUNCT
chd-130	669	27	y.	y.	PROPN
chd-130	669	28	,	,	PUNCT
chd-130	669	29	hatakeyama	hatakeyama	PROPN
chd-130	669	30	,	,	PUNCT
chd-130	669	31	k.	k.	PROPN
chd-130	669	32	(	(	PUNCT
chd-130	669	33	1998	1998	NUM
chd-130	669	34	)	)	PUNCT
chd-130	669	35	.	.	PUNCT
chd-130	670	1	mutations	mutation	NOUN
chd-130	670	2	of	of	ADP
chd-130	670	3	p53	p53	NOUN
chd-130	670	4	in	in	ADP
chd-130	670	5	gallbladder	gallbladder	NOUN
chd-130	670	6	carcinomas	carcinoma	NOUN
chd-130	670	7	in	in	ADP
chd-130	670	8	high	high	ADJ
chd-130	670	9	-	-	PUNCT
chd-130	670	10	incidence	incidence	NOUN
chd-130	670	11	areas	area	NOUN
chd-130	670	12	of	of	ADP
chd-130	670	13	japan	japan	PROPN
chd-130	670	14	and	and	CCONJ
chd-130	670	15	chile	chile	PROPN
chd-130	670	16	.	.	PUNCT
chd-130	671	1	cancer	cancer	NOUN
chd-130	671	2	epidemiol	epidemiol	PROPN
chd-130	671	3	biomarkers	biomarker	NOUN
chd-130	671	4	prev	prev	X
chd-130	671	5	.	.	PUNCT
chd-130	672	1	7	7	NUM
chd-130	672	2	,	,	PUNCT
chd-130	672	3	297	297	NUM
chd-130	672	4	-	-	SYM
chd-130	672	5	301	301	NUM
chd-130	672	6	.	.	PUNCT
chd-130	673	1	yoshida	yoshida	PROPN
chd-130	673	2	,	,	PUNCT
chd-130	673	3	t.	t.	PROPN
chd-130	673	4	,	,	PUNCT
chd-130	673	5	sugai	sugai	NOUN
chd-130	673	6	,	,	PUNCT
chd-130	673	7	t.	t.	NOUN
chd-130	673	8	,	,	PUNCT
chd-130	673	9	habano	habano	PROPN
chd-130	673	10	,	,	PUNCT
chd-130	673	11	w.	w.	PROPN
chd-130	673	12	,	,	PUNCT
chd-130	673	13	nakamura	nakamura	PROPN
chd-130	673	14	,	,	PUNCT
chd-130	673	15	s.	s.	PROPN
chd-130	673	16	,	,	PUNCT
chd-130	673	17	uesugi	uesugi	ADJ
chd-130	673	18	,	,	PUNCT
chd-130	673	19	n.	n.	NOUN
chd-130	673	20	,	,	PUNCT
chd-130	673	21	funato	funato	PROPN
chd-130	673	22	,	,	PUNCT
chd-130	673	23	o.	o.	PROPN
chd-130	673	24	,	,	PUNCT
chd-130	673	25	saito	saito	PROPN
chd-130	673	26	,	,	PUNCT
chd-130	673	27	k.	k.	PROPN
chd-130	673	28	(	(	PUNCT
chd-130	673	29	2000	2000	NUM
chd-130	673	30	)	)	PUNCT
chd-130	673	31	.	.	PUNCT
chd-130	674	1	microsatellite	microsatellite	ADJ
chd-130	674	2	instability	instability	NOUN
chd-130	674	3	in	in	ADP
chd-130	674	4	gallbladder	gallbladder	NOUN
chd-130	674	5	carcinoma	carcinoma	NOUN
chd-130	674	6	:	:	PUNCT
chd-130	674	7	two	two	NUM
chd-130	674	8	independent	independent	ADJ
chd-130	674	9	genetic	genetic	ADJ
chd-130	674	10	pathways	pathway	NOUN
chd-130	674	11	of	of	ADP
chd-130	674	12	gallbladder	gallbladder	NOUN
chd-130	674	13	carcinogenesis	carcinogenesis	NOUN
chd-130	674	14	.	.	PUNCT
chd-130	675	1	j	j	PROPN
chd-130	675	2	gastroenterol	gastroenterol	PROPN
chd-130	675	3	.	.	PUNCT
chd-130	676	1	35	35	NUM
chd-130	676	2	,	,	PUNCT
chd-130	676	3	768	768	NUM
chd-130	676	4	-	-	SYM
chd-130	676	5	74	74	NUM
chd-130	676	6	.	.	PUNCT